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FO01-01
LIVE DONOR LIVER
TRANSPLANTATION USING DUAL
GRAFTS
ChulSoo Ahn, Shin Hwang, Ki-Hun Kim, DoekBok
Moon, TaeYong Ha, GiWon Song, DongHwan Jung,
GilChun Park and Sung-Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Most important factor for the success of
live donor liver transplantation (LDLT) is good size
matching between donor and recipient. But some donor
and recipient pair cannot progress to transplantation
with usual single lobe graft due to various reasons.
Dual donor LDLT which using two grafts for one reci-
pient is a good alternative modality for these donor
and recipient group.
Method: In Asan Medical Center, we performed 331
cases of dual graft LDLT from 2000 to 2011.
Results: Mean GRWR of dual graft LDLT was 1.03,
which is similar with that of single right lobe graft
(GRWR was 1.04). Though this method requires three
operation simultaneously, if two left lobe grafts were
used its overall donor complication rate is smaller than
standard right lobe graft. Various combinations are pos-
sible between various grafts including left lateral seg-
ment, left lobe, right lobe and right posterior segment.
This combination is decided by recipient’s requirement
and donor liver condition and right-left proportion.
Most common course of dual graft is cooperative regen-
eration but competitive regeneration can be occurred
between two grafts. But atrophy of inferior graft
occurred slowly and due to its gradual functional shift-
ing to dominant graft, recipient’s condition was good
without any complication. Acute cellular rejection rate
after dual graft LDLT is similar to that of single lobe
graft. It can be occurred in unilateral graft or bilateral
grafts. Overall survival results for dual graft LDLT after
learning curve is similar to that of single graft LDLT.
Conclusions: In conclusion, dual grafts LDLT is a
good alternative option to the selective donor-recipient
patients who cannot perform conventional single graft
LDLT.
FO01-02
A SIMPLER, MORE POWERFUL
DONOR RISK SCORE
Carlo Pulitano1, David Joseph1, Charbel Sandroussi1,
Deborah Verran1, Michael Fink2 and
Michael Crawford1
1Royal Prince Alfred Hospital, Australia; 2Austin
Hospital, Australia
Introduction: An increasing number of patients are
referred for liver transplantation (LT), but the number
of available grafts remains stagnant. To compensate for
this shortage, marginal deceased donors are more fre-
quently considered as a potential sources of allograft.
However, the use of such donors may influence out-
comes after liver transplantation. In order to analyse
the donor risk, different prognostic scoring systems
have been proposed. However these scores lack practi-
cality and have limited clinical utility. The objective of
our study was to design a new simple donor risk index
score and compare it to two recently proposed prog-
nostic scores.
Method: Prospectively collected data from 1,168
patients, transplanted at two centers between January
2000 and December 2011 were included in the analysis.
Data were analyzed with Kaplan–Meier and Cox
regression models. The performance of our score was
compared with the Donor Risk Index (DRI) developed
within the Organ Procurement and Transplantation
Network and the eurotransplant DRI (E-DRI). The
discriminative abilities of the staging system were evalu-
ated using cox proportional hazard models and boot-
strap corrected concordance index (c). Bootstrap
techniques were used for internal validation.
Results: Overall graft survival of the cohort was 90%
at 1 year and 85% at 3 years. After multivariate analy-
sis the interaction among the variables donor age, cold
ischemia time, and steatosis remained significant
(p < 0.0001). These factors were used to create the Aus-
tralian Donor Risk Index (A-DRI). The A-DRI score
clearly stratified patients (p < 0.0001, c = 0.670) and
identified clearly three distinct prognostic groups. DRI
and E-DRI demonstrated poor-average discriminatory
ability, c = 0.550 and c = 0.570 respectively.
Conclusions: The present study presents a simple score
system that is practical, and easily applicable to every-
day clinical practice. The A-DRI is superior to DRI
and E-DRI for predicting the risk of graft failure after
liver transplantation.
FO01-03
BILIARY ANATOMY IN LIVING DONOR
LIVER TRANSPLANTATION
Chih-Chi Wang, Chao-Long Chen, Tsan-Shiun Lin,
Shih-Ho Wang, Chih-Che Lin, Yueh-Wei Liu,
Chee-Chien Yong, Ting-Lung Lin and Wei-Feng Li
Kaohsiung Chang Gung Memorial Hospital, Taiwan
Introduction: The incidence of biliary complication in
living donor liver transplantation (LDLT) has been
reported from 16% to 67%. Several factors have been
reported related with biliary stricture. The number of
graft bile duct opening and size of bile duct were the
key factors to ensure good outcome of biliary recon-
struction (BR). The aim of this study is to describe the
biliary anatomy in donor and BR in recipient.
Method: From March 2006 to June 2012, 584 of BR
wee performed at Kaohsiung Chang Gung Memorial
Hospital. Biliary anatomy was mapped by preoperative
MRCP and intraoperative cholangiography at 2/3
parenchymal transection of donor hepatectomy.
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Results: The number of graft bile duct opening and
types of BR are showed as Table 1.
Total no. of biliary reconstructions 584
Single duct opening in the donor graft 437 (74.89%)
No. of 1-to-1 reconstruction (%) 437 (65.18%)
1-to-1 duct-to-duct reconstruction 350 (52.61%)
1-to-1 duct-to-jejunum reconstruction 87 (12.57%)
Two duct openings in the donor graft 134 (23.33%)
No. of 2-in-1 reconstruction (%) 50 (8.12%)
2-in-1 duct-to-duct reconstruction 43 (6.77%)
2-in-1 duct-to-jejunum 7 (1.35%)
No. of 2-to-1 reconstruction (%) 6 (0.39%)
No. of 2-to-2 unmixed (%) 74 (11.03%)
2-to-2 duct-to-duct 66 (9.86%)
2-to-2 duct-to-jejunum 8 (1.16%)
No. of 2-to-2 mixed (%) 4 (0.58%)
Three duct openings in the donor graft 9 (1.78%)
No. of 3-in-1 duct-to-duct 2 (0.39%)
No. of 3-to-3 duct-to-duct unmixed (%) 2 (0.39%)
No. of 2-in-1 duct-to-duct and 1-to-1
duct-to-duct unmixed
5 (0.77%)
Total no. of duct-to-duct and duct-to-jejunum
anastomoses
667
Total no. of duct-to-duct anastomoses: 473 (81.0%).
Total no. of duct-to-jejunum anastomoses: 111
(19.0%).
Conclusions: Under microsurgical technique, biliary
complication does not increase in BR with more than
one bile duct.
FO01-04
LAST MINUTE DONOR EXCLUSION IN
LIVING DONOR LIVER
TRANSPLANTATION: IMPACT ON
EVALUATION PROGRAM
Hany Shoreem, Hossam Eldeen Soliman, Osama
Hegazy, Wael Abdelrazek, Nirmeen Fayed, Sherief
Saleh, Taha Yassen, Tarek Ibrahim and Ibrahim
Marwan
National Liver Institute, Egypt
Introduction: Minimizing the risk imposed to a healthy
donor is one of the complex aspects of LDLT and
implies a highly scrutinized evaluation process. Never-
theless, late events could lead to exclusion of some of
those evaluated donors.We investigated the late causes
of exclusion of a potential LDLT donor and how far
these reasons contributed to changing our donor evalu-
ation program
Method: Throughout 10 years more than 2,500 poten-
tial living donor had been evaluated for liver donation
for about 1,500 recipients who presented for LDLT in
National Liver Institute, Menoufyia University, from
them only 194 were transplanted. The evaluation
records of those donors were retrospectively analyzed
for causes of late exclusion
Results: Only 15% of the evaluated potential donors
were accepted for donation and only 7.8% were
donated. Exclusion reasons included family pressure to
withdraw consent in one donor, substance abuse in 2
donors and late psychological instability in 2 donors.
Early pregnancy was discovered in one female donor
2 weeks pre-transplantation. One donor was convicted
and imprisoned 2 weeks before LDLT. The pre-opera-
tively revised blood group of another donor was dis-
covered to be incompatible as the previously
determined blood group was wrong. The presence of
Factor V Leiden homozygous mutation was diagnosed
in 2 donors. In four cases, LDLT was aborted after
donor laparotomy due to macroscopic diffuse hepatic
changes considering the liver unsuitable for donation.
Most of these exclusions evoked discussions led to
modifications in the evaluation protocol and had an
impact on both donors and recipients.
Conclusions: Late pre-transplantation donor exclusion
had its impact in donors, recipients and resources.
Reassessment of the donor evaluation protocol should
be a dynamic process, and it found to be greatly
affected by these late exclusions.
FO01-05
UNUSUAL EVENTS IN DONOR
SURGERY: THE “NEAR MISSES”
Neerav Goyal, Manav Wadhavan, Shaleen Agarwal,
Ramdip Ray, Shishir Pareek, Giriraj Bohra,
Muhammad Nayeem, Ravichand Siddhachari and
Subash Gupta
Indraprastha Apollo Hospital, India
Introduction: Donor safety takes precedence in LDLT.
Still donor hepatectomy can have life threatening com-
plications and ‘near misses’. We are a high volume
LDLT centre. Over years, we have had ‘near misses’
and potentially life threatening events in donor hepa-
tectomy and learning from them our technique and
decision-making has evolved and progressed to make
donor hepatectomy safer. We share our experience with
the same.
Method: From September 2006 to July 2013, 1,103
donor hepatectomies were performed. We retrospec-
tively analyzed ‘near misses’ by dividing them into
complications involving: hepatic veins and IVC; portal
vein, hepatic artery; quality of graft; bowel injury;
DVT and pulmonary embolism; anesthetic and meta-
bolic. These donors were evaluated for errors in preop-
erative assessment, intra operative events, postoperative
complications, remedial measures, repetitiveness of sim-
ilar complications post event.
Results: Sixteen donors (1.5%) had ‘near miss’ events.
Two donors had slippage of RHV clamp leading to tor-
rential bleeding. One donor had cautery incision over
IVC with excessive bleeding during transection of cau-
date lobe. Three donors developed limited thrombus of
the RPV intraoperatively. Three donors developed inti-
mal dissection of the RHA. One donor developed small
bowel perforation peritonitis. Two donors developed
DVT of lower limbs post operatively and one developed
pulmonary embolism. One donor developed intra oper-
ative malignant hyperthermia from isoflurane. Another
donor, had ventilator issues after intraoperative cholan-
giogram. One donor had postoperative hemolysis and
high serum bilirubin of 9 mg/dl%. One donor devel-
oped an anaphylactic reaction to intraoperative admin-
istration of I.V Diclofenac sodium. Six donors of
nineteen had a prolonged hospital stay but all were sub-
sequently discharged and did well. Modifications were
made in technique and monitoring after each of these
instances, which have made donor surgery safer.
Conclusions: Safety in donor surgery is of prime impor-
tance. Technical modifications have led to making it
safer and reducing morbidity and mortality.
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FO01-06
USEFULNESS OF PROTHROMBOTIC
SCREENING OF POTENTIAL DONORS
IN LIVING RELATED LIVER
TRANSPLANTATION
Kumar Palaniappan, Gomathy Narashiman,
Srinivas Reddy, Vivekanandan Shanmugam,
Ilankumaran Kaliamoorthy, Olithselvan J,
Joy Varghese, Dinesh Jothimani,
Thomas Cherian and Mohamed Rela
Global Hospitals & Health City, Chennai, India
Introduction: Bleeding and thrombosis are major compli-
cations following LDLT. Donor selection and evaluation
has become specialised, because donor health and safety
are most important factor in LDLT. To improve outcomes,
we systematically screen our donors for prothrombotic &
hemostatic factors. The aim of this paper was to describe
the results of a screening for coagulation disorders, includ-
ing for thrombophilic factors, in potential living liver graft
donors and to evaluate thrombotic and bleeding events in
donors and recipients, during and after the procedure.
Method: From Jan 2010 till July 2013, 164 LDLT were
performed at our center. Total of 300 potential donors
were screened & 164 were found suitable for donation.
Screening was done for prothrombotic factors in 164
potential donors. All donors were screened for Protein
C, S, Factor V Leiden, Antithrombin III activity. 26
donors (15.8%) were detected to have at least one
abnormality. All donor data were maintained in a pro-
spective database & was analysed retrospectively.
Results: All donors were administered anticoagulation
before surgery & intra op prophylaxis included
mechanical compression therapy, and early aggressive
mobilisation in perioperative period. Protein S defi-
ciency was commonest in 11donors (42.3%), followed
by Anti-thrombin III in 8(30.7%), Protein C 5 donors
(19.2%), Factor V leiden 2 donors (7.6%). One donor
(0.06%) developed deep vein thrombosis in postopera-
tive period (Negative for thrombotic screening). Among
recepients, HAT was found 2 pts, one donor had Pro-
thrombotic abnormality, PVT in 1 patient & no HVT
Conclusions: Systematic screening for prothrombotic
factors is recommended in all potential donors to pre-
vent more morbidity in a procedure which already has
more chances of bleeding and thrombosis. A systematic
protocol for donor management in the pre operative,
peri operative period is recommended for reduced mor-
bidity & early recovery.
FO01-07
RELEVANCE OF MALE-TO-FEMALE
MISMATCH IN LIVER
TRANSPLANTATION FOR PRIMARY
BILIARY CIRRHOSIS
Michał Grazt1, Zbigniew Lewandowski1, Karolina
Maria Wronka1, Karolina Grazt1, Joanna Ligocka1,
Hanna Zborowska1, Waldemar Patkowski1 and
Marek Krawczyk1
1Medical University of Warsaw, Poland
Introduction: As male-to-female transplantations are
related to exposure to H-Y minor histocompatibility
antigen present on biliary epithelial cells, sex matching
may influence long-term outcomes after liver transplan-
tation for cholestatic diseases. The purpose of this
study was to evaluate the relevance of male-to-female
mismatch in liver transplantation for primary biliary
cirrhosis (PBC).
Method: Out of 1,277 liver transplantations performed
in the Department of General, Transplant and Liver
Surgery until June 2013, 97 (7.6%) primary transplan-
tations in patients with PBC were identified. Study
cohort comprised 82 female recipients with PBC as the
only cause of liver disease and without hepatic malig-
nancies. Female recipients of grafts procured from
female and male donors were compared with respect to
graft survival at 10 years (primary outcome measure).
The relevance of several known risk factors for poor
outcomes was evaluated separately for female-to-female
and male-to-female transplantations.
Results: In general, graft survival was 80.8% at 5 years
and 75.2% at 10 years. No differences with respect to
graft survival were observed between female recipients
of grafts procured from female or male donors (74.7%
vs. 73.1% at 10 years, p = 0.676). However, duration
of cold ischemia exceeding median (8 hours) and blood
transfusions over median (4 units) were associated with
significantly inferior outcomes after male-to-female
(p = 0.0386 and p = 0.0390, respectively) but not after
female-to-female (p = 0.843 for cold ischemia and
p = 0.110 for blood transfusions) transplantations.
Moreover, 10-year graft survival was lower after male-
to-female as compared to female-to-female transplanta-
tions in subgroups of patients with blood transfusions
exceeding 4 units (61.4% vs. 100.0%, p = 0.063) and
duration of cold ischemia over 8 hours (54.7% vs.
75.8%, p = 0.418).
Conclusions: There are no major differences in long-
term outcomes after male-to-female and female-to-
female liver transplantations for PBC. However, the
negative impact of cold ischemia and blood transfu-
sions is more pronounced in case of male-to-female
mismatch.
FO01-08
TECHNICAL ADVANCE IN HYBRID
DONOR HEPATECTOMY IN LIVING
DONOR LIVER TRANSPLANTATION
Akihiko Soyama, Mitsuhisa Takatsuki,
Masaaki Hidaka, Tomohiko Adachi, Amane Kitasato,
Tamotsu Kuroki and Susumu Eguchi
Nagasaki University Graduate School of Biomedical
Sciences, Japan
Introduction: We have reported hybrid donor hepatec-
tomy with partly using laparoscopic procedure in living
donor liver transplantation (LDLT), which is so-called
hybrid procedure. For standardization with maintain-
ing safety and quality of the procedure, we have
applied several devices that have been already proved
effective in conventional open procedure.
Method: Between 1997 and Aug 2013, 184 LDLTs
were performed at Nagasaki University Hospital.
Among them, recent 49 donors underwent hybrid
donor hepatectomy. Twenty-seven donors underwent
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left hemihepatectomy; 21 donors underwent right hemi-
hepatectomy, and 1 patient underwent posterior sec-
tionectomy. Eight centimeter subxiphoid midline
incision was created for hand assistance. Under pneu-
moperitoneum, mobilization of the liver was achieved.
Thereafter, the incision was extended up to 12 cm for
the right lobe and posterior sector graft and 10 cm left
lobe graft procurement. Management of vessels were
performed under direct vision. Parenchymal transection
was performed with liver hanging maneuver. For visu-
alizing planned cutting point of the bile duct was done
by encircling the bile duct using a radiopaque marker
filament under real-time C-arm cholangiography. Hepa-
tic vein was transected by a vascular stapler for pre-
venting any risk of accidental declamping of the
remnant end of hepatic vein.
Results: All the procedures have been completed with-
out any extra subcostal incision. All the grafts were
safely extracted through the upper midline incision.
The median operation duration was 433 minutes. The
median amount of blood loss was 600 g, and no donors
required allogenic transfusion. All the donors have
returned to the preoperative activity level. Morbidity
was recognized in 4 cases (Clavien-Dindo classification
I, n = 3, III, n = 1). Wound-related complaints were
less seen during follow-up in out-patient clinic com-
pared to conventional open procedure.
Conclusions: Our method of minimal invasive living
donor hepatectomy was safely conducted without
increasing morbidity, operation duration, and blood
loss.
FO02-01
IMPACT OF SURGICAL MARGINS ON
OVERALL AND DISEASE-FREE
SURVIVAL IN PARENCHYMA-SAVING
LAPAROSCOPIC LIVER RESECTIONS
WITH THE SURGICAL ASPIRATOR
FOR COLORECTAL METASTASES
Roberto Montalti1, Simone Sebastiani1, Stephanie
Laurent2, Liesbeth Ferdinande3, Louis J. Libbrecht3,
Peter Smeets4, Xavier Rogiers1, Bernard De
Hemptinne1, Karen Geboes2 and Roberto I. Troisi1
1Hepato-Biliary Surgery, Liver Transplantation Service,
Belgium; 2Oncology, Belgium; 3Pathology, Belgium;
4Radiology, Belgium
Introduction: The relationships between surgical mar-
gins and local/distant recurrence of colorectal liver
metastases (CRLM) remain controversial. The impact
of surgical margins in laparoscopic liver resections
(LLR) for CRLM with the surgical aspirator on overall
(OS) and disease-free (DFS) survival has never been
evaluated. We focus our experience on this issue.
Method: From 2005 to 2012, 116 first LLR for CRLM
were analyzed retrospectively. M/F ratio was of 69/
31% and the mean age of 67y. Chemotherapy was
given in 93% of patients. R1 margins were defined as a
cutting edge <1 mm.
Results: Major resection rate was 16%; the mean surgi-
cal time was of 112  282 min and the mean blood
loss of 480  675 cc; the Pringle manoeuver was
needed in 9.4% and the conversion rate was of 15.5%,
mainly for oncological reasons. The mean hospital stay
was of 6.1  3 days. The mean nodules number was of
1.7  1.2 (range 1–7), and the total size was of
40.9  31 mm (range 3.5–145). The mean margin dis-
tance was of 6.3  7.6 mm (range 0–40), R1 was
recorded in 14 (12.1%) cases. In case of hepatic recur-
rence (27 pts) repeated hepatectomy was done in 63%
of cases. Local recurrence was similar in R0 and R1
(39% vs. 46.1%, p = 0.43). After a mean follow up of
30  18.5 months, overall survival was 98–75.1–59%
at 1–3–5 years respectively. R1 margins were not signif-
icantly related to the DFS survival but to a lower OS
(p = 0.05). Multivariate analysis showed major hepatec-
tomy and total lesions diameter as independent vari-
ables for DFS (p = 0.04 and <0.001 respectively).
Conclusions: Parenchyma-saving surgery with the surgi-
cal aspirator do not worse the oncological outcome
allowing a higher percentage of redo-hepatectomy. In
this context, the oncological results of patients with R1
margins receiving a parenchyma-saving surgery with
perioperative chemotherapy are not compromised.
FO02-02
COLORECTAL LIVER METASTASES:
HEPATIC PEDICLE CLAMPING
DURING HEPATECTOMY REDUCES
THE INCIDENCE OF TUMOR
RECURRENCE IN SELECTED
PATIENTS. CASE-MATCHED ANALYSIS
Alessandro Giacomoni, Stefano Di Sandro,
Giacomo Concone, Plamen Mihaylov, Andrea
Lauterio, Iacopo Mangoni and Luciano De Carlis
Niguarda Ca’ Granda Hospital, Italy
Introduction: Hepatic pedicle clamping (HPC) during
Liver Resection (LR) is a vascular procedure designed
to prevent bleeding from the liver during hepatectomy.
Outgrowth of pre-existing colorectal micrometastases
may occur 5–6 times faster in occluded liver lobes than
in non-occluded lobes. We conducted a case-matched
analysis at our Institution to assess the effects of HPC
on overall and recurrence-free survival in highly
selected patients, who underwent LR due to Colorectal
liver metastases (CLM)
Method: From January 2002 to December 2010, 120
patients operated for CLM were included into this case
matched study. Patients were allocated to two groups:
Group-A patients who underwent HPC during LR;
Group-B patients who underwent LR without HPC
Results: HPC during liver resection was associated with
better overall patient 5-year survival (47.2% in Group-
A and 32.1% in Group-B) (p = .06), and significantly
better 5-year recurrence free survival (49.9% in Group-
A vs. 18.3% in Group-B) (p = .010) The Cox regres-
sion model identified the following risk factors for
worse prognosis in terms of shorter recurrence-free sur-
vival and higher incidence of tumor recurrence: no
HPC (Group-B) (p = .032) and positive lymph nodes at
the time of LR (p = .018)
Conclusions: Lack of HPC in selected patients who
underwent LR for CLM results to be a strong indepen-
dent risk factor for higher patient exposure to tumor
recurrence. We suggest that hepatic hilum clamping
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should be seriously taken into consideration in this
patient setting.
FO02-03
TAILORING THE SURGICAL
STRATEGY OF LOW AND MIDDLE
RECTAL CANCER WITH
SYNCHRONOUS LIVER METASTASES
REMAINS DIFFICULT. AN INTENTION
TO TREAT ANALYSIS.
Jean-Marc Regimbeau, Charles Sabbagh, Tiana
Ravololoniaina, Bruno Chauffert, Jean-Paul Joly and
Francois Mauvais
Amiens University Hospital, France
Introduction: In rectal cancer, the incidence of synchro-
nous liver metastases (SLM) ranges between 14% and
30%. The treatment of SLM combines neo-adjuvant
treatment with surgical resection (rectum resection first,
simultaneous resection or liver resection first). The aim
of this study was to evaluate the success of each of
these three oncological strategies in achieving complete
(R0) resection and assesses predictive factors for com-
plete resection.
Method: From January 2005 to December 2010, we
included retrospectively all patients with low and mid-
dle rectal cancer (MLRC) and SLM operated on with
curative intent. The endpoints were the proportion of
R0 at both sites, the postoperative morbidity rate, the
long-term outcome and risk factors for incomplete
resection.
Results: Of the 49 included patients, 49% had under-
gone a rectum-first treatment strategy, 30.6% under-
went a simultaneous resection strategy and 20.4%
underwent a liver-first strategy. There were no differ-
ences in the incidence of R0 at both sites (p = 0.6).
There was no difference in the overall complication rate
after rectal resection (p = 0.1) or liver resection
(p = 0.8). There were no differences in overall (p = 0.4)
and disease-free survival (p = 0.1). Emergency surgery
was the only risk factor for treatment failure.
Conclusions: None of the oncological strategies were
associated with a low complete resection rate or a poor
long-term outcome.
FO02-04
SYNCHRONOUS SURGERY FOR
COLORECTAL CANCER AND LIVER
METASTASES: LAPAROSCOPIC
COLORECTAL RESECTION IMPROVES
SHORT TERM OUTCOME.
A COMPARATIVE STUDY
Francesca Ratti, Luca Aldrighetti, Marco Catena,
Saverio Di Palo, Carlo Staudacher and
Gianfranco Ferla
Saaffaele Hospital, Italy
Introduction: 30% of patients with colorectal cancer
presents with liver metastases at diagnosis. Long-term
survival is influenced by obtaining a complete removal
of the primary tumor and liver metastases. Aim of this
study was to assess short-term outcome of combined
resection of left colon or rectum cancer and liver
metastases, comparing the results of the primary tumor
resection performed laparoscopically or by laparotomy.
Method: From January 2004 to July 2013, 106 patients
underwent combined resection of colorectal cancer and
synchronous liver metastases. 69 patients underwent
laparoscopic colorectal resection (LPS Group), and
were compared with 37 patients undergoing colorectal
resection by laparotomy (LPT Group). Right colonic
resections were excluded from the analysis. A further
analysis was performed, including only the colonic
resection.
Results: The groups resulted comparable in terms of
patients and disease characteristics, extent of liver
resection, lymphadenectomy and length of surgery.
Patients in the LPS Group had a significantly lower
blood loss (400 mL vs. 650 mL, p < 0.001) and rate of
intraoperative transfusions (19.3% vs. 47.2%, p = 0.04)
compared to the LPT Group. LPS Group was associ-
ated with a lower postoperative morbidity (24.6% vs.
44.4%, p = 0.039), and a shorter postoperative median
hospital stay (9 vs. 13 days, p < 0.001). Blood loss,
morbidity and length of postoperative stay were not
correlated to liver resection extent. The analysis of the
subgroup of patients undergoing colon resection con-
firmed a significant reduction in postoperative morbid-
ity and length of hospital stay.
Conclusions: Laparoscopic resection of colorectal can-
cer in patients undergoing simultaneous resection of
liver metastases by laparotomy is associated with a
reduction of blood loss, morbidity and postoperative
hospital stay, without affecting the oncologic radicality.
In simultaneous resections of colorectal cancer and
liver metastases, postoperative morbidity and hospital
stay are mainly conditioned by the type of approach to
intestinal surgery (laparoscopic or open), rather than
the extent of liver resection.
FO02-05
SURGICAL MANAGEMENT OF
SYNCHRONOUS COLORECTAL LIVER
METASTASES: SIMULTANEOUS
VERSUS STAGED RESECTIONS
Anton Burlaka, Andriy Lukashenko, Olena Kolesnik,
Viktor Priymak and Ighor Shchepotin
National Cancer Institute, Ukraine
Introduction: Surgical treatment of metastatic colorectal
cancer remains the only method that improves overall 5-
year survival. But the optimal surgical strategy for resect-
able, synchronous, colorectal liver metastases remains
unclear. This study aimed to compare the surgical out-
come and survival benefit between synchronous and
staged resection of liver metastases from colorectal cancer.
Method: Clinicopathologic data, treatments, and post-
operative outcomes from 110 patients who underwent
simultaneous (48 patients, group A) or staged (62
patients, group B) colorectal and hepatic resections at
clinic of National cancer institute in period of 2008–
2013 were reviewed.
Results: Postoperative complications in patients with
simultaneous resections (group A) were observed in 13
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cases (27.1%), including 5, 1, 4, 2, 0 and 1 of grades I,
II, IIIa, IIIb, IV and V respectively. Similar results
have been reported in group B after staged resections,
where overall postoperative complications registered in
16 patients (25.8%), including 4, 3, 6, 3, 0 of grades I,
II, IIIa, IIIb, IV respectively. Overall level of post-oper-
ative complications in the groups A and B after surgi-
cal stages finishing did not differ statistically (p = 0.96).
Overall 3-year survival in the group of patients with
simultaneous resections (group A) was 42 % and in the
group B 55 % (p = 0.22).
Conclusions: Analysis of our research indicated neces-
sity of the development of differentiated approach in
management of synchronous colorectal liver metastatic
cancer. Simultaneous resections of colorectal cancer
primary lesions and hepatic metastases were safe and
could serve as a primary option for selected patients.
Subsequent research should be directed towards study
of prognosis factors and criteria for patients selection
for surgical treatment groups, assessment of economic
effect, and patients life quality.
FO02-06
COMPARABLE MORBIDITY,
MORTALITY AND PATIENT LONG-
TERM SURVIVAL CAN BE ACHIEVED
IN PATIENTS WITH COLORECTAL
LIVER METASTASES UNDERGOING 2
STAGE OR DOWNSTAGING LIVER
RESECTIONS
Eugenia Ip1, Paul Bergamin1, Jasmine Wong1,
David Goldstein1, Eva Segelov2, Morteza Aghmesheh3
and Koroush Haghighi1
1The Prince of Wales Hospital, Australia; 2St Vincent’s
Hospital, Australia; 3The Wollongong Hospital, Australia
Introduction: Increasing numbers of liver resections
(LR) are being performed for extensive colorectal liver
metastases (CLM), including those requiring planned
two-stage LR or downstaging chemotherapy. We
audited morbidity, mortality and long term survival of
patients undergoing LR in these groups.
Method: Patients were compared in 3 groups, CLM
that did not require downstaging (G1), redo resections
for CLM (G2) and downstaging or two-stage LR (G3).
Prospectively collected database was analysed for
patient demographics, postoperative complications
(Dindo-Clavien classification) and long long-term sur-
vival (Kaplan-Meier curves). All LR were performed
by KSH. All patients had PET scans prior to surgery.
Results: 144 patients underwent LR for CLM, with
60% (n = 86), 15% (n = 22) and 25% (n = 36) in G1,
G2 and G3 respectively. Median age of 62 in G1, 63 in
G2 and 64 in G3 was recorded. Males accounted for
65.1% (n = 56), 54.5% (n = 12) and 58.3% (n = 21) of
patients in G1, G2 and G3. Extended LR accounted
for 68.6% (n = 59) and 55.6% (n = 20) of G1 and G3,
whilst only for 31.8% (n = 7) in G2. 7.0%, 9.1% and
22.2% required transfusions in G1, G2 and G3. Length
of HDU/ICU and hospital stay was comparable with a
median stay of 1 and 7–8 days. 4.5%, 0.9% and 5.6%
patients experienced major complications in G1, G2
and G3 respectively. 90 day mortality was 1%, 0% and
5% respectively for G1, 2 and 3. Overall long term sur-
vival of all patients with CLM was 93%, 70% and
46% at 1, 3 and 5 years respectively. 5 year survival
was 56%, 20% and 33% for G1, G2 and G3 respec-
tively.
Conclusions: Long term survival can be achieved in
recurrent as well as downstaged and two-stage liver
resections for CLM, with acceptable morbidity
and 90 day mortality.
FO02-07
SAFETY AND EFFICACY OF ALPPS
PROCEDURE FOR RAPID LIVER
HYPERTROPHY: A COMPARISON
STUDY WITH PORTAL VEIN
EMBOLIZATION
Tung Yu Tsui1, Oliver St€oltzing2, Emre F. Yekebas3,
Andreas Koops4, Gerhard Adam4 and
Jakob R. Izbicki1
1University Medical Center Hamburg-Eppendorf,
Germany; 2Helios Hospital Berlin-Buch, Germany;
3Darmstadt Clinic, Germany; 4University Medical
Center Hamburg-Eppendorf, Germany
Introduction: The in situ split of the liver and portal
vein ligation/transection (ALPPS) represents an innova-
tive surgical technique to induce rapid liver hypertro-
phy. The future liver remnant increased significantly
after the procedure. In the study we compared the peri-
operative data of the new technique with the conven-
tional portal vein embolization.
Method: we collected the data of the consecutive 36
patients underwent right trisegmentectomy from 2009
to 2012. Twenty of 36 patients received right portal
vein and Seg IV portal vein embolization to induce the
hypertrophy of future Seg 2 and 3 liver remnants
(PVE). Sixteen of 31 patients received the in situ split
and right portal vein transection after implementation
of the new technique (ISS). The efficacy and outcome
of two procedures were analyzed.
Results: There is no significant difference in terms of
patient characteristics. In situ split induced comparable
hypertrophy of future liver remnant (median: 526 mL
in ISS group vs. 428 mL in PVE group) in significantly
shorter interval (median 9 days vs. 30 days). The per-
centage of the volume of the future liver remnant was
35% of estimated standard liver volume (ESLV) that
was higher than those in PVE group (26.8%). The
delta% of ESLV was 16 in ISS group, which is signifi-
cantly higher than those in PVE group (median 8.2%).
Perioperative data showed that there was lower inci-
dence of small-for-size syndrome in ISS group as com-
pared with PVE group. In addition, there was no
difference in terms of the rate of postoperative compli-
cations, hospital mortality and the one-year survival of
patients after the surgery.
Conclusions: The ALPPS is a safe and feasible procedure
to induce rapid hypertrophy of future liver remnant. The
selection of patients might be of crucial to achieve the
optimal outcome. Further studies should address on the
oncological outcomes of ALPPS procedure.
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FO02-08
ASSOCIATING LIVER PARTITION AND
PORTAL VEIN LIGATION FOR STAGED
HEPATECTOMY (ALPPS): THE
BRAZILIAN EXPERIENCE
Orlando Torres1, Cassio Oliveira2, Cristiano Lima3,
Eduardo Fernandes4, Fabio Waechter5, Jose Maria
Moraes Junior1, Marcel Machado6, Marcelo Linhares7,
Paulo Herman8 and Rinaldo Pinto9
1Federal University of Maranhao, Brazil; 2Federal
University of Paraıba, Brazil; 3Federal University of
Minas Gerais, Brazil; 4Hospital Silvestre Rio de Janeiro,
Brazil; 5Santa Casa from Porto Alegre, Brazil;
6Hospital Sırio Libane^s S~ao Paolo, Brazil; 7Federal
University of S~ao Paulo, Brazil; 8University of S~ao
Paulo Medical School USP, Brazil; 9Hospital Santa
Catarina Blumenau, Brazil
Introduction: Postoperative liver failure consequent to
insufficiency of remnant liver is a feared complication
in patients who underwent extensive liver resections. To
induce rapid and significant hepatic hypertrophy, asso-
ciating liver partition and portal vein ligation for
staged hepatectomy (ALPPS) has been recently devel-
oped for patients which tumor is previously considered
unresectable. The aim of this study is to present the
Brazilian experience with associating liver partition and
portal vein ligation for staged hepatectomy (ALPPS)
approach.
Method: Were analyzed 39 patients who underwent
hepatic resection using ALPPS approach in nine hospi-
tals. The procedure is performed in two steps. The first
operation is portal vein ligation (PVL) and in situ split-
ting (ISS). In the second operation the right hepatic
artery, right bile duct and the right hepatic vein are
then isolated and ligated. The extended right lobe is
removed. There were 22 male (56.4%) and 17 female
(43.6%). At the time of the first operation, the median
age was 57.3 years (range: 20–83 years).
Results: The most common indication was liver metas-
tasis in 32 patients (82.0%), followed by cholangiocar-
cinoma in three patients (7.7%). Two patients died
(5.2%) during this period and did not undergo the sec-
ond operation. The mean interval between the first and
the second operation was 14.1 days (range: 5–30 days).
The volume of the left lateral segment of the liver had
increased 83% (range 47–211.9%). Significant morbid-
ity after ALPPS was seen in 23 patients (59.0%). The
mortality rate was 12.8% (five patients).
Conclusions: The ALPPS approach can enable resec-
tion in patients with lesions previously considered unre-
sectable. It induces rapid liver hypertrophy avoiding
liver failure in most patients. However still has high
morbidity and mortality.
FO03-01
DOES ABERRANT ANATOMY OF THE
HEPATIC ARTERY AFFECT RESECTION
MARGIN IN
PANCREATICODUODENECTOMY?
Patrick Casey, Rosanna Desouza, Snehal Lapsia,
Kariem Elhadd, Zaria Ali, David Chang,
Ambareen Kausar, Anton Krige, Joanne Thomas and
Daren Subar
East Lancashire Hospital Trusts, United Kingdom
Introduction: Several studies have demonstrated that
resection margin, tumour differentiation and adjuvant
treatment affects survival after resection for pancreatic
adenocarcinoma. This study aims to assess the associa-
tion between the presence of abnormal arterial anat-
omy (in particular a replaced or aberrant right hepatic
artery) and resection margin status.
Method: This is a retrospective study of all patients
with pancreatic adenocarcinoma who underwent Pan-
creaticoduodenectomy procedure between 2007 and
2012. Patient demographics and pathology were analy-
sed. Aberrant arterial anatomy as per Michels classifi-
cation with identified and reported by a single
Consultant Radiologist. Statistical analysis was con-
ducted using SpSS (IBM) statistical program.
Results: Between January 2007 and December 2012
there were 148 pancreaticoduodenectomies of which 75
were for adenocarcinoma of the head of the pancreas.
The male to female ratio was 45:30. The mean age was
65 years (range 39–84 years). Fifty-nine patients had a
positive resection margin with 16 having negative mar-
gins. The medial (SMV) margin was the most com-
monly involved. Fifteen patients (21%) had aberrant
arterial anatomy of the hepatic artery course. The pres-
ence of aberrant arterial anatomy did not have a statis-
tically significant impact on the R Status (p = 0.67),
involvement of the medial (p = 0.34), or Transection
margin (p = 0.22). In concordance with other studies,
R status correlated with overall survival (p = 0.02) sug-
gesting that the presence of arterial variation does not
affect survival in adenocarcinoma of the pancreas.
Conclusions: There appears to be no increased risk of a
positive resection margin in pancreaticoduodenectomy
in the presence of variant arterial anatomy of the right
hepatic artery. Identification of vascular anomalies by
pre-operative imaging will reduce the risk of intraoper-
ative injury.
FO03-02
THE “TOTAL ARTERIAL
DEVASCULARIZATION FIRST”
TECHNIQUE FOR RESECTION OF
PANCREATIC HEAD CANCER DURING
PANCREATICODUODENECTOMY
Renyi qin, Min Wang and Feng Zhu
Affiliated Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology, China
Introduction: Integrated resection of the pancreatic head
is the most difficult step in radical pancreaticoduodenec-
tomy (RPD) in patients with the portal vein (PV) and
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superior mesenteric vein (SMV) invasion or oppression
by the tumor. Here we introduce a new idea and skill
named the “total arterial devascularization first” tech-
nique and its applications on RPD.
Method: The principle is that four arterial blood sup-
plies of pancreatic head were obstructed before veins
dissection. The key steps were first exposure of the
anterior surface of the abdominal aorta by completely
transecting neural and connective tissue between SMA
and pancreatic head, and transecting the mesounsinate
from the origin of SMA to the root of the celiac trunk.
From January 2012 through May 2013, a total of 58
patients with PV/SMV invasion or oppression under-
went RPD underwent pancreaticoduodenectomy using
this technique.
Results: The median operative time was 5.1 hours
(range, 4.5–8.1 hours). The median intraoperative
blood loss was 450 mL (range, 200–900 mL). No intra-
operative and postoperative bleeding of pancreatic head
region. Among the 58 patients, 21 underwent vessel lat-
eral wall angiectomy or angiorrhaphy. And 10 under-
went angiectomy and end-to-end anastomosis. The
incidence rates of postoperative bleeding, postoperative
pancreatic fistula and biliary fistula were 5.2%, 6.8%,
and 1.7%, respectively. No patients died after 3 months
of operation.
Conclusions: The “total arteries devascularization first”
technique is a new method for intricate pancreaticoduo-
denectomy. It could improve the security of surgery
and reduce intraoperative bleeding, which is expected
to become standardized surgical approach of pancreati-
coduodenectomy.
FO03-03
ISOLATED ROUX LOOP
PANCREATICOJEJUNOSTOMY
VERSUS
PANCREATICOGASTROSTOMY AFTER
PANCREATICODUODENECTOMY (A
PROSPECTIVE RANDOMIZED STUDY)
Waleed Asker, Ayman El Nakeeb and
Talaat Abd Allah
Mansoura university, Egypt
Introduction: Morbidity and mortality after pancreati-
coduodenectomy (PD) are related to surgical manage-
ment of the pancreatic stump. The best type of
pancreatic reconstruction, and anastomotic technique
are still debated
We compared the outcomes of isolated Roux loop pan-
creaticojejunostomy (GI) with that of pancreaticoga-
strostomy (GII) after PD.
Method: Consecutive patients with periampullary
tumour treated by PD at our center were evaluated for
inclusion.
Main outcome measures: The primary outcome measure
was the rate of POPF; secondary outcomes included
operative time, day to resume oral feeding, postopera-
tive morbidity and mortality, exocrine and endocrine
pancreatic functions.
Results: Ninety patients with periampullary tumour
treated by PD were randomized. The median total
operative time was significantly longer in GI (320 vs.
300 minutes, p = 0.05). POPF developed in 9 (20%)
patients in GI and 10 (22.2%) patients in GII, p = 0.8
(7 vs. 4 patients had a POPF type B and C, p = 0.8).
The time to resume oral feeding was earlier in GI (5 vs.
6 days, p = 0.03). Steatorrhae after one year was 22%
in GI, and 42.2% in GII, respectively (p = 0.04). The
albumin level after one year was 3.6 gm% in G1, and
3.3 gm in GII (p = 0.001).There was no statistically sig-
nificant difference regarding body weight, BMI and
development of DM in both groups.
Conclusions: Isolated Roux loop PJ did not associated
with a lower rate of POPF but decrease the severity of
leak and decrease the incidence of postoperative steatorr-
hae. Isolated Roux loop PJ allowed early oral feeding.
FO03-04
RESULTS OF LONG TERM AFTER
PANCREATICOGASTROSTOMY
ANASTOMOSIS ON
PANCREATICODUODENECTOMY
Yuko Mataki, Hiroyuki Shinchi, Kosei Maemura,
Hiroshi Kurahara, Yota Kawasaki, Satoshi Iino,
Masahiko Sakoda, Shinchi Ueno, Sonshin Takao and
Shoji Natsugoe
Kagoshima University, Japan
Introduction: Pancreatic anastomotic leakage remains a
persistent problem after pancreaticoduodenectomy
(PD). We have reported pancreaticogastrostomy (PG)
for the method of reconstruction. Especially, our
method, what is called the transfixing suture method,
has leaded to good results in the postoperative short
period. (JHPBS 2012, J Surg Res 2011). In this paper,
we examined the results in the longitudinal period of
PG reconstruction after PD.
Method: This study retrospectively analyzed 50 patients
who survived over three years among 88 cases receiving
PD between 2005 and 2010. We inserted the pancreatic
tube in the anastomosis of PG in all patients. The dila-
tion of main pancreatic duct was defined as over 5 mm.
Results:
1. Change of weight of whole body: The body
weight reduced to 89% compared with the preop-
eration. The weight recovered gradually 6M, 1y,
every other year after that, and it had increased
to 95% after four years.
2. The period of release of pancreatic tube: The
median time of release of pancreatic tube from
the anastomosis after PD and the cumulative def-
ecation rate at 1 year were 2.8 months and 87%,
respectively.
3. In seven cases, pancreatic duct tube did not
release from the anastomotic lesion for more
than a year, but there were no characteristic fac-
tors such as hardness of pancreatic parenchyma,
type of disease, type of operation, and pancreatic
duct diameter.
4. 11 patients whose main pancreatic duct extended
after surgery were observed. Among them, the
preoperative extension was observed in six cases,
non-extension was in five cases. Features of the
five cases were early postoperative complications
and soft pancreas.
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5. Diabetes mellitus: Diabetes mellitus newly devel-
oped in 6 cases and glucose tolerance impaired in
2 cases. But we could not detect the predictive
factor retrospectively.
Conclusions: PG anastomosis method in PD has a
good result in the perioperative period and it may be
acceptable in the longitudinal period.
FO03-05
LAPAROSCOPIC
PANCREATICODUODENECTOMY
ASSISTED WITH MINI-LAPAROTOMY
Jun Suh Lee and Tae Ho Hong
Catholic University of Korea, Seoul St. Mary’s Hospital,
Korea
Introduction: Pancreaticoduodenectomy (PD) is the
treatment modality of choice for periampullary disease
requiring resection. Even with the increasing number of
successful reports from around the globe, laparoscopic
pancreticoduodenectomy (LPD) is still not fully
accepted. We report the results of our experience of
LPD assisted with mini-laparotomy.
Method: A retrospective review study was performed
on 42 patients who received LPD assisted with mini-
laparotomy, between March 2009 and March 2012.
Clinical outcomes such as patient age, pathologic diag-
nosis, pancreas nature, operation time, conversion rate,
hospital stay, postoperative complication, and mortality
rate were reviewed.
Results: A total of 42 patients, aged between 42 and
70, received LPD assisted with mini-laparotomy. The
mean incision length of laparotomy was 5.5 cm. Mean
operative time was 420 minutes, and 3 cases required
conversion to open surgery. Mean postoperative hospi-
tal stay was 15 days, and the thirty-day mortality rate
was zero. There were 2 cases of pancreaticogastrostomy
leakage, 2 cases of postoperative bleeding, 3 cases of
delayed gastric emptying, 1 case of bile leakage, and 3
cases of pulmonary complications. Of the 3 patients
with pulmonary complications, one patient died.
Conclusions: When performed by a surgeon with ample
experience in laparoscopic surgery, LPD assisted with
mini-laparotomy for selected cases is a safe, feasible
alternative for conventional PD. With the method we
have described, pancreaticoenteric anastomosis can be
performed in the same manner as open PD, while taking
advantage of the merits of minimally invasive surgery.
FO03-06
DRAINAGE PROCEDURES FOR SMALL
DUCT DISEASE IN CHRONIC
PANCREATITIS: A FEASIBLE OPTION
Venkatarami Reddy
Assistant Professor, India
Introduction: Surgery is the treatment of choice for
intractable pain in chronic pancreatitis (CP). But the
best results with surgery are seen in group of patients
where the main pancreatic duct is dilated. Our aim was
to assess prospectively the feasibility of drainage proce-
dures in patients with CP with small duct disease
Method: All consecutive patients with CP with small
duct disease (diameter less than 5 mm) were included.
All patients underwent surgical intervention (lateral
pancreaticojejunostomy with head coring). The primary
outcome measures were pain relief and morbidity.
These outcomes were compared with patients with CP
with large duct disease (diameter more than 7 mm)
Results: 114 patients with CP underwent surgery. Of
these 24 (21.05%) patients had CP with small duct dis-
ease and 90 (78.95%) patients had large duct disease.
Demographic profile of the two groups was comparable.
Mean pain scores were similar (47.75  6.85 vs.
51.38  7.40; p = 0.14). Patients with large duct disease
had higher incidence of diabetes mellitus (44.44% vs.
8.33%; p = 0.02), but exocrine insufficiency was similar.
All patients had calcifications in both the groups. Mean
intra ductal pressures measured intra operatively were
significantly high in patients with large duct disease
(22.99  5.65 vs. 18.33  3.52; p = 0.001). Frequency of
complications at presentation were similar in both the
groups (p = 0.29). Surgery relieved pain in 21/24
(87.5%) patients with small duct disease and 82/90
(91.11%) patients with large duct disease. Mean post
operative scores in small duct disease group (7.50  9.61
vs. 51.38  7.40; p < 0.001), and large duct disease
group (5.14  7.88 vs. 47.75  6.85; p < 0.001) were
significantly reduced, when compared to pre operative
scores. Incidence of post operative complications was
similar in both groups (16.66% vs. 14.44%)
Conclusions: Lateral pancreticojejunostomy with head
coring is feasible for CP patients with small duct dis-
ease with good pain relief.
FO03-07
THE COMPARISON OF SINGLE AND
TWO LAYER
PANCREATICOJEJUNOSTOMY IN THE
FREY’S OPERATION: THE RESULTS OF
PROSPECTIVE RANDOMIZED STUDY
Saulius Jurevicius, Audrius Sileikis and
Kezstutis Strupas
Vilnius University Faculty of Medicine, Lithuania
Introduction: The duodenum-preserving pancreatic
resection (Frey’s operation) is a standard operation for
patients with complicated chronic pancreatitis. The
pancreojejunostomy is usually performed using two
layer sutures. The aim of this study – to compare the
results of single versus two layer the pancreaticojejun-
ostomy for Frey’s operation and to assess the changes
of the quality of life 12 months after operation.
Method: The prospective randomised trial was per-
formed in the Centre of Abdominal Surgery in Vilnius
University Hospital „Santariskiu Klinikos” in 2010-
2012. A total of 80 patients, age between 24 and
59 year, were enrolled in the clinical trial. They were
randomly allocated into two groups: I group – 38
patients, for whom pancreojejunostomy was performed
using continuous single layer suture; II group – 42
patients, for whom pancreaticojejunostomy was per-
formed using interrupted two layer suture.
Results: There were no statistically significant differ-
ences comparing the age, sex and the stage of chronic
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pancreatitis, preoperative pain and the results of SF-36
questionnaire. Overall time of the operation
(208  46 minutes and 255  58 minutes) and the
suturing time (19  6 minutes and 51  18 minutes)
were significantly shorter in the single layer anastomo-
sis group. Postoperative complications, the prevalence
of pancreatic fistula, the length of stay did not differ in
both groups. There was a statistically significant
improvement of the quality of life 12 months after
operation.
Conclusions: The continuous single layer suture reduces
the suturing time of pancreaticojejunostomy and over-
all time of the Frey’s operation when comparing to
interrupted two layer suture. There was no statistically
significant difference in the prevalence of the pancreatic
fistula, postoperative complication rate, the length of
stay between both methods. Frey’s operation is an
effective surgical treatment of chronic pain caused by
chronic pancreatitis and improves the quality of life of
the patients.
FO03-08
SURGICAL UTILITY OF
INTRAOPERATIVE DOPPLER
ULTRASONOGRAPHIC GUIDED
VESSEL NAVIGATION IN
PANCREATICODUODENECTOMY
Kosei Maemura, Hiroyuki Shinchi, Yuko Mataki,
Hiroshi Kurahara, Youta Kawasaki, Satoshi Iino,
Masahiko Sakoda, Shinichi Ueno, Sonshin Takao and
Shoji Natsugoe
Kagoshima University, Japan
Introduction: The color Doppler flow imaging has
become one of the diagnostic methods for the delinea-
tion of the anatomy, identification of the vascular
structures and the vascular invasion of the malignant
tumor. We assessed the utility of intraoperative Dopp-
ler ultrasonographic vessel navigation for identifying
critical arteries in order to improve safety during pan-
creaticoduodenectomy (PD).
Method: In all, 102 cases of pancreas head cancer
(ampullary or periampullary) were separated into 2
groups based on perioperative imaging modality: the
preoperative 3D-CT group (control group; n = 66), and
the preoperative 3D-CT and intraoperative Doppler
ultrasound vessel navigation group (Dop-Navi group;
n = 36). The latter technique was used to visualize the
bifurcation of the inferior pancreaticoduodenal artery
(IPDA) around the superior mesenteric artery (SMA)
and performed real time tracing of these vessels during
tumor resection. The operative status of the patients in
the Dop-Navi group was compared with control group.
Results: Real-time Dop-Navi during surgery distin-
guished the IPDA from the SMA by its shorter wave-
forms and 3-times greater maximum flow velocity. The
Dop-Navi patients had significantly reduced operation
times (536 minutes vs. 629 minutes) and bleeding vol-
umes (1,146 mL vs. 1,532 mL) than the control
patients, without a significant difference in occurrence
of postoperative complications. In the Dop-Navi
group, only 3% (1/35) of patients had residual tumor
(R1) tissue after surgery, compared to 25% (13/53) of
the control group.
Conclusions: Doppler ultrasonography detection of
artery surrounding pancreas head is effective approach
for collecting useful information for perfoming PD.
Vessel navigation surgery using intraoperative Dop-
Navi is a safe and effective technique to perform PD
and clearly identify vessels targeted for ligation while
avoiding vessel injury.
FO04-01
TARGETED INHIBITION OF THE AKT
PATHWAY IN
CHOLANGIOCARCINOMA BY MK2206
Jacob Wilson, Selvi Kunnimalaiyaan,
Muthusamy Kunnimalaiyaan and John Miura
Medical College of Wisconsin, USA
Introduction: Cholangiocarcinoma (CCA) is a rare but
aggressive disease with an overall five year survival rate
of only 5%. There is, therefore, an urgent need for
identification of novel therapeutic strategies. The PI3K/
Akt pathway represents an attractive therapeutic target
due to its frequent dysregulation in CCA. MK2206, an
allosteric Akt inhibitor, has reduced cellular prolifera-
tion in other cancer types. However, its effect on CCA
cells and its mechanism of action are not fully under-
stood. We hypothesized that MK2206 inhibition of Akt
in human CCA cells would impact cell viability and
sought to establish a dose and time correlate.
Method: Human CCLP and SG231 cell lines were trea-
ted with 0–2 lM MK2206. MTT assay was used to
assess cellular viability at 96 hours. Expression levels of
apoptotic markers and cell cycle proteins were deter-
mined via western blot post treatment.
Results: At 96 hours, CCLP viability was significantly
reduced at MK2206 concentrations of 0.5 lM, 1 lM,
and 2 lM by approximately 44%, 53%, and 64%
respectively (p < 0.01). SG231 also demonstrated signif-
icant reduction in viability of 32%, 32%, and 42%
respectively for the same treatment concentrations at
96 hours (p < 0.05). Western analysis revealed a strong
decrease in phosphorylated AKTSer473, while phosphor-
ylated AKTThr308 remained unchanged in both cell
lines. In addition, cleaved PARP expression increased
while pro-caspase 3 and 9 expression was reduced upon
treatment. Interestingly, survivin expression increased
with treatment in both cell lines.
Conclusions: Our study clearly demonstrates that by
blocking phosphorylation of Akt at serine 473, CCA
cellular growth is reduced. This growth suppression is
mediated via apoptosis induction. Importantly, the con-
centrations needed for growth reduction in CCA are
less than those needed in other cancer types. It is antic-
ipated that these concentrations could be achieved in
vivo with limited toxicity.
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FO04-02
IMMUNOPROFILING
BILIOPANCREATIC
ADENOCARCINOMAS:
CLINICOPATHOLOGICAL
SIGNIFICANCE
Melroy D’souza1, Carlos Fernandez Moro2,
Benedek Bozoky2, Olof Danielsson2, Qianni Zhang3,
Tomas Piatrik3, Bengt Isaksson1 and Bela Bozoky2
1Division of Surgery, Sweden; 2Division of Pathology,
Sweden; 3School of Electronic Engineering and
Computer Science, United Kingdom
Introduction: Adenocarcinomas arising in the biliopan-
creatic system include intrahepatic cholangiocarcinomas
(ICC), perihilar cholangiocarcinomas (PHCC), adeno-
carcinomas of the gallbladder (GBC), distal bile duct
adenocarcinoma (DBC), pancreatic ductal adenocarci-
nomas (PDAC) and ampullary adenocarcinomas (AC).
Immunohistochemistry (IHC) is used clinically to diag-
nose and subtype these tumours. This study was done
to investigate the clinicopathological significance of im-
munoprofiling biliopancreatic tumors by IHC.
Method: Between 2002 and 2013 an extended IHC
panel was used to analyse biopsies and operated speci-
mens of patients with biliopancreatic tumors. In total
250 patients were prospectively included in the study
and up to 26 antibodies were included in the IHC panel.
28 patients with hepatocellular carcinoma (HCC) were
included as an internal control. A clinical database was
maintained. Immunoreactivity was quantitatively scored
based on the percentage of positive tumor cells. Using
bioinformatic techniques, unsupervised cluster analysis
was performed on the data and statistical significance
testing was carried out on the resulting clusters.
Results: Unsupervised clustering classified these tumors
into 2 distinct groups based on immunoprofile, “intra-
hepatic” and “extrahepatic”. The HCCs formed a dis-
tinct cluster separate from these groups. The
“extrahepatic” group included the majority of PHCCs,
GBCs, DBCs, ACs and also a significant fraction of
ICCs. The “intrahepatic” cluster on the other hand was
composed predominantly of ICCs. A minor subcluster
of intestinally differentiated tumors was also found in
the extrahepatic group. The significant IHC markers
for the discrimination of these clusters were then identi-
fied by statistical methods.
Based on these results, a computerized automated clas-
sification system has been developed using machine-
learning techniques.
Conclusions: Biliopancreatic adenocarcinomas can be
classified into two major immunohistochemical profiles:
“intrahepatic” and “extrahepatic”. A significant frac-
tion of ICCs however show an “extrahepatic” immuno-
profile. The significance of this immunohistochemical
classification has diagnostic implications and the poten-
tial in better understanding tumor biology, cancer
prognosis and therapeutic possibilities.
FO04-03
RESECABILITY OF HILAR
CHOLANGIOCARCINOMA: ROLE OF
MDCT
Isidoro Di Carlo1, Francesco Loria2, Giusaeppe Loria2,
Giuseppe Crea2, Salvatore Basile2, Luciano Frosina2,
Silvia Cantoni2 and Antonio Barone2
1Hamad General Hospital, Qatar; 2ASP 5 Palmi
Hospital, Italy
Introduction: Assess the accuracy of MDCT for the
evaluation of the resacability of hilar cholangiocarcino-
ma on the basis of revisited criteria for unresecability
using sergery as the reference standard.
Method: From 2000 to 2012, 55 patients underwent pre-
operative multiphasic MDCT, US and cholagiography.
The revisited criteria for unresecability were controlat-
eral hepatic artery invasion, main or controlateral por-
tal vein invasion longer than 2 cm, biliary extension to
controlateral secondary branches, farther than 2 cm
from hepatic hilum, enlarged lymph-nodes at the celiac,
porto-caval and paraaortic area and othe ancillary
findings.
Results: For depiction of portal vein invasion (in 26
patients) MDCT yelded an accuracy of 85.5%.
Arterial invasion was found at surgery in 19 patients
with MDCT accuracy 83.6%.
The extent of ductal involvement could be accurately
predicted in 46 patients (84%).
The diagnosis of resecability was confirmed at surgery
in 30/42 patients (71.4% PPV).
The diagnosis of unresecability was confirmed in 11/13
patients (84.6% NPV).
Overall accuracy of resecability was 74.5%.
Conclusions: MDCT is accurate in depicting portal
vein and hepatic artery involvement and accurately
assess the extent of biliary ductal involement.
In conclusion, interpretation with MDCT of revisited
criteria allows accurate prediction of resecability for
hilar cholangiocarcinoma.
FO04-04
IMPACT OF NODAL DISSECTION IN
110 PATIENTS WITH INTRAHEPATIC
CHOLANGIOCARCINOMA
Akinori Miyata, Yoshihiro Sakamoto, Taku Aoki,
Junichi Shindoh, Takeaki Ishizawa, Junichi Kaneko,
Kiyoshi Hasegawa, Yasuhiko Sugawara and
Norihiro Kokudo
The University of Tokyo Hospital, Japan
Introduction: It is known that the prognosis of patients
with nodal metastasis from intrahepatic cholangiocarci-
noma (ICC) is dismal. Therefore, significance of
systematic nodal dissection in patients with resectable
ICC is controversial.
Method: Data base of 110 patients undergoing curative
resection for primary ICC excluding combined ICC
and HCC between 1994 and 2011 in a University Hos-
pital was analyzed to discriminate the impact of nodal
dissection. All the patients underwent hepatectomy with
(n = 34) or without (n = 76) biliary resection and
reconstruction. 28 patients underwent systematic nodal
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dissection, 29 patients underwent sampling of the nodes
in the hepatoduodenal ligament or in the lesser gastric
curvature, and 53 patients did not undergo any nodal
dissection.
Results: The 5-year survival rate of 24 patients with
nodal metastasis was significantly lower than that of 76
patients without metastasis (49.9% vs. 0%, p < 0.01).
In 86 patients with pathological or clinical N0, there
was no difference among the three groups of nodal dis-
section (0.837). In 24 patients with N1, there was also
no difference between the systematic dissection and
sampling (p = 0.22).
Conclusions: Although this is a single institutional ret-
rospective analysis, systematic nodal dissection does
not appear to improve the survival of patients. Effec-
tive adjuvant chemotherapy would be required for
patients with nodal metastasis.
FO04-05
A NEW PROGNOSTIC NOMOGRAM
FOR PERIHILAR
CHOLANGIOCARCINOMA AFTER
SURGICAL RESECTION: COMPARISON
WITH THE CURRENT STAGING
SYSTEMS
Andrea Ruzzenente, Alessandro Valdegamberi,
Calogero Iacono, Fabio Bagante,
Francesca Bertuzzo, Tommaso Campagnaro,
Simone Conci, Guido Mantovani,
MichelaDe Angelis and Alfredo Guglielmi
Unit of HPB surgery, Division of General Surgery A,
University of Verona Medical School, Italy
Introduction: Few prognostic classification for perihilar
cholangiocarcinoma (PCC) are available in literature
and their clinical application is limited due to complex-
ity and poor performances.
Aims of this study were (1) to create an effective prog-
nostic nomogram for resected patients with PCC and
(2) to compare its performances with other available
staging systems (TNM stage 7th edition, MSKCC stag-
ing system, JSBS staging system and Kaiser prognostic
scoring system).
Method: Sixty-nine patients submitted to surgical resec-
tion with radical intent for PCC between 1990 and
2012 were included into this study. A prognostic nomo-
gram was created based on prognostic factors from
multivariate analysis and patients were stratified in low
(<50%), medium (between 50% and 75%) and high
risk (>75%) to die within 3 years.
The performance of the model was assessed by compar-
ing the predicted versus observed survival rates. Boot-
straps with 5,000 resamples were used for internal
validation. The discriminatory ability of each staging
system and of our nomogram was compared with Cox
model on the basis of the Akaike Information Criterion
(AIC).
Results: Significant prognostic factor for survival identi-
fied at multivariate analysis (Ca 19.9 > 500 U/mL, num-
ber of lymph node harvested, number of positive lymph
node, caudate lobe resection and portal vein resection)
were selected for nomogram. The performances of our
nomogram was validated and we confirm good correla-
tion between predicted and observed 3-years survival
rates. Estimating different class of risk the observed sur-
vival between the three group of patients (low vs. med-
ium risk) and low versus high risk was significantly
different (p = 0.04 and p < 0.001, respectively).
Our proposed nomogram reached the greatest signifi-
cant value in predicting survival compared to the other
four staging systems (AIC 286.9).
Conclusions: Our prognostic nomogram resulted to be
more accurate in predict survival for patients with peri-
hilar cholangiocarcinoma submitted to surgical resec-
tion compared to current staging systems.
FO04-06
SUGGESTIONS FOR IMPROVING
PERIHILAR CHOLANGIOCARCINOMA
STAGING BASED ON AN EVALUATION
OF THE SEVENTH EDITION AJCC
CANCER STAGING
Wooil Kwon, Jin-Young Jang, Ye Rim Chang,
Woohyun Jung, Mee Joo Kang and Sun-Whe Kim
Seoul National University Hospital, Korea
Introduction: Separate staging for perihilar cholangio-
carcinoma (PHCC) was introduced for the first time. A
retrospective review was done to identify some areas
where progress can be made in future PHCC staging
system by evaluating the seventh edition AJCC cancer
staging system.
Method: Three hundred and seventy-eight patients
underwent surgery for PHCC at a third referral center
between 1990 and 2011. Pathologic report, radiologic
studies, and operation records were reviewed to deter-
mine the TNM stages and R status of each patient.
The survival status and durations were obtained from
the registry of the Ministry of Public Administration
and Security. Stagings for each of 6th and 7th edition
were done. Survival analysis was done using Kaplan–
Meier method and log-rank test.
Results: Although stages have been up-numbered from
I to II and II to III, the 6th and 7th edition had inter-
corresponding stages providing nearly the same classifi-
cations. By the changes in the 7th edition, 9.8% were
down-staged and 1.3% upstaged. Several points need-
ing further discussion and investigations were identified.
First of all, both editions failed to discriminate node-
free locally advanced resectable disease group and
node-positive resectable disease group. Secondly, stage
IVA and IVB in the 7th edition seemed to demonstrate
different prognosis and stage IVA may have been over-
staged. Third, in the 7th edition, the prognosis of liver
invading disease (T2b) seemed to resemble that of T3
more than T2a, warranting further investigation into
down staging of liver invasion. Lastly, curative resec-
tions were possible in some Bismuth type 4 PCC allow-
ing better survival, and so classifying them as
unresectable disease (T4) should be revised.
Conclusions: A discrete staging for PHCC is necessary;
however some points need further clarifications. How-
ever, a single center review has many limitations as
PHCC is relatively uncommon. Therefore, a larger
scale study on multicenter or multinational level is pro-
posed to improve the current staging system.
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FO04-07
PORTAL VEIN RESECTION IN
PATIENTS WITH HILAR
CHOLANGIOCARCINOMA (KLATSKIN
TUMORS) – NOT ALWAYS BUT
WHENEVER NEEDED
Katrin Hoffmann, Benjamin G€oppert, Ulf Hinz,
Markus W. B€uchler and Peter Schemmer
Ruprecht Karls University Heidelberg, Germany
Introduction: Liver resection for hilar cholangiocarcino-
ma (HCA) is challenging because of the complex and
variable anatomy as well as unanticipated vascular and
longitudinal bile duct invasion. Surgical strategies to
achieve negative resection margins vary in tertiary
referral centers and especially the influence of portal
vein resection (PVR) is discussed widely. The aim of
this retrospective study was to investigate the influence
of additional portal vein resection (PVR) on the out-
come after liver resection.
Method: Data of 54 patients (37% with PVR) under-
going liver resection for HCA were collected. Analysis
of overall survival, disease-free survival and multivari-
ate analysis of prognostic factors were performed.
Results: 45% of resections were performed for Bismuth
type III and 53% for type IV. All patients underwent
major liver resection with 68.5% undergoing extended
right or left hepatectomy. Tumor differentiation and
negative resection margin were identified as indepen-
dent prognostic factors for overall survival in multivari-
ate analysis. The post-operative morbidity and
mortality rates were comparable between patients with-
out vascular resection and patients undergoing liver
resection with PVR. PVR was no independent risk fac-
tor for inhospital mortality (p = 0.346). The likelihood
to achieve R0 resection margin was the same between
patients undergoing liver resection only compared to
patients with PVR. The median overall survival and 5-
year overall survival rate were not statistically different
in patients undergoing liver resection only compared to
patients with PVR (21.8 months, 7.4% vs. 18.8 months,
6.3%), (p = 0.4650). Patients without vascular resection
showed a median disease free survival of 17.3 months
compared to patients with PVR with 19.9 months
(p = 0.6003).
Conclusions: liver resection with PVR is a safe treat-
ment option in patients with HCA when necessary to
achieve curative operative results. However, it does not
improve overall and disease free survival or the likeli-
hood to achieve R0 resection. Therefore, concomitant
PVR should be applied only in well selected patients.
FO04-08
SURGICAL OUTCOMES ACCORDING
TO THE TYPES OF HEPATECTOMY IN
TYPE IIIA HILAR
CHOLANGIOCARCINOMA
Huisong Lee, Dong Wook Choi, Jin Seok Heo and
Seong Ho Choi
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: The aim of this study is to evaluate the
bile duct margin and compare the survival according to
the types of hepatectomy in type IIIA hilar cholangio-
carcinoma.
Method: From October 1994 to July 2010, the patients
who underwent major hepatectomy for the treatment
of type IIIA hilar choangiocarcinoma were identified.
The patients were divided by the different types of hep-
atectomy: right hemihepatectomy (RH) or right trisec-
tionectomy (RTS) with or without caudate lobectomy
(CL). The perioperative and survival outcomes were
investigated retrospectively.
Results: Total 95 patients were included. In RTS
group, more patients underwent portal vein emboliza-
tion preoperatively (p = 0.012). There was no signifi-
cant difference in morbidity and mortality according to
the types of surgery. Both RTS and CL were associated
with low margin positive rate (p = 0.018) (p = 0.041).
After median 27 months follow-up, there was no statis-
tically significant difference in disease free survival.
However, the overall survival (OS) curves of RTS and
CL were superior to the one of the opponent group
(p = 0.020, p = 0.019).
Conclusions: Both RTS and CL contributed to the
improvement of OS in type IIIA hilar cholangiocarci-
noma.
FO05-01
PROSPECTIVE STUDY FOR THE
EFFECTS OF PANCREATIC ENZYME
SUPPLEMENT THERAPY ON QUALITY
OF LIFE AND NUTRITIONAL
ASSESSMENT AFTER PANCREAS
RESECTION
Jae Woo Park1, Jin-Young Jang1, Dae Wook Hwang2,
Mee Joo Kang1, Wooil Kwon1, Ye Rim Chang1, In
Woong Han1 and Sun-Whe Kim1
1Seoul National University College of Medicine, Korea;
2Seoul National University Bundang Hospital, Korea
Introduction: After pancreas resection, impairment of
pancreas exocrine function reported up to 68~80%. But
there were not many studies about effects of pancreatic
enzyme supplements (PES) therapy after operation.
Aim of this study is to analyze the effects of PES ther-
apy on nutrition and quality of life after pancreas
resection.
Method: This study was prospective RCT (randomized
controlled trial) comparing pancreatic enzyme supple-
ment (lipase 25,000 unit/cap) group with placebo
group. From 2009 to 2011, 222 patients with informed
consent were enrolled. 64 patients were excluded from
this study for recurrence, follow-up loss and medication
protocol violations. Finally 158 patients (study group
99, placebo 59) were analyzed with body weight, triceps
skin fold thickness (TSFT), serum albumin, protein,
prealbumin, transferrin, questionnaire about quality of
life and symptoms including diarrhea and steatorrhea.
Follow-up schedules were prospectively planned; preop-
erative, postoperative, post-op 3 months and post-op
6 months.
Results: One hundred and nine pancreaticoduodenecto-
my (PD), 44 distal pancreatectomy (DP) and 5 other
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type operations were analyzed. Diarrhea symptom
decreased in PES group (p = 0.063) but other symp-
toms and nutritional index were not different between
two groups. As a result of subgroup analysis between
preoperative and 6 months F/U, PES group showed
increased albumin, prealbumin than placebo group in
PD group (p = 0.075, 0.076), increased protein, preal-
bumin in chemotherapy group (p = 0.021, 0.065). In
comparison between 3 months and 6months F/U, PES
group showed better body weight, relative body weight
(RBW) than placebo group in cancer, cancer with PD,
chemotherapy group (p = 0.028, 0.019, 0.059). PES
group also revealed increased prealbumin in overall
study populations (p = 0.048), increased protein in che-
motherapy group (p = 0.021)
Conclusions: PES group showed marginal improvement
trend in several nutritional factors and symptoms in
PD group, not DP group, and chemotherapy group.
But, study population number is relatively small and
statistical power is not high enough. Additional clinical
studies using higher-dose PES is needed.
FO05-02
PERIOPERATIVE RISK FACTORS FOR
DELAYED GASTRIC EMPTYING
FOLLOWING
PANCREATICODUODENECTOMY
Kamran Idress, Paula Marincola, Julia Shelton,
Nipun Merchant, Jamie Robinson and
Alexander Parikh
Vanderbilt University Medical Center, USA
Introduction: Delayed gastric emptying (DGE) is a fre-
quent complication of pancreaticoduodenectomy (PD)
responsible for increased morbidity and prolonged hos-
pital stay. We sought to further define the incidence of
DGE after PD based on the International Study Group
of Pancreatic Surgery (ISGPS) definition and evaluate
the perioperative risk factors associated with DGE.
Method: Four hundred and twenty consecutive patients
who underwent PD at our tertiary referral center were
reviewed. Using a stepwise multivariate logistic regres-
sion model, perioperative factors as they correlate with
the development of clinically significant DGE as
defined by ISGPS grades B and C were assessed.
Results: Clinically significant DGE occurred in 24% of
patients (n = 98) with Grades B and C occurring at
13.5% (n = 55) and 10.5% (n = 43), respectively. Those
with Grade B or C DGE had a significantly longer
mean hospital stay (20 vs. 9 days, p < 0.001) and a
higher rate of 90-day readmission (32% vs. 18%,
p = 0.004) than those without DGE. By univariate
analysis, white race, increasing ASA class, BMI >35,
OR length>6 hours, preoperative weight loss and octre-
otide use were associated with increased risk of DGE.
By stepwise multivariable regression, BMI >35
(OR = 3.42), OR length >6 hours (OR = 2.97), preop-
erative weight loss (OR = 2.05), and use of octreotide
(OR = 2.33) were independently associated with the
increased risk of DGE.
Conclusions: DGE remains a significant cause of mor-
bidity, increased hospital stay and readmission rates
after PD. Our findings suggest patients with BMI >35,
significant preoperative weight loss, or longer OR times
be considered for gastrostomy and/or jejunostomy tube
placement and limited octreotide use to decrease the
potential risk and consequences of DGE following PD.
FO05-03
EARLY BILIARY COMPLICATIONS
(EBC) AFTER
PANCREATICODUODENECTOMY (PD):
PREVALENCE AND RISK FACTORS
Brice Malgras, Sandrine Duron, Sebastien Gaujoux,
Benjamin Blanc, Safi Dokmak, Beatrice Aussilhou,
Jacques Belghiti and Alain Sauvanet
Ho^pital Beaujon, AP-HP, France
Introduction: Commonest postoperative complications
after PD are pancreatic fistula and gastric delayed emp-
tying. EBC are poorly known and various: bilio-enteric
anastomotic stricture (BEAS), bile leak (BL), cholangi-
tis (CL), and transient jaundice (TJ). The aim of this
study was to assess incidence, predictive factors (PF)
and treatment of EBC following PD.
Method: From 2006 to 2010, 352 patients underwent
PD for periampullary disease (30% benign, 70% malig-
nant). A statistical analysis including logistic regression
was performed to determine their incidence and PF.
Small common bile duct (SCBD) was defined by a
diameter ≤5 mm.
Results: Fifty-two patients (14%) developed EBC with
a 0% mortality rate and a 16% rate of reoperation.
EBC included 7 BEAS (2%), 7 BL (2%), 20 CL (5%),
and 18 TJ (5%). All 7 BEAS were associated with
SCBD and 5 (70%) required reoperation. BL resolved
spontaneously in 4 (57%), otherwise required reopera-
tion due to sepsis or high output. CL presented with
bacteremia in 9 (45%) patients, and recurred after anti-
biotics discontinuation in 4 (20%). TJ resolved sponta-
neously in all cases.
Multivariate analysis revealed that, overall, PF of EBC
were male gender and SCBD. PF of BEAS were blood
transfusion, SCBD. For CL, PF were benign disease,
neo-adjuvant treatment for malign disease whereas
SCBD was the only PF for TJ. No PF was found for
BL.
Conclusions: After PD, EBC were observed in 14% of
cases, especially in case of male gander and SCBD.
Most of EBC were treated medically except SBEA
which often required reoperation. EBC did not increase
mortality rate of PD. Whereas BEAS, BL and TJ
occurred precociously and generally with SCBD, CL
tended to come later, with risk of recurrences and most
of the time without SCBD.
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FO05-04
MANAGEMENT OF DELAYED
ARTERIAL HEMORRHAGE
FOLLOWING
PANCREATICODUODENECTOMY:
A SINGLE-CENTER EXPERIENCE
Jaehong Jeong, Seong Ho Choi, Dong Wook Choi,
Jin Seok Heo, Dong Hun Kim and Hui Song Lee
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: The mortality rate after pancreatic sur-
gery in large-volume centers has decreased markedly
over the last several decades less than 3%. However,
morbidity rate still remains high. Postpancreatectomy
hemorrhage (PPH) is a relatively rare complication but
a lethal complication that makes patients lead to
deaths. Especially, the formation of pseudoaneurysm
after pancreaticoduodenectomy is a important cause of
delayed PPH.
Method: The medical records of 1,905 patients who
underwent pancreaticoduodenectomy between October
1994 and December 2012 were reviewed retrospectively.
Of 1,905 patients, 40 (2.2%) patients with pseudoaneu-
rysm were included in this study.
Results: : Of 40 patients, 18 (42.9%) patients had
pseudoaneurysms of gastroduodenal artery, 13 (31.0%)
patients had those of common hepatic artery. Two
patients underwent immediate re-laparotomy and 38
patients managed by radiologic intervention. Of 38
patients, three patients failed to be managed by radio-
logic intervention. A total 35 patients were managed by
radiologic intervention successfully. 14 selective emboli-
zations of pseudoaneurysm in nine patients were per-
formed. 7 (50%) cases of 14 selective embolizations
had rebleeding and one patients had subclinical liver
infarct. Whereas, 17 total embolizations of in-out arte-
rial flow in 17 patients were performed. Only 2 (11.8%)
patients had rebleeding but, 2 (11.8%) patients had
severe hepatic necrosis. Insertion of stent graft in 3
superior mesenteric arteries and 9 hepatic arteries was
performed. 2 (16.7%) patients had rebleeding and 3
patients had stent occlusions.
Conclusions: Radiologic intervention is a best option
for the management of pseudoaneurysm after pancrea-
ticoduodenectomy. Stent graft is not superior to the
total embolization of in-out arterial flow. Rebleeding
and stent thrombosis are still problematic.
FO05-05
VALIDATION OF A PREOPERATIVE
PREDICTIVE SCORING SYSTEM FOR
POSTOPERATIVE PANCREATIC
FISTULA AFTER
PANCREATICODUODENECTOMY
Ti Zhang, Huikai Li, Yunlong Cui and Qiang Li
Tianjin Medical University Cancer Institute & Hospital,
China
Introduction: Post operative pancreatic fistula (POPF)
is one of the most common and severe complications
after pancreaticoduodenectomy. It has been shown that
POPF are not only closely associated with hardness of
pancreatic parenchyma, diameter of pancreatic duct
and tumor site, but also affected by surgeon’s experi-
ence and surgical techniques. A preoperative predictive
scoring system may enable selection of high risk
patients for POPF and devise counter measures.
Method: Data from 145 consecutive patients with pe-
riampullary tumor who underwent PD in Tianjin
Medical University Cancer Institute and Hospital
between October 2008 and August 2013 were
reviewed. Factors potentially associated with POPF
were analyzed. The sensitivity and specificity of a
predictive scoring system established by Japanese clini-
cians were determined by receiver operating character-
istic (ROC) curve analysis.
Results: The incidence of POPF was higher in male
than in female(22/91 vs. 5/54, p = 0.028).The hard pan-
creas had the lowest POPF rate(0/22), while medium
hard and soft pancreas accounted for the high POPF
rate(7/60, 20/63)(p = 0.001). Patients with pancreatic
cancer had lower POPF rate than non-pancreatic can-
cer(7/71 vs. 20/74, p = 0.01). Portal vein involvement
was negative factor for the occurrence of POPF(11/92
vs. 16/53, p = 0.008). Anastomosis methods were also
found to be associated with POPF. Traditional duct to
mucosa pancreaticojejunostomy(2/34)and Blumgart
anastomosis (5/43)had lower POPF rate compared with
End to End(12/50)or End to Side(8/18)anastomosis
(p = 0.003). ROC curve analysis showed that the sensi-
tivity and specificity of this system were 92.6% and
78.8%, respectively. The nomogram showed an area
under the curve (AUC) of 93.1%(p = 0.000).
Conclusions: With satisfactory sensitivity and specific-
ity, this scoring system can predict the occurrence of
POPF and deserves wide clinical application. Surgical
technique, like Blumgart anastomosis may be a good
choice for preventing POPF.
FO05-06
WHICH ONE IS BETTER FOR
PREDICTING PANCREATIC FISTULA
AFTER
PANCREATICODUODENECTOMY;
DRAIN AMYLASE OR LIPASE?
Jae Keun Kim, Dong Sup Yoon and
Joon Seong Park
Gangnam Severance Hospital, Yonsei University, Korea
Introduction: Pancreatic fistula is a main complication
after pancreatic resection. ISGPF classification with
postoperative drain amylase level has been considered
as a standard of grading system. But the ISGPF classi-
fication has a critical limitation in prediction of clinical
pancreatic fistula. This study analyzed postoperative
drain pancreatic enzymes for predicting clinical pancre-
atic fistula and aimed to present the drain pancreatic
enzyme which one is more specific for reporting clinical
complication than the other.
Method: January 2006 to March 2013, 257 patients
with pancreas resection were included in this study.
Drain amylase and lipase level were measured after the
operation. ISGPF grade B and C were considered a
clinical fistula. Concentrations of amylase and lipase on
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each postoperative day were compared with Receiver
operation curves for predicting clinical fistula.
Results: Eighty one patients (35.0%) were identified
pancreatic fistula under ISGPF classification. 68
patients (26%) were Grade A. 23 patients (9%) were
clinical fistula. Each lipase concentration in drain dur-
ing postoperative 3 days was more accurately predicted
pancreatic fistula than amylase in concentration in
drain.
Conclusions: Drain lipase more accurately predicted
clinical pancreatic fistula than amylase in concentration
in drain. Further investigations are needed to improve
clinical relevant complication reporting system for post-
operative pancreatic fistula with drain pancreatic
enzymes.
FO05-07
MULTICENTRE ANALYSIS OF A
SCORE TO PREDICT PANCREATIC
FISTULA FOLLOWING
PANCREATODUODENECTOMY
Keith Roberts1, James Hodson1, Jamil Ahmed2,
Sara Napetti3, Alex Navarro1, Krashna Patel4,
Nehal Shah5, Guy Shingler6 and Rowland Storey7
1University Hospitals Birmingham NHS Trust, United
Kingdom; 2Southampton University Hospitals NHS
Trust, United Kingdom; 3Edinburgh Royal Infirmary,
United Kingdom; 4Cambridge University Hospitals NHS
Trust, United Kingdom; 5Royal Free Hospital, London,
United Kingdom; 6Morriston Hospital, Swansea, United
Kingdom; 7Leeds University Teaching Hospitals NHS
Trust, United Kingdom
Introduction: Post operative pancreatic fistula (POPF)
is the major contributor to morbidity and mortality fol-
lowing pancreatoduodenectomy (PD). A pre-operative
score (based upon body mass index, BMI, and pancre-
atic duct width) to predict POPF has been designed.
The aim of this study was to assess the performance of
this score and risk factors for POPF based upon a mul-
ticentre patient cohort.
Method: Patients who underwent PD over an
18 month period at 7 centres (collaborating centres:
Cambridge, Edinburgh, Leeds, Royal Free London,
Southampton, Swansea and Birmingham, UK) were
identified. Patient variables, preoperative blood tests,
data from pre-operative CT imaging, intra- and post
operative outcomes were assessed. The ISGPF defini-
tion of POPF was used.
Results: Five hundred and sixty five patients underwent
PD with 126 occurrences of POPF (22.3%). BMI, peri-
renal fat thickness on CT, pancreatic duct width on CT
and at operation, bilirubin, underlying pathology, T
stage, N stage, R status and gland firmness at opera-
tion were all significantly associated with POPF. The
nature of pancreatic reconstruction (PJ/PG, single/dou-
ble layer anastomosis, dunking, or a separate pancre-
atic limb) did not affect the rate of POPF. The score
predicted POPF (p < 0.001); the area under the ROC
curve being 0.712 (95% CI 0.653–0.770). A higher pre-
dictive score was associated with increasing severity of
POPF (p < 0.001). Multivariate analysis of pre-opera-
tive variables demonstrated that BMI and PD width as
measured on CT were associated with POPF. The addi-
tion of intra-operative variables to this analysis showed
that intra-operative duct width was independently asso-
ciated with POPF.
Conclusions: This pre-operative predictive score of
POPF has been successfully validated upon this multi-
centre patient cohort. A separate score could be created
with the addition of intra-operative variables and this
may improve the scores performance however this
could only be performed at the time of operation. Pro-
spective multicentre evaluation is planned.
FO05-08
DIVISION OF THE SURGEON’S
WORKLOADS IN
PANCREATICODUODENECTOMY
Dong Hun Kim1, Seong Ho Choi1, Dong Wook Choi1,
Jin Seok Heo1, Jaehong Jeong1, Huisong Lee1 and
Min Jung Kim2
1Samsung Medical Center, Sungkyunkwan University,
Korea; 2Jeju National University Hospital, Korea
Introduction: Many authors have suggested factors that
affect pancreatic leakage after pancreatoduodenectomy
(PD), but there was little report for surgeon’s factor to
predominate in pancreatic fistula. We attempted to
determine if surgeon’s workload of PD could impact
on postoperative pancreatic fistula (POPF).
Method: The risk factors for POPF were analyzed ret-
rospectively for 270 consecutive patients who under-
went conventional pancreatoduodenectomy or pylorus-
preserving pancreatoduodenectomy between January
2008 and June 2013 by a single surgeon. These patients
were divided into those underwent PD totally by a sin-
gle surgeon (Group 1) and just reconstructions after
resection by secondary surgeons (Group 2). Duct-to-
mucosa pancreaticojejunostomy was performed on all
patients. The POPF was defined by the International
Study Group on Pancreatic Fistula criteria.
Results: There were 157 patients (58.1%) in Group 1
and 113 patients (41.9%) in Group 2. Postoperative
morbidity rate was comparable between the two groups
(55.4% vs. 52.2%; p = 0.603), but clinical pancreatic
fistula (grade B/C) rate was significantly different
(10.8% vs. 2.8%; p = 0.011). Postoperative mortality
was one patient (0.4%). A significant association with
clinical pancreatic fistula was found for soft pancreas
(p = 0.046), preoperative serum albumin levels ≤3.5 g/
dL (p = 0.008), PD performed totally by a single sur-
geon (p = 0.011). A multivariate logistic regression
analysis revealed that PD performed totally by a single
surgeon [odds ratio (OR) 4.1, p = 0.029] was the signifi-
cant predictive risk factor for clinical pancreatic fistula.
Conclusions: Division of the surgeon’s workloads in
PD is associated with a lower rate of pancreatic fistula.
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FO06-01
CLINICAL SAFETY AND EFFICACY OF
EARLY ORAL FEEDING FOLLOWING
PANCREATICODUODENECTOMY
Si Eun Hwang1, Baik Hwan Cho2, Jae Doo Yang3,
Hong Pil Hwang3, Sang In Bae3, Mi Jin Jung3 and
Hee Chul Yu2
1Daejeon Sun Hospital, Korea; 2Chonbuk National
University Medical School, Korea; 3Chonbuk National
University Hospital, Korea
Introduction: Pancreaticoduodenctomy (PD) has been
associated with high postoperative morbidity and mortal-
ity rates, despite advances in surgical techniques and peri-
operative care. Although experimental studies have
shown that early postoperative enteral nutrition improves
postoperative outcomes, there is limited clinical informa-
tion on postoperative early oral feeding (EOF) after PD.
This study examined the clinical efficacy and nutritional
effects of early oral feeding following PD.
Method: Postoperative outcomes were retrospectively
investigated in 131 patients who underwent PD between
October 2003 and April 2013, including 81 who com-
menced oral feeding within 48 hours (EOF group) and
50 who commenced oral feeding after 48 hours (late oral
feeding, LOF, group). Parameters measured included
postoperative complications, energy intake and length of
hospital stay (LOS) by nutritional discharge index
(NDI).
Results: EOF and LOF group were homogenous in
patient’s demographics. LOS (25.9  8.5 days vs.
32.3  16.3 days; p = 0.01) and LOS by NDI
(22.2  7.1 days vs. 28.5  15.0 days; p = 0.01) were
significantly shorter in the EOF than in the LOF group.
The rates of wound infection, intra-abdominal abscess,
upper gastrointestinal bleeding, pleural effusion, pneu-
monia, postoperative bleeding and small bowel obstruc-
tion were similar in the two groups, but the rates of
delayed gastric emptying (37.0% vs. 94.0%; p = 0.00),
anastomotic leak (1.2% vs. 16%, p = 0.00) and reopera-
tion (3.7% vs. 20%, p = 0.01) were significantly lower
in the EOF group. In the clinically acute postoperative
phase, from days 1 to 5, the mean daily calorie intake
(847.0 kcal vs. 745.6 kcal; p = 0.04) and mean protein
intake (42.2 g vs. 31.9 g; p = 0.00) were significantly
greater in the EOF than in the LOF group.
Conclusions: Postoperative EOF enhanced recovery
after surgery without compromising the anastomotic
safety of PD. Postoperative EOF is safe, feasible and
effective as a method of nutritional support following
PD.
FO06-02
SINGLE INCISION LAPAROSCOPIC
CHOLECYSTECTOMY-A SINGLE
CENTRE EXPERIENCE USING
CONVENTIONAL INSTRUMENT
Manash Sahoo1, Ved Bhaskar2 and Anil Kumar2
1Associate Professor, India; 2Post graduate, India
Introduction: Laparoscopic cholecystectomy with four
ports is the standard operation for gallbladder diseases
worldwide. The established use of 5 or 10 mm instru-
ments and ports leads to small skin incisions in the
upper abdominal wall. However, these scars are still
visible and might be a potential risk factor for incision-
al hernia or adhesions. At the present time, it becomes
more important for younger patients to undergo sur-
gery with none or least scars. Our present study is to
assess the feasibility of single-incision laparoscopic sur-
gery using conventional laparoscopic instruments.
Method: From January 2009 to March 2012, 120
patients with symptomatic gallbladder disease chosen
strictly as per criteria mentioned later underwent Single
Incision Laparoscopic surgery (SILS) through a 2–
2.5 cm umbilical incision using a three-port technique.
For nearly all the patients, a 30 degree angled conven-
tional scope was used. The gallbladder was retracted,
with one suture placed over the fundus of gallbladder.
These sutures were taken on the fundus and puppet
technique was used to obtain a critical view of Calot’s
triangle. The cystic duct and artery were well visual-
ized, clipped, and divided. Cholecystectomy was com-
pleted, and the specimen was retrieved through the
umbilical incision (11 mm port).
Results: In this series 85 females and 35 males
(n = 120), average age 42.5 years (19–77 years) chosen
by predefined criteria underwent SILS using conven-
tional straight instruments. The mean operative time
was 86.5 minutes (65–120 minutes). A three trocar sin-
gle incision technique was feasible for 95% (n = 115)
of the patients. For the remaining patients, conversion
to standard 4 port approach was done. No conversion
to open surgery was required. Patients have been fol-
lowed up for a mean of 13 months (5–30 months) and
till now no notable complications have been reported.
Conclusions: Single-incision laparoscopic cholecystec-
tomy is safe, feasible, and quite reproducible in experi-
enced hands.
FO06-03
A DOUBLE BLIND EVALUATION OF
SUBDIAPHRAGMATIC PRE-EMPTIVE
LIDOCAINE INSTILLATION TO
CONTROL POSTOPERATIVE PAIN AND
HEMODYNAMIC CHANGE IN
LAPAROSCOPIC CHOLECYSTECTOMY
Sung Su Yun, Dong Shick Lee, Hwa Kyung Jung,
Man Ki Kim, Hong Jin Kim, Heung Dae Kim and
Sun Ok Song
Yeungnam University Medical Center, Korea
Introduction: One third of our patients still need opi-
oids after laparoscopic cholecystectomy (LC) and he-
modynamic changes (systemic vascular resistance: SVR
↑, cardiac index: CI ↓, blood pressure: BP ↑ etc)
induced by CO2 pneumoperitoneum during LC can
cause serious problems in patients with advanced car-
diopulmonary disease. We designed this study to evalu-
ate the efficacy of pre-emptive subdiaphragmatic
lidocaine instillation in postoperative pain and hemody-
namic changes during LC
Method: Twenty patients (25–65 years old) were
enrolled in this study with informed consent and proto-
col was designed with prospective, randomized, double
blind method. Patients with cardiopulmonary disease
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(hypertension, COPD etc) were excluded. Ten minutes
before CO2 pnemoperitoneum, control group received
normal saline 200 cc and lidocaine group received
0.2% lidocaine 200 cc in both subdiaphragmatic spaces
(150 cc in right side, 50 cc in left side). Hemodynamic
changes (SVR, BP, CI etc) were monitored every
5 minutes during LC with NICO system. Postoperative
pain was monitored 1, 3, 6, 12, 18 and 24 hours after
LC with visual analogue and numerical pain scale. We
also observed adverse effects (nausea, vomiting, shoul-
der pain and bowel movement, etc).
Results: Pre-emptive lidocaine instillation attenuates
adverse hemodynamic effects of CO2 pnemoperitone-
um. In lidocaine group, systolic blood pressure and
SVR were lower but CI was higher than those observed
in control group (data at 25, 30 minutes after CO2
pneumoperitoneum were statistically significant,
p < 0.05). Pre-emptive lidocaine instillation also mini-
mized the postoperative pain especially 1 and 3 hours
after LC (p < 0.05). No significant side effect was
observed after lidocaine instillation. Nausea, vomiting
and return of bowel movement were not significantly
different between two groups.
Conclusions: Pre-emptive subdiaphragmatic lidocaine
instillation before CO2 pnemoperitoneum induction
may help the patients with advanced cardiopulmonary
disease to attenuate the adverse hemodynamic effects
and to have less pain in LC.
FO06-04
THE COMPARISON OF
LAPAROSCOPIC PARTIAL
SPLENECTOMY AND LAPAROSCOPIC
TOTAL SPLENECTOMY IN TUMOROUS
LESION OF SPLEEN
Soo Ho Lee, Tae Ho Hong, Dong gu Kim,
Young Kyoung You, Gun Hyung Na and
Jae Hyun Han
Catholic University of Korea, Seoul St. Mary’s Hospital,
Korea
Introduction: Laparoscopic partial splenectomy (LPS)
has emerged as a surgical option for splenic mass, with
the goal of reducing postoperative complication while
preserving splenic function. The authors report on the
surgical outcomes and postoperative complication of LPS
compared with laparoscopic total splenectomy (LTS).
Method: The medical records of laparoscopic splenec-
tomized patients who underwent a LPS and LTS in
Seoul St. Mary’s Hospital between 2009 and 2013 were
collected. The medical records of hematologic splenic
disease were excluded and only 26 splenectomized
patients with tumorous lesion of spleen were analyzed.
Results: There were no statistical differences in the
operation time (LPS: 141.1  49.7 minutes, LTS:
128.0  50.3 minutes, p = 0.560), intraoperative blood
loss (LPS: 336  348.9 mL, LTS: 376.4  535.0 mL,
p = 0.443), transfusion rate (LPS: 1 of 9 patients, LTS:
7 of 17 patients, p = 0.190), and hospital stay (LPS:
7.1  6.9 days, LTS: 5.7  4.2 days, p = 0.526)
between LPS group and LTS group. However, postop-
erative complications, postoperative pleural effusion
(LPS: 0 patient, LTS: 7 of 17 patients, p = 0.016) and
postoperative splenic vein thrombosis (LPS: 0 patient,
LTS: 6 of 17 patients, p = 0.030), were significantly
lower in the LPS group.
Conclusions: In comparison with LTS, the surgical out-
comes are similar with LPS, but postoperative compli-
cations, such as postoperative pleural effusion and
splenic vein thrombosis occur less in LPS group. There-
fore, LPS is feasible and safe, could be a good alterna-
tive method for tumorous lesion of spleen.
FO06-05
LIVER TRANSPLANT COST IN
PATIENTS WITH HIGH MELD SCORE:
THE DIALYSIS IMPACT IN INTENSIVE
CARE UNIT
Wellington Andraus, Luciana Haddad,
Anto^nio Turri, Marcio Diniz and
Luiz Augusto Carneiro D’Albuquerque
S~ao Paulo University, Brazil
Introduction: The liver transplant is a high cost proce-
dure and it has a big impact in health economics. The
aim of this study was to determine the components of
liver transplant hospital costs, relating it with MELD
score.
Method: Economic evaluation using micro cost analy-
sis was performed in a series of liver transplantation
during 2012 in a single center. The costs were related
according to the facilities: surgical center (SC), inten-
sive care unit (ICU) and ward. For each location,
the cost components were discriminated (drugs, materi-
als, human resources, laboratory exams, etc.).
Results: There were a total of 79 transplants, 75
deceased donors and 4 living donors. The average
MELD was 27.2  13.6 and the age, 49  12. The
most frequent etiology was HCV cirrhosis (27.8%) fol-
lowed by alcoholic cirrhosis (11.4%). The average of
transplantation cost during hospitalization was
$24,110  $28,354. The average of day cost was
$1,128  $1,855. The ICU produced a significantly big-
ger cost than the surgical center and ward (ICU
$10,804  20,789, SC $ 7,333  2,254 and ward
$5,926  8,612, p < 0.001 – Kruskal–Wallis test). In
the ICU, the main component of cost was dialysis, fol-
lowed by human resources. There was a significant rela-
tionship between cost and MELD score (MELD <20:
$15,248  5,220, MELD 20-29: $18,364  7,749,
MELD> 29: $36,917  43,526, p = 0.006 Kruskal–
Wallis test).
Conclusions: Liver transplant costs are significantly
higher in patients with MELD scores above 29. The
budget impact is higher in intensive therapy, and occurs
due to the increased need of dialysis in these patients.
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FO06-06
COST-EFFECTIVENESS OF SURGICAL
RESECTION VERSUS PALLIATIVE
TREATMENT IN PATIENTS WITH
LOCALLY ADVANCED PANCREATIC
CANCER
Nishma Patel1, Stephen Morris1, Nicola Orell1,
Rachael Hunter1, Brian Davidson2 and
Kurinchi Gurusamy2
1University College London, United Kingdom;
2University College London and Royal Free Hospital,
United Kingdom
Introduction: Standard management for resectable pan-
creatic cancer is removal of the tumour by resection
and palliative treatment. This paper explores the cost-
effectiveness of surgical resection versus palliative treat-
ment in patient with locally advanced pancreatic can-
cer, from the perspective of the UK National Health
Service.
Method: A decision model was used to calculate the
costs and benefits of surgical resection and palliative
treatment for patients with locally advanced pancreatic
cancer. Benefits were measured in terms of quality
adjusted life years (QALYs), and costs and QALYs
were measured over a time horizon of 5 years. Model
inputs were derived from published studies. Probabilis-
tic sensitivity analysis was used to generate a cost-effec-
tiveness acceptability curve.
Results: Surgical resection accrued mean costs of
£20,576 (95% CI £9,008 to £60,028) and a mean benefit
of 1.28 QALYs (95% CI 0.88. to 1.72.) per patient.
Palliative treatment produced lower mean costs
(£7,583, 95% CI £2,812 to £25,363) and QALYs (0.57.
95% CI 0.25. to 0.91). The incremental cost per QALY
gained was £18,347 (95% £7,861 to £52,885). Probabi-
listic sensitivity analysis showed that if the NHS was
willing to pay an extra £20,000 for an additional
QALY, the probability of surgical resection being cost-
effective was 64%.
Conclusions: Surgical resection in patients with locally
advanced pancreatic cancer is cost-effective compared
with palliative treatment, offering extended survival for
a modest increase in cost.
FO06-07
ASSESSING IMPACT OF SENIORITY
ON OPERATIVE TIME IN
LAPAROSCOPIC CHOLECYSTECTOMY
IN TRAINING SURGICAL
DEPARTMENT OF A DEVELOPING
COUNTRY
Amine Benkabbou, Amine Souadka,
Sayed Mohammed Naya, Badr Serji,
Hadj Omar El Malki, Raouf Mohsine, Lahsen Ifrine
and Abdelkader Belkouchi
Ibn Sina Hospital, Morocco
Introduction: Resident participation in laparoscopic
cholecystectomy (LC) is the first step of laparoscopic
training but seems to increase the time of operation.
This time cost in training programs is not well defined
especially in developing countries. This study aimed to
compare and determine the effect of seniority on the
operative performance of laparoscopic cholecystectomy.
Method: We underwent a retrospective study of all
consecutive laparoscopic cholecystectomy for gallblad-
der lithiasis performed over two academic years in our
Moroccan training program.
We compared Operations performed by junior (PGY 4-
5) or senior (PGY 6) residents and attending surgeons,
assisted by junior residents, none of whom had fellow-
ship training in advanced laparoscopy.
All data concerning Demographics (ASA, ECOG score,
body mass index and indications), surgeons, operative
time (from skin incision to closure), conversion rate,
and operative complications (clavien-Dindo classifica-
tion) were recorded and analysed. ANOVA, Student’s
t-test, and chi2 tests were used as appropriate with sta-
tistical significance attributed to p < 0.05. Post hoc
benferony test were used when needed.
Results: One hundred thirty for LC were performed.
No differences were found on univariate analysis
between groups in demographics or diagnosis category.
The overall rate of operative complications or conver-
sions and hospital stay were not significantly different
between the 3 groups. However Mean Operative times
were longer for junior (n = 27): 115  24 minutes; than
seniors (n = 37): 77  35 minutes than attending sur-
geons (n = 66): 55  17 minutes (p < 0.001).
Conclusions: Laparoscopic cholecystesctomy performed
by Residents is safe and feasible, however seniority
influences operative time but not complications rate.
This information may improve surgical educating pro-
grams in developing countries to assess the importance
of early initiation to laparoscopic skills to reduce the
time cost.
FO06-08
EFFECT OF MULTIDISCIPLINARY
CARE ON THE TREATMENT OF
SURGICAL PATIENTS
Johanna Tol, Els Nieveenvan Dijkum,
Jean Klinkenbijl, ThomasVan Gulik,
Olivier Busch and Dirk Gouma
Academic Medical Center Amsterdam, The Netherlands
Introduction: High volume hospitals and surgeons
report the lowest mortality rates after complex surgery.
There is an ongoing discussion about the impact of vol-
ume and experience on the high quality of care versus
the role of hospital structure and process of care. Mul-
tidisciplinary approach is important in these processes
to generate an optimal interaction between different
physicians. The aim of this study was to evaluate the
effect of weekly multidisciplinary approach during pre-
operative and postoperative meetings.
Method: During a period of 15 weeks a consecutive
group of patients with suspected periampullary tumors
presented at the weekly preoperative multidisciplinary
team (MDT) meeting, were prospectively registered.
Simultaneously all patients at the postoperative MDT
meeting at the surgical gastro-intestinal (GI) ward were
registered. Preoperative alterations by members of the
MDT of initial treatment strategies set by the referring
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hospital and additions to the postoperative surgical
treatment by members of the MDT were also scored.
Results: During the preoperative MDT meeting 128
patients were discussed, 41 patients were referred for a
specific treatment strategy set by the referring hospital
which was altered during the MDT meeting in 14
patients (34%). During postoperative MDT meeting
additions to the initial treatment strategies set by sur-
geons were made after suggestions of the other mem-
bers of the MDT in 42/149 patients (28%). Additions
were based on treating existing co-morbidity in 18
patients and postoperative complications in 24 patients.
Alterations in medication, infusion or additional diag-
nostics were mainly performed. There was no mortality
among the study patients.
Conclusions: A multidisciplinary approach during pre
and post-operative meetings on patients with complex
GI pathology leads to alterations of the initial treat-
ment strategy set by the referring hospital in 34% and
additions to the postoperative surgical treatment in
28%. This shows a clear effect of MDT meetings on
the treatment strategy of patients.
FO07-01
LAPAROSCOPIC VS OPEN LIVER
RESECTION FOR LARGE
COLORECTAL LIVER METASTASES:
OUTCOMES AND LONG-TERM
SURVIVAL
Joel Lewin1, Stephanie Huxley1, David Cavallucci2,
Richard Bryant1, Ian Martin2, Leslie Nathanson1 and
Nicholas O’Rourke1
1Royal Brisbane Hospital, Australia; 2Wesley Hospital,
Australia
Introduction: Open liver resection for large (>5 cm
diameter) colorectal liver metastases (CLM) is w ell
accepted, with laparoscopic resection also becoming an
increasingly accepted treatment modality for CLM.
The international Position on Laparoscopic Liver Sur-
gery (2008) recommends a laparoscopic approach for
lesions 5 cm or less. This study is a retrospective analy-
sis comparing long-term survival and outcomes
between laparoscopic and open groups for resection of
large CLM.
Method: Patients undergoing liver resection for large
colorectal liver metastases (>5 cm) by 6 surgeons in 3
institutions between 2000 and 2013 were collected in a
prospective database. Patient groups of open and intent
to treat laparoscopic were matched using propensity
scores, based on age, number of lesions, lesion size,
pre- and post-Basingstoke Predictive Index (BPI) scores
and major hepatectomy status. Survival analysis was
carried out using Kaplan-Meier estimates.
Results: Patient groups were well matched post pro-
pensity score matching. The laparoscopic group con-
sisted of 26 resections in as many patients, with a 5-
year overall survival of 52% and 5-year primary disease
free survival of 29%. The open group consisted of 31
resections in 28 patients with 5-year overall and pri-
mary disease free survival of 57% and 32% respec-
tively. Log-rank comparison between laparoscopic and
open groups in overall (p = 0.87) and disease-free
(p = 0.43) Kaplan–Meier estimates were not significant.
Mean blood loss (MD 69 mL, p = 0.52) and operating
time (MD 41 minutes, p = 0.14) were less in the laparo-
scopic group but not statistically significant. Mean hos-
pital length of stay in the laparoscopic group was
6.1 days and in the open group 8.1 days (p = 0.06). No
difference was determined between groups for mean
margin distance or frequency of positive margin.
Conclusions: For resection of large CLM, short term
outcomes and long-term survival are comparable
between laparoscopic and open groups, indicating large
tumour size is not an absolute contraindication to lapa-
roscopic liver resection.
FO07-02
SURGICAL MANAGEMENT OF
METASTATIC COLON CANCER IN THE
ELDERLY
Ponnandai S Somasundar1, Adam Olszewski2 and
Hadi Khan1
1Roger Williams Medical Center, USA; 2Brown
University, USA
Introduction: Increased emphasis is recently placed on
the curative potential of surgery in selected patients
(pts) with stage IV colon cancer. The objective of this
study was to evaluate survival after resection of pri-
mary tumor and/or metastatic sites, by age and the
extent of nodal spread, using the population-based
SEER registry.
Method: We extracted data on pts ≥20 years old, diag-
nosed with adenocarcinoma of the colon between 2000
and 2010 (n = 232,640). We analyzed the extent of
nodal involvement using current staging schema (N0-2)
in cases with ≥12 lymph nodes examined (LNE) and
identified stage IV pts with recorded resection of pri-
mary tumor or of metastases. Association of overall
survival (OS) with metastatectomy was evaluated in
multivariable Cox models, reporting hazard ratios
(HR) and 95% confidence intervals (95%CI).
Results: Among 41,590 pts with stage IV cancer, 67%
underwent primary surgery and 11% metastatectomy.
Older pts were more likely to have <12 LNE, but also
to have N0 status when adequately staged (Table,
p < .0001).
Metastatectomy (n = 4,506) was less common in older
patients. OS after resection was inversely associated
with age, nodal involvement, tumor grade and subopti-
mal staging with <12 LNE (p < .0001). However, the
OS benefit of metastatectomy was significant in all age
groups except those ≥85 years old (Table) and was
independent of the extent of nodal spread (HR, 0.71,
0.68 and 0.77 for N0, N1 and N2 cases, respectively) or
tumor grade.
Conclusions: The survival advantage of metastatic site
resection in colon cancer is present in ages up to
85 years. Adequate nodal resection favorably correlates
with survival after metastatectomy, and older pts are
more likely to be node-negative at resection with ≥12
LNE. These results support offering curative metasta-
tectomy and resection of the primary tumor in this age
group.
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FO07-03
HEPATIC RESECTION IS SUPERIOR TO
RADIOFREQUENCY ABLATION FOR
THE TREATMENT OF SYNCHRONOUS
COLORECTAL LIVER METASTASIS: A
RETROSPECTIVE COHORT STUDY
Huisong Lee1, Jin Seok Heo1, Yong Beom Cho1,
Seong Hyeon Yun1, Hee Cheol Kim1, Woo Yong Lee1,
Seong Ho Choi1, Dong Wook Choi1, Kyung Uk Jung2
and Ho-Kyung Chun2
1Samsung Medical Center, Sungkyunkwan University,
Korea; 2Gangbuk Samsung Medical Center, Korea
Introduction: The size of CLM has been verified in
many previous studies. CLM size is an important factor
that determines the effectiveness of RFA. However, the
importance of the location and number of CLM has
not been evaluated.
The aim of this study is to compare the outcomes of ra-
diofrequency ablation (RFA) and hepatic resection (HR)
for the treatment of synchronous colorectal liver metas-
tases (CLM) stratified by location, number, and size.
Method: Between January 2000 and December 2009, a
total of 235 patients who underwent HR with curative
intent or RFA were identified from a prospectively col-
lected database. Patients were stratified according to
the location, number, and size of CLM. Perioperative
outcomes and survival were compared retrospectively
between RFA (n = 46) and HR (n = 189) groups.
Results: The median follow-up period was 42.5 months
(range, 4–158). There were no differences between the
RFA and HR groups in perihepatic complication rates
(p = 0.707). Local recurrence rate was 11% after RFA
and 3% after HR (p = 0.042). Disease-free survival
(DFS) at the 1 and 5 years was 42.3% and 37.5% after
HR and 28.3% and 22.6% after RFA respectively
(p = 0.122). The 3- and 5-year overall survival (OS)
rates were 70.7% and 58.6% after HR and 57.2% and
42.0% after RFA respectively (p = 0.048). The OS of
the HR group was superior to RFA group regardless
of the location and number (p = 0.037, p = 0.030).
Conclusions: HR is superior to RFA and must be con-
sidered as the first line treatment if surgery is not con-
traindicated.
FO07-04
VALIDATION OF COMPUTER
ASSISTED PERCUTANEOUS
MICROWAVE ABLATION OF LIVER
TUMOURS – FEASIBILITY AND
SAFETY ASSESSMENT
Jennie Engstrand1, Henrik Nilsson1,
Grzegorz Toporek2, Matthias Peterhans2 and
Jacob Freedman1
1Karolinska Institut, Sweden; 2University of Bern,
Switzerland
Introduction: For patients with liver tumours not treat-
able with open liver surgery due to comorbidities or
where the tumour is not visible with ultrasound or in
the situation with vanished lesions, an alternative could
be CT-guided microwave ablation with computer
assisted navigation (CAS-one, Cascination AG, Bern,
Switzerland). Compared to standard CT-guidance, the
addition of CAS-one could improve accuracy, reduce
radiation dose and anaesthesia time.
Method: Stereotactic instrument guidance is provided
based on previously acquired 3D image data. By relat-
ing the position of the image data to real-time measure-
ments of the patient position and instrument tracking,
the relative position of the needle and the target are
visualized without requiring CT acquisitions during
needle insertion.
General feasibility and safety of the navigated
approach is assessed. Targeting accuracy is measured
by calculations from control CT-scans.
20 patients scheduled for CT guided percutaneous
microwave ablation, with 1 to 2 metastases, are selected
from the Stockholm liver conference.
Results: From March until July 2013, 11 patients (4
females and 7 males) of the planned 20 patients have
been treated. 7 with HCC and 4 with CRLM. Median
number of lesions treated was 1 (1–3) with a median
size of 28 mm (10–42). Patients were discharged after a
median of 1 day (1–2) without complications, but one
patient showing a thrombosis of the superior mesen-
teric vein at 30d follow-up. The accuracy of the navi-
gated needle placement was 6.02  3.58 mm. In the
analysis two patients were excluded because of mal-
functioning targeting system.
Conclusions: The procedure is feasible and continuing
logistic and technical improvements have been accom-
plished. If this proves to be reliable a new group of
patients could be offered a minimal invasive approach.
It might even expand the indication for ablation in
other organs like kidneys, spleen, lungs and pancreas.
FO07-05
RELIABILITY, SAFETY AND
ONCOLOGICAL SUITABILITY OF
INTRAOPERATIVE ULTRASOUND
CRITERIA FOR HEPATIC VEINS
SPARING ONCE IN CONTACT WITH
COLORECTAL LIVER METASTASES AT
THE CAVAL CONFLUENCE:
VALIDATION ON
Fabio Procopio, Matteo Donadon, Matteo Cimino,
Daniele Del Fabbro, Guido Costa, Andrea Gatti,
Angela Palmisano and Guido Torzilli
University of Milan, Humanitas Clinical and Research
Center, Milan, Italy
Introduction: Major hepatectomies are generally selected
for tumors in contact-involving the hepatic vein (HV)
at caval confluence (CC). Whenever a conservative
approach is attempted, HV reconstruction is recom-
mended. The use of criterion based on intraoperative
ultrasonography (IOUS) may limit the need for extensive
hepatectomy in these conditions. An intention-to-treat
prospective study to validate this hypothesis has been
conducted in a cohort of patients carrier of at least one
colorectal metastasis (CLM) in contact with a HV at CC.
Method: Thirty-eight patients showing at preoperative
imaging at least one CLM in contact with a HV at CC
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were enrolled. Based on IOUS-findings, 3 patterns of
presentation were recognized and respective surgical
policies were established: Type A-HV in contact with
CLM for <1/3 of its circumference, regardless of longi-
tudinal extension:vein-sparing with tumor-detachment
was planned; Type B-HV involvement ranging 1/3–2/3
of its circumference, regardless of longitudinal exten-
sion:vein-sparing with HV wall resection and recon-
struction by direct-suture or patching was planned;
Type C-HV involvement for ≥2/3 of its circumference
with or without interruption of vessel wall at IOUS:
vein-resection was planned.
Results: In 28 (74%) patients a J-shaped-thoracophren-
olaparotomy was performed. At IOUS exploration of
the 38 patients, 25 included at least a Type A contact,
13 a Type B, while 9 a Type C invasion. No major hep-
atectomy was required. Tumor-detachment from HV
was feasible in 30 (79%) patients, HV reconstruction
with direct-suture was needed in 13 (34%), while HV-
resection was performed in 9 (23%). Median operation
and clamping time was 501 minutes (range 303–889),
121 minutes (range 56–279), respectively. Blood trans-
fusions rate was 16%. Postoperative mortality was nil.
Overall and major morbidity rate was 39%, 5%,
respectively. No local-recurrences have been observed
at a median follow-up of 13 months (range 6–34).
Conclusions: Preserving liver parenchyma in hepatec-
tomy is the key-factor to ensure better postoperative
results. This proposed tumor-vessel classification has
been validated on an intention-to-treat perspective and
in all patients was able to predict the proper surgical
strategy. Adopting these criteria major hepatectomies
can be avoided in favor of a surgical policy, which is
safe and featured by acceptable oncological radicality.
FO07-06
PORTAL VEIN EMBOLIZATION AND
STEM CELLS APPLICATION IN
PRIMARY UNRESECTABLE
COLORECTAL LIVER METASTASES.
Vladislav Treska, Tomas Skalicky, Jakub Fichtl,
Daniel Lysak, Slauf Frantisek and Bruha Jan
University Hospital, Medicine Faculty, Czech Republic
Introduction: Only 20–25% of patients with colorectal
liver metastases (CLM) can undergo a radical surgery.
Insufficient future liver remnant volume (FLRV) is one
of the causes of CLM unresectability. Portal vein
embolization (PVE) together with administration of ha-
ematopoietic stem cells (HSC) may significantly expand
resectability of primarily radically unresectable CLM.
Method: Authors report on 10 patients with primary
unresectable CLM (FLRV <30%), who underwent
PVE on the side of the CLM with a subsequent appli-
cation of autologous HSC to the non-embolized branch
of the vena portae on the other side.
Results: The PVE with application of HSC was with-
out any complications. In all patients, the liver volume
growth was sufficient after 3–4 weeks after HSC appli-
cations. R0 hepatectomy was performed in seven
patients (70%). Exploratory laparotomy was performed
in three patients (2- tumour progression, 1-severe adhe-
sions). One and three years overall survival rate was
66.7, resp. 33.3%. Median of progression free survival
was 9 months. One patient died 15 months after
extended right hepatectomy due to disease progression.
Other patients are between 3–12 months after the sur-
gery and in good condition; one of them was diagnosed
with pulmonary metastasis after nine months that was
successfully treated with laser metastasectomy.
Conclusions: Combination of PVE with administration
of HSC appears to be a promising method that stimu-
lates growth of FLRV with a subsequent possibility of
early radical liver resection. The issue is a danger of
tumour progression in the liver parenchyma following
the PVE with HSC. The current randomized study
should answer this question.
FO07-07
INDICATION CRITERIA OF
PREOPERATIVE CHEMOTHERAPY
FOR COLORETCAL LIVER
METASTASES
Hiroshi Kawamoto, Hiroaki Terajima, Sena Iwamura,
Rei Toda, Yoshikage Inoue, Mami Yoshitomi,
Yoichiro Uchida, Taku Iida, Shugo Ueda and
Akiyoshi Kanazawa
Kitano Hospital, Japan
Introduction: It remains to be discussed what is the
appropriate criteria for applying preoperative chemo-
therapy (PreC) for coloretcal liver metastases (CRLM).
The significance of PreC and its indication criteria for
CRLM was retrospectively investigated by using the
nomogram analysis predicting disease free survival after
hepatectomy (J Hepatobiliary Pancreat Sci (2012)19:
72–84).
Method: Six preoperative risk factors associated with
disease free survival and their respective risk scores of
recurrence were determined based on the multicenter
data collection: (1) synchronous, 3 pts.; (2) primary
lymph node positive, 3 pts.; (3) number of tumors 2–4,
4 pts. and ≥5, 9 pts.; (4) largest tumor diameter >5 cm,
2 pts.; (5) extrahepatic metastases at hepatectomy, 4
pts.; (6) preoperative carbohydrate antigen 19-9 level
>100, 4 pts. Ninety-three patients undergoing initial
hepatectomy for CRLM from 2001 to 2013 in our insti-
tute were divided into 2 groups based on the sum of
the forementioned risk scores: group H (risk scores 0–
6; n = 36) and group L (risk scores ≥7; n = 57).
Results: In the group L, median progression free sur-
vival (PFS) of patients with PreC (n = 6) was signifi-
cantly shorter than that without PreC (n = 30)
(7.4 months vs. 21.6 months, p = 0.0009), suggesting
no beneficial effect of PreC. In the group H, median
PFS of patients with PreC (n = 35) was not signifi-
cantly different from that without PreC (n = 22)
(12.4 months vs. 10.1 months, p = 0.68). However,
considering the significantly higher risk scores in
patients with PreC (12.4 vs. 9.1, p = 0.0001), PreC may
provide a better therapeutic efficacy compared with
surgery alone.
Conclusions: Only the high risk group of recurrence
evaluated by the nomogram analysis may be a candi-
date for PreC in the treatment of CRLM.
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FO07-08
DEFINING THE OPTIMAL
CONVERSION CHEMOTHERAPY
REGIMEN FOR PATIENTS WITH
INOPERABLE LIVER ONLY
METASTASES FROM COLORECTAL
CANCER – A SYSTEMATIC REVIEW
AND META-ANALYSIS
Stuart Robinson, John Moir, Ashraf Azzabi,
Derek Manas, Ian Pedley and Steven White
Freeman Hospital, United Kingdom
Introduction: A significant proportion of patients with
colorectal liver metastases present with inoperable dis-
ease. For these patients the only realistic prospect for
achieving long term cure is through the administration
of systemic chemotherapy with the goal of shrinking
disease to facilitate surgery.
The aim of the current study was to determine the most
effective conversion chemotherapy regimen in patients
with liver only metastases.
Method: MEDLINE, EMBASE and CENTRAL were
searched to identify RCT’s reporting the proportion of
patients with inoperable liver only metastases who were
able to undergo curative intent surgery after systemic
chemotherapy. Meta-analysis was performed using a
fixed effects model with outcomes reported as relative.
The correlation between resection rate and response
rate was assessed with Spearmans correlation co-effi-
cient.
Results: Ten studies reporting outcomes of 1,567
patients with liver only metastases were suitable for
inclusion. The combination of 5-FU/Irinotecan appears
to be less effective than 5-FU/Oxaliplatin in achieving
conversion to operability (RR 0.19; 95% CI 0.04–0.83;
p = 0.03).
The three agent regimen of 5-FU/Irinotecan/Oxaliplatin
is more effective that 5-FU/Irinotecan alone in achiev-
ing conversion to operability (RR 3.02; CI 1.20– 7.59;
p = 0.019). There was insufficient data to be able to
draw firm conclusions about the use of the biological
agents Bevacizumab and Cetuximab.
A precise definition of operable disease was only pro-
vided in 3 out of 10 studies. Response rate and resec-
tion rate do correlate within the included studies
although this association is week (r = 0.44; p = 0.046).
Conclusions: First line treatment with an Oxaliplatin
containing regimen appears to be the most effective
conversion chemotherapy regimen. Evidence to support
the routine use of biological agents is lacking when
resection rate is used as an outcome measure.
Future studies should include a precise assessment of
what constitutes operable/inoperable disease and con-
version to operability as a primary outcome measure.
FO08-01
LIVER RESECTION IN PATIENTS WITH
NUMEROUS (>7) COLORECTAL LIVER
METASTASES. OUTCOMES AND
SELECTION OF CANDIDATES FOR
SURGERY
Luca Vigano1, Lorenzo Capussotti1, Pietro Majno2,
Alessandro Ferrero1, Christian Toso2,
Giovanni De Rosa1, Laura Rubbia-Brandt2 and
Gilles Mentha2
1Ospedale Mauriziano Umberto I, Torino, Italy;
2University Hospitals, Geneva, Switzerland
Introduction: Patients with numerous colorectal liver
metastases (CRLM) are potential candidates for resec-
tion, but their benefit from surgery is unclear. Is there
a numerical limit to resectability? To investigate out-
come of surgery in patients with >7 CRLM.
Method: 849 patients undergoing resection for CRLM
between 1998 and 2012 were analyzed. Patients were
categorized into two groups: 743 with 1–7 metastases
(Group A) and 106 with >7 metastases (Group B).
Results: Group B had more often synchronous (86.8%
vs. 56.8%, p < 0.0001) and bilobar metastases (87.7%
vs. 32.6%, p < 0.0001). Almost all group B had preop-
erative chemotherapy (95.3% vs. 60.2%, p < 0.0001).
Group B had higher proportion of major hepatecto-
mies (52.8% vs. 33.6%, p < 0.0001), two-stage hepatec-
tomies (50.0% vs. 5.8%, p < 0.0001) and 0-mm margin
(31.1% vs. 15.0%, p < 0.0001).
90-day mortality was 0.4% (3/849, all group A
patients). Morbidity rates were similar. Group A had
higher survival (median follow-up 36.8 months): 5-year
overall survival 44.2% versus 19.7%, p < 0.0001; 5-year
recurrence-free survival 29.2% versus 14.8%,
p < 0.0001. Group B had more hepatic recurrences
(58.1% versus 37.2%, p = 0.005). Overall and recur-
rence-free survival rates were similar for patients with
8-10 (n = 48), 11–15 (n = 40) or >15 metastases
(n = 18).
In the group B, the multivariate analysis identified
three adverse preoperative prognostic factors: rectal
cancer (p = 0.005); extra-hepatic disease (p = 0.003); no
response to chemotherapy (p = 0.028). Patients with >1
risk factor had no benefit from surgery (median overall
and recurrence free-survival 16.9 and 6.9 months versus
33.2 and 9.3 if one risk factor versus 54.3 and 22.2 if
none, p < 0.05).
Conclusions: Liver resection is safe and effective also
for patients with >7 metastases. Their outcome is
poorer than patients with 1–7 lesions, but long surviv-
als are possible, independently from the number of
metastases. Benefit from resection is lost only in
patients with >1 negative prognostic factor (rectal can-
cer, extra-hepatic disease, no response to chemother-
apy), for whom surgery should not be scheduled.
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FO08-02
IMPACT OF POSTOPERATIVE
COMPLICATIONS ON RECURRENCE IN
LIVER RESECTION FOR COLORECTAL
METASTASES
Miroslav Levy, Vladimir Visokai, Ludmila Lipska,
Marek Mracek, Karel Veskrna and Jaromir Simsa
First Medical Faculty Charles University, Thomayer
Hospital Prague, Czech Republic
Introduction: Liver metastases will appear approxi-
mately in 40% of patients with colorectal carcinoma,
synchronous metastases are present at time of diagnosis
of CRC in 15–20% of patients, in another 20% of
patients will develop metachronous metastases (most
often within 2 years) after resection of primary CRC.
Surgery remains the only option for curative radical
treatment for liver metastases for colorectal carci-
noma. Aim of our study was to evaluate the impact of
postoperative complications following radical surgery
for colorectal cancer metastases on disease free interval.
Method: There were 185 liver resections in 155 patiens
operated for CRLM between 1996 and 2012 at our sur-
gery. Fifty two patients were operated for metachro-
nous, 103 patients for synchronous liver metastases, 80
of these operated simultaneously with colon or rectum
resection. Postoperative complications occur in 37 oper-
ations.
We identified minor complications (Clavien-Dindo clas-
sification I, II): wound abscess, pneumonia, postopera-
tive bowel obstruction and other in 22 patients
(59.5%), moderate complications (Clavien-Dindo III):
intraabdominal abscess, colon anastomotic leakage,
severe bleeding in 8 patients (21.6%), and severe septic
complications: sepsis, peritonitis, liver failure in 7
patients (18.9%).
Results: Median follow up was 2.1 year. Significantly
worse disease-free interval was found in patients with
severe septic complications. Other, less serious compli-
cations also increase the risk of recurrence, but not sta-
tistically significantly. In all patients, in contrary to
simillar study in colon cancer resection, there is no sta-
tistical significancy in reccurency in liver between
patients with and without postoperative complications.
Conclusions: Severe septic complications have an
adverse effect on the further course of the disease in
terms of relapse. In addition, serious complications
increases postoperative mortality, prolong hospitaliza-
tion, increase the cost of treatment. Supported by
grants: GAAV IAA500200917, IGA NT13424-4/2012,
GACR P304/12/1585.
FO08-03
RECURRENCE PATTERN AND
SURVIVAL IN PATIENTS UNDERGOING
SIMULTANEOUS RESECTION FOR
SYNCHRONOUS LIVER METASTASES
FROM PRIMARY COLORECTAL
CANCER
Rajay Kumar1, Sang-Jae Park2, Seong Hoon Kim2,
Sung-Sik Han2, Young-Kyu Kim2, Seung-Duk Lee2,
Sung Chan Park2 and Jae Hwan Oh2
1Fellow, India; 2National Cancer Center, Korea
Introduction: The optimal treatment strategy for
patients with resectable synchronous liver metastases
from colorectal cancer (SLMCC) is unknown, and the
pattern of recurrence after simultaneous resection has
not been well understood. In this study which is the
largest series to date, the authors examined recurrence
patterns and survival after simultaneous resection for
SLMCC.
Method: Two hundred and forty-five consecutive
patients with SLMCC who underwent complete simul-
taneous resection of both the rectal primary and liver
metastases with curative intend between May 2001 and
December 2010 were identified from a prospective data-
base. Demographical and Clinicopathological factors
were retrospectively analyzed to investigate initial
recurrence pattern, overall survival and recurrence free
survival. A review of literature was done and the results
were compared with historical data.
Results: There was no mortality in our study.
There was 86.5% 3 years/55.4% 5 years OS and 28.9%
3 years/ 25.9% 5 years RFS for the entire cohort with
a median follow-up of 60.8 months for survivors. One
hundred eighty one patients (73.8%) developed a recur-
rence. Most common site of the initial recurrence was
the liver (50.2%), followed by the lung (25.9%) and lo-
coregional (10.4%). Site of recurrence had a significant
impact on survival and prognosis. Preoperative chemo-
therapy (p < 0.001), postoperative radiotherapy and
lymphovascular invasion (p = 0.024) were significant
factors affecting overall survival while hepatic resection
margin (p-0.033), number of hepatic metastases (p-
0.028) and PNI (p-0.051) were significant factors affect-
ing RFS.
Conclusions: This study establishes the safety and
oncological feasibility of simultaneous resection of
SLMCC. All the results of this study were comparable
to historical data available including recent large series,
systemic recurrences were overwhelmingly more com-
mon than pelvic recurrences. Initial recurrence patterns
were important to predict survival, evaluate prognosis
and suggest treatment options. Neoadjuvant chemora-
diotherapy to achieve local control in these patients
might not be necessary routinely.
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FO08-04
PROGNOSTIC SCORE FOR
COLORECTAL LIVER METASTASES
Yuriy Kovalenko1, Alexey Zhao1 and
Andrey Chugunov2
1Member of IHPBA, Russia; 2 Russia
Introduction: The multidisciplinary approach to treat-
ment of patients with colorectal liver metastases has
improved long-term results. The prognosis of recur-
rence depends on the individual complex assessment of
the clinicopathologic and molecular factors having
maximum “weight” for survival.
Method: 77 patients underwent liver resection for colo-
rectal metastases were studied. The effect independent
clinicopathologic and molecular predictors on outcome
were tested using univariate and multivariate analyses
by the Cox regression. This study evaluated immuno-
histochemical expression CК 20, b-cat, Ki-67 in 20 sur-
gically resected specimens of liver metastases. The
prognostic molecules were significantly associated with
recurrence after hepatic resection. Our prognostic sys-
tem based on calculation of number of the points cor-
responding to clinicopathologic and molecular factors.
The data was applied to our proposed mathematical
formulas.
Results: Survival was estimated using the Kaplan–Me-
ier analysis. The overall and recurrence-free 5-year sur-
vival rates were 31% and 16%, respectively.
Histological differentiation and molecular markers b-
cat, Ki-67, CK 20 were the major determinants of sur-
vival and recurrence for total patient population. The
univariate analysis indentified only histological differen-
tiation as independent and clinically significant corre-
lates of both survival and recurrence. The more patient
gathered points, the prognosis was worse. The proba-
bility of recurrence for patient was 85% at 2 years. In
15 patients was moderate prognosis (recurrence from
12 to 24 months), in 5 patients – poor prognosis (recur-
rence to 12 months). In 88% patients calculated prog-
nosis was confirmed within 2 years after operation.
Conclusions: Prediction of recurrence will allow have
adequate follow up in long-term period and regimens
of the neoadjuvant chemotherapy after liver resection.
FO08-05
PROGNOSTIC IMPLICATION OF
MUCINOUS HISTOLOGY IN RESECTED
COLORECTAL CANCER LIVER
METASTASES
Marcos Perini1, Fabricio Coelho2, Evandro Mello2,
Jaime Kruger2, Gilton Marques2, Renato Lupinacci2
and Paulo Herman1
1Attending surgeon, France; 2Attending surgeon, Brazil
Introduction: Colorectal mucinous adenocarcinoma is a
subtype of colorectal adenocarcinoma with prominent
mucin production associated with proximal location of
tumor, advanced stage at diagnosis, microsatellite insta-
bility, and BRAF mutation. The prognostic implication
of mucinous adenocarcinoma (MAC) in colorectal can-
cer liver metastases (CRCLM) is unknown. The pur-
pose of our study was to determine the frequency and
elucidate the prognostic implication of mucinous histol-
ogy in resected CRCLM.
Method: The medical records of 118 patients who
underwent resection of CRCLM during the period
between 2000 and 2010 were reviewed. Clinicopatho-
logic variables and outcome parameters were examined.
Resected specimens were submitted to routine histologi-
cal evaluation. Patients were grouped according to the
metastasis mucinous content: >50%, mucinous adeno-
carcinoma (MAC); <50%, adenocarcinoma with inter-
mediated mucinous component (AIM); and without
any mucinous component, non-MAC (NMA).
Results: Mean follow-up after resection was
38 months. Tumor recurrence was observed in 76
patients. Overall survival and disease-free survival
(DFS) rates after hepatectomy were 62%, 56%, and
26%, 24% at 3-, and 5-years, respectively. Tumors with
mucinous component (AIM and MAC) were related to
proximal location of the primary tumor and were more
frequently observed in females. Multivariate analysis
revealed that MAC was an independent negative prog-
nostic factor (HR 2.77, 95%CI 1.28–5.97; p = 0.009)
compared with non-MAC (NMA and AIM). Also,
AIM when compared with NMA was independently
associated with worse OS.
Conclusions: AIM and MAC have an adverse prognos-
tic impact compared with NMA which could have
potential influences on therapeutic choices. It raises an
important subject for discussion and future investiga-
tion.
FO08-06
THE BIOLOGICAL AND CLINICAL
SIGNIFICANCE OF DIFFERENT
MORPHOLOGIC TYPES OF
COLORECTAL LIVER METASTASES
Pulathis Siriwardana1, Mohamed Ghazalay1,
Tu Vinh Luong2, Jennifer Watkins2, Helen Turley3,
Kevin Gatter4, Manlio Vinciguerra5, Adrian Harris3,
Daniel Hochhauser6 and Brian Davidson1
1Royal Free Hospital and UCL medical school, United
Kingdom; 2Royal Free Hospital, United Kingdom;
3University of Oxford, United Kingdom; 4Oxford
University Hospital, United Kingdom; 5University
College London, United Kingdom; 6University College
London Cancer Institute, United Kingdom
Introduction: Colorectal cancer is the third commonest
cancer in the world. A third of patients develop colo-
rectal liver metastases (CRLM). Approximately 60% of
patients who have had curative resection for CRLM
eventually develop recurrent and/or metastatic disease
and 80% are unsuitable for further resection. Under-
standing the morphology and biology of CRLM may
lead to better prognostication and treatment.
Method: Microsections (5lM) of CRLM from n = 30
chemo-naive patients were stained with Haematoxylin-
eosin (H&E) to study the tumour morphology. Immu-
nostaining for Hypoxia-Inducible-Factor1a (HIF1a),
Ki67 and CD31 was performed. HIF1a expression; per-
centage of stained nuclei and cytoplasms, tumour pro-
liferative index (TPI); number of Ki67 stained cells per
1,000 cells, intra-tumoural microvascular density
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(IMD); number of CD31 stained microvessels /25 mm2
in a X200 field in a vascular-hotspot and intratumoural
vascular pattern in the different morphological types
were studied. Tumour morphology was collated with
the overall survival (OS).
Results: There were three morphological types. ‘Des-
moplastic’; (n = 10.33%), had fibrous tissue separating
the metastasis from the surrounding liver parenchyma.
Whilst peri-tumoural-hepatocytes were infiltrated in
‘Infiltrative’; (n = 12.40%), they were compressed in
‘Pushing’; (n = 1.3%). Seven tumours (24%) had a
mixed morphology. The glandular structures in the
Desmoplastic and Pushing types were large, complex
and cribriform with micro-vessels confined to a fibro-
vascular stroma whilst in the Infiltrative type, glands
were single, well-formed with micro-vessels between
glands. The IMD was significantly higher in the Infil-
trative type than in the Desmoplastic (Mean  SEM
33.5  3.5 vs. 12.2  1.6; p < 0.0001). Although the
mean TPI (657  57.5 vs. 533  55.1) and HIF1a
expression (High expression in 89% vs. 58% tumours)
were higher in the Desmoplastic than the Infiltrative
type respectively the difference was not statistically sig-
nificant. The OS of patients with Desmoplastic type
was significantly higher than those with the Infiltrative
type (108 months  10 vs. 72  55; p < 0.036); log-
rank.
Conclusions: Different types of CRLM have unique
morphology, vasculature, biology and clinical. Further
studies are needed to determine any causative interac-
tions.
FO08-07
ISOLATED HEPATIC PERFUSION FOR
OCULAR MELANOMA METASTASIS –
REGISTRY DATA SUGGESTS A
SURVIVAL BENEFIT
Per Lindner1, Jan Mattson2, Magnus Rizell1 and
Roger Olofsson2
1Transplant institute, Sweden; 2Department of Surgery,
Sweden
Introduction: Uveal melanoma is the most common
primary intraocular malignancy in adults. Despite suc-
cessful control of the primary tumor, metastatic disease
will ultimately develop in approximately 35% of the
patients with the liver being the most common site for
metastases. These metastases are generally refractory to
systemic chemotherapy and the median survival for
patients with liver metastases is about 6 months. This
phase II trial reports the experience of isolated hepatic
perfusion (IHP) as a treatment option.
Method: Thirty-four patients with isolated liver metas-
tasis from ocular melanoma underwent IHP. An overall
survival (OS) comparison was made using data
retrieved from the National Patient Register managed
by the Swedish National Board of Health and Welfare
Results: An overall radiological response was seen in
23 of 34 patients (68%) with four patients having a
complete response (CR 12%). Hepatic progression-free
survival was 7 months and twenty-three patients (68%)
developed extra-hepatic metastases after a median of
13 months. Twenty-five patients (74%) have died with
a median survival of 24 months. Significant prognostic
factors for increased survival were all related to tumor
burden. There was a significant survival advantage of
14 months (p = 0.029) when comparing these patients
with a control group consisting of the longest surviving
patients in Sweden with uveal melanoma liver metasta-
ses, not treated with IHP.
Conclusions: IHP is a treatment option with a high
response rate and a potential survival benefit of more
than one year. IHP should be considered an option in
the treatment of uveal melanoma metastases. A ran-
domized trial comparing IHP and best alternative care
will start during 2013 (the SCANDIUM trial, Clinical-
Trials.gov identifier NCT01785316).
FO08-08
SURGICAL OUTCOMES AND
CLINICOPATHOLOGIC
CHARACTERISTICS OF
GASTROENTEROPANCREATIC
NEUROENDOCRINE TUMORS WITH
HEPATIC METASTASIS: A SINGLE
CENTER EXPERIENCE
Shunda Du1, Zi Wang1, Yilei Mao1, Xinting Sang1,
Xin Lu1, Chunmei Bai1, Wenze Wang1,
Hua Fan Minogue2, Shouxian Zhong1 and
Jiefu Huang1
1Peking Union Medical College Hospital, China;
2Stanford University, USA
Introduction: Complete surgical resection has been used
as a curative therapy for neuroendocrine liver metasta-
sis (NELM) patients. However, the surgical outcome
and clinicopathologic feature of NELM are still not
determined. We aimed to identify prognostic factors
and evaluate the outcome of surgery and other thera-
pies.
Method: A retrospective cohort study was performed
on 76 patients undergoing surgery (n = 46) or other
types of treatments (n = 30) for NELM from 1990 to
2012 at Peking Union Medical College Hospital (PUM-
CH). Relevant clinicopathologic data were analyzed
using Kaplan–Meier and COX regression models.
Results: Pancreas was the origin in 65.8% of NELM
patients. Synchronous hepatic metastasis was found in
85.5% of patients at the first diagnosis. Syn was posi-
tive in 95.5% of the IHC staining of the tumor tissues
and CA199 was positive in 28.1% of the blood sample.
Univariate analyses identified diagnostic age >50 (log-
rank, p = 0.018), primary tumor resection (log-rank,
p = 0.000), hepatic metastasis size >5 cm (log-rank,
p = 0.013), positive vessel invasion (log-rank,
p = 0.007) as worse prognostic factors of statistical sig-
nificance. On multivariate analyses, Age >50
[HR = 2.6], Primary tumor size >3 cm [HR=4.6], non-
resected primary tumor [HR = 10.4] remained predic-
tive of poor survival (all p < 0.05). Among the 46
patients accepting primary tumor resection, median and
5-year survival were 120 months and 77% for hepatic
metastatic tumor resection versus 78 months and 62%
for other liver-directed therapies (But p > 0.05). Surgi-
cal resection of the primary tumor also provided a sur-
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vival benefit among patients with diffuse, unresectable
hepatic metastases (p = 0.000).
Conclusions: Pancreas remains the most common ori-
gin of NELM. Young patients with smaller primary
tumor size derive the greatest survival benefits from
surgical resection of primary tumor, even when hepatic
metastases are diffuse and unresectable. Surgical resec-
tion of hepatic metastases may possibly benefits sur-
vival, which needs further investigation.
FO09-01
PRE-OPERATIVE CHEMOTHERAPY
ADMINISTERED IN RECOMMENDED
DOSES DOES NOT INCREASE
MORBIDITY AND MORTALITY RATES
IN LIVER RESECTIONS
Jasmine Wong, Paul Bergamin, Eugenia Ip and
Koroush Haghighi
The Prince of Wales Hospital, Australia
Introduction: Pre-operative chemotherapy can be
administered to patients with resectable lesions as neo-
adjuvant chemotherapy or to downstage inoperable dis-
ease. Current literatures suggest that pre-operative
chemotherapy can increase postoperative mortality and
morbidity in patients due to damage to hepatic paren-
chyma. This study compares the effects of pre-operative
chemotherapy on the outcomes of liver resections.
Method: A retrospective analysis of prospective data
collected on 364 patients undergoing liver resection
between January 2007 and July 2013 in Prince of Wales
and St. Vincents Hospitals in Sydney by a single sur-
geon (Haghighi KS). The outcomes of patients who
received pre-operative chemotherapy (Group 1) were
compared to patients who had surgery alone (Group
2).
Results: There are 113 patients in group 1 and 251
patients in group2. There were 11.5% and 18.3% of
patients ≥75 years old in group 1 and 2 respectively.
55.8% (n = 63) of patients in group1 underwent
extended resections compared to 50.8% (n = 120) in
group2. The mortality rates were 1.7% (n = 2) in
group1 and 0.4% (n = 4) in group2. According to the
Clavien-Dindo Classification, the major morbidity rates
were 8% (n = 8) and 6.4% (n = 13) for group1 and 2
respectively. The median length of ICU stay was 1
(range 0–7) for group1 and 1 (range 0–5) for group 2.
The median length of stay in hospital is 8 days (range
1–43) in group1 and 7 days (range 3–27) in group2.
14.2% (n = 16) of patients in group 1 received intraop-
erative blood transfusions compared to 15.5% (n = 39)
in group 2.
Conclusions: Our study demonstrates that there is no
significant increase in perioperative morbidity or mor-
tality associated with pre-operative chemotherapy when
administered appropriately in the recommended dose.
FO09-02
A PREDICTIVE POWER OF
PROTHROMBIN TIME AND SERUM
TOTAL BILIRUBIN FOR
POSTOPERATIVE MORTALITY AFTER
MAJOR HEPATECTOMY WITH
EXTRAHEPATIC BILE DUCT
RESECTION
Yukihiro Yokoyama, Tomoki Ebata, Tsuyoshi Igami,
Gen Sugawara, Takashi Mizuno and Masato Nagino
Nagoya University Graduate School of Medicine, Japan
Introduction: In 2011, the International Study Group
of Liver Surgery defined posthepatectomy liver failure
using the prothrombin time international normalized
ratio (PT-INR) and total serum bilirubin concentration
(T-Bil). However, the data analyzing the clinical impact
of PT-INR and T-Bil on postoperative mortality are
still limited, especially for the cases of major hepatec-
tomy with extrahepatic bile duct resection (HEBR).
Method: Prospectively collected data from 545 patients
who underwent HEBR in a single institution from 2002
to 2011 were analyzed. Receiver operating characteris-
tics (ROC) analyses of PT-INR and T-Bil on postoper-
ative days (POD) 1, 3, and 5 were used to determine
optimal cut-off values for predicting postoperative mor-
tality.
Results: Most of the treated diseases were biliary tract
cancers, including perihilar cholangiocarcinoma
(n = 418), gallbladder carcinoma (n = 52), and intrahe-
patic cholangiocarcinoma (n = 27). The mean values
for PT-INR and T-Bil on POD 1, 3, and 5 were signifi-
cantly higher in the patients who died due to postoper-
ative complications than in the patients who survived.
On POD 5, the area under the ROC curve for predict-
ing postoperative mortality and the optimal cut-off
value for PT-INR were 0.876 and 1.68 mg/dL, respec-
tively, whereas those of T-Bil were 0.889 and 4.0 mg/
dL, respectively. A combination of PT-INR and T-Bil
showed a strong predictive power (i.e., more than 40%
of the patients with values beyond the cut-off value for
both factors on POD 5 died).
Conclusions: We recommend monitoring both PT-INR
and T-Bil to accurately predict which patients are at a
high risk after HEBR.
FO09-03
A SYSTEMATIC REVIEW AND
META-ANALYSIS OF ISCHEMIC
PRECONDITIONING IN HEPATIC
RESECTION: PERSPECTIVE FROM
TRANSLATIONAL MEDICINE
Han Zhang1, Xing Huang2, Shu-Yang Dai2,
Yi-Nan Shen1, Shou-Xin Yuan1, Tian Yang1,
Meng-Chao Wu1 and Feng Shen1
1Eastern Hepatobiliary Surgery Hospital, China;
2Second Military Medical University, China
Introduction: Hepatic ischemia/reperfusion injury (IRI)
during major liver surgeries, especially those using vas-
cular occlusion techniques, is a main contributing fac-
tor to perioperative morbidities and mortalities. The
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beneficial effect of ischemic preconditioning (IP) to IRI
has been proven in various organs. However, studies
on the protective effect of IP on IRI of the liver in
hepatic resection have yielded controversial results.
Method: A comprehensive retrieve for animal experi-
ments reporting IP in hepatic resection, as well as clini-
cal RCTs comparing IP with control for hepatic
resections published prior to July 2013 were performed
by searching Pubmed, Embase, OvidSP and the Coch-
rane Library. A total of 20 animal studies and 14 clini-
cal investigations were analyzed. Reviews of each study
were conducted and data were extracted. In meta-
analysis, data pooling was done using Random effect
methods.
Results: Five animal studies and 14 clinical investiga-
tions were included for systematic review. No signifi-
cant baseline demographic different was found among
human subjects. Data for meta-analysis were retrieved
from 8 RCTs consisting of 464 patients. Aspartate ami-
notransferase (AST) and alanine aminotransferase
(ALT) levels on the first postoperative day in the is-
chaemic preconditioning group were significantly lower
than that in the control group. No statistically signifi-
cant differences were found in mortality, rate of liver
failure, perioperative complications, perioperative trans-
fusion, length of hospital stay and operating time.
Conclusions: In warm liver ischemia and hepatic resec-
tion in animals, IP is associated with an increased sur-
vival rate and decreased extent of liver injury. While
despite decreased liver enzyme levels and a shorter hos-
pital stay, beneficial effects of IP in surgery-related
mortality and morbidities were not seen in the clinical
setting.
FO09-04
PROSPECTIVE VALIDATION OF THE
PORTAL VEIN PRESSURE AFTER
HEPATECTOMY AS A PREDICTOR OF
POSTHEPATECTOMY LIVER FAILURE
Kenichiro Araki, Marc-Antoine Allard, Petru Bucur,
Oriana Ciacio, Gabriella Pittau, Antonio Sa Cunha,
Daniel Cherqui, Denis Castaing, Rene Adam and
Eric Vibert
Hopital Paul Brousse, France
Introduction: In our previous study, portal vein pres-
sure (PVP) measured intraoperatively after hepatec-
tomy higher than 20 mmHg was identified as a
predictor of postoperative liver failure (PLF) after
major hepatectomy on non-cirrhotic liver. Whether
high PVP is associated with PLF in a prospective study
remains unknown. We investigated prospectively the
relationship between PVP and PLF and to assess rela-
tionship between PVP and the future remnant liver vol-
ume (FLRV) / body weight (BW) ratio.
Method: The PVP was prospectively measured in all
consecutive patients (n = 43) operated on for a major
hepatectomy on non-cirrhotic liver from May 1st 2012
to July 1st 2013 at our institution. The primary end
point of the study was PLF defined by the “50-50” cri-
teria.
Results: The median PVP observed was 12 mmHg
(range, 3–23 mmHg). All patients had a FLRV/BW >
0.5%. There was no death within the 90-day postopera-
tive period. Three patients developed PLF. The median
PVP value of patient with PLF was 21 mmHg (12–23)
versus 11 mmHg (3–22) in patients without PLF
(p = 0.055, Mann–Whitney test). Of the 4 patients who
had a PVP >20 mmHg, two (50%) developed PLF ver-
sus a single one (2.5%) among the 39 patients who pre-
sented a PVP <21 mmHg (p = 0.019; Fisher test).
There was no significant linear relationship between
PVP after resection and the FLRV/BW ratio
(p = 0.19). However, 12 patients (39%) with a ratio
<1% had a PVP ≥15 mmHg versus 1 patient (8%) of
the 12 with a ratio ≥1% (p = 0.07).
Conclusions: The results of this prospective study con-
firm the impact of intraoperative high PVP on the risk
of PLF with cutoff value of 20 mmHg.
FO09-05
INTRAHEPATIC
CHOLAGIOCARCINOMA: A SINGLE-
INSTITUTION TWELVE-YEAR
EXPERIENCE WITH 144 CASES
Jin Ho Lee and Gi Hong Choi
Yonsei University College of Medicine, Korea
Introduction: Intrahepatic cholangiocarcinoma (ICC) is
a rare primary malignant disease of liver. And surgical
treatment is the only known cure for the disease. In
this study, we examine the impact factor of tumor
recurrence and recurrence pattern of tumor according
to the tumor location of liver and nodal status. And we
were investigated prognostic factors of ICC which
influence the survival.
Method: We reviewed the medical records of 144
patients diagnosed with intrahepatic cholangiocarcino-
ma from January 1995 to November 2012 retrospec-
tively. Patient and tumor characteristics including
oncologic outcomes were analyzed.
Results: Eighty-nine patients were male and 55 were
female, with a mean age of 62.51  9.8 years. During
the follow up period 78 (54.1%) patients were recur-
rence of ICC. The median disease free survival (DFS)
was 57.6 months. And the median overall survival (OS)
was and 57.7 months and the 1-, 3-, 5 year survival
rate were 68%, 57%, 43% respectively. Perineural inva-
sion (PNI) (p = 0.023) and pathologic tumor size (pTS)
(p = 0.023) were statistically significantly correlation of
survival. And pT stage was statistically significant cor-
relation with recurrence (p = 0.014) and recurrence pat-
tern was statistically significant correlation according to
tumor location of liver (p = 0.043). If the tumor was
on the left lobe of liver the intrahepatic and other
organ recurrence were more common than right or cen-
tral lobe of liver. In addition, DFS (5 year DFS of
17.7%, p = 0.048) and OS (5 year OS 68.5%,
p = 0.026) were improved in LN negative patients
groups but DFS and OS were not statistically signifi-
cantly different among the pT stage and pTNM stage
respectively. However, LN metastasis (p = 0.272) and
tumor location of liver (p = 0.666) was not statistically
significant correlation with recurrence.
Conclusions: The PNI and pTS were associated with
survival. Although LN metastasis provides no prognos-
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tic information, active lymphadenectomy should be
considered because up to 40% of patients will have LN
metastasis.
FO09-06
SHORT AND LONG TERM OUTCOME
OF 74 LIVER RESECTIONS FOR
POLYCYSTIC LIVER DISEASE
Beatrice Aussilhou, Safi Dokmak, Olivier Farges,
Alain Sauvanet and Jacques Belghiti
Beaujon Hospital, France
Introduction: To analyse the short and long term
results of a large unicentric series of partial liver resec-
tions for highly symptomatic polycystic liver disease
(PLD).
Method: Since 1995, among 281 patients with PLD
managed in our department, 74 including 70 females
aged 31 to 80, underwent partial liver resection for
highly symptomatic PLD. Exclusion criteria were severe
renal insufficiency, ascites and/or marked denutrition.
Patients were stratified in Gigot classification (GC):
type I (12 = 16%), type II (32 = 43%) and type III
(30 = 41%). Resections included 35 left hepatectomies,
23 right hepatectomies, 14 left lateral sectionnectomies
(LLS) and 2 limited resections. All were associated with
unroofing of the cysts in the remnant liver.
Results: The mean operative duration (315 minutes)
ranging from 200 to 375 was similar in all type of
resections. The transfusion rate was related to the GC:
type I (17%), type II (34%) and type III (47%), respec-
tively, (p < 0.05). One patient died postoperatively
(1.3%). The overall morbidity was observed in 51%,
including ascites in 45% with 80% after right hepatec-
tomy (p < 0.05), haemorrhage (15%), biliary fistula
(14%), transitory liver insufficiency (12%) and fever
(16%). No alteration of renal function was noted. The
highest morbidity (ascites and liver insufficiency) was
noted after right hepatectomy in Gigot III. After a
mean follow-up of 48 months (3–278), excellent symp-
tomatic relief was noted in 94% and 83% at 3 and
24 months, respectively. Recurrence of the symptoms
was mainly observed in GC III who had LLS.
Conclusions: This large series confirms the excellent
long-term outcome observed after partial liver resection
for symptomatic PLD in highly specialized liver unit.
Partial liver resection should be considered in priority
before considering unroofing or discussing liver trans-
plantation for this benign disease.
FO09-07
ONE HUNDRED AND NINETY ONE
LIVER RESECTIONS FOR
HEPATOCELLULAR ADENOMA <5 CM:
A MULTICENTER EUROPEAN STUDY
Alexis Laurent
Henri Mondor Hospital - Creteil France, France
Introduction: Hepatocellular Adenoma (HCA) is a rare
benign hepatic tumor (1/106 /an). Surgical resection is
the recommended treatment for HCA > 5 cm. For
HCA <5 cm, surgical indications are still debated. This
study aimed to investigate the safety of hepatectomies
for HCA <5 cm.
Method: Data on 576 patients who underwent a liver
resection for HCA between 2000 and 2012 were retro-
spectively collected in a multicenter European database.
Among them, 191 patients had a HCA <5 cm.
Results: They were 169 females (88.5%) and 22 men;
mean age 39.5  10.4 years; mean BMI 24.9  5.7.
Twenty six patients (13.6%) had a ruptured HCA and
among them, 2 were operated in emergency. Eighteen
patients required major hepatectomies (13 right and 5
left), 28 left lateral sectionectomies, 14 other bisegmen-
tectomies, 32 monosegmentectomies and 99 wegde
resections. In 89 patients (46.6%) a laparoscopic
approach was performed. No patient died and 148
patients (77.5%) had uneventful postoperative course.
According to Clavien classification, postoperative com-
plications grade I, II, IIIa and IIIb occurred in 27
(14.1%), 8 (4.2%), 6 (3.1) and 2 (1%) patients respec-
tively. Morbidity was similar in laparoscopy versus
open surgery groups
Conclusions: Liver resection is a safe procedure in elec-
tive surgical setting for symptomatic AHC <5 cm.
FO09-08
SURGICAL MANAGEMENT OF
HEPATIC HEMANGIOMAS: AN
INTERNATIONAL MULTI-
INSTITUTIONAL EXPERIENCE
John Miura1, Aijun Li2, Shishir Maithel3, Emily
Winslow4, Mark Bloomston5, Timothy Pawlik6,
Allan Tsung7, Kiran Turaga1, Thomas Gamblin1 and
Mengchao Wu2
1Medical College of Wisconsin, USA; 2Eastern
Hepatobiliary Surgery Hospital, The Second Military
Medical University, China; 3Emory University School of
Medicine, USA; 4University of Wisconsin School of
Medicine and Public Health, USA\; 5The Ohio State
University Medical Center, USA; 6Johns Hopkins
University School of Medicine, USA; 7University of
Pittsburgh Medical Center, USA
Introduction: Management of hepatic hemangiomas
remains ill defined. We sought to investigate the indica-
tions, surgical management, and outcomes of patients
with hemangiomas of the liver.
Method: A retrospective review from 7 major liver cen-
ters identifying patients who underwent surgery for
hepatic hemangiomas between 1994 and 2013 was per-
formed. Clinico-pathologic, treatment and perioperative
data were evaluated.
Results: Of 1,899 patients identified, the median age was
45 years (IQR: 39–52) with patients being predominantly
female (69.9%). Majority of hemangiomas were solitary
lesions (54.8%) with a median size of 8 cm (IQR: 6–10).
Surgery was performed for abdominal symptoms (19%),
diagnostic uncertainty (6%), increasing hemangioma size
(31%), and patient preference (44%). Patients undergo-
ing resection at western centers (W) were more likely to
have symptomatic hemangiomas as compared to the
eastern center (E) (66.4 vs. 9.7%, p < 0.01). Surgical
resection requiring a hemihepatectomy or greater was
performed on 535 patients (28.1%). Median length of
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stay was 13 days (W: 5 vs. E: 14 days, p < 0.01). Clavien
Grade 3 or higher complications occurred in 43 patients
(2.3%). The 30 day mortality was 0.2% (n = 4) with no
additional mortalities at 90 days. Final pathology
revealed 13 patients (1%) harbored a concomitant malig-
nancy within the resected hemangioma specimen; eight
of the 13 patients underwent surgery secondary to radio-
graphic uncertainty. Of patients with abdominal symp-
toms at the time of surgery, 75% reported improvement
of symptoms postoperatively.
Conclusions: Surgery for hemangiomas can be safely
performed at high volume institutions. Variable indica-
tions for liver surgery demonstrate a regional difference
in approach to management.
FO10-01
PRIORITIZE POLICY OF ALLOCATION
DECEASED LIVER IN PATIENT WITH
HEPATOCELULAR CARINOMA IN
ARGENTINA. RESULTS IN A NEW
LIVER TRANSPLANT PROGRAM
Matıas Ezequiel Morra, Marcos Garcia Ejarque,
Nadia Daciuk, Eugenia Caggiano, Ezequiel Silberman,
Diego Bogetti, Martın Fauda, Rafael Jose Maurette
and Gustavo Luis Podesta
British Hospital of Buenos Aires, Argentina
Introduction: The policy of prioritize the hepatocellular
carcinoma (HCC) in deceased liver donor allocation
system has some differences around the world. Argen-
tina since 2005 adopted the UNOS policy.
The objective of this communication is to look the
results of the Argentinean allocation system for HCC
in a new liver transplant program.
Method: It is a retrospective analysis. Include patients
referred for liver transplant (LT) between July 2010
and July 2013. They were divided into two groups
(Non-HCC group and HCC group), excluding the
acute hepatic failure (AHF). The variables analyzed
were: destiny in the waiting list (WL) and the applica-
bility of LT.
Results: Two hundred and thirteen candidates were
evaluated for LT, 166 were placed in the WL, 43 were
not (11 extended HCC, and 32 medical condition), 4
excluded because presented with AHF. The Non-HCC
group comprised 111 patients: 22 drop out of the WL
(17 deaths and 5 because co-morbidities) and 46 were
transplanted (applicability 41.4%) with a median time
in the WL of 111 days (1–552), 43 patients continue in
WL. In the HCC group, 55 patients were placed in the
WL (46 with the diagnosis of HCC, and 9 developed
HCC in the WL).Of the 41 with supplemental MELD
score: 35 were transplanted (applicability 85%) with a
median time in WL of 164 days (14–575), 5 patients
continue in the WL and 1 died. Of the 14 patients with
no additional score: 5 were transplanted, 4 were
removed (3 progression of disease and 1 death), 5 con-
tinue in the WL (1 waiting to receive extra point). The
median time in the WL for these patients was of
184 days (1–530).
Conclusions: The policy of prioritize the HCC in the
WL favor the applicability of LT for this group of
patients, but do not reduce the waiting time in the list.
FO10-02
RIGHT LIVING DONOR VS WHOLE VS
SPLIT LIVER TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
Alexis Laurent1, Denis Castaing2, Olivier Boilot3,
Jacques Belghiti4, Olivier Soubrane5 and
Daniel Azoulay1
1Henri Mondor Hospital – Creteil France, France; 2Paul
Brousse Hospital – Villejuif, France; 3Ho^pital Edouard-
Herriot – Lyon, France; 4Beaujon Hospital, France;
5Saint-Antoine Hospital, France
Introduction: For cirrhotic patients with hepatocellular
carcinoma (HCC), living donor liver transplantation
(LDLT) reduces waiting time and dropout rates. The
place of LDLT in this field is still debated in terms of
indication and results compared to other types of graft.
Method: Seven hundred and eighty-eight consecutive
cirrhotic patients with HCC were listed for liver trans-
plantation over a 10 years period in 5 centers to receive
whole (WLT), split (SLT) or LDLT. Tumor recurrence
was the primary end point. Mainly due to tumor pro-
gression (82%), 89 patients (11.3%) dropped out.
Results: The dropout rate of patients waiting for
LDLT was nil. The mean waiting time was shorter for
LDLT (p < 0.001). At transplant, patients of the
LDLT group showed significantly more severe tumor
criteria for size and AFP level than those receiving
WLT or SLT. The recurrence rates at 5 years were sim-
ilar in the 3 groups (12.8%, 7.0% and 10.9% for WLT,
SLT and LDLT respectively; p = 0.7). Overall (p = 0.5)
and disease free survival (p = 0.7) were similar in the 3
groups. AFP score before transplant (C Duvoux, Gas-
troenterology 2012), macroscopic vascular invasion and
differenciation according to Edmonson Grade on the
specimen were independently associated with recur-
rence. Overall patients beyond the Milan and UCSF
criteria, showed a trend towards worse outcomes
Conclusions: Despite more severe tumors in LDLT
group, the recurrence and survival outcomes following
LDLT, WLT or SLT are similar. Absence of dropout
and shorter waiting time are additional advantages of
LDLT. LDLT for HCC patients beyond validated cri-
teria should be proposed with caution.
FO10-03
TREATMENT OF HCC MEETING
MILAN CRITERIA BY LIVING DONOR
LIVER TRANSPLANTATION OR LIVER
RESECTION
Kuan-Chun Hsueh1, Teng-Wei Chen2, Shung-Sheng
Tsou1, Tzu-Ming Chang1, Chew-Teng Kor1 and
Chung-Bao Hsieh2
1Tungs’ Taichung MetroHarbour Hospital, Taichung,
Taiwan; 2Tri-Service General Hospital, National Defense
Medical Center, Taipei, Taiwan
Introduction: Liver resection (LR) and liver transplan-
tation (LT) are considered curative treatments for early
hepatocellular carcinoma (HCC). Owing to the short-
age of donor organs, living donor liver transplantation
(LDLT) has been administered widely in recent years.
The study investigated the survival of patients with
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HCC conforming Milan criteria undergoing different
curative therapies and analyzed the risk factors related
to the survival and tumor recurrence.
Method: Between January 2006 and June 2012, 222
patients with HCC met Milan criteria in Tri-Service
General Hospital and Tungs’ Taichung Metroharbor
Hospital underwent curative treatment, including LR
(n = 182) or living donor liver transplantation (LDLT)
(n = 40). The overall survival (OS), disease-free survival
(DFS) and associated factors were investigated.
Results: Patients treated by LDLT had poorer liver
functions than those treated by LR. The 1-, 3-, 5-year
OS rates were 92.2%, 79.1%, 54.7% for LDLT and
98.3%, 84.4%, 77.2% for LR,, respectively (p = 0.054).
The 1-, 3-, 5-year DFS rates were 94.2%, 88.1%, 77%
for LDLT, 86.9%, 61.7%, 48.8% for LR, respectively
(p < 0.0001). On multivariate analysis, F4 cirrhosis of
nontumorous parenchyma, platelet count less than
100,000 and multiplicity of tumors were associated with
increased risk of tumor recurrence. The factors affect-
ing OS included vascular invasion, tumor larger than
3 cm in size, multiplicity of tumor and existence of F4
cirrhosis.
Conclusions: No significant difference in 5-year survival
between LDLT and LR in patients with HCC fulfilling
Milan criteria, despite of some selection bias. The DFS
was significantly better after LDLT. However, factors
associated with survival and tumor recurrence were
related to tumor characteristics, underlying cirrhosis
and lower platelet count, irrespectively of types of
treatment strategy.
FO10-04
ADVANCED HEPATOCELLULAR
CANCER AND LIVER
TRANSPLANTATION: LONG TERM
EFFICACY OF REPETITIVE
TRANSARTERIAL
CHEMOEMBOLIZATION
Quirino Lai1, Gerd Otto2, Ivo Graziadei3,
Pasquale B Berloco4, Giuseppe Tisone5,
Salvatore Agnes6 and Jan Lerut1
1University Hospitals St. Luc, Universite catholique
Louvain, Italy; 2University of Mainz, Mainz, Germany;
3Medical University Innsbruck, Austria; 4University
Sapienza, Umberto I Hospital, Rome, Italy; 5Foundation
PTV, University Tor Vergata, Rome, Italy; 6University
Cattolica, Agostino Gemelli Hospital, Rome, Italy
Introduction: The efficacy of trans-arterial chemoembo-
lization (TACE) and the impact of repetitive TACE are
two controversial issues in the management of potential
liver recipients presenting hepatocellular cancer (HCC)
exceeding Milan Criteria (MC). The aims of the present
study are: investigate the benefit of TACE in relation
to intention-to-treat (ITT) survival and recurrence rate
of HCC after liver transplantation (LT); analyze the
role of repetitive TACE in reducing the risk of post-
transplant HCC recurrence.
Method: Two hundred patients were listed for LT dur-
ing the period March 1987–March 2012. Seventy nine
were ‘directly transplanted’ and 121 had TACE at
insertion on the waiting list. Their median follow-up
was 3.5 years (IQR 1.0–7.2).
Results: At multivariate analysis, TACE before LT was
protective against the risk of recurrence (HR = 0.55;
p = 0.05). Downstaged patients displayed excellent 5-
year ITT survival compared to ‘directly transplanted’
patients (77.5 vs. 43.8%; p = 0.003). Downstaged
patients also had significantly lower recurrence rates
(17.9 vs. 40.4%; p = 0.01). The higher the number of
TACE procedures, the higher was the protection
against HCC recurrence (>3 TACE: OR = 0.30;
p = 0.008).
Conclusions: MC-OUT patients treated with TACE
during the waiting time had excellent long-term ITT
survival rates and significantly reduced recurrence rates.
Repetitive TACE is useful and especially beneficial in
this group of patients.
FO10-05
IMPACT OF GRAFT REGENERATION
TO THE RECURRENCE OF
HEPATOCELLULAR CARCINOMA
AFTER LIVING DONOR LIVER
TRANSPLANTATION
Su Hyung Lee, Dong Jin Joo, Myoung Soo Kim,
Dai Hoon Han, Jung Jun Lee, Kyu Ha Huh,
Gi Hong Choi, Jin Sub Choi and Soon Il Lim
Yonsei University College of Medicine, Korea
Introduction: It has been suggested that tumor recur-
rence after resection for hepatocellular carcinoma
(HCC) was related with remnant liver regeneration. In
living donor liver transplantation (LDLT), graft liver
usually experience regeneration and this may stimulate
the growth of microscopic HCC tumors. The aim of
this study was to assess the changes in graft volumes
after LDLT and its relations with the recurrence of
HCC.
Method: A total 140 liver transplantations were per-
formed for patients with HCC between September 2005
and December 2012. Of them, deceased donor and
unavailable data were excluded. All patients were mea-
sured preoperative and postoperative at 1 week and
4 weeks graft liver volume by volumetric computed
tomography (CT). The study patients were divided into
two subgroups according to median value of graft-reci-
pient weight ratio (GRWR) and increasing rate of graft
liver at postoperative 1 week and 4 weeks.
Results: Of the 128 recipients, 16 recipients had a
recurrence of HCC. Recurred patients showed signifi-
cantly higher level or incidence of pre-transplant alpha-
fetoprotein (AFP), Protein induced by vitamin K
antagonist (PIVKA-II) and largest size of HCC, portal
vein invasion, microvascular invasion, and satellite nod-
ule in pathologic findings. Increasing rate of graft liver
at postoperative 1 week and 4 weeks were significantly
higher in lower GRWR group than those in higher
GRWR group, respectively. There were no differences
in preoperative GRWR and increasing rate of graft
liver at postoperative 1 week and 4 weeks between the
two groups. Recurred HCC patients showed more
‘beyond Milan criteria’ and higher tumor markers than
non-recurred patients.
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Conclusions: This study showed that the lower GRWR
group has higher graft regeneration rate than those in
higher GRWR group. However, this study could not
find significant relation between the recurrence of HCC
and graft regeneration.
FO10-06
SALVAGE TRANSPLANTATION FOR
POST RESECTION RECURRENCE IN
HEPATOCELLULAR CARCINOMA
ASSOCIATED WITH HEPATITIS C
VIRUS ETIOLOGY - A FEASIBLE
STRATEGY?
Bhavin Vasavada1, Andrzej Komorowski2,
Karan Julka1 and Chao-Long Chan3
1Fellow liver surgery and transplant, India; 2Fellow, liver
surgery and liver transplant, Poland; 3Professor and
Superintendent, Taiwan
Introduction: We analyzed feasibility of salvage liver
transplant after liver resection in Hepatocellular carci-
noma with HCV etiology.
Method: All the patients with HCC with HCV etiology
who underwent living donor liver transplant from July
2002 to November 2012 were studied. Their recurrence
rate, mortality, and prognostic factors were analyzed
and compared between primary transplant and salvage
transplant. Statistical analysis was done using SPSS
version 21. (IBM).
Results: One hundred and nine patients underwent liver
transplant for hepatocellular carcinoma associated with
HCV etiology within UCSF criteria. 17 were post hepa-
tectomy salvage transplants and 92 were primary trans-
plants. Median follow-up time was 31 months. One,
three and five year recurrence free survivals were 94%,
94%, 56% for salvage group and 96%, 82% and 60%
for primary transplant group which were not statistical
significant (p = 0.836). One, three and five year over all
survival rates were 76%, 68% and 68% in salvage group
and 92%, 82% and 82% in primary transplant group
respectively. Thus survival rate were significantly lower
in salvage transplant group (p = 0.031). Preoperative
AFP levels were significantly associated with recurrence
(p = 0.017). No antiviral treatment (p = 0.009 overall
and p = 0.036 in primary transplant), pre transplant out-
side Milan criteria (p = 0.016 over all and 0.039 in pri-
mary transplant), recurrence month (p = 0.021) and
waiting months for transplants (p = 0.001) were signifi-
cantly associated with mortality. No factors were signifi-
cantly associated with mortality in salvage transplant
group. Multivariate analysis showed only recurrence
months independently predicted over all mortality
(p = 0.002). Microvascular invasion, histological grade
of the tumor were not significantly associated with mor-
tality or recurrence rate in any group.
Conclusions: Salvage transplant have inferior survival
rates than primary transplant in hcc associated with
HCV. Factors like early recurrence, out side Milan cri-
teria, waiting time and no preoperative anti viral treat-
ments are associated with worse outcomes. HCC with
hcv etiology should be offered primary transplant
rather than salvage transplant particularly within Milan
criteria.
FO10-07
EARLY RECURRENCE OF
HEPATOCELLULAR CARCINOMA
AFTER INITIAL LIVER RESECTION IS
ASSOCIATED WITH POOR OUTCOME
OF SALVAGE LIVER
TRANSPLANTATION
Sanghoon Lee1, Choon Hyuck Kwon1, Jae-Won Joh1,
Jong Man Kim1, Bong-Wan Kim2, Hee-Jung Wang2,
Kwang-Woong Lee3, Kyung-Suk Suh3 and
Suk-Koo Lee1
1Samsung Medical Center, Sungkyunkwan University,
Korea; 2Ajou University School of Medicine, Korea;
3Seoul National University College of Medicine, Korea
Introduction: Salvage liver transplantation (LT) is con-
sidered a feasible option for treatment of recurrent
hepatocellular carcinoma (HCC), especially when liv-
ing-donor LT is a possible option. We performed this
multicenter study to assess the risk factors associated
with recurrence of HCC and patient survival after sal-
vage LT.
Method: Between 2000 and 2011, 101 patients who had
previously received liver resection (LR) for HCC under-
went LT in 3 transplant centers in Korea. After exclud-
ing 19 patients due to incomplete data collection and
operative mortality, 82 patients’ data were retrospec-
tively reviewed for analysis.
Results: Thirty-three patients had recurrence of HCC
during a median follow-up period of 27 months (range
2–189 months) after salvage LT. There were 29 deaths,
15 due to HCC recurrence. 5-year survival was 62%.
The following factors were associated with reduced
recurrence-free survival after salvage LT in univariate
analysis: microvascular invasion (p < 0.001) and T
stage (p = 0.003) of the HCC at primary LR, microvas-
cular invasion (p = 0.003) and T stage (p < 0.001) of
the HCC at the time of LT, cause of salvage LT (HCC
recurrence vs. cirrhosis progression, p = 0.03), donor
type (living vs. deceased, p = 0.048), and Milan criteria
(within vs. outside, p = 0.009). In multivariate analysis,
more progressed T stage of the HCC at primary LR
and HCC outside of the Milan criteria at salvage LT
(HR 6.064, p < 0.001) were significant risk factors for
early recurrence after salvage LT.
Conclusions: Stage of the HCC at primary LR and LT
for HCC recurrence outside of the Milan criteria were
significantly associated with reduced recurrence-free
survival following salvage LT. We have shown, through
this multicenter analysis, that the biology of the pri-
mary HCC plays a role in the outcome after salvage
LT. This data may help guide clinicians on their deci-
sion of whether or not to perform salvage LT in a
patient who has HCC recurrence after LR.
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FO10-08
SINGLE NUCLEOTIDE
POLYMORPHISMS IN THE
METASTASIS-ASSOCIATED IN COLON
CANCER-1 GENE PREDICT THE
RECURRENCE OF HEPATOCELLULAR
CARCINOMA AFTER
TRANSPLANTATION
Zhiyun Zheng, Sheng Gao, Zhe Yang, Haiyang Xie,
Cheng Zhang, Bingyi Lin, Lin Zhou and Shusen Zheng
Key Lab of Multi-Organ Transplantation, The First
Affiliated Hospital, Zhejiang University, China
Introduction: The newly identified metastasis-associated
in colon cancer-1 (MACC1) gene is involved in angio-
genesis, epithelial-to-mesenchymal transition (EMT),
invasiveness, and metastasis in a variety of malignan-
cies. Overexpression of MACC1 gene is a prognostic
marker for poor outcome of hepatocellular carcinoma
(HCC) patients. However, the association between
genetic polymorphisms of MACC1 gene and poor out-
come in HCC has been not been performed. We there-
fore investigated the correlation of MCAA1 single
nucleotide polymorphisms (SNPs) with tumor recur-
rence and overall survival in HCC patients undergoing
liver transplantation (LT).
Method: The study included 187 HCC patients treated
with LT. Five polymorphisms in the MACC1 gene
(rs1990172, rs3735615, rs4721888, rs2241056, rs975263)
were genotyped in 183 cases of tumorous tissue sample
and 117 cases of adjacent non-tumorous tissue sample
using SNaP-Shot assays. The association of SNPs with
tumor recurrence and overall survival was then ana-
lyzed by additive, dominant, recessive, and overdomi-
nant models in a cohort of 156 HCC patients.
Results: In terms of tumor recurrence, heterozygous of
SNP rs1990172 and SNP rs975263 showed a significant
high risk of relapse using univariate and multivariate
analysis (overdominant, HR (95% CI) = 2.27[1.41–
3.66], p = 0.001; HR (95% CI) = 2.16 [1.37–3.39],
p = 0.001). But the difference between heterozygous of
these two SNPs and overall survival did not reach a
significance in all models. The other three investigated
SNPs were not significantly associated with tumor
recurrence and overall survival (p > 0.05). In addition,
we found no significant difference in genotype frequen-
cies between HCC and controls.
Conclusions: Our data suggest that SNP rs1990172 and
SNP rs975263 in the MACC1 gene may be potential
genetic markers for HCC recurrence in LT patients.
FO11-01
EARLY RESULTS OF IN VIVO
ASSESSMENT OF THE LIVER
MICROCIRCULATION: A NOVEL
METHOD TO PREDICT THE OUTCOME
OF LIVER RESECTION AND
TRANSPLANTATION
Carlo Pulitano, Phong Ho, Leon Edwards,
Charbel Sandroussi, David Joseph, Deborah Verran,
Nicholas Shackel and Michael Crawford
Royal Prince Alfred Hospital, Australia
Introduction: The complex functions of the liver includ-
ing metabolism, biosynthesis, and host defense are
closely dependent on microcirculation. Ischemia reper-
fusion, or conditions associated with portal hyperperfu-
sion such as extended liver resection or small for size
syndrome are associated with microcirculatory damage.
However, in vivo assessment of microcirculation by real
time visualization has not been previously possible. The
aim of this study was to evaluate the feasibility of
studying microcirculation in situ by Sidestream dark-
field (SDF), a new technology allowing direct visualiza-
tion of microcirculation using a hand-held probe.
Method: Twenty-four patients undergoing major liver
resection and liver transplantation were included.
Images were obtained using SDF imaging on the sur-
face of the liver after laparotomy and 20 minutes after
liver transection in case of liver resection, and 20 min-
utes after reperfusion in case of liver transplantation.
Haemodinamic parameters that may affect microcircu-
lation were also considered. The microvascular parame-
ters were compared with markers of liver function and
serum level of endothelin-1.
Results: Hepatic perfusion, as given by the functional
sinusoidal density, sinusoidal diameter, and postsinusoi-
dal venular diameter, following major resection was
found significantly reduced compared to baseline. Micro-
circulation findings significantly influenced postoperative
transaminase release. The lower the microcirculatory per-
fusion, the higher the transaminase levels on postopera-
tive day 2 (p < 0.05; r = 0.62) and day 3 (p < 0.05;
r = 0.72), and bilirubin on on postoperative day 2
(p < 0.05; r = 0.69), and day 3 (p < 0.05; r = 0.70).
Conclusions: These data demonstrate that SDF imaging
is a noninvasive method for accurate quantification of
the microcirculatory parameters of the liver in situ. The
use of SDF imaging intraoperatively may potentially be
used to estimate the risk of postoperative liver failure
or identify patients at risk of small for size syndrome
who may benefit from therapeutic interventions.
FO11-02
AGGRAVATION OF POST-ISCHEMIC
LIVER INJURY BY OVEREXPRESSION
OF IGFBP-3
Jae Do Yang, Hee Chul Yu, Baik Hwan Cho, Sang In
Bae, Byung Hyun Park and Hong Pil Hwang
Chonbuk National University Hospital, Korea
Introduction: Insulin-like growth factor binding pro-
tein-3 (IGFBP-3) is known to interfere NF-jB signaling
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pathway in response to a diverse range of stimuli. Liver
ischemia/reperfusion injury is associated with rapid
activation of NF-jB signaling, but the role of NF-jB
in hepatic ischemia/reperfusion injury remains contro-
versial. The NF-jB signaling pathway mediates both
protective and deleterious effects in the liver. Here, we
examined whether IGFBP-3 inhibited or aggravated
hepatic ischemia/reperfusion injury.
Method: We overexpressed IGFBP-3 in the liver of
C57BL/6 mice. Mice underwent 45 min of partial hepa-
tic ischemia and were then reperfused.
Results: Mice subjected to ischemia/reperfusion injury
showed increased NF-jB activation, as evidenced by
phosphorylation of IjBa and nuclear translocation of
NF-jB. Prior infection with Ad-IGFBP-3 attenuated
NF-jB activation. Serum aminotransferases, hepatocel-
lular necrosis, and hepatic neutrophil infiltration were
markedly increased compared to those of uninfected or
control virus infected mice. In addition, IGFBP-3
mutant devoid of IGF binding affinity but retains IG-
FBP-3 receptor binding ability (Ad-IGFBP-3GGG) also
exhibited similar effects as Ad-IGFBP3 did, suggesting a
ligand-independent effect of IGFBP-3 on liver damage.
Conclusion: These results suggest that inhibition of
NF-jB activation by IGFBP-3 aggravated partial hepa-
tic ischemia/reperfusion injury. Understanding how the
NF-jB pathway plays a role in directing a clinical out-
come may lead to better prospects of more rational
approaches to reduce post-ischemic liver injury.
FO11-03
ASPIRIN ENHANCES IFN-a INDUCED
GROWTH INHIBITION AND APOPTOSIS
OF HEPATOCELLULAR CARCINOMA
VIA JAK1/STAT1 PATHWAY
Xu-Ting Zhi, Tao Li and Zhao-Ru Dong
Qilu Hospital of Shandong University, China
Introduction: Interferon-a (IFN-a) has been reported to
be effective in postponing recurrence and improving
overall survival in patients after curative resection of
hepatocellular carcinoma (HCC). Our previous study
has demonstrated that low concentrations of Aspirin
(1 mM) did enhance IFN-a induced apoptosis and anti-
proliferation effect of HCC, which has been reported at
ILCA2012. We will further illuminate the mechanism
of this phenomenon.
Method: Human HC Bel-7402 cells were cultured. Wes-
tern Blot was used to measure the change of JAKs-
STAT1/3 signaling pathway in response to IFN-a stim-
ulation with or without Aspirin at various time points.
Q-PCR was further used to examine the regulation of
ISGs after BEL-7402 cells were treated with IFN-a,
Aspirin or the combination. Data are expressed as
mean  SEM. Student’s t-test and one-way ANOVA
test were used for statistical analyses of the data.
Results: When IFN-a was combined with Aspirin, the
duration and level of p-STAT1 were significantly
enhanced than IFN-a treatment alone, but the expres-
sion of IFN-a induced p-STAT3 was still not changed
significantly after 18 hours stimulation of Aspirin.
When IFN-a was combined with Aspirin, the p-JAK1
and p-JAK2 was further elevated, as the p-TYK2 was
significantly inhibited. After blocking the activity of
JAK2 by AG490, the level of p-STAT1 in combined
group was not significantly decreased, compared to the
group in which JAK2 activity was not inhibited. Q-
PCR analysis revealed that Aspirin increased the IFN-a
induced transcription of XAF-1, and inhibited the tran-
scription of GIP3.
Conclusions: Low concentration of Aspirin enhances
IFN-a-induced growth inhibition and apoptosis of
HCC via JAK1/STAT1 pathway, which induces the
upregulation of proapoptotic ISGs of XAF1 and down-
regulation of antiapoptotic ISGs of G1P3. These results
may provide a new potential therapeutic strategy for
patients with HCC or other cancers.
FO11-04
MIR-93 PROMOTES METASTATIC
PROCESS AND CELL SURVIVAL BY
REGULATING EPHA4-MEDIATED
EPITHELIAL-MESENCHYMAL
TRANSITION IN HEPATOCELLULAR
CARCINOMA FOLLOWING LIVER
TRANSPLANTATION
Sheng Gao, Zhe Yang, Zhi Yun Zheng, Li Ming Wu,
Zhi Kun Liu, Hai Yang Xie, Lin Zhou and
Shu Sen Zheng
First Affiliated Hospital of Medical School Zhejiang
University, China
Introduction: The function of miR-93 in human hepa-
tocellular carcinoma (HCC) remains largely undefined.
We investigated the roles and mechanisms of miR-93 in
HCC following orthotopic liver transplantation (OLT).
Method: We used in situ hybridization and quantitative
reverse transcriptase polymerase chain reaction to mea-
sure expression of miR-93 in human HCC tissues and
cell lines. Human HCC cell lines were transduced with
lentiviruses that expressed miR-93, its inhibitor
sequence targeted miR-93 or a scrambled sequence
(control); proliferation, metastasis, invasion and colony
formation were analyzed. We analyzed growth of
human HCC cells that overexpress miR-93 or its inhibi-
tor in severe combined immune-deficient mice. Western
blot, and luciferase reporter assays were used to mea-
sure expression and activity of Eph tyrosine kinase
receptor (EphA4) and related signaling molecules.
Results: Human HCC tissues and cell lines had
increased levels of miR-93 compared with the noncan-
cerous corresponding tissues and cells. The expression
of miR-93 was associated with overall survival and
recurrence–free survival following OLT. Overexpression
of miR-93 increased proliferation of HCC cells, metas-
tasis, invasion and colony formation in vitro, whereas
miR-93 depletion reduced these parameters. In severe
combined immune-deficient mice, overexpression of
miR-93 by HCC cells increased tumor growth and
overexpression of the miR-93 inhibitor reduced it. The
EphA4 was identified as the direct and functional tar-
get gene of miR-93. Knockdown of EphA4 phenocop-
ied the effect of miR-93 and ectopic expression of
EphA4 restored the effect of miR-93 on proliferation,
migration, invasion and adhesion in HCC cells. We fur-
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ther demonstrated that miR-93 and EphA4 regulated
the epithelial-mesenchymal transitioin (EMT) process
to affect cell invasion and metastasis.
Conclusions: Our findings revealed that miR-93 may be
a survival predictor for HCC following OLT, and fur-
ther we highlight the importance of miR-93 in regulat-
ing the metastatic properties of HCC by directly
targeting EphA4. This may provide new insights into
the recurrence mechanism of HCC following OLT.
FO11-05
ANTICANCER EFFECTS OF
EVEROLIMUS AND KU-0063794 ON
HUMAN HEPATOCELLULAR
CARCINOMA HEPG2 CELLS BY
INHIBITING MTORC1 AND MTORC2
Say-June Kim and Jae Woo Park
Catholic University of Korea, Daejeon St. Mary’s
Hospital, Korea
Introduction: Due to the frequent dysregulation of the
PI3K/mTOR signaling pathway, modulation of mTOR
expression has been a suitable therapeutic target in
hepatocellular carcinoma (HCC). Everolimus, a rapa-
mycin derivative, inhibits the mTOR pathway by acting
on the mTORC1, and Ku-0063794 is a potent and
highly specific dual-mTOR inhibitor of mTORC1 and
mTORC2. In this study, we investigated the contribu-
tion of mTORC1 and mTORC2 on the HCC carcino-
genesis by treatment of mTOR inhibitors, such as
everolimus, Ku-0063794, and the combination of them.
Method: Everolimus and Ku-0063794 were treated to
human HCC cell line, HepG2, respectively or combina-
tion of both mTOR inhibitors. Proliferation of the cells
was measured by EZ-cytox assay at 24, 48 and
72 hours after treatment. Also, cell cycle analysis and
autophagy level analysis were performed by FACS and
autophagy kit. Cell signaling effects of mTOR inhibi-
tors were assessed in HepG2 cell by western blot.
Results: There was an improved increase in repression
of cell proliferation with combined everolimus and Ku-
0063794 compared with either drug alone. The combi-
nation treatment noticeably suppressed the phosphory-
lation of AKT, p70S6K and STAT3. Although the
addition of the Ku-0063794 only slightly suppressed the
phosphorylation of AKT induced by everolimus, and
downstream signaling p70S6K is lowered in the combi-
nation. Also, autophagy is significantly inhibited by the
combination of everolimus and Ku-0063794.
Conclusions: Our results demonstrate that dual targeting
of mTORC1 and mTORC2 by use of everolimus and
Ku-0063794 does effectively inhibit proliferation of
HCC cell lines. These data suggest that combined treat-
ment with everolimus and Ku-0063794 may be a promis-
ing therapy approach in the treatment of hepatocellular
carcinoma.
FO11-06
THE ROLE OF EMT INDUCER PRRX1
ON THE ACQUISITION OF CANCER
STEM CELL PROPERTIES IN HUMAN
HEPATOCELLULAR CARCINOMA
Keishi Sugimachi1, Hidenari Hirata1,
Yusuke Takahashi1, Tae Matsumura1,
Yoshiaki Shinden1, Hidetoshi Eguchi1, Tomoya Sudo1,
Ken Shirabe2, Yoshihiko Maehara2 and
Koshi Mimori1
1Kyushu University Beppu Hospital, Japan; 2Kyushu
University, Japan
Introduction: Epithelial-mesenchymal transition (EMT)
is an important process for the progression of hepato-
cellular carcinoma (HCC). EMT is known to induce
the acquisition of cancer stem cell (CSC) properties of
the cancer. The decreased expression of paired related
homoeobox 1 (PRRX1), the EMT inducer, is reported
to be associated with CSC properties. The purpose of
the study is to investigate the role of the aberrant
expression of PRRX1 on the progression and stemness
of human HCC.
Method: (1) The expression of PRRX1 was analyzed
by quantitative RT-PCR in 62 cases of HCC who
underwent hepatic resection, and clinicopathological
parameters including long-term prognosis were studied.
(2) PRRX1 gene was transfected into 2 HCC cell lines
(HuH7, HepG2) using a lentivirus vector and PRRX1
stable expressing cell lines were established. The expres-
sion levels of cell surface markers related to CSC of
HCC (CD13, CD133, EpCAM) were examined using
flowcytometry and RT-PCR. Anchorage-independent
growth related to the CSC was evaluated with sphere
formation assay.
Results: (1) The 5-year overall survival of HCC
PRRX1 low expression group (n = 34) was significantly
lower than that of high expression group (n = 28)
(49.8% vs. 80.3%, p = 0.014), and the PRRX1 low
expression was an independent prognostic risk factor
by a multivariate analysis (p = 0.026). (2) The PRRX1
expression induced EMT, which was independent of
conventional EMT inducer Twist and Snail. The CSC
markers (CD13, CD133, EpCAM) were significantly
decreased in PRRX1 expressing HCC cells, which indi-
cated that HCC cells acquired the CSC properties by
the decreased expression of PRRX1.
Conclusions: The present study indicated that PRRX1
induced EMT and stemness through the pathway which
was independent of the Twist/Snail. PRRX1 low
expression was the independent prognostic factor and
contributed to the progression of HCC by the acquisi-
tion of CSC properties in HCC.
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FO11-07
MICRORNA-29A PROTECTS AGAINST
ACUTE LIVER INJURY IN A MOUSE
MODEL OF OBSTRUCTIVE JAUNDICE
VIA INHIBITION OF THE EXTRINSIC
APOPTOSIS PATHWAY
Ying-Hsien Huang
Kaohsiung Chang Gung Memorial Hospital and Chang
Gung University College of Medicine, Kaohsiung,
Taiwan
Introduction: Recent studies have shown that microR-
NA-29 (miR-29) is significantly decreased in liver fibro-
sis, as demonstrated in human liver cirrhosis, and that
its downregulation influences the activation of hepatic
stellate cells. In addition, both cleaved caspase-3 pro-
duction and apoptosis play a role in cholestatic liver
injury. However, it is unknown if miR-29 is effective in
modulating the extent of injury.
Method: We employed miR-29a transgenic mice (miR-
29aTg mice) and wild-type (WT) littermates to clarify
the role of miR-29 in hepatic injury and fibrogenesis,
using the bile duct-ligation (BDL) mouse model.
Results: After BDL, all 3 members of the miR-29 fam-
ily were significantly downregulated in the livers of WT
mice, and miR-29b and miR-29c were significantly
downregulated in the livers of the miR-29aTg mice.
Liver function, as measured by alanine transaminase
and aspartate transaminase activity, was significantly
improved in the miR-29aTg mice than in the WT litter-
mates, following 1 week of obstructive jaundice. In
addition, overexpression of miR-29a was associated
with a significant downregulation of the expression of
collagen-1a1, collagen-4a1, phospho-FADD, cleaved
caspase-8, cleaved caspase-3, Bax, Bcl-2, PARP, and
nuclear factor-jB, as well as an upregulation of phos-
pho-AKT expression. In addition, there were signifi-
cantly fewer TUNEL-positive liver cells in the miR-
29aTg group than in the WT littermates after BDL.
Conclusions: Our results indicate that miR-29a
decreases cholestatic liver injury and fibrosis after
BDL, at least partially, by modulating the extrinsic
rather than intrinsic pathway of apoptosis.
FO11-08
BENEFICIAL EFFECTS OF
LIPOPOLYSACCHARIDES-INDUCED
POTENTIATION OF ADIPOSE-TISSUE
DERIVED STEM CELLS ON HEPATIC
RECOVERY IN PARTIALLY
HEPATECTOMIZED MICE
Say-June Kim1 and Dong-Goo Kim2
1Catholic University of Korea, Daejeon St. Mary’s
Hospital, Korea; 2Catholic University of Korea, Seoul
St. Mary’s Hospital, Korea
Introduction: Adipose-tissue derived stem cells (ASC)
secrete high levels of growth factors and cytokines
valuable to hepatic recovery. As considerable aspects of
ASC’s therapeutic potential are attributed to the secre-
tome, the detection of optimizing secretome by adjust-
ing culturing environment is getting attention.
Lipopolysaccharides (LPS) are large molecules consist-
ing of a lipid and a polysaccharide joined by a covalent
bond and elicit strong immune responses. Therefore,
we were intended to validate the enhanced hepatic
recovery prompted by LPS-treated ASC.
Method: We conditioned ASC with 24-hour treatment
of 100 ng/mL LPS. After in vitro evaluations, including
assessment of the ASC mRNA expression and the
release of cytokines and growth factors, the therapeutic
potentials of LPS-treated ASC were determined using
partially hepatectomized mice.
Results: LPS-treated ASC effectively induced higher
mRNA expression and extracellular release of IL-6,
TNF-a, VEGF, and hepatocyte growth factors than
control ASC. In vivo experiment comparing the mice -
control, ASC, and LPS-treated ASC -, mice with LPS-
treated ASC, showed the highest liver regenerating
capacity estimated by BrdU, Ki67, and PCNA immuno-
histochemical stains. Also the significant reductions in
serum alanineaminotransferase (ALT) and aspartatea-
minotransferase (AST) were noted in the LPS-treated
ASC group. Through co-culture between injured hepa-
tocyte and ASC with/without LPS treatment, the possi-
ble mechanism of LPS enhancing ASC function was
proved to be mediated by IL-6 related STAT3 pathway.
Conclusions: In conclusion, these findings provide evi-
dence for a crucial role of LPS treatment in enhancing
the potential of ASC by inducing favorable secretome
by way of IL-6 related STAT3 pathway.
FO12-01
COMPARISON OF INTRA ABDOMINAL
PRESSURE WITH RANSON’S CRITERIA
IN PROGNOSIS OF ACUTE
PANCREATITIS
Mohanish Kumar Sinha1, Shantanu Kumar Sahu2,
Prashant Kumar Singh3 and Sohaib Ahmad2
1M.B.B.S, MS (Final year), India; 2Associate
Professor, India; 3Assistant Professor, India
Introduction: Intra-abdominal Hypertension (IAH) and
Abdominal Compartment Syndrome have described in
patients with severe acute pancreatitis, but its clinical
impact remains unclear. The aim of study was to assess
whether increased intra-abdominal pressure affects clin-
ical course in patients with acute pancreatitis and com-
pare Intra Abdominal Pressure with Ranson’s Criteria
in prognosis of Acute Pancreatitis.
Method: The present study was conducted in Depart-
ment of Surgery at Himalayan Institute of Medical
Sciences, HIHT University, Swami Ram Nagar, Dehra-
dun, India over period of 12 months. All patients
admitted in hospital with confirmed diagnosis of Acute
Pancreatitis were included in study and were followed
up by measurement of intra abdominal pressure (IAP)
by intra-vesicular method at time of admission and
daily monitoring of IAP for one week. The incidence of
IAH (defined as intra-abdominal pressure >12 mmHg),
occurrence of organ dysfunction and outcome of dis-
ease was studied and compared with Ranson’s Score.
Results: The analysis included 65 patients, all patients
were subjected Ranson’s score and IAP monitoring,
IAH was found in 54 patient 83%. The incidence of
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organ dysfunction was high in patients with IAH:
respiratory failure 83%, cardiovascular failure 70%,
and renal failure 85%. ICU stay and mortality in the
patients with IAH was similar as in Ranson’s score.
Five patients underwent surgery for abdominal com-
partment syndrome and infected pancreatic necrosis,
three of whom died in the early postoperative course.
Conclusions: IAH is frequent finding in patient of acute
pancreatitis, associated with high occurrence rate of
organ dysfunction. From Ranson’s scores of the
patients, it seems that more severe the disease, the
higher likelihood to develop IAH. But IAH itself may
be an early predictor of severe disease. The IAP moni-
toring is useful, inexpensive, easy method and can con-
sidered independent prognostic marker for the
evolution and complications of acute pancreatitis espe-
cially in developing countries like India.
FO12-02
MINIMALLY INVASIVE APPROACH
FOR INFECTED PANCREATIC
NECROSIS
Mariano Gimenez, Mariano Palermo, Dario
Berkowski, Pablo Cordoba, Gary Duran,
Jorge Cardoso and Eduardo Houghton
Hospital de Clinicas, Argentina
Introduction: Conventional treatment of infected pan-
creatic necrosis is the open necrosectomy. As alterna-
tives, there are less invasive techniques as percutaneous
drainage, the trans-gastric endoscopic drainage and the
minimally invasive retroperitoneal approach.
The aim of this study is to present our experience in
the step up approach, without initial necrosectomy of
the infected pancreatic necrosis.
Method: 82 patients were treated with severe acute
pancreatitis who followed infected pancreatic or peri-
pancreatic necrosis that received, as a first step, a per-
cutaneous drainage. Forty-nine patients were male and
33 female, the average age was 51.15 years. In 36
patients (43.9%) was observed, at the time of the initial
drainage, one or more organ failure.
The percutaneous procedures were made under the CT
scan control and followed by daily flushing with high
volume fluid until we achieve the complete removal of
the waste of the infected necrosis
Results: In 59 patients (71.9%), was achieved the heal-
ing only with drains, new drains and antibiotics. In 9
opportunities (10.9%) was carried out the percutaneous
video-assisted necrosectomy by persistence or recur-
rence of the SIRS despite the new drains. Performed
open necrosectomy in 14 patients (17%). The mortality
in the group with organ failure was 20% and in the
group without organ failure 4%.
Conclusions: We conclude that the initial minimally
Invasive handling with percutaneous drains of the pan-
creatic infected necrosis could solve the majority of the
cases without necrosectomy, leaving this last when fails
the initial treatment.
FO12-03
EUS GUIDED NECROSECTOMY
TEMPORARY CYSTOGASTROSTOMY
WITH COVERED STENT FOR
PANCREATIC NECROSIS
Arunkumar Krishnan1 and Ravi Ramakrishnan2
1Research Associate, India; 2Senior Consultant, India
Introduction: Pancreatic pseudocyst with infected
necrotic tissue is associated with a high rate of compli-
cations and death. Standard treatment is open necro-
sectomy but is associated with significant morbidity,
mortality, and prolonged hospital stay. Endoscopic cyst
drainage with necrosectomy is an alternative and less
invasive technique.
Aim: to evaluate pseudocyst drainage with cystoga-
strostomy and endoscopic necrosectomy for infected
pancreatic necrosis with fully covered self-expanding
metallic stents (CSEMS).
Method: Twelve patients underwent endoultrsound
guided endoscopic necrosectomy and temporary cysto-
gastrostomy for infected pancreatic necrosis. Patient
details, severity scores assessed at CT, treatment, and
outcome were recorded. Patients proceed to interven-
tion if infection is strongly suspected on clinical and
radiological grounds or is confirmed bacteriologically.
After the necrosis cavity had been accessed, with endo-
scopic ultrasound, a large orifice was created and
necrotic debris was removed using special short fully
covered 15 mm diameter SEMS with large flares was
deployed across the tract under radiological control.
Completeness of the necrosectomy procedure was ascer-
tained by visualization of a clear pseudocyst cavity on
endoscopy.
Results: A total of 12 patients (median age 39) who
were treated successfully. Median APACHE-2 score on
presentation was 11. Two patients presented with organ
failure and needed intensive care. Necrosis was success-
fully treated endoscopically in all patients, requiring a
median of 2 endoscopic interventions (range 1  4).
The tissue samples obtained at the first necrosectomy
confirmed infection in 12 patients. Complication
included superinfection in patient who made an
uneventful recovery. After median of 5 weeks the metal
SEMS was extracted by endoscopy. The patients have
remained asymptomatic and median follow-up was 4
(2  11) months.
Conclusions: Endoscopic necrosectomy and temporary
cystogastrostomy with self-expanding metallic stent
approach is feasible, safe, and effective in patient with
infected pancreatic necrosis. The benefits of this endo-
scopic approach using fully covered self-expandable
metallic stent in terms of less morbidity is conceivable
and our report demonstrates that such an approach is
feasible.
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary Association HPB 2014, 16 (Suppl. 2), 128–160
164 Free Oral
FO12-04
RISK OF RECURRENT PANCREATITIS
AND PROGRESSION TO CHRONIC
PANCREATITIS AFTER ACUTE
PANCREATITIS
Usama Ahmed Ali1, Yama Issa1, Julia C Hagenaars1,
Olaf J Bakker2, HarryVan Goor3, BertVan
Ramshorst4, Marc G Besselink1, Hein G Gooszen5,
Hjalmar CVan Santvoort2 and Marja A Boermeester1
1Academic Medical Center Amsterdam, The
Netherlands; 2University Medical Center Utrecht,
Utrecht, The Netherlands; 3Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands;
4St Antonius Hospital, Nieuwegein, The Netherlands;
5Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
Introduction: Patients with acute pancreatitis (AP)
often achieve complete recovery, but certain patients
may develop recurrences and even progress to chronic
pancreatitis (CP). This study aims to evaluate this risk
and its determining factors.
Method: A cross-sectional survey and retrospective
review of an initially prospectively collected cohort of
patients with a first episode of acute pancreatitis was
performed. Primary endpoints were development of
recurrent acute pancreatitis (RAP) and progression to
CP. Risk factors for RAP and CP were evaluated using
regression analysis, and cumulative risk was assessed
using Kaplan-Meijer analysis.
Results: We included 670 patients that survived a first
acute pancreatitis episode. Median follow-up was
5 years. RAP and CP were observed in 124 (19%) and
42 (6.3%) patients, respectively. RAP was observed in
13%, 24.8% and 25.8% of patients with biliary, alco-
holic and idiopathic/other etiology, respectively. For
progression to CP, these rates were 2.3%, 15% and
7.4%, respectively. Etiology, smoking and pancreatic
necrosis were independent risk factors for both RAP
and CP. APACHE-II score was an additional indepen-
dent risk factor for RAP. Cumulative risk for RAP
over 5 years was the highest among smokers (about
50% over 5 years). For progression to CP, presence of
both alcohol history and smoking resulted in a cumula-
tive risk of about 30%. Non-smoking patients with
alcohol use and patients with idiopathic/other etiology
of AP (irrespective of smoking) had a comparable
cumulative risk of about 10%.
Conclusions: The risk of developing RAP and CP
depends highly on risk factors. For RAP, smoking seems
to play an essential role with equal high rates in combi-
nation with alcoholic and idiopathic/other etiology. For
CP, combined alcohol use and smoking results in the
highest cumulative risk. The strong association of pan-
creatic necrosis with RAP and CP provides support for
the ‘necrosis-fibrosis-sequence’ as a potential pathophys-
iological mechanism for disease progression.
FO12-05
ROLE OF FREY’S PROCEDURE FOR
CHRONIC PANCREATITIS – OUR
EXPERIENCE & INITIAL RESULTS
Mukund Joshi1, Anurag Dadu1, Sudhir Dube1, Shaila
Jadhav1 and Ranjana Bhadbhade2
1B. J. Medical College, India; 2Joshi Clinic, India
Introduction: In India we have a mixed spectrum of
tropical calcific Pancreatitis & Alcoholic Pancreatitis.
We selected Frey’s head coring procedure for the
patients with predominant disease in head of Pancreas.
Method: Frey’s procedure was performed in 28/86
cases that were associated with head mass. Frey’s pro-
cedure involves coring of the pancreatic head along
with laying open of the pancreatic duct & lateral anas-
tomosis. Male to female ratio was 4:1. Age group ran-
ged from 24 to 60 years. The main complaint was
epigastric pain and weight loss. 64/86 cases were those
with features of Tropical calcific pancreatitis (TCP)
with no history of Alcoholism & 22/86 gave history of
Chronic alcoholism. Ultrasonography and CT scan
were performed in all patients. 32/86 cases were shown
to have complicated disease in the head. 28/32 patients
underwent Frey’s procedure. Selection of patients for
Frey’s procedure was made by radiological assessment
in 21/28 & in 7/28 cases during Surgery. 6/28 patients
were diagnosed to have diabetic status. Average blood
loss was 350 cc. Mean operation time was 4:30 hours.
Results: There was no mortality. 2 patients had superfi-
cial wound infections. Six patients had melena for aver-
age of 5 days. Mean post-operative hospital stay was
14 days. 24/28 patients had excellent pain relief in the
early post-operative period especially in the alcoholic
group.
Conclusions: Frey’s procedure is more elaborate than
classical longitudinal pancreatico-jejunostomy. The dia-
betic status remained unchanged. Frey’s procedure
offered better pain relief than with lateral pancreatico-
jejunostomy alone and appears less cumbersome than
Beger’s procedure. Advantage of Frey’s procedure in
the TCP group of patients needs to be assessed further.
Frey’s Procedure seems ideal for the disease predomi-
nantly in the head of pancreas with H/O alcoholism.
FO12-06
RESULTS OF WITH CHRONIC
PANCREATITIS SURGICAL
TREATMENT FOR PATIENTS WITH
FIXED OBSTRUCTION-COMPLICATED
INTRAPANCREATIC PORTION OF THE
DISTAL COMMON BILE DUCT
Alexey Shabunin, Vladimir Bedin and
Alexey Gerasimov
Moscow Pirogov’s state hospital #1, Russia
Introduction: Improve the results of surgical treatment
of patients with chronic pancreatitis complicated by
fixed obstruction of the intrapancreatic portion of the
distal common bile duct.
Method: From 2003 to 2012 there were treated 111
chronic pancreatitis patients with predominant lesions of
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the pancreatic head. Fixed obstruction of the intrapan-
creatic portion of the distal common bile duct was
detected in 35 (31.5%) patients, of which 30 (27%)
patients demonstrated obstructive jaundice of varying
severity.
In the presence of obstructive medium to severe jaun-
dice, cholangitis, and severe comorbidity, as the first
step to decompression of the bile duct, endoscopic ret-
rograde cholangiopancreatography (ERCP) with retro-
grade endobiliary stenting was performed for 15
procedures. In the absence of conditions for retrograde
decompression, percutaneously transhepatic biliary
drainage method was applied for 10 procedures.
83 (74.8%) patients underwent the following types of
surgical treatment: 18 (21.7%) - pylorus-preserving
pancreatic duodenectomy, isolated resection of pancre-
atic head – 65 (78.3%), Beger procedure – 7 (8.4%),
Beger procedure in Berne modification - 58 (69.9%), of
which 18 (21.7%) with intraparenchymal bilio-pancrea-
tico-digestive anastomosis and 17 (20.5%) – with hepa-
ticojejunostomy by Roux.
Results: The rate of postoperative complications was
18% (15 cases), with fatalities – 1 (1.2%). The results
revealed that of the 18 (21.7%) patients who underwent
the formation of internal bilio-pancreatico-digestive
anastomosis, 6 (33.3%) patients were subsequently
diagnosed with symptoms of biliary hypertension as a
consequence of scar stricture of anastomosis. This
required a re-surgery forming holedohoeyunostomy by
Roux on a previously excluded section. In a retrospec-
tive analysis, the inner diameter biliopancreatic anasto-
mosis formed in these patients was less than 8 mm.
Conclusions: Forming the inner bilio-pancreatico-diges-
tive anastomosis diameter of 8 mm minimum, a high
risk of its scar stricture development exists, which
requires a consequential surgical re-treatment: forming
of the hepaticojejunostomy by Roux.
FO12-07
COST-EFFECTIVENESS OF EARLY
LAPAROSCOPIC CHOLECYSTECTOMY
FOR MILD ACUTE GALLSTONE
PANCREATITIS
Steve Morris1, Kurinchi Gurusamy2, Nishma Patel1
and Brian Davidson2
1University College London, United Kingdom;
2University College London and Royal Free Hospital,
United Kingdom
Introduction: A recent Cochrane review found that lapa-
roscopic cholecystectomy performed within 3 days after
onset of mild acute gallstone pancreatitis was safe and
shortened overall hospital length of stay (LOS). We com-
pared the cost-effectiveness of laparoscopic cholecystec-
tomy performed within 3 days, after 3 days but during
the initial admission or on a subsequent admission.
Method: Model based cost-utility analysis estimating
mean costs and quality-adjusted life years (QALYs) per
patient from the perspective of the UK National
Health Service over a 1 year time horizon. A decision
tree model was constructed and populated with proba-
bilities, outcomes and cost data from published sources,
including one-way and probabilistic sensitivity analyses.
Results: Laparoscopic cholecystectomy within 3 days
of admission produced savings of £668–£842 per
patient. Differences in QALYs were negligible com-
pared to laparoscopic cholecystectomy beyond 3 days
but within the same admission, the next best treatment
option. Early laparoscopic cholecystectomy had a 91%
probability of being cost-effective at a maximum will-
ingness to pay for a QALY of £20,000 to £30,000.
Conclusions: Performing laparoscopic cholecystectomy
for mild acute gallstone pancreatitis within 3 days of
admission is cost effective. Adopting this within the
NHS would result in an annual cost saving of approxi-
mately £2.9 million.
FO12-08
BENEFICIAL EFFECT OF GARLIC
(ALLIUM SATIVUM) ON L-ARGININE
INDUCED CHRONIC PANCREATITIS IN
RATS
Surendra Kumar Sharma1, SatyaVati Rana1,
Deepak Kumar Bhasin1, Surinder Rana1,
Ritabhara Nada2 and Samir Malhotra2
1Post Graduate Institute of Medical Education and
Research, India; 2Post Graduate Institute of Medical
Education and Research, Sector-12, India,
Introduction: Protective role of Garlic (Allium sativum)
has been reported in various chronic diseases in human
as well as animals. However it’s role in chronic pancre-
atitis has not yet been studied.
Method: 36 Wistar rats of either sex were divided into 6
groups. Group 1(Control): Rats were given IP injections
of normal saline on day 1, 4, 7, 10, 13, 16 & 19 and water
intragastrically daily 2 days before starting IP injections.
Group2: L-arginine hydrochloride (250 mg/100 g bw/
day) IP injections in 2 repeated doses of 1 hour interval
on day 1 and single dose on day 4, 7, 10, 13, 16 & 19.
Group 3–5: Rats received freshly homogenized Garlic in
water intragastrically at different doses i.e. 0.1, 0.25,
0.50 g/kg b.wt daily 2 days before starting of IP injec-
tions of L-arginine as per group 2. Group6: Animals
received freshly homogenized garlic alone at highest dose
of 0.5 g/kg b.wt. Levels of serum amylase, lipase, TNF-a
and pancreatic glutathione (GSH) & lipid peroxidation
(LPO) were studied on day 21. H&E and Masson’s tri-
chrome stain were used for histology.
Results: Levels of serum amylase & lipase were signifi-
cantly higher in arginine group as compared to control
group and they significantly decreased with supplemen-
tation of 0.25, 0.5 g/kg bwt. of garlic. Levels of LPO in
pancreatic tissue were significantly higher where as
GSH levels were significantly lower in arginine group.
In garlic treated groups, GSH levels were significantly
increased (p < 0.05) while LPO decreased significantly
(p < 0.05) as compared to L-arginine group. Histologi-
cally, fibrosis, fat infiltration and acinar atrophy scores
were significantly higher in arginine group as compared
to garlic treated group. Levels of serum TNF-a found
significantly higher (p < 0.05) in L-arginine group as
compared to garlic groups.
Conclusions: Garlic supplementation (0.25 g/kg bw/
day) significantly reduced severity of chronic pancreati-
tis in experiment model of rats.
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FO13-01
A SYSTEMATIC REVIEW AND META-
ANALYSES OF HEPATIC ARTERY
BASED THERAPIES FOR
UNRESECTABLE INTRAHEPATIC
CHOLANGIOCARCINOMA
John Miura, Lucas Boehm, Thejus Jayakrishnan,
Kiran Turaga, Fabian Johnston, Susan Tsai and
Thomas Gamblin
Medical College of Wisconsin, USA
Introduction: Intrahepatic cholangiocarcinoma (ICC) is
a rare cancer that often presents as unresectable. Hepa-
tic artery based therapies (HAT) are offered for these
patients with potential impact on their survival. The
present study is a systematic review and meta-analyses
of current evidence on the comparative effectiveness of
HAT – hepatic artery infusion (HAI), transcatheter
arterial chemoembolization (TACE), drug-eluding bead
TACE (DEB-TACE), and Yttrium90 radioembolization
(Y90) for unresectable ICC.
Method: A prospectively registered study protocol
(PROSPERO International registry of systematic
reviews ID CRD42013004830) utilized specific key
words to find peer-reviewed, English language articles
published in PubMed (1990–2013). Eligible articles
were selected using predetermined inclusion-exclusion
criteria. The primary outcome was median overall sur-
vival (OS), and the secondary outcome was tumor
response (RECIST criteria).
Results: Of the 793 articles identified in our search
strategy, 20 were selected for data extraction (n = 627
patients). Complete tumor response was reported in
two patients (one TACE and one DEB-TACE). Partial
response to therapy was highest with HAI (41.3%,
range 12–100%, n = 63) vs. DEB-TACE (32.4%, range
4.2–90%, n = 34) vs. Y-90 (26.4%, range 10.5–35.3%,
n = 121) vs. TACE (12.6%, range 0–45%, n = 333).
Incidence of progressive disease was lowest in HAI
(12.7%, 3.8–20%) and highest with TACE (25.5%, 0–
75%). The rates were intermediate for Y-90 (14.9%,
4.5–21.7%) and DEB-TACE (20.6%, 0–29.1%). Med-
ian OS (calculated from the date of initiation of HAT)
was highest for HAI (21, 11–31) months compared to
Y-90 (14, 9–22) months vs. TACE (13, 6–16) months
vs. DEB-TACE (12, 12–13) months.
Conclusions: In the present comparative effectiveness
study of hepatic artery based therapies for unresectable
ICC, hepatic artery infusion (HAI) reported best out-
comes in terms of overall response to therapy and med-
ian OS. The comparative cost-effectiveness and
optimization by patient and disease characteristics are
a focus for future research.
FO13-02
HISTOLOGIC DETERMINATION OF
THE PRIMARY SITE OF PERIHILAR
CHOLANGIOCARCINOMA BASED ON
MICROSCOPIC TUMOR INVASION OF
THE VASCULO-BILIARY SHEATHS
Toshifumi Wakai, Jun Sakata, Yuki Hirose,
Tomohiro Katada, Natsuru Sudo, Taku Ohashi,
Kazuyasu Takizawa, Kabuto Takano,
Takashi Kobayashi and Masahiro Minagawa
Niigata University Graduate School of Medical and
Dental Sciences, Japan
Introduction: This study aimed to histologically charac-
terize microscopic tumor invasion of the vasculo-biliary
sheaths in perihilar cholangiocarcinoma so as to deter-
mine the primary tumor site and to clarify clinicopath-
ologic differences according to the primary site.
Method: A retrospective analysis was conducted of 52
patients who underwent resection for perihilar cholan-
giocarcinoma involving both the hepatic hilus and the
liver, verified histologically. Histologic features of the
vasculo-biliary sheath invasion were evaluated by dou-
ble staining with hematoxylin-eosin to assess general
morphology and Victoria Blue to detect the elastic
fibers of the vasculo-biliary sheaths.
Results: In the present study, determination of the pri-
mary site of perihilar cholangiocarcinoma is possible in
clinical cases, by using double staining with hematoxy-
lin-eosin and Victoria Blue to discriminate between
tumors of extrahepatic and intrahepatic origin. The
perihilar cholangiocarcinomas were classified into extra-
hepatic-type (34 patients), featuring an extrahepatic
component involving the liver through the vasculo-bili-
ary sheaths, and intrahepatic-type (18 patients), featur-
ing an intrahepatic component involving the hepatic
hilus through the vasculo-biliary sheaths. Hemihepatec-
tomy with extrahepatic bile duct resection was the most
common surgical procedure. Tumor size (p = 0.002),
pN classification (p = 0.005), and pM classification
(p = 0.023) were significant independent prognostic fac-
tors. The primary site was not significantly associated
with survival after resection (p = 0.214), as patients
with extrahepatic-type tumors had a cumulative 5-year
survival rate of 32%, compared with 28% for patients
with intrahepatic-type tumors.
Conclusions: Double staining with hematoxylin-eosin
and Victoria Blue permits histologic discrimination
between tumors of extrahepatic and intrahepatic origin,
and thereby determination of the primary tumor site in
clinical cases of perihilar cholangiocarcinoma. Combin-
ing extrahepatic-type and intrahepatic-type tumors
under the term perihilar cholangiocarcinoma is valid
clinically, as these tumors show comparable surgical
outcomes with similar clinical management.
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FO13-03
CLINICOPATHOLOGICAL FEATURES
AND SURGICAL OUTCOMES OF
INTRADUCTAL PAPILLARY
CHOLANGIOCARCINOMA:
COMPARISON WITH FLAT-TYPE
CHOLANGIOCARCINOMA
Sungho Jo and Sanghyun Song
Dankook University Medical College, Korea
Introduction: Despite a marked clarification for intra-
ductal papillary neoplasm of the bile duct over recent
several years, its malignant form, intraductal papillary
cholangiocarcinoma (IPC), remains unknown and has
been vaguely considered to have a good prognosis. This
study was performed to evaluate clinicopathological
features and prognosis of IPC, compared with conven-
tional flat-type cholangiocarcinoma (FTC).
Method: Between July 1995 and June 2013, a total of
85 patients underwent surgical resections with curative
intent for intrahepatic and extrahepatic cholangiocarci-
noma at Dankook University Hospital. The patients
were divided into two groups according to the perma-
nent pathologic diagnosis; IPC and FTC group. The
clinicopathological characteristics and long-term out-
comes were compared between both groups.
Results: A total of 11 patients (12.9%) received surgi-
cal resection for IPC. Mean age of the patients with
IPC was 57.7 (38–72 years) and male patients were
dominant. Of them, two patients underwent surgery for
recurrent lesions in a regional lymph node and remnant
distal bile duct, respectively, and are now in disease-
free status. One patient was postoperative mortality
and two patients died of recurrent disease about 1 and
4 years after surgery. There were no statistical differ-
ences in age, gender, tumor location, hospital mortality,
and disease-free survival between the groups. However,
surgical radicality, stage, and overall survival were bet-
ter in the IPC group. The overall 3-year and 5-year sur-
vival rates of the patients with IPC were 81.8% and
68.2%.
Conclusions: The patients with IPC showed an excel-
lent prognosis compared to the patients with FTC. In
addition, an aggressive surgery for recurrent IPC could
prolong survival in selected cases.
FO13-04
BISMUTH-CORLETTE TYPE IV
PERIHILAR CHOLANIOCARCINOMA:
IS THERE NO CLINICAL BENEFIT OF
SURGERY?
Dae Wook Hwang, Yoo-Seok Yoon, Jai Young Cho,
Young Ki Kim, Woohyung Lee, Hong Kyung Shin
and Ho-Seong Han
Seoul National University Bundang Hospital, Korea
Introduction: According to the seventh edition of the
AJCC Cancer Staging Manual, Bismuth-Corlette (BC)
type IV perihilar cholangiocarcinoma is T4 and stage
IVA, by itself, with the median survival of patients is
8 – 13 months. In this study, improved clinical out-
comes could be obtained by aggressive surgical
approach for the patients who were diagnosed BC type
IV, preoperatively.
Method: A total of 19 patients underwent surgery for
BC type IV hilar cholangiocarcinoma at the Seoul
National University Bundang Hospital, from 2004 to
2012. Clinical, radiological, and pathological data were
analyzed retrospectively. Concomitant hepatic resection
was performed in 17 patients, but only staging laparot-
omy in two patients.
Results: The mean age was 65.8  9.8 (range 46–80)
years, and the proportion of gender was 3.75:1 (15
males and 4 females). For the type of hepatic resection
in 17 patients received curative intent surgery, extended
left hepatectomy was performed in 9 patients, extended
right hepatectomy in 5 patients, and left hepatectomy /
right hepatectomy / right trisectionectomy in 1 patient,
respectively. The mean operative time was
442.2  108.7 minutes, and the mean estimated blood
loss was 1,183.7  752.5 mL. The rate of R0 resection
was 52.6% (10/19). The morbidity was 52.6% (10/19),
and there was no in-hospital mortality. The median
overall survival of patients was 24.0 months and 11
patients still survive more than 15 months after sur-
gery.
Conclusions: Even aggressive surgical approaches, it is
difficult to obtain R0 in BC type IV patients. However,
some changes including active adoptation of left-sided
hepatectomy and multidisciplinary approach enhances
the outcomes in BC type IV, Stage IVA perihilar cho-
langiocarcinoma.
FO13-05
SURGICAL TREATMENT OF
PERICHILLAR
CHOLANGIOCARCINOMA WITH
VASCULAR INVASION
Oleg Kotenko, Denis Fedorov, Alexander Grinenko,
Alexander Korshak, Alexey Popov, Andrey Gusev and
Marat Grigoryan
National Institute of surgery and transplantology,
Ukraine
Introduction: Vascular invasion is a main cause irresec-
tability of perihilar cholangiocarcinoma. However inno-
vative surgical technologies allow resecting involved
portal vein with acceptable mortality. Invasion of the
hepatic artery, often combined with invasion of portal
vein, still remains the most serious obstacle in resection
of this disease.
Method: The aim of our study was to asses results of
surgical treatment of perichillar cholangiocarcinoma
with portal vein and hepatic artery invasion.
Results: We studied results of surgical treatment 136
patients with Klatskin tumor period 2003–2012 years.
T2a TNM stage had 1.6% patients, T2b – 2.2%
patients, T3 TNM stage had 38% patients, and most
patients had T4 stage TNM (58% patients). Bismuth
type B2 had 1 patient, B2a – 41 patients, B3b – 36
patients, B 4 – 58 patients. In patients with small rem-
nant liver volume less than 40%, we did preoperative
PV embolization of a resected part of the liver. PV
resection was made 71 (52.2%) patients, Right HA
resection and reconstruction we did for 8 cases, com-
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bined PV and HA resection and reconstruction we did
for 8 –cases, hepatopancreatoduodenectomy for 7
patients. In all cases we made extended lymphadenecto-
my. Mortality was 8.1% (11 patients). 3 and 5 years
reccurence-free survival was higher in group with R0
resection 33.3% and 20.8% respectively, for patients
with vascular reconstruction – 14.6 and 6.3%, and was
smaller for group with R1 resection. 3 and 5 years sur-
vival was higher in group with R0 resection 58.3% and
33.3% respectively, for patients with vascular recon-
struction – 31.5% and 18.8%, and was smaller for
group with R1 resection – 22.2% and 11.1%.
Conclusions: Aggressive surgical treatment for cholan-
giocarcinoma the confluence of bile duct with hepatic
artery and portal vein resection can be performed safely
with acceptable lethality and long term survival rate.
FO13-06
HILAR CHOLANGIOCARCINOMA IN
CIRRHOTIC LIVER
Mohamed El Sorogy1 and Mohamed Wahab2
1Assistant lecturer of General and digestive surgery,
Egypt; 2Professor, Egypt
Introduction: Despite great evolution in surgery and
surgical techniques, resectional surgery for central cho-
langiocarcinoma remains a challenge especially in cir-
rhotic patients.Despite great evolution in surgery and
surgical techniques, resectional surgery for central cho-
langiocarcinoma remains a challenge especially in cir-
rhotic patients.
Method: Between January 1995 and December 2010,
243 patients with central cholangiocarcinoma under-
went surgical resection at gastro-enterology surgical
center, Mansoura University. Of these patients, 102
were cirrhotic while 141 had normal livers. Their mean
age was 54.2 years  9.6 for cirrhotic group and
52.5 years  10.2 for non cirrhotic group.
Regarding sex, 65% of cirrhotic group were males,
35% were females and 53% of non cirrhotic group
were males, 47% were females.
All patients presented with jaundice while pain was
present in 47% in cirrhotic group and 27% in non cir-
rhotic group, weight loss in 43% in cirrhotic group and
47% in non cirrhotic group.
Pre operative biliary drainage was done in 47% of patients
in cirrhotic group and 42% in non cirrhotic group.
Major surgical resection was done in 59.8% in cirrhotic
group and 79.4% in non cirrhotic group. While seg-
ment 1 resection done in 26.5% in cirrhotic group and
53.2% in non cirrhotic group.
Results: Hospital mortality occurred in 3.9% of cir-
rhotic patients and 2.8% in non cirrhotic patients. Post
operative complications included liver cell failure in
26.5% of cirrhotic patients and 8.5% of non cirrhotic
patients, bile leak in 40.2% in cirrhotic and 29.1% in
non cirrhotic patients, internal hemorrhage in 7.8% of
cirrhotic and 5% in non cirrhotic patients.
Recurrence occurred in 44.1% in cirrhotic and 33.4%
in non cirrhotic patients.
Conclusions: As a conclusion, hepatic resection for
hilar cholangiocarcinoma in cirrhotic liver, although
risky, can be achieved with good surgical technique
and experienced surgical team.
FO13-07
HILAR CHOLANGIOCARCINOMA:
PREOPERATIVE LIVER
OPTIMIZATION WITH
MULTIDISCIPLINARY APPROACH.
TOWARDS BETTER OUTCOME
Francesca Ratti, Federica Cipriani, Fabio Ferla,
Marco Catena, Michele Paganelli and Luca Aldrighetti
San Raffaele Hospital, Italy
Introduction: Klatskin tumour is a relatively rare dis-
ease with a poor prognosis: currently the only possible
treatment is represented by the removal of the tumour
associated with radical surgery, still associated with sig-
nificant morbidity and mortality; short term outcome is
therefore related to a proper preoperative optimization
of the patient, consisting of staging laparoscopy, biliary
drainage and portal vein embolization. The aim of this
study was to evaluate the short-and long-term impact
of preoperative optimization in patients affected by
hilar cholangiocarcinoma.
Method: From January 2004 to May 2012, 94 patients
with preoperative diagnosis of Klastkin tumours were
candidates to surgery. The data of all patients were
prospectively collected and retrospectively reviewed.
The outcome was evaluated in terms of perioperative
morbidity and mortality and overall and disease-free
survival. Short term outcome of patients undergoing
preoperative optimization was compared to outcome of
patients who did not require it.
Results: Of 94 patients undergoing surgery, 80 under-
went hepatic and biliary carrefour resection. Fourteen
patients were considered unresectable due to the pres-
ence of peritoneal carcinomatosis or advanced disease
seen during staging laparoscopy or at laparotomy and
were therefore excluded from the analysis. Seventy-five
(93.7%) patients underwent major liver resections: in
14 of these, surgery was performed at a distance of 30–
40 days from PVE. In 55 patients biliary drainage was
preoperatively placed for palliation of obstructive jaun-
dice. The postoperative morbidity rate was 51.2% and
mortality 6.2%. The most frequent cause of death was
postoperative liver failure. 5 years survival rate was
29%. Patients undergoing preoperative optimization
experienced a significant reduction of postoperative
morbidity, especially in terms of infectious related
events.
Conclusions: Klatskin tumour still remains a disease
associated with poor prognosis, but a correct preopera-
tive diagnostic and therapeutic management provides
tools to perform this type of surgery with acceptable
morbidity and mortality, improving long term results.
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FO13-08
SURGICAL TREATMENT FOR
RECURRENT BILIARY CARCINOMA:
RESULTS OF 23 RESECTED CASES
Takehiro Noji1, Takahiro Tsuchikawa2, Yuma
Ebihara2, Soichi Murakami2, Eiji Tamoto2, Toru
Nakamura2, Joe Matsumoto2, Eiichi Tanaka2, Toshiaki
Shichinohe2 and Satoshi Hirano2
1Yakumo General Hospital, Japan; 2Graduate School of
Medicine, Hokkaido University, Japan
Introduction: Few reports have described surgical treat-
ment for recurrent biliary carcinoma. The purpose of
this study was to evaluate surgical treatment for recur-
rent biliary carcinoma.
Method: This case-control study was conducted to inves-
tigate the feasibility of surgical intervention for recurrent
biliary cancer following radical operation. From Febru-
ary 2000 to February 2013, a total of 30 patients under-
went laparotomy for recurrent biliary carcinoma. Seven
patients underwent laparotomy alone, and the remaining
23 patients (14 men, 9 women; median age, 68 years; age
range, 45-84 years) underwent resection.
Results: There were two cases (4 operations) of intrahe-
patic cholangiocarcinoma (IHC), 12 cases (14 opera-
tions) of extrahepatic bile duct cancer (ExHBDC), 7
cases (7 operations) of gallbladder carcinoma (GBC)
and 2 cases (3 operations) of papilla of Vater carcinoma
(PVC). Recurrent sites consisted of liver metastases (14
operations for 12 patients), local/fistula recurrence (6
operations for 6 cases), bile duct recurrence (6 opera-
tions for 6 cases), lymph node recurrence (1 operation
for 1 case) and lung metastasis (1 operation for 1 case).
Median interval between primary resection and recur-
rent site resection (OI) was 19 months (range, 9–
114 months). Overall 5-year survival rate was 32%.
Median survival time was 20 months overall,
18.5 months for ExHBDC, and 11 months for GBC.
Median survival times with liver metastasis, bile duct
recurrence, and local recurrence were 33 months,
7 months, and 11 months, respectively. Median survival
times for OI >19 months and OI <19 months were
18.5 months and 29.4 months, respectively. No signifi-
cant differences were evident in survival between groups
(p = 0.120). Five patients showed long-term survival (3
cases with liver metastases, 1 with lymph node recur-
rence, and 1 with locoregional recurrence).
Conclusions: Surgical treatment for selected patients
with recurrent biliary carcinoma appears feasible.
FO14-01
PREOPERATIVE NEUTROPHIL-
LYMPHOCYTE RATIO PREDICT
SURVIVAL AFTER RESECTION FOR
PANCREAS CANCER PATIENTS
Daisuke Ishii, Koichiro Uchida, Koji Imai,
Mikako Gochi, Tomoyuki Seki, Kenji Watanabe,
Masashi Miyamoto, Suguru Matsuzaka and
Masahiko Taniguchi
Asahikawa Medical University, Japan
Introduction: To select the candidates for resection for
pancreas cancer (PC) via radiographic appearances,
response to chemotherapy or biomarker provide favor-
able outcome due to their aggressive biological behav-
ior and high perioperative mortality. Recently
inflammatory response to cancer progression and recur-
rence had been reported in several cancer but few in
PC. Aim of this study is to evaluate the impact of pre-
operative neutrophil-lymphocyte ratio (NLR) on out-
come after resection for PC.
Method: From 2000 to 2010, 76 consecutive R0 or R1
resection were performed for PC. Follow up is until
DEC 2012. The date were retrospectively corrected and
analyzed.
Results: Median follow-up of 24 months. The 5-year
overall survival (OS) and disease free survival (DFS)
rate are 34.0% and 22.0% respectively. Lymphatic
invasion, lymph node metastasis, portal vein invasion
(PVI), preoperative NLR ≥5 (n = 5) and platlet lym-
phocyte ratio were associated with both poor survival
and early recurrence in univariate analysis. Multivariate
analysis showed that lymph node metastasis and also
NLR ≥5 were independent factors associated with both
early recurrence and poor survival.
Conclusions: High inflammatory circumstance, such as
NLR ≥5, has significant impact on survival for resected
PC patients. Preoperative NLR measurement provides
simple method of identifying patients with the high bio-
logical activity of PC.
FO14-02
THE IMPLICATIONS OF PERITONEAL
WASHING CYTOLOGY IN
RESECTABLE PANCREATIC CANCER
Osamu Kainuma, Hiroshi Yamamoto, Akihiro Cho,
Yorihiko Muto and Hiroo Yanagibashi
Chiba Cancer Center, Japan
Introduction: Positive peritoneal washing cytology
(PWC) is a poor prognostic factor in unresectable
advanced-stage pancreatic cancer. However, the impli-
cations of PWC in resectable pancreatic cancer are still
controversial. Strategy of treatment for PWC patients
has not yet established. The aim of this study is to
investigate the implications of PWC in patients with
pancreatic cancer and efficacy of postoperative chemo-
therapy for PWC patients.
Method: Between January 2006 and December 2012, a
total of 140 patients with pancreatic cancer were
explored peritoneal washing cytology at the time of
pancreatic resection. Malignant cells were identified in
19 patients (13.5%). Curative intent operation was per-
formed irrespective of cytological status. The prognos-
tic factors were evaluated in univariate and
multivariate analysis. Adjuvant chemotherapy was
ordinary performed for 6 months in negative cytology
patients, but was administered as long as possible until
recurrence was noticed in PWC patients. Log-rank test
and Cox proportional hazards model was used for sta-
tistical analysis.
Results: Preoperative CA19-9 level (1,000 ≤ U/mL),
tumor location (pancreatic head), blood loss
(1,000 mL≤), and PWC were poor prognostic factors in
univariate analysis. On multivariate analysis, tumor
location (HR, 1.686; 95% CI, 1.038–2.806; p = 0.035),
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blood loss (2.022; 1.230–3.292; 0.007), and PWC
(2.044; 1.017–3.924; 0.045) were independently associ-
ated with overall survival. Median survival time of
PWC patients including 2 five-year survivors was
15.6 months. Mean duration of postoperative chemo-
therapy was 18.2 months (1.9–62.5) in PWC patients.
Peritoneal recurrence in patients with negative and
positive was observed in 14 (12%) and in 3 (16%),
respectively.
Conclusions: PWC was one of the poor prognosis fac-
tors in pancreatic cancer. However, curative intent
operation followed by long-term postoperative chemo-
therapy could be useful for selected patients. We should
not exclude all PWC patients from surgical treatment.
FO14-03
THE PROGNOSIS ANALYSIS OF
PORTAL VENOUS INVOLVEMENT BY
PANCREAS DUCTAL
ADENOCARCINOMA; ACCORDING TO
THE LOCATION AND EXTENT OF
VENOUS INVOLVEMENT
Ji Woong Hwang1, Song Cheol Kim2, Jae Hoon Lee2,
Ki Byung Song2, Jeong Su Nam2, Jong Hee Yoon2,
Kwang-Min Park2 and Young-Joo Lee2
1Hallym University Chuncheon Medical Center, Korea;
2Asan Medical Center, Ulsan University, Korea
Introduction: The aim of this study is to evaluate the
surgical outcome in patients with pancreas head cancer
according to the location and extent of venous involve-
ment.
Method: From January 2003 to December 2010, 124
patients were included who underwent pancreaticoduo-
denectomy (PD) or pylorus-preserving pancreaticoduo-
denectomy (PPPD) with concomitant venous resection.
We classified subgroups according to the location (por-
tal vein [PV] group, portal vein confluence [PVC]
group, and superior mesenteric vein [SMV] group) and
extent (Group A, the tumor surrounded up to 2/3 the
vessel perimeter; Group B, the tumor extended over 2/3
of the vessel perimeter) of venous involvement on
radiologic finding.
Results: Among portal vein resection group, the med-
ian overall survival of PV (n = 9), PVC (n = 36), and
SMV group (n = 79) were 17.1 (5.1–29.1), 14.0 (8.9–
19.1), and 18.6 (15.2–22.0) months, respectively
(p = 0.042). Also, the median overall survival of Group
A (n = 96) and B (n = 28) were 18.2 (14.0–22.4) and
13.6 (11.9–15.3) months, respectively (p = 0.008). PV,
SMV group, and Group A showed similar surgical out-
comes compared with conventional PPPD.
At univariate analysis, the location and extent of
venous involvement were determined as significant
prognostic variables. At multivariate analysis, the loca-
tion of venous involvement (HR, 1.581 [95% CI,
1.015–2.465]; p = 0.043), the extent of venous involve-
ment (HR, 1.840 [95% CI, 1.141–2.8968]; p = 0.012),
LN involvement (HR, 1.587 [95% CI, 1.041–2.419];
p = 0.032), and adjuvant chemotherapy (HR, 0.531
[95% CI, 0.339–0.833]; p = 0.006) independently pre-
dicted overall survival.
Conclusions: The surgical outcomes of PV group, SMV
group, and Group A were comparable with conven-
tional PPPD. Thus, surgical resection and adjuvant
chemotherapy should be performed in these patients.
However, the tumor invaded portal vein confluence or
extended over 2/3 or the vessel perimeter had poorer
prognosis. Therefore we recommend that neoadjuvant
chemoradiotherapy should be applied in such patients.
FO14-04
BIOLOGICAL MARKERS FOR
IMMUNOHISTOCHEMICAL
DIAGNOSIS OF PANCREAS DUCTAL
ADENOCARINOMA
Leyo Ruo1, Sherrie Orr1 and Jasim Radhi2
1Juravinski Hospital and Cancer Centre, Canada;
2McMaster University Medical Centre, Canada
Introduction: Pancreas ductal adenocarcinoma (PDAC)
is a lethal malignancy for which histologic diagnosis
may be required for palliative chemotherapy. The
objective of this study was to evaluate several com-
monly investigated immunohistochemical markers to
specifically distinguish PDAC from benign processes,
such as chronic pancreatitis.
Method: Molecular biomarkers (EGFR, IGFP, Mes-
othelin, p53) previously shown to be overexpressed in
PDAC were chosen. We assessed the immunohisto-
chemical expression of each marker in tissue samples
representing PDAC, chronic pancreatitis, and normal
pancreatic parenchyma from almost 100 patients. Each
marker was evaluated for its ability to diagnose PDAC
in histologic specimens.
Results: The sensitivity (96%) and specificity (100%)
for diagnosis of pancreas cancer was best for mesoth-
elin, which was able to consistently identify PDAC in
tissue samples and distinguish it from both chronic
pancreatitis and normal pancreas. The positive likeli-
hood ratio for mesothelin could not be determined as
the calculated positive predictive value was 100% with
a negative predictive value of 94%. IGFP was sensitive
(95%) but not specific (31%), whereas p53 was less sen-
sitive (71%) but retained high specificity (96%). EGFR
had a sensitivity of 90% and specificity of 77% for
diagnosis of PDAC. The positive likelihood ratio was
17 (95% CI 2.5–116) for p53 and 3.9 (95% CI 2.6–5.9)
for EGFR. The negative likelihood ratio was best for
mesothelin (0.044, 95% CI 0.02–0.12) with acceptable
values for EGFR (0.13, 95% CI 0.07–0.25) and IGFP
(0.16, 95% CI 0.06–0.44) that could also be applied to
estimating the probability for diagnosis of PDAC.
Conclusions: Strong mesothelin expression in pancre-
atic ductal adenocarcinoma samples, but not in chronic
pancreatitis or normal pancreas samples, confirms that
this marker may have some diagnostic utility in dis-
criminating between neoplastic and nonneoplastic pan-
creatic ductal epithelium.
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FO14-05
CLINICAL EFFICACY OF STAGING
LAPAROSCOPY IN PATIENTS WITH
RADIOGRAPHICALLY-DEFINED
LOCALLY ADVANCED PANCREATIC
CANCER
Hironori Ryota
Kansai Medical University, Japan
Introduction: The aims of this study were to verify
whether staging laparoscopy (stag-lap) is useful for
detecting the presence of occult distant organ metasta-
sis, and to find prognostic factors in patients with
radiographically-defined (RD-LA) locally advanced
pancreatic cancer.
Method: Stag-lap was performed in 58 patients with
RD-LA pancreatic cancer, who were divided into 4
groups according to metastatic site: Group CY (perito-
neal fluid or washing cytology positive and without any
distant organ metastasis); Group P (peritoneal dissemi-
nation); Group L (liver metastasis); Group LA (pure
locally advanced pancreatic cancer without positive
cytology and any distant organ metastasis). Clinical
backgrounds and survival curves were compared
among groups, and prognostic factors were investigated
for this population. All patients were followed up for
at least one year.
Results: Exploration using stag-lap demonstrated posi-
tive cytology in 16 patients (CY, 25%), peritoneal dis-
semination in 13 patients (P, 20%), liver metastasis
only or concomitant with peritoneal metastasis in 8
patients (L, 13%), and locally advanced disease in 27
patients (LA, 42%). Median survival time was
13 months in the CY group (including 2 resected
patients) or 12 months in the LA group (including 1
resected patient), which was significantly better than
7 months in the P or L group, respectively (p < 0.05).
The rate of emergence of ascites in LA was significantly
better than in CY or P group (Kaplan-Meier,
p < 0.05). Multivariate analysis showed that the pres-
ence of partial response on CT scan and Gemcitabine
and S-1 administration were significant independent
prognostic factors.
Conclusions: Patients with pure locally advanced pan-
creatic cancer comprised only 42% of patients with
RD-LA pancreatic cancer who underwent stag-lap.
Gem/S-1 administration and responsiveness to chemo-
therapy were associated with favorable prognosis.
FO14-06
THE CLINICAL IMPACT OF
PATHOLOGICAL SUBTYPE AND
FACTORS PREDICTING SURVIVAL IN
PATIENTS WITH AMPULLARY
ADENOCARCINOMA
Keiichi Okano, Naoki Yamamoto, Minoru Oshima,
Eisuke Asano and Yasuyuki Suzuki
Kagawa University, Japan
Introduction: Ampullary adenocarcinomas arise from
the epithelium of the pancreas, biliary duct, or the
ampulla itself. The aims of this study were to identify
clinicopathological factors associated with survival and
clarify the characteristics of 2 different pathological
subtypes of ampullary adenocarcinoma.
Method: The medical records of 101 patients who were
treated for ampullary neoplasms between 2000 and
2012 at 12 principal hospitals in Kagawa prefecture,
Japan, were reviewed. The histological subtype was
reviewed prospectively by a pathologist blinded to the
clinical outcomes.
Results: The actuarial 1-, 3-, and 5-year postoperative
survival rates for ampullary adenocarcinomas (94
patients) were 84%, 67%, and 63%, respectively. Pre-
operative biliary drainage, serum levels of CA19-9
(≥36 U/mL) and total bilirubin (≥1.0 mg/dL), patho-
logic grade (moderately to poorly), perineural invasion,
vascular invasion, lymphatic invasion, pancreas inva-
sion, nodal metastasis, and pancreatobiliary subtype
were predictor for poor survival. In multivariate mod-
els, only an elevated serum CA19-9 level predicted sur-
vival (HR 5.6; p = 0.023). Patients with
pancreatobiliary type tumors presented with elevated
serum CA19-9 and total bilirubin levels and lymphatic,
perineural, and pancreas invasion more often than
patients with intestinal type tumors; they also had an
advanced overall stage. Preoperative endoscopy
revealed a red coloration more frequently in intestinal
type tumors.
Conclusions: An elevated serum CA19-9 level is an
independent prognostic factor for ampullary cancer
and is associated with pancreatobiliary type tumors.
Pancreatobiliary type adenocarcinoma is characterized
by aggressive invasiveness and poor survival.
FO14-07
OUTCOME AFTER SURGICAL
RESECTION FOR SMALL PANCREATIC
NEUROENDOCRINE TUMORS (PNET)
Anneke Jilesen, SusanneVan Eeden, Joanne Verheij,
Olivier Busch, ThomasVan Gulik, Dirk Gouma and
Els Nieveenvan Dijkum
Academic Medical Center, The Netherlands
Introduction: pNET is a rare disease and surgery is the
only curative treatment. MEN1 patients generally will
undergo resection if pNET size exceeds >2 cm. In
patients with non-function pNET (NF-pNET), this is
unclear. In this study the outcome after surgical resec-
tion for small versus large NF-pNET was compared.
Method: All patients with NF-pNET operated between
January 2000 and July 2013 were selected. Patients
were categorized in two groups based on tumor size
small ≤2 cm or large >2 cm. Clinicopathologic charac-
teristics were analysed according the tumor size using
univariate statistics. Tumor grade was classified based
on the WHO classification 2010.
Results: 71 patients underwent resection for NF-pNET,
26 patients had a small tumor and 45 patients a large
tumor. All patients with a small tumor had a grade 1
tumor. In patients with a large tumor, 47% had a
grade 1 tumor, 47% a grade 2 tumor and 6% a grade
3 tumor (p < 0.05). The incidence of nodal metastases
in resected specimen in patients with small tumors was
significant lower compared with patients with large
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tumors (2/26 vs. 21/45). In patients with small tumors,
5% had recurrent disease compared with 38% patients
with large tumors (p < 0.05). After an average follow-
up of 45 months, 11 patients died. Six patients died of
disease progression, 2 patients with a small tumor.
Conclusions: Tumors size ≤2 cm is associated with
more tumor grade 1, lower risk of nodal metastasis in
resected specimen and recurrent disease. However,
there were no differences in overall survival.
In patients with small tumors, intensive follow-up may
be considered as an alternative for resection.
FO14-08
PANCREATICODUODENECTOMY,
VOLUME AND OUTCOME EFFECT: AN
AUSTRALIAN INSTITUTION
EXPERIENCE
Olukunle Onasanya, Mark Boccola, Valery Usatoff,
Marty Smith, Julian Choi, Nezor Houli and
Stephen Chan
Western Hospital, Footscray, Victoria 3011, Australia
Introduction: Surgical resection remains the only poten-
tially curative option in the management of pancreatic
cancer. Although the inverse relationship between hos-
pital volume and outcome following pancreaticoduo-
denectomy has been reported in many countries, there
is a paucity of data concerning this in Australia. Our
goal is to assess if better operative outcome is a func-
tion of high volume of resection. We consider our insti-
tution as a medium-high volume centre as we perform
about 10 Whipple’s operation in a year.
Method: A retrospective review of the records of 86
patients that underwent pancreaticoduodenectomy
(Whipple’s procedure) in Western Hospital between
2002 and 2012 was conducted. Data pertaining to pro-
cedure, histology, in - hospital mortality, length of
admission, complications, follow-up and survival were
analysed. Survival was established through hospital
records, information from operating surgeons’ room
and General Practitioners’ records.
Results: 97% of patients were successfully discharged
from hospital with a mean hospital stay of 12 days. In
addition, about 10% of our patients had grade 4 opera-
tive complications and above, while only 1% of our
patients had grade C pancreatic fistula. The overall 5-
year survival rate in patients with histological confirma-
tion of carcinoma was 20%.
Conclusions: Our result is comparable to what obtains
internationally, that high volume centres are linked
with better outcomes. Is it time to consider centraliza-
tion of pancreaticoduodenectomy in Australia?
FO15-01
CONTRAST-ENHANCED
INTRAOPERATIVE ULTRASONIC
CHOLANGIOGRAPHY FOR REAL-TIME
BILIARY NAVIGATION IN
HEPATOBILIARY SURGERY
Takeshi Urade, Takumi Fukumoto, Motofumi Tanaka,
Masahiro Kido, Atsushi Takebe, Kaori Kuramitsu,
Masashi Chuma, Tetsuo Ajiki, Ippei Matsumoto and
Yonson Ku
Kobe University Graduate School of Medicine, Japan
Introduction: Precise assessment of biliary anatomy
during hepatobiliary operations is necessary to prevent
biliary complications. Although radiographic intraoper-
ative cholangiography (IOC) has been widely used, it
has several drawbacks; it exposes patients and medical
staff to radiation; it requires a large C-arm machine for
fluoroscopy as well as an attendant to operate it; and it
requires special techniques to generate 3D images. Con-
trast-enhanced intraoperative ultrasonic cholangiogra-
phy (CE-IOUSC) can address these issues. In this
study, we demonstrate the usefulness of CE-IOUSC
using an ultrasound contrast agent (Sonazoid) as a tool
for real-time biliary navigation.
Method: From April 2012 to August 2013, 25 patients
were scheduled to undergo hepatobiliary surgery includ-
ing open hepatectomy and/or bile duct resection. CE-
IOUSC was performed using an AplioXG ultrasound
imaging system with a 4D probe, a T-shaped intraopera-
tive linear probe and a micro-convex probe (Toshiba
Medical Systems). After temporary clamping of the
common bile duct, diluted Sonazoid was injected via a
4Fr transcystic catheter. 3D CE-IOUSC using the 4D
probe was performed to delineate the biliary tree. 2D
CE-IOUSC of the entire liver was performed using the
linear probe. If necessary, 2D CE-IOUSC of the hepatic
hilum was also performed using the micro-convex probe.
Results: 2D and 3D CE-IOUSC clearly visualized the
biliary tree from CHD to the peripheral branches. The
detectability for CHD, LHD, RHD, and peripheral
branches was 96%, 92%, 92%, and 96% in 2D and
84%, 88%, 88%, and 92% in 3D, respectively. No in-
traoperative or postoperative complications related to
Sonazoid occurred.
Conclusions: CE-IOUSC is a feasible and valuable pro-
cedure that provides 3D mapping and 2D regional
anatomy of the biliary tree for real-time biliary naviga-
tion. This novel technique has the potential to super-
sede radiographic IOC because it is a less invasive,
convenient, real-time, repeatable modality for obtaining
useful biliary information for hepatobiliary surgeons.
FO15-02
4D FUSION IMAGING SYSTEM FOR
ULTRASONOGRAPHY
Yoshihiro Nagao, Michele Diana, Patrick Pessaux,
Peter Halvax, Damien Metz, Sung woo Cho, Yu-Yin
Liu, Didier Mutter and Jacques Marescaux
IRCAD-IHU, University Hospital of Strasbourg, France
Introduction: In this study, ACUSON S3000TM, mount-
ing a novel ultrasound technology called 4D fusion
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imaging system, enabling automatic fusion of CT or
MRI image with real-time ultrasound image via a sin-
gle click, was used and its feasibility was evaluated.
Method: Two experts, who perform liver ultrasonogra-
phy as routine work, and four surgeons, who have
experience of ultrasonography but don’t perform as
routine work, were involved in this study. Biocompati-
ble gels, invented in our institute, was percutaneously
injected into six living pig to create phantom of liver
tumour. Randomly four to six phantoms were created
into each pig. Experts and surgeons were asked to
detect the number and location of phantoms with ultra-
sonography under various conditions in random order,
(1) without any information, (2) with beforehand CT
image observation, (3) with 4D fusion imaging system.
Time; defined as consuming time to detect each tumor
with ultrasonography, Miss; defined as number of
phantoms which was not detected, and Error; defined
as number of incorrectly detected lesions which was not
phantoms, were recorded and evaluated statistically.
Results: The average of time consumed for setting up
fusion imaging system before ultrasonography was
267  51 seconds.
Without any information, Time, Miss rate, and Error
rate were 151  111 seconds versus 197  121 seconds,
13% (2/15) versus 52% (13/25), 0% (0/15) versus 16%
(4/25) (Expert vs. Surgeon respectively), with previous
CT image, 102  65 seconds versus 149  150 seconds,
6% (1/15) versus 33% (10/30), 0% (0/15) versus 26%
(8/30). Finally, surgeon with fusion imaging system
recorded 61  35 seconds, 3% (1/30), 0% (0/30) (time,
missing rate, and error rate respectively). Comparison
between surgeon with fusion imaging system and expert
with previous CT imaging showed surgeon could per-
form ultrasonography within statistically less time
61  35 seconds versus 102  65 seconds (p = 0.01)
and equivalent missing and error rate.
Conclusions: Four dimensional fusion imaging system
(ACUSON S3000TM) might be useful for minimally
invasive procedure with ultrasonography.
FO15-03
GLYPICAN-3 TARGETED
89ZIRCONIUM-PET IMAGING OF
HEPATOCELLULAR CARCINOMA
Jonathan Sham, Forrest Kievit, John Grierson,
Robert Miyaoka, Miqin Zhang, Satoshi Minoshima
and James Park
University of Washington, USA
Introduction: Hepatocellular carcinoma (HCC) is a
devastating malignancy in which imperfect imaging
plays a primary role in diagnosis. Glypican-3 (GPC3) is
an HCC-specific cell surface proteoglycan over-
expressed in the majority of HCCs. Few data exist
regarding the use of GPC3 as a target for molecular
imaging. This study presents the use of Zirconium-89
(89Zr) conjugated monoclonal antibody against GPC3
(aGPC3) for intrahepatic tumor localization using
micro positron emission tomography (micro-PET).
Method: PCR confirmed relative GPC3 expression in
multiple cell lines. Radioactive 89Zr was conjugated to
aGPC3 via the chelator p–isothiocyanato-benzyldesfer-
rioxamine. In vitro binding and in vivo biodistribution
and micro-PET studies were performed in GPC3-
expressing HepG2 and GPC3 non-expressing HLF cells
and RH7777 orthotopic xenografts. Tumors of various
sizes were evaluated.
Results: 89Zr-aGPC3 demonstrated antibody-depen-
dent, antigen-specific tumor binding. HepG2 liver
tumors exhibited high peak micro-PET signal
(836.63  86.55%ID/g) compared with background
liver (27.50  1.60% ID/g). Tumor-to-liver contrast
ratio was high and peaked at 32.46. The smallest
HepG2 tumor (<1 mm) showed lower peak micro-PET
signal (42.54  6.36% ID/g) and tumor-to-liver con-
trast (1.57), but was still clearly visible on micro-PET
images. Day 7 tissue activity was still substantial in
HepG2 tumors (466.38  87.58%ID/g) compared with
control RH7777 tumors (3.85%  1.25% ID/g,
p < 0.01) indicating antigen-specificity by 89Zr-
aGPC3. HepG2 tumor treated with heat denatured
89Zr-aGPC3 demonstrated comparable tumor activity
(2.08% ID/g) to control xenografts confirming anti-
body-dependency.
Conclusions: This study demonstrates the feasibility of
utilizing 89Zr-aGPC3 to image HCC tumors in the liver
as well as determining their GPC3 expression via
micro-PET. The ability to clarify the identify of small
liver lesions with an HCC-specific micro-PET imaging
probe would provide clinicians with vital information
that would drastically alter patient management and
therefore warrants further investigation for clinical
translation.
FO15-04
DIAGNOSTIC VALUE OF A
PANCREATIC MASS ON COMPUTED
TOMOGRAPHY IN PATIENTS
UNDERGOING
PANCREATODUODENECTOMY FOR
PRESUMED PANCREATIC CANCER
Arja Gerritsen1, Thomas L. Bollen2, Yung Nio3,
I. Quintus Molenaar1, Koert P.De Jong4, ErwinVan
der Harst5, Michael F. Gerhards6, Casper H.Van
Eijck7, Olivier R.C. Busch3 and Marc G.H. Besselink3
1University Medical Center Utrecht, The Netherlands;
2St.Antonius hospital Nieuwegein, The Netherlands;
3Academic Medical Center Amsterdam, The
Netherlands; 4University Medical Center Groningen, The
Netherlands; 5Maasstad Ziekenhuis Rotterdam, The
Netherlands; 6OLVG, The Netherlands; 7Erasmus
Medical Center Rotterdam, The Netherlands
Introduction: Some patients undergoing pancreatoduo-
denectomy for suspected malignancy are ultimately
diagnosed with benign disease. We aimed to determine
the diagnostic value of a pancreatic mass on computed
tomography (CT) in patients with presumed pancreatic
cancer and the additional value of reassessment by
expert-radiologists.
Method: We performed a multicenter retrospective
cohort study in 1,629 consecutive patients undergoing
pancreatoduodenectomy for suspected malignancy
(2003–2010). All patients with unexpected benign dis-
ease at postoperative pathological diagnosis were
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included in a 1:3 ratio with random patients with (pre)
malignant disease. The preoperative CT scan was reas-
sessed by two expert-radiologists separately and subse-
quently (after defining a mass as ‘a measurable space
occupying soft tissue density, except for an enlarged
papilla or focal steatosis’) in consensus.
Results: 86 patients with benign and 258 patients with
(pre)malignant disease were included. A mass was
reported in the original CT report in 66% of patients
versus 48% and 50% on reassessment by the two
expert-radiologists, respectively. Interobserver agree-
ment among expert-radiologists was moderate
(kappa = 0.47, 95% CI 0.38–0.56); they disagreed on
the presence of mass in 29% of patients. The incidence
of mass decreased to 44% after consensus reading
(p < 0.001 vs. original report). 167/212 (79%) masses
identified in the original report proved to be malignant
after pancreatoduodenectomy versus 139/150 (93%)
masses identified by expert-radiologists in consensus
(p < 0.001). The sensitivity, specificity, positive predic-
tive value, negative predictive value and accuracy of
masses identified in the original CT report were 68%,
42%, 79%, 30%, and 62%, respectively. For masses
identified by expert-radiologists in consensus these were
54%, 87%, 93%, 39% and 62%, respectively.
Conclusions: In patients with presumed pancreatic can-
cer, expert-radiologists less frequently identified a pan-
creatic mass on CT as compared to the original CT
reports, with doubled specificity for malignancy. As in-
terobserver agreement, even among expert-radiologists,
is only moderate, the use of a uniform definition for
pancreatic mass is recommended.
FO15-05
WORLD REVIEW OF LAPAROSCOPIC
TREATMENT OF LIVER HYDATID
DISEASE-914 CASES
Tuxun Tuerhongjiang, Hao Wen, Jin-Hui Zhang,
Jin-Ming Zhao, Qin-Wen Tai, Jun Cao,
Mahumuti Maerdan and Abudurexiti Mierxiati
The first affiliated hospital of Xinjiang Medical
University, China
Introduction: The purpose of this study is to provide
comprehensive review of the English literatures on all
reported cases of laparoscopic liver hydatid cyst.
Method: We conducted a literature search using Pub-
Med, screening all English publications on laparoscopic
treatment of liver hydatid cyst. All data were analyzed
and apparent case duplications in updated series were
excluded from the total number of patients. Operative
characteristics, perioperative morbidity, and clinical
outcomes were tabulated.
Results: A total of 57 published articles of original case
series and reports on laparoscopic treatment of liver
hydatid cyst were identified, and accounted for 914
patients with 1,116 hydatid cysts. Of the cystic type,
forty seven percent were for Type one, 7% were for
Type two, 17% were for Type three, 5% were for Type
four, 1% were for Type five, and the rest were indeter-
minate. The most common location for the cyst was
right hepatic lobe (57.6%). Of the resection in 914
patients, 89.17% were performed totally laparoscopical-
ly, 5.58% were gas-less, and other techniques. The most
common laparoscopic procedure was cystectomy
(60.39%), followed by partial pericystectomy (14.77%)
and pericystectomy (8.21%), the rest were left lateral
sectionectomy and segmentectomy. Conversion from
laparoscopy to open laparotomy occurred in 4.92% of
reported cases (45/914). The common cause of conver-
sion to open was anatomical limitations / inaccessible
locations (16/45). Overall mortality was 2 of 914
patients (0.22%), and morbidity was 15.07%, with no
intraoperative deaths reported. The most common
complication was bile leakage (57/914). The postopera-
tive recurrence was ten 0f 914 patients (1.09%).
Conclusions: In experienced hands, laparoscopic treat-
ment of liver hydatid cyst is safe with acceptable mor-
tality and morbidity for both conservative and radical
resections in selected patients. Clinical outcomes are
comparable to open surgery, albeit in a selected group
of patients.
FO15-06
MANAGEMENT OF POST-
ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY
PERFORATION: WHEN TO AND WHEN
NOT TO OPERATE?
Kitty Lo, Ka Wing Ma, Nam Hung Chia and
Moon Tong Cheung
Queen Elizabeth Hospital, Hong Kong, China
Introduction: Post-endoscopic retrograde cholangiopan-
creatography (ERCP) perforation is an uncommon yet
life-threatening condition.
Method: We retrospectively reviewed all patients with
post-ERCP perforation in our institution over a 7.5-
year period (2006–2013).
Results: There were 13 cases of perforation from
7,617 ERCP (0.17%), 8 were female (61.5%). Median
age was 77 (range 43–91). Time to diagnosis ranged
from 0 to 30 hours, with most (61.5%) diagnosed
immediately during ERCP. Overall mortality was
30.8%. Stapfer type I (duodenal perforation) was the
most common injury with six patients (46.2%),
including three with previous polya gastrectomy and
afferent loop perforation. Stapfer type II (periampul-
lary perforation) was found in four patients, followed
by two Stapfer type III (common bile duct perfora-
tion) and one Stapfer type IV (pneumo-retroperitone-
um only). Surgery was performed for all patients
with Stapfer type I and one with Stapfer type II
injury. There were two postoperative mortalities and
one had delayed surgery. Non-operative management
was instituted in six patients; one died of terminal
malignancy and another with poor premorbid state
died of sepsis. Pneumoperitoneum was found in seven
patients. Except for one, all had Stapfer type I injury
and received surgery. The exception was a patient
with Stapfer type III injury who remained stable with
no peritoneal sign, and was managed successfully
conservatively. For the six patients without pneumo-
peritoneum, one received surgery, as indicated by
stent protrusion into the pancreas, who succumbed.
The rest were managed non-operatively. Univariate
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analysis found emergency ERCP (p = 0.057), high bil-
irubin (p = 0.004) and low albumin level (p = 0.036)
to be associated with higher mortality.
Conclusions: Duodenal/ afferent loop perforations
should be treated surgically. Pneumoperitoneum usually
indicates surgery, although in exceptional cases non-
operative management may be attempted. Those with-
out pneumoperitoneum can often be managed non-
operatively, although some may still require surgery.
Emergency ERCP, high bilirubin and low albumin level
were associated with higher mortality.
FO15-07
GUIDE-WIRE-TYPE MANOMETER IS
FEASIBLE FOR DIAGNOSIS OF
SPHINCTER OF ODDI DISORDER
Arata Sakai, Saori Kakuyama, Kentaro Nobutani,
Atsuhiro Masuda, Mamoru Takenaka,
Hideyuki Shiomi, Maki Sugimoto, Yoshifumi Arisaka,
Takeshi Azuma and Hiromu Kutsumi
Kobe University, Japan
Introduction: Sphincter of Oddi manometry (SOM) is
recognized as the standard diagnostic modality for
sphincter of Oddi disorder (SOD). However, SOM is
not commonly performed because of its technical diffi-
culty and the high incidence of post-procedural pancre-
atitis. To diminish post-procedural pancreatitis, we
tried to develop a new method of SOM. We have
reported that SOM using a guide-wire-type manometer
is feasible for the clinical assessment of biliary SO
motility. We examined by adding the feasibility of pan-
creatic SOM with a guide-wire-type manometer.
Method: A total of 43 procedures were performed in 9
patients with biliary SOD and 19 patients with other
disease. We performed SOM using the guide-wire- type
manometer, and measured amplitude, duration, fre-
quency and the area under the curve (AUC) of SO con-
tractions. This study protocol was approved by ethics
review board of Kobe University and the online regis-
try number is UMIN000003126.
Results: In 35 of 43 evaluations (81.4%), amplitude,
frequency, duration and AUC could be analyzed easily.
However, in 8 studies, such analyses were impossible
owing to movement artifacts. Biliary SOM was per-
formed in 18 cases, and Pancreatic SOM was in 6
cases. In this study, mild pancreatitis was observed in
only one patient.
Conclusions: SOM using a guide-wire-type manometer
is safe, reliable and easy to apply for the clinical assess-
ment of SO motility.
FO15-08
INTRAOPERATIVE PANCREATOSCOPY
– A NOVEL TECHNIQUE AND ITS
CLINICAL APPLICATIONS
Mahesh Sundaram, Guduru Venkat Rao, Pradeep
Rebela and Duvvuru Nageshwar Reddy
Asian Institute of Gastroenterology, India
Introduction: Intra-operative pancreatoscopy (IOP) is a
novel technique to study the pancreatic ductal abnor-
malities. We present here its potential applications in
pancreatic surgery.
Method: The clinical, imaging and histological details
of 7 patients who underwent IOP were analysed. After
pancreatic transection, depending on the ductal diame-
ter, the flexible 3.3 mm pancreatoscope or spyglass
scope or the spyglass optical fibre was introduced into
the remnant pancreatic duct and then the specimen
both with and without narrow band imaging (NBI).
Saline irrigation and video monitoring were utilized.
Results: The average age of the 7 patients was
52.3 years and 4/7 were female. All underwent contrast
enhanced CT but endoultrasound was done as neces-
sary. Indications for surgery were: main duct IPMN
(4), side branch IPMN (1), carcinoma head of pancreas
(1) and chronic pancreatitis (CP)-1. Complete examina-
tion of main pancreatic duct was possible in all without
any procedural complications. The mean duration
added to the surgery was 10.3 minutes. IOP led to a
change in the operative plan of 3 patients none diag-
nosed on preoperative evaluation: in 2 IPMN patients,
the resection margin which was negative on frozen sec-
tion was revised due to identification of downstream
skip lesion; in one CP patient who underwent distal
pancratectomy, a further stricture was noted proximally
leadint to revised margin. Further in one patient with
carcinoma head of pancreas, adequate resection margin
could be confirmed and additional tumor was excluded.
In 2 IPMN patients, skip lesions could be excluded.
Overall 1 patient had post operative pancreatic fistula
(grade A) and no mortality occured.
Conclusions: IOP is a novel technique that is safe and
feasible in pancreatic ducts of various sizes. It is a
promising technique to detect subclinical strictures,
early lesions and skipped synchronous lesions especially
in IPMN. It may help intraoperative decision making
regarding the type and extent of pancreatic surgery in
select patients.
FO16-01
COMPARISON OF SURGICAL
OUTCOME BETWEEN MINIMALLY
INVASIVE LIVER RESECTION AND
CONVENTIONAL OPEN LIVER
RESECTION FOR THE TREATMENT OF
HEPATOCELLULAR CARCINOMA: A
PROPENSITY-SCORE MATCHED
ANALYSIS
Dai Hoon Han, Eun Jung Park, Gi Hong Choi and
Jin Sub Choi
Severance Hospital, Yonsei University, Korea
Introduction: This study aimed to analyze operative
and survival outcomes of minimally invasive liver resec-
tion (MILR) versus conventional open liver resection
(COLR) for the treatment of hepatocellular carcinoma
(HCC). Moreover, we attempted to reveal the role of
the robotic system in MILR (HCC).
Method: From May 2002 to December 2012, 928 con-
secutive patients underwent curative liver resection of
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HCC. Among these patients, 99 patients with MILR
were matched to 198 patients with COLR by one-to-
two propensity-score matched analysis. A multivariable
logistic model based on age, gender, etiology of HCC,
tumor size, multiplicity of tumor, the presence or
absence of liver cirrhosis, tumor location, platelet count
and extent of liver resection was used to estimate pro-
pensity score. Perioperative surgical outcomes and
long-term survival were compared between two groups.
Results: The amount of blood loss during operation
and postoperative complication rate were significantly
lower in MILR groups. Mean length of hospital stay
after operation was significantly shorter in MILR
group (8.39 vs. 13.39 days, p < 0.001). There were 8
cases of open conversion from MILR and all cases
were laparoscopic attempted liver resections. In MILR
group, most of major resections were performed with
robotic system (n = 10, p < 0.001). Anatomic liver
resections were performed for 15 of 16 patients using
robotic system. There was no difference in primary
recur site between two groups. The 1-, 2-, 3-year dis-
ease-free survival rate of MILR were 86.1%, 64.4%,
and 58.4% respectively, which were comparable to
those of COLR (p = 0.810).
Conclusions: MILR showed better perioperative out-
comes with comparable oncologic outcomes for the
treatment of HCC. According to the complexity of pro-
cedures, the robotic surgery may expand the indication
of minimally invasive liver resection in patients with
HCC.
FO16-02
5 YEAR RESULT OF LAPAROSCOPIC
LIVER RESECTION FOR
HEPATOCELLULAR CARCINOMA
Long Tran Cong Duy, Bac Nguyen Hoang,
Thuan Nguyen Duc, DatLe Tien and Viet Dang Quoc
Vietnam
Introduction: Laparoscopic surgery, with minimally
invasive techniques, potentially brings benefits to
patients who need liver resection for HCC. The aim of
our study is to evaluate the effectiveness, safety and
benefits of laparoscopic liver resection for HCC with
long-term follow-up.
Method: This is a Cohort study with 5-year results of
total laparoscopic hepatectomy for HCC in one center.
Results: From January 2008 to December 2012, we
had 173 enrolled patients with HCC underwent laparo-
scopic liver resection. Mean of age: 56 Follow-up was
fullfiled in 130 patients for 21.6  16.0 months (0–
60 months). Mean tumor size was 3.73 cm. Stage of
HCC (according to BCLC): 0 (6%), A1 (59.5%), A2
(6.9%), A4 (2.9%) and B (27.2%). We had to convert
to other techniques in 4 patients (2.3%). Type of resec-
tion: one segment (II,III, IV, V,VI,VII,VIII): 43.8%,
two segments (posterior sector, anterior sector, segment
V&VI and left lateral sector): 47.9%, three segments
(left liver resection or central hepatectomy): 4.7% and
right liver resection: 3.6%. Mean operation time:
112  56 minutes. Median blood loss was 100 mL (20–
1,200 mL). Mean hospital stay: 6.5  2.0 days. There
was no perioperative mortality. The overall survival at
1, 2, 3, 4, and 5 years were 94.2%, 87%, 72.9%,
72.9%, and 72.9%, respectively. The disease free sur-
vival at 1, 2, 3, 4, and 5 years were 79.1%, 60%, 57%,
52%, and 26.3%, respectively.
Conclusions: Laparoscopic liver resection for
HCC is feasible, safe, and effective with good oncolog-
ic results.
FO16-03
LAPAROSCOPIC VERSUS OPEN LIVER
RESECTION FOR HEPATOCELLULAR
CARCINOMA AT A NORTH-AMERICAN
CENTRE OF EXCELLENCE: A 2-TO-1
MATCHED PAIR ANALYSIS
John Jonghun Lee, John B. Conneely, Faizal Bhojani,
Rory L. Smoot, Paul D. Greig, Steven Gallinger,
Ian McGilvray, Carol-anne Moulton, Alice C. Wei and
Sean P. Cleary
University of Toronto, Canada
Introduction: Laparoscopic liver resection (LLR) is
growing in popularity. Whereas its role in treatment of
benign and metastatic disease is well described, its
application to primary hepatic malignancy is not well
defined. Herein we describe our institutional experience
with LLR for Hepatocellular Carcinoma (HCC). We
compare our outcomes with LLR versus standard open
liver resection (OLR) on a 2:1 case matched basis.
Method: We have evaluated all LLRs from 2006 to
2013. Each was matched to 2 open cases for age at
operation, maximal tumor size, tumor number and
number of segments resected. Non-parametric statistical
analysis was used to compare surgical outcomes. This
is one of the largest series in North America comparing
LLR and OLR for outcomes of HCC.
Results: Forty-one patients underwent LLR for HCC.
Demographic characteristics were similar between
groups. The estimated blood loss was lower in the LLR
vs. OLR at 529 mL and 866 mL respectively
(p = 0.02). Also, the 30 day readmission rate was 0%
and 27% for LLR and OLR respectively (p < 0.01).
Operative time, overall survival, length of stay, admis-
sion to ICU, ER visits and complication rates were
similar.
Conclusions: Our experience suggests that LLR is both
safe and oncologically equivalent to OLR for HCC in
the short and long term. Furthermore, LLR confers the
widely-accepted benefits of laparoscopic surgery,
namely reduced blood loss and lower 30 day readmis-
sion rates. Long-term outcome of overall survival was
equivalent in both LLR and OLR groups. We propose
that LLR for HCC should be considered for appropri-
ately selected patients in centers with requisite volume
and expertise.
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FO16-04
VARIOUS LAPAROSCOPIC LIVER
HANGING MANEUVERS IN
ANATOMICAL LIVER RESECTION
Ji Hoon Kim
Chungbuk National University Hospital, Korea
Introduction: Liver hanging maneuver (LHM) is a
widely used novel technique for liver resection. How-
ever, the LHM during laparoscopic liver resection is
not routinely used because this requires blind dissection
of the retrohepatic space, anterior to the IVC. The aim
of this study is to introduce various types of laparo-
scopic LHM in anatomical liver resection.
Method: The upper end of hanging tape is located
along lateral side of the hepatic vein (the right side of
the right hepatic vein during right hepatectomy or left
side of the left hepatic vein during left hepatectomy).
For this technique, it is not necessary to dissect
between the right (or left) hepatic vein and the middle
hepatic vein in right (or left) hepatectomy, like the tra-
ditional hanging maneuver or modified hanging maneu-
ver. The retrohepatic approach on the right side of the
IVC is usually assisted by a metal suction tip on lapa-
roscopic view in right hepatectomy.
Results: From February to August 2013, this technique
was used in 11 patients. Laparoscopic anatomical liver
resections included 3 left lateral sectionectomies, 5 left
hepatectomies, 2 right hepatectomies and 1 right poster-
ior sectionectomy. The median resection time and blood
loss were 50 minutes (range, 22–80 minutes) and
400 mL (range, 200–700 mL) respectively. There
was no open conversion and no major morbidity or
mortality.
Conclusions: This technique is simple and safe because
blunt dissection of the retrohepatic space is not neces-
sary for this maneuver. This method of LHM can be a
useful technique for laparoscopic anatomic liver resec-
tion.
FO16-05
RIGHT TRISECTIONECTOMY AND
COMPLETE INFERIOR VENA CAVA
RESECTION IN TWO-STAGE LIVER
RESECTION WITH LIVER
PARENCHYMA TOURNIQUET AND
RIGHT PORTAL VEIN OCCLUSION
(ALTPS)
Ricardo Robles, Asuncion Lopez Conesa,
Roberto Brusadin, Vıctor Lopez, Pilar Jimeno and
Pascual Parrilla
Virgen de la Arrixaca University Hospital, Murcia,
Spain
Introduction: We present the results of right trisection-
ectomy (RT) and complete inferior vena cava resection
(IVCR) in 2-stage, using an original method for achiev-
ing rapid hypertrophy of the functional liver remnant
(FLR). In the first stage we only occlude the intrahe-
patic circulation placing a tourniquet on umbilical cisu-
ra (through the extra-Glissonian hepatic hilum)
associating a right portal vein occlusion (ALTPS).
Method: Between September 2011–July 2013 we have
performed ALTPS technique in 30 patients with a small
FLR. In 7 cases we performed a ERT + IVCR in 2-
stage, replacement IVC with a 2 cm ring goretex graft
(in 1 case we resected portal vein and biliary duct with
HJ). We occluded IVC lower left hepatic vein without
by-pass venovenous. In the remaining 23 cases we per-
formed ALTPS without IVCR (11 right hepatectomy
and 12 RT was performed).
Results: Median age was sixty years. All patients had
one nodule (median size 12 cm, range 7–20). Median
FLR was 410 mL, increasing at 7 days to 870 mL
(112%). During first stage median blood losses were
0 mL (range 0–100), median surgical time 120 minutes
(range 120–180 minutes). In the second stage median
blood losses were 600 mL (range 300–1500), requiring
a transfusion in three patients (43%) (median 0 UI;
range 0–6), with a median surgical time of 300 minutes
(range 150–360). IVC occlusion time was 58 minutes
(range 44–70). No morbidity after the first stage, and 4
(57%) after the second one. One female with HJ steno-
sis died (14%) at 2 months. The median hospital stay
was 20 days, without recurrence at 11 months (range
2–22) of follow up.
Conclusions: Our ALTPS technique gets hypertrophy
of FLR in 7 days and achieves good results in extended
hepatectomy with vascular resection.
FO16-06
DOES ALPPS REGULARLY INCREASE
THE FUTURE REMNANT LIVER AND
PREVENT POSTOPERATIVE LIVER
FAILURE?
Safi Dokmak, Fanjandrainy Rasoaherinomenjanahary,
Francois Cauchy, Beatrice Aussilhou and
Jacques Belghiti
Beaujon Hospital, France
Introduction: ALPPS allows major liver resection with-
out postoperative liver failure (LF) by sequential liver
splitting with portal vein section followed latter by liver
resection. Our aim was to study in a monocentric cen-
ter the rate of future remnant liver (FRL) regeneration
and the incidence of LF after each step. Signs of LF
were defined according to 50/50 criteria or prolonged
jaundice (>85 mmol/L) on POD 5.
Method: From April 2011- October 2012, eleven
patients (10 men) with a median age of 59 years old
(37– 63) underwent ALPPS for CRLM (n = 6) and bili-
ary cancer (n = 5). Underlying liver disease was present
in 5 including one PSC and 4 with CRLM who
received >12 cycles of chemotherapy. Patients under-
went right trisectionectomy (6) or hepatectomy (5) and
4 had associated pancreaticoduodenectomy. All except
one underwent the second step within a mean time of
10 days (6–20) with a mean blood loss of 300 mL
(100–1,500) and operation time of 235 (75–480) min-
utes. Volumetric assessment was done on POD7.
Results: RLV increase from 408 mL (208–754) to
553 mL (320–821) with a median hypertrophy rate
(HR) of 69% (8–175), including 4 with HR <25% (8–
24). These 4 patients had a mean FRL volume at 21%
(13–31) and 3 received >12 cycles of chemotherapy.
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After the first step, four had signs of LF and one had
portal thrombosis. After the second step, six (60%)
showed signs of LF. Major morbidity (clavien >III)
was observed in 40% with an average hospital stay of
40 days (5–120). Mortality was observed in 3 patients
(27%) who all had small FRL (<25%) and insufficient
HR (<25%).
Conclusions: ALPPS do not regularly induce acceler-
ated hypertrophy, especially in patients with small FRL
and/or intense chemotherapy, with the high risk of
postoperative mortality.
FO16-07
LIVER RESECTION WITH HEPATIC
VEIN RECONSTRUCTION IS A VIABLE
OPTION IN SELECTED PATIENTS
Rory Smoot, Pablo Serrano, David Cavallucci,
John Conneely and Ian McGilvray
University of Toronto, Canada
Introduction: The morbidity and mortality associated
with liver resection has continued to decrease while the
experience with living donor liver transplantation has
increased. These factors have facilitated the consider-
ation of extended liver resection for tumors, which
includes resection and reconstruction of the major
hepatic venous outflow.
Method: Patients undergoing liver resection with major
hepatic venous reconstruction between the years 2005-
2013 were reviewed. Demographic, clinical, procedural,
and follow-up data were analyzed.
Results: For the study years a total of 18 patients were
identified. Median age was 49.5 years (24–67) for 11
men and 7 women. The pathology included colorectal
cancer (7 patients), cholangiocarcinoma (6 patients),
sarcoma (3 patients), hepatocellular carcinoma (1
patient), and perivascular epitheliod tumor (1 patient).
Resection included the inferior vena cava in 8 patients,
and 7 patients underwent reconstruction with ringed
PTFE grafts. In situ cold perfusion was used in all
patients. The venous outflow reconstruction included
left hepatic vein (LHV) to graft (4 patients), LHV to
cava (3 patients), Right hepatic vein (RHV) to graft (3
patients), RHV to cava (4 patients), middle hepatic vein
(MHV) to cava (1 patients), RHV and MHV to cava
(1 patient), MHV reconstruction with vein patch (1
patient), and LHV reconstruction with vein patch (1
patient). Perioperative mortality was 6% (1 patient)
and a complication rate of 78% (14 patients). Compli-
cations included Clavien grade 5 (1 patient), grade 3b
(4 patients), grade 3a (3 patients), grade 2 (5 patients),
and grade 1 (1 patient). Six patients had died at the
time of last follow-up, four of those patients with
tumor recurrence. The cohort had a median overall sur-
vival of 15.4 months.
Conclusions: In selected patients resection and recon-
struction of the major venous outflow can be completed
with reasonable morbidity and mortality.
FO16-08
VASCULAR RECONSTRUCTIONS
AFTER HEPATECTOMIES FOR
MALIGNANT LIVER TUMORS:
A MONOCENTRIC SERIES ABOUT
84 CASES
Daniel Azoulay1, Gerard Pascal1, Chady Salloum1,
Rene Adam2 and Denis Castaing2
1Henri Mondor Hospital – Creteil France, France; 2Paul
Brousse Hospital – Villejuif, France
Introduction: After 1990 years, vascular reconstruction
techniques after hepatectomy contributed to increase
the resectability of malignant liver tumors. However,
the majority of reports are anecdotal in this field. This
single centre large retrospective series analysed the mor-
bidity, mortality and risk factors of liver resections with
vascular reconstruction.
Method: Patients who underwent hepatic resection com-
bined with vascular resection and reconstruction in our
institution between 1997 and 2009 were included in this
study. Indications for surgery, morbidity and ninety-day
mortality are reported along with a statistical analysis
of predictive factors of postoperative mortality.
Results: Eighty-four patients had liver resection com-
bined with 101 vascular resections and reconstructions.
The male to female ratio was 44/40 with a mean age of
56.9  12 years. All patients had primary or metastatic
liver tumors. Mean follow-up was 37.3  34.1 months.
Global morbidity was 63% (53 patients). According to
Dindo and al. classification, morbidity grade III and
IV rate was 31% (26 patients) and mortality rate (grade
V) was 15.5% (13 patients). Predictors of postoperative
mortality were: bilirubin >34 lmol/mL (p = 0.02), in-
docyanine green retention rate at 15 minutes > 10%
(p = 0.03), ischemic time (p = 0.01), units of blood
transfused (p = 0.02) and combined major extrahepatic
procedure (p = 0.04). Actuarial 3 and 5 year global sur-
vival rates were 43.6% and 25.5% respectively.
Conclusions: Liver resection with combined vascular
resection and reconstruction can be performed in
selected patients with acceptable morbidity and mortal-
ity. The lack of alternative therapeutics and the poor
outcome of un-operated patients seems to justify this
approach. The identification of risk factors should help
to improve patients selection and postoperative out-
come as well as facilitate objective risk-communication
with surgical candidates.
FO17-01
NOVEL TECHNIQUE OF PORTAL VEIN
RECONSTRUCTION IN PEDIATRIC
LIVER TRANSPLANTATION WITH
PORTAL VEIN HYPOPLASIA
Nam-Joon YI, Jeong-Moo Lee, Suk-Won Suh,
Tae You, Young Rok Choi, Heyoung Kim, Hae Won
Lee, Kwang-Woong Lee and Kyoung-Suk Suh
Seoul National University College of Medicine, Korea
Introduction: Children with portal vein (PV) hypoplasia
(≤4 mm in diameter) represent a challenge for liver
transplantation (LT). A variety of techniques including
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an interposition conduit or patch-plasty have been used
to overcome size mismatch in PV reconstruction of
these patients. We simplified a PV reconstruction tech-
nique without interposition graft in children with PV
hypoplasia.
Method: Between Oct 2012 and Jun 2013, consecutive
7 pediatric recipients (median age; 8 months, 4 males)
with PV hypoplasia underwent LTs (living donor LTs
in 5, split LT in 3) due to biliary atresia. The median
pre-transplant maximum main PV (MPV) diameter on
the contrast CT scans was 2.89 mm (range, 1.66–3.69).
Direct anastomosis was made in eliptoid appearance
between donor left PV and recipient MPV without
interposition graft (Figure). The MPV diameters and
flow rates were serially measured on Doppler ultraso-
nography or contrast CT scans at 1- and 3-month after
transplantation.
Results: All grafts and patients were survived. PV
problem was not detected during a median follow-up
of 198 (90–321) days. The post-transplant MPV diame-
ter was 8.28 (range, 6.82–10.1) mm at one month and
8.70 (range, 7.90–11.60) mm at 3 months after LT.
Conclusions: This direct eliptoid anastomosis is simple
and its short-term results are encouraging in pediatric
LT with PV hypoplasia. PV patency should be closely
monitored during long-term follow-up.
Figure. Xxxx
FO17-02
LONG-TERM OUTCOME OF DUCT-TO-
DUCT BILIARY RECONSTRUCTION IN
LIVING DONOR LIVER
TRANSPLANTATION FOR SMALL
PATIENTS WITH THE BODY WEIGHT
LESS THAN 10 KG
Yukihiro Inomata1, Hidekazu Yamamoto1, Shintaro
Hayashida1, Takayuki Takeichi1, Kwang-jong Lee1,
Masaki Honda1, Takahiro Murokawa1, Masashi
Kadohisa1, Mohammed Asar2 and Katsuhiro
Asonuma1
1Kumamoto University, Japan; 2Al-Azhar University,
Egypt
Introduction: In biliary reconstruction of pediatric liv-
ing donor liver transplantation (LDLT), Roux-en-Y
(RY) hepaticojejunostomy is more popular than duct-
to-duct (DD) anastomosis partly because the most
common indication is biliary atresia. In our program,
DD has been applied as the primary procedure for bili-
ary reconstruction when it is possible even in small
children or infants. In the present study, long-term out-
come was evaluated for DD biliary reconstruction in
pediatric recipients with the weight less than 10 kg at
the time of operation.
Method: Sixty-three recipients weighing less than 10 kg
at the time of LDLT have undergone LDLTs in our
institution from 1998 to 2011. Of these, twenty consec-
utive patients who underwent DD biliary reconstruc-
tion were enrolled and analyzed by reviewing the
clinical records. Mean age was 10.3 months, and four-
teen were infants. Mean body weight was 6.9 kg, with
minimum of 2.6 kg. The minimal follow-up period was
2 years. The anastomosis was performed using inter-
rupted sutures of 6-0 polydioxanone absorbable mono-
filament under 2.5 times loupe. The knots were outside
the lumen. External biliary stent (3 or 4 French poly-
ethylene tube) was placed and kept around 4 months
after the transplant.
Results: In all the cases, whole or reduced left lateral
segment of the parents was used. Four patients died
after the LDLT with DD reconstruction. Any death was
not related to the biliary reconstruction. One patient
developed biliary stricture six weeks after the transplant
and underwent conversion from DD anastomosis to RY
anastomosis eight months after the LDLT. The other 14
recipients have been doing well after the transplant.
Conclusions: Long term result of DD biliary recon-
struction in pediatric LDLT for recipients with body
weight less than 10 kg was quite satisfactory. DD
reconstruction should be considered more in LDLT for
such generation.
FO17-03
RECONSTRUCTION OF VENOUS
OUTFLOW IN PEDIATRIC LDLT
RECIPIENTS
Oleg Kotenko and Denis Fedorov
National Institute of surgery and transplantology,
Ukraine
Introduction: Main problem of hepatic vein (HV)
reconstruction in left lateral section (LLS) transplanta-
tion is donor variant anatomy with absence of common
HV trunk.
Method: Forty-five pediatric recipients and their
related living donors where evaluated.
Results: Nakamura and Tsuzuki (1981) classification is
not suitable for LLS transplantation because it
describes variants of left and middle HV. For this rea-
sons we purpose modification of this classification
based on LLS HV anatomy. We divide all described by
Nakamura and Tsuzuki HV variants into 4 groups:
Type A – normal anatomy with common LHV trunk,
longer 5 mm; Type B – common LHV trunk, less then
5 mm length; Type C – separate inflow of Sg 2 and 3
HV with distance between them less then 5 mm; Type
D – separate inflow of Sg 2 and 3 HV with distance
between them more then 5 mm. Type A anatomy is
acceptable for standard HV plastic, for type B, C and
D we purpose non-standard HV reconstruction meth-
ods. From 45 donors 30 (66.6%) had normal type A
anatomy, 4 (8.8%) had type B, 6 (13.3%) had type C
and 5 (11.1%) had type D anatomy. Thus in 66.6%
transplantations standard HV plastic was made. For
other 33.3% we used one of HV reconstruction meth-
ods: (1) Circular plastic of common Sg 2-3 hepatic
veins orifice by autovenouse patch from recipient portal
vein confluence, which was performed in 3 cases with
type B anatomy; (2) Forming of common Sg 2-3 graft
hepatic veins orifice from separate Sg 2 and Sg 3 veins.
Used in 5 cases with type C anatomy; (3) Harvesting of
left lateral section graft with common orifice of donor
left and middle hepatic veins. Performed in 4 cases with
type D anatomy.
Conclusions: Donor HV anatomy determinates HV
reconstruction method in LLS LDLT.
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FO17-04
SIGNIFICANCE OF PRIMARY POOR
FUNCTION FOR THE PROGNOSIS
AFTER LIVER TRANSPLANTATION
Gilles Uijtterhaegen, Ivo Haentjens, Roberto Troisi,
GeorgesVan Maele, HansVan Vlierberghe and
Xavier Rogiers
University of Ghent, Belgium
Introduction: Primary poor function (PPF) is a term
used to describe temporary malfunction of the trans-
planted liver. Over 20 different definitions of PPF can
be found in the literature and there are only a few cases
in which its impact on survival is described. In this
paper we try to define the impact of different defini-
tions of PPF on medium term patient and graft sur-
vival.
Method: Data of 90 transplantations performed
between July 2007 and October 2009 at the University
Hospital of Ghent were analyzed retrospectively. The
transplantations were classified by 7 definitions of PPF
and correlated with patient and graft survival.
Results: The main indications for transplantation were
alcoholic cirrhosis (40.0%) and HCV cirrhosis (10.0%).
Mean age of transplantation was 53.6 years. Mean fol-
low-up duration was 33.8 months (range 24–
47 months) The rate of PPF differed from 10.0% to
55.6% depending on the definition used. Of the 7 tested
definitions only 2 (Strasberg et al. and Cieslak et al.)
showed a significant correlation with graft- and patient
survival according to Kaplan-Meier tests. The defini-
tion of Strasberg et al. (The presence of at least one of
the following: AST or ALT >2000 IU/L on post-opera-
tive day 2, INR >1.6 or serum bilirubin >10.0 mg/dL
on post-operative days 2–10) showed a very significant
correlation (p < 0.001).
Conclusions: Our study shows that only two of the
seven most used definitions of PPF show a significant
correlation with short and medium term graft and
patient survival. The definition of Strasberg et al.
defines best the risk of the patient for graft loss and
death and should therefore be used as the definition of
choice.
FO17-05
PRETRANSPLANT MALNUTRITION
PREDICTS POST TRANSPLANT
RESPIRATORY COMPLICATION IN
LIVING DONOR LIVER
TRANSPLANTATION FOR BILIARY
ATRESIA- SINGLE CENTER
RETROSPECTIVE ANALYSIS OF 110
CHILDREN
Bhavin Vasavada1, Karan Julka1, Chao long Chen2
and Andrzej Komorowski3
1Fellow liver surgery and transplant, India; 2Professor,
Taiwan; 3Fellow liver surgery and liver transplantation,
Poland
Introduction: Biliary atresia is commonly associated
with malnutrition and failure to thrive. Very few stud-
ies have been published on impact of preoperative mal-
nutrition or growth retardation on post transplant
outcome in these children.
Method: 110 children underwent living donor liver
transplantation between January 2003 to march
2013.Pre transplant malnutrition was defined according
to z scores for weight for age and weight for height as
per who definition. Patients having both Z score of <
-2 (moderate or sever malnutrition as per who defini-
tion) were compared with control group. Post operative
complications, mortality rates were compared between
two groups. Statistical analysis was done using chi
square tests for categorical variables and Mann–Whit-
ney U test for continuous variables. Statistical analysis
were done using SPSS version 21 (IBM).
Results: Thirty-nine children out of 110 were having z
score for weight for age < -2.There was no statistical
difference between peld score, graft weight, grwr, intra-
operative blood loss between to groups.22 out of 39
patients in malnourished group developed clavein grade
3, garde 4 complications and 32 patients out of 71 in
control group developed clavien grade 3 grade 4 com-
plications. Which was not significant statistically
(p = 0.318). 3 patient in study group and 2 in control
group died in follow up giving over all mortality rate
of 4.5% and group specific mortality rates 7.69% and
2.81% respectively (p = 0.278).Total 14 patient devel-
oped post operative pulmonary complications which
included ARDS, post operative pneumonia, post opera-
tive atelectasis. Out of 14 patients 10 were having pre-
operative malnutrition and growth retardation and 4
were having normal preoperative z score. Which was
highly statistically significant with p = 0.003 (odds ratio
5.603 and 95% confidence interval 1.623–19.351). Roc
curve showed AUROC of 0.703.
Conclusions: Preoperative malnutrition is associated
with high postoperative pulmonary complication rate
in liver transplantion for biliary atresia.
FO17-06
ADULT LIVING DONOR LIVER
TRANSPLANTATION FOR HIGH MELD
(≥30): SINGLE CENTER
RETROSPECTIVE STUDY
Gi-Won Song, Sung-Syu Lee, Shin Hwang, Ki-Hun
Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha,
Dong-Hwan Jung and Gil-Chun Park
Asan Medical Center, Ulsan University, Korea
Introduction: The operative risk to live liver donor can
be justified by the acceptable outcome in recipient.
Based on this background concept, therefore, the adult
living donor liver transplantation (ALDLT) for patients
with high MELD (≥30) has been criticized and
regarded as a relative contraindication due to the con-
cern about poor survival outcome in recipient.
Method: From Februray 2003 to Februray 2013, 3,100
liver transplantation (LT) have been performed.
Among them, 2,520 ALDLTs were retrospectively
reviewed after excluding 190 pediatric and 390 deceased
donor LTs.
Results: Among 2520 ALDLTs, 619 (24.6%) patients
had MELD over than 30. When we divided patients
into two groups (group1: MELD <30, Group2: ≥30)
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and compare 2 groups, the in-hospital mortality (IHM)
of group1 (12.6%) was significantly higher. The 3-
month and 1-year patient survival rate of group1 was
89.3 and 83.8% which was significantly lower than that
of group2. Excluding IHM, the 5 and 10-year patient
survival rate, however, there was no significant differ-
ence. In univariate analysis for the risk factor to affect
survival in group 1, risk factors are as following: donor
age >50, pre-LT altered mentality, ICU stay, renal
replacement therapy, ventilator care, the use of vaso-
pressor, bacteremia, septic shock, HCV and recipient
age >43. In multivariate analysis, recipient age >43,
pre-LT altered mentality and septic shock were inde-
pendently significant risk factors. And the number of
risk factor was closely related with IHM: 0~1 (6.7%), 2
(16.1%) and 3 (26.8%).
Conclusions: ALDLT for patients with high MELD
score showed inferior but acceptable IHM and patient
survival rate. The long-term survival was not affected
by MELD. But, recipient age, pre-LT mentality and
septic condition were associated with high IHM rate.
Therefore, we need more cautious patient selection and
post-LT care to justify inevitable donor risk in
ALDLT.
FO17-07
MASSIVE ASCITES AFTER LIVING
DONOR LIVER TRANSPLANTATION
Muhammad Zakria Wahla, Chao-Long Chen,
Bhavin Vasavada, Chee-Chien Yong, Chih-Chi Wang
and Chih-Che Lin
Chang Gung Memorial Hospital Kaohsiung, Taiwan
Introduction: There is limited research on massive asci-
tes after living donor liver transplantation. Prolonged
ascites after living donor liver transplantation adds sig-
nificantly to the morbidity of patients. Aim of this
study was to find out important factors responsible for
this complication. Massive ascites was defined as ascitic
fluid more than 500 mL/day for more than 10 consecu-
tive postoperative days.
Method: One hundred and eleven patients who under-
went living donor liver transplantation in a calendar
year 2010 were analyzed retrospectively. After applying
the exclusion criteria patients were divided into two
groups. Group 1, with massive ascites and Group 2,
without massive ascites. Univariant, multivariant and
Fisher exact tests were applied and ROC curves were
prepared. Statistical analysis was done using SPSS Ver-
sion 18(IBM).
Results: 71 out of 111 patients developed massive asci-
tes as per our definition. In Univariant analysis pre-
operative spleen size (p = 0.000), MELD (p = 0.009),
Pre-operative renal insufficiency (p = 0.002), pre-opera-
tive presence of ascites (p = 0.000)(calculated as ascites
on opening of abdomen), blood loss during surgery
(p = 0.005), serum bilirubin(p = 0.002) and liver
enzymes (ALT) (p = 0.004) at day 10 achieved statisti-
cal significance in predicting massive ascites after liver
transplantation. However in multivariate logistic regres-
sion, only spleen size (p = 0.008) and ascites at opening
(p = 0.000) were found to be significant factors in devel-
oping massive ascites. AUROC indicated >0.7 for both.
Conclusions: From this study we can conclude that
although Pre-operative renal insufficiency, MELD,
blood loss during surgery, serum bilirubin and liver
enzymes (ALT) at day 10 are important predictors of
massive postoperative ascites but preoperative spleen
size and presence of ascites are independent predictors
for postoperative massive ascites. As these factors are
markers of degree of portal hypertension it seems
degree of preoperative portal hypertension is the main
factor responsible for postoperative prolonged ascites.
FO17-08
PRIMARY HYPEROXALURIA TYPE 1:
SIMULTANEOUS LIVER-KIDNEY
TRANSPLANTATION PROVIDES
BETTER RESULTS THAN KIDNEY
ALONE FIRST TRANSPLANTATION.
A FRENCH MULTICENTER STUDY
Philippe Compagnon1, Philippe Metzler9, Christophe
Camus4, Patrick Niaudet2, Didier Samuel5, Antoine
Durrbach6, Philippe Lang1, Daniel Azoulay1, Cyrille
Feray1 and Karim Boudjema3
1Ho^pital Henri Mondor, Creteil, France; 2Ho^pital
Necker, Paris, France; 3Ho^pital Pontchaillou, Rennes,
France; 4Hopital Paul Brousse, Villejuif, France;
5Ho^pital Bicetre, Paris, France
Introduction: Primary Hyperoxaluria type 1 (PH1) is a
rare hepatic metabolic defect leading to renal failure.
Post-transplant recurrence of kidney disease has led to
propose combined liver-kidney transplantation (LKT).
Whether or not LKT is better option than kidney alone
transplantation (KAT) remains unclear.
Method: An unselected consecutive series of 54 patients
with PH1 was analyzed according to the type of trans-
plantation initially performed from May 1979 and June
2010 in 10 French centers.
Results: Duration of dialysis, presence of extra-renal
symptoms, age at transplantation and mean follow-up
were similar between groups. Patient survival at
10 years was similar between LKT (n = 33) and KAT
(n = 21) groups (78% vs. 70%). Kidney graft survival
at 10 years was better after LKT compared to KAT
(87% vs. 13%; p < 0.0001). Four patients (12%) lost
their first kidney graft in the LKT group as compared
to 19 patients (90%) in the KAT group (p < 0.0001).
Need for kidney retransplantation was increased in
KAT group relative to LKT group (p < 0.001). Recur-
rence of oxalosis was observed in 11 renal grafts (52%)
of the KAT group and in none of the LKT group;
p < 0.0001). Loss of kidney allograft due to rejection
was higher in the KAT group relative to the LKT
group [4/21 (19%) vs. 3/33 (9%); p < 0.0001]. Time
spent on dialysis did not impact patient survival. Age
at transplantation and the period of transplant (before
or after 1995) did not impact renal allograft survival.
Major post-operative complication and mortality rates
were similar between groups.
Conclusions: LKT for PH1 is associated with better
kidney graft survival and a trend to better patient sur-
vival compared to KAT. This unselected series confirms
that LKT should be proposed as first-line treatment for
PH1 patients with end stage renal disease.
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FO18-01
OUTCOME OF 268 CASES OF BILIARY
ATRESIA: A SINGLE – CENTER
EXPERIENCE OVER SEVENTEEN
YEARS
Ibrahim Marwan, Hosam Soliman, Sherif Saleh,
Hany Shoreim, Osama Hegazy, Taha Yassen,
Amr M. Aziz, Ahmed Sera and Khalid Abo Elella
National Liver Institute, Menoufeya University, Egypt
Introduction: We present the outcome and congenital
anomalies associated with 268 case of BA from a single
– center experience in Egypt.
Methods: From February 1995 to February 2013, 275
cases with preliminary diagnosis of BA were admitted
to the Hepato-biliary Surgery Department, National
Liver Institute, Menoufeya University. Seven cases were
excluded after Intra-operative cholangiograghy (2.5%).
Surgical management included: Hepatico-jejunostomy
on Roux- en -Y. loop for type I, Hepatic portochole-
cystostomy for type II and Hepatic portoenterostomy
Kasai operation for type III.
Results: There were 135 males and 133 females with
mean age of 68 days. 90% (241) of the cases presented
with type III BA. Six cases presented with type I BA
(2%) while type II (21) represents 8% including one
pair of male twins. Twenty four cases were above
100 days of age at operation (9%), while the remaining
cases were between 45–100 days. Associated congenital
anomalies with BA occurred in 10% of the cases
including: polysplenia (5), malrotation with or without
polysplenia (4), situs inversus totalis (4), pre-duodenal
portal vein 6), hydrocephalus (1), liver haemangioma
(3), Non-communicating choledochal cyst (7) and Bifid
spleen (2). Hospital mortality was 9% (25 cases) includ-
ing all cases of situs inversus totalis. 136 cases (56%)
were clinically non-icteric with serum bilirubin level
below 2 mg/dL after surgical correction. Five years sur-
vival with native liver was 49% while ten years survival
was 12.6% (15cases). Nine cases with a failed Kasai
operation were treated by Living Donor Liver Trans-
plant (LDLT) with an overall survival of 80%.
Conclusions: Our results conclude that Kasai operation
remains the best initial choice for BA patient’s in spite
of the high mortality in cases with situs inversus totalis.
Liver transplantation should be considered in cases
with failed Kasai procedure or if life-threatening com-
plications developed.
FO18-02
CORRELATIONS OF PORTAL PRESSURE
IN POST CHOLECYSTECTOMY BENIGN
BILIARY STRICTURE
Hirdaya nag1, Asit Arora2, Ila Tyagi3, Dinesh
Ramaswamy2, Nilesh Patil2, Puja Sakhuja4, Renuka
Saha5 and Anil Agarwal6
1Associate Professor, India; 2 Senior Resident, India;
3Senior Research Associate, India; 4Professor, India;
5Assistant professor, India; 6Professor and Head, India
Introduction: Patients with post cholecystectomy benign
biliary stricture (PCBBS) may have associated Portal
hypertension (PH) which can adversely affect their out-
come. Experimental studies showed that chronic bile
duct obstruction leads to hepatic fibrosis, bile duct dila-
tation, bile duct proliferation and changes in portal he-
modynamics, all these are responsible for the
development of PH. These changes are reversible ini-
tially but delay in treatment may culminate into cirrho-
sis and irreversible PH. Study of portal pressure (PP) in
PCBBS and its correlation with factors contributing
towards development of PH in PCBBS, in human
model, will help to prevent this complication.
Method: This prospective study was conducted from
September 2010 to December 2012. Total 30 patients of
PCBBS without overt PH were included. Portal pres-
sure (PP), biliary pressure (BP), injury repair interval
(IRI) and stage of hepatic fibrosis (FS) were recorded.
PP ≥22 mmHg (omental vein pressure) was considered
as PH. Appropriate statistical methods were employed
for correlation and comparison, p ≤ 0.05 was consid-
ered as significant.
Results: Mean age was 37  9.9 years, females 53.3%
(16), mean PP, BP and median IRI were
19.4  4.74 mmHg, 20.1  3.99 mmHg and 145 days
(range: 23–825) respectively. Incidence of PH was
33.3%. Correlation coefficients of PP to FS, IRI and
BP were 0.50 (p = 0.04), 0.56 (p = 0.001) and 0.38
(p = 0.03) respectively. Patients with PH had signifi-
cantly higher FS and IRI (p < 0.05).
Conclusions: Portal pressure in Post cholecystectomy
benign biliary stricture has a positive correlation with
hepatic fibrosis, injury repair interval and biliary pres-
sure whereas correlation with former two (FS and IRI)
is relatively stronger.
FO18-03
LIVER RESECTION IN PATIENTS WITH
BILIARY STRICTURE ON PRIMARY
SCLEROSING CHOLANGITIS: AN
OPTION THAT SHOULD BE
CONSIDERED
David Fuks, Francois Cauchy, Safi Dokmak,
Giulia Boarini, Sebastien Gaujoux, Valerie Paradis and
Jacques Belghiti
Beaujon Hospital, France
Introduction: While liver transplantation (LT) is the
treatment of choice for selected patients with cholan-
giocarcinoma (CC) developed on primary sclerosing
cholangitis (PSC), liver resection (LR) has long been
considered as a contraindication. We therefore aimed
to examine the results of LR in this subset of patients.
Method: Characteristics and outcomes of 15 patients
with PSC undergoing hepatectomy with en-bloc resec-
tion of the extra-hepatic bile duct between 1997 and
2012 were retrospectively analyzed.
Results: Nine patients (60%) were males and median
age was 62 years (14-74). Indication for LR was steno-
sis of either hilar confluence (n = 11) or intrahepatic
ducts (n = 3) and gallbladder tumor (n = 1). Major
resection was performed in 13 (87%) patients including
2 with associated pancreaticoduodenectomy. Median
operative time and blood loss were 460 minutes (375–
625) 850 cc (150–1,500) respectively. One (7%) patient
died postoperatively and 14 (93%) patients experienced
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complications including 8 (53%) major ones (Clavien-
Dindo ≥3). Severe (F3-F4) underlying fibrosis was
observed in 8 (53%) patients on final pathological
examination and was significantly associated with both
increased rates of major complications (63 vs. 43%,
p = 0.03) and longer hospital stay (26 vs. 12 days,
p = 0.001). Among the 11 patients resected for hilar
stenosis, those displaying CC were all <50 years. Five-
year overall survivals were 100% in patients resected
for benign disease and 45% in malignant disease
(n = 8), respectively, including 2 patients undergoing
pre-emptive LT.
Conclusions: Despite high complication rate, LR
should not be discarded in patients with PSC, especially
in patients >50 years considering the exceptional risk of
malignancy.
FO18-04
REVISED INTERNATIONAL
GUIDELINES (TOKYO GUIDELINES
2013) FOR DIAGNOSIS, SEVERITY
GRADING, FOR ACUTE CHOLANGITIS
AND PROPOSAL OF NEW
INTERNATIONAL PROJECT
Toshijiko Mayumi1, Tadahiro Takada2, Seiki
Kiriyama3, Takao Itoi4, Toshio Tsuyuguchi5, Harumi
Gomi6, Sung Gyu Lee7, Myung-Hwan Kim7, Miin-Fu
Chen8 and Masahiro Yoshida9
1University of Occupational and Environmental Health,
Japan; 2Teikyo University School of Medicine, Japan;
3Ogaki Municipal Hospital, Japan; 4Tokyo Medical
University, Japan; 5Graduate School of Medicine, Chiba
University, Japan; 6Jichi Medical Universit, Japan;
7Asan Medical Center, Ulsan University, Korea; 8Lin-
Kou Chang Gung Memorial Hospital, Taiwan; 9Clinical
Research Center Kaken Hospital, International,
University of Health and Welfare, Japan
Introduction: Since the publication of the Tokyo
Guidelines for the management of acute cholangitis
and cholecystitis (TG07), diagnostic and severity assess-
ment criteria for acute cholangitis have been extensively
used as the primary standard all over the world. How-
ever, it has been found that there are crucial limitations
in these criteria. Moreover, TG07 did not include the
whole technique of standard endoscopic transpapillary
biliary drainage.
Method: The updated Tokyo Guidelines (TG13) have
been revised through clinical implementation and its
assessment by means of multicenter analysis.
Results: The diagnostic criteria of the updated Tokyo
Guidelines (TG13) have high sensitivity (87.6%) and
high specificity (77.7%). TG13 has better diagnostic
capacity than TG07. The severity assessment criteria of
TG13 have been revised so as not to lose the timing of
biliary drainage or treatment for etiology.
TG13 include the whole technique of standard endo-
scopic transpapillary biliary drainage, for example, bili-
ary cannulation techniques including contrast medium
assisted cannulation, wire-guided cannulation, and
treatment of duodenal major papilla using endoscopic
papillary balloon dilation (EPBD). Furthermore,
recently single or double-balloon enteroscopy-assisted
biliary drainage (BE-BD) and endoscopic ultrasonogra-
phy-guided biliary drainage (EUS-BD) have been
reported as special techniques for biliary drainage.
To update causative organisms and prevalence of resis-
tance among patients with acute cholangitis and search
adequate timing of cholecystectomy in acute cholecysti-
tis assessed by TG13, a multi-center retrospective
observational study in Asian countries were planed.
Conclusions: The diagnostic criteria and severity assess-
ment TG13 are better than those of TG07. New inter-
national project will work to update TG13.
FO18-05
PREOPERATIVE [18F] FDG PET/CT
MAXIMUM STANDARDIZED UPTAKE
VALUE PREDICTS RECURRENCE OF
BILIARY DUCT CANCER
Min-Su Park, Yoon-Hwan Nam and Sang-Mok Lee
Kyung Hee University Medical Hospital, Korea
Introduction: [18F] Fluorodeoxyglucose positron emis-
sion tomography ([18F]FDG PET/CT) is an imaging
technique based on the increased uptake of glucose
characteristically seen in malignant lesions. The preop-
erative SUVmax of FDG PET/CT has been identified
the powerful significant prognostic factor for predicting
recurrence in malignant tumor. Therefore, the aim of
this study was to determine whether FDG PET/CT
imaging has prognostic significance in patients with bil-
iary tract cancer after surgical resection.
Method: From April 2006 to February 2013, 64
patients who underwent curative resection for biliary
tract cancer were reviewed. Demographics and tumor
characteristics were evaluated retrospectively by review
of a clinical database and review of pathologic reports.
Results: The study group comprised 42 men and 22
women, with a mean age of 61.3  10.7 years. Clinical
diagnosis of these patients were intrahepatic cholangio-
carcinoma (n = 6), hilar cholangiocarcinoma (n = 6),
extrahepatic cholangiocarcinoma (n = 22), gall bladder
cancer (n = 14) and ampullar cancer (n = 16). Mean
preoperative SUVmax values was 5.1  4.7. Mean fol-
low-up was 27 months. Recurrence-free survival at 1-,
2- and 5-years were 75.9%, 63.3% and 47.1%. In the
univariate analysis, N stage, poor tumor differentiation,
the presence of lymphatic invasion and high SUVmax
(>5.0 mg/L) were significant risk factors for recurrence.
The multivariate analysis showed high SUVmax
(>5.0 mg/L) to be independent risk factors for tumor
recurrence (p = 0.008, HR 4.124, 95% CI 1.459–
11.661).
Conclusions: Preoperative FDG uptake by primary
tumor showed a significant association with recurrence
in patients with biliary tract cancer.
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ROLE OF STAGING LAPAROSCOPY IN
GALL BLADDER CANCER IN THE ERA
OF 18F-FDG PET/CT
Ujwal Zambare, Thakur deen Yadav, Lileshwar
Kaman, Vikas Gupta, Rajesh Gupta, Ashim Das and
Bhagwantrai Mittal
Postgraduate Institute of Medical Education and
Researh, India
Introduction: Gall bladder cancer (GBC) is a rare neo-
plasm with poor prognosis. Most patients present in
advanced stage. Staging laparoscopy is a recommended
modality to prevent nontherapeutic laparotomy. PET/
CT imaging has the potential to improve preoperative
staging and identify unresectable cases. The present ser-
ies studies the efficacy of PET/CT vis-a-vis staging lap-
aroscopy vis-a-vis both in the management of GBC.
Method: Between January 2011 and August 2013, con-
secutive patients with suspected GBC who were deemed
resectable on MDCT imaging underwent FDG PET/
CT imaging. Thirty nine patients were staged using lap-
aroscopy after excluding extra abdominal metastasis on
PET/CT. Ascitic fluid, when present, was sent for
malignant cytology. Biopsy specimens taken from peri-
toneum, omentum and liver nodules suspected metasta-
sis were subjected to frozen section and histopathology.
Standard lymph node dissection was done for resect-
able cases. Data were prospectively collected and ana-
lyzed.PET/CT and laparoscopy were assessed for their
ability to detect peritoneal and liver surface metastasis.
Role of PET/CT vis-a-vis MDCT was assessed in
detection of lymph node metastasis.
Results: In detecting surface metastases PET/CT and
staging laparoscopy had sensitivity, specificity and accu-
racy of 45.5%, 100%, 84.6% and of 75%, 100%, 94.7%
respectively. When used in combination, sensitivity,
specificity and accuracy was 81.8%, 100% and 94.9%
respectively (p = 0.001). Their combined use detected
unresectable disease in 9 out of 15 patients (60%) and
prevented nontherapeutic laparotomy in 23% patients.
MDCT accurately staged lymph nodes in 16 (66.7%)
patients while PET/CT was useful in 19 (79.2%) of the
24 patients (n = 24) who underwent curative resection.
Conclusions: Staging laparoscopy and PET/CT have
roles complementary to each other in the staging and
management of GBC. PET/CT holds an edge over
MDCT in detecting lymph node metastasis.
FO18-07
PROGNOSIS OF PATIENTS WITH PT1B/
T2 GALLBLADDER CARCINOMA WHO
HAVE UNDERGONE LAPAROSCOPIC
CHOLECYSTECTOMY AS AN INITIAL
OPERATION
Youngin Yoon, Ye-Jong Park, Shin Hwang, Ki-Hun
Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha
and Gi-Won Song
Asan Medical Center, Ulsan University, Korea
Introduction: This study intended to analyze the prog-
nosis of patients with pT1b/T2 GBC who have under-
gone Laparoscopic cholecystectomy (LC) and the
outcome of extended re-operation.
Method: After analyzing the institutional profiles of
500 GBC patients who have undergone surgical resec-
tion, we selected 64 patients who underwent LC ini-
tially whose gallbladder pathology was confined to
pT1b or pT2 lesions. Of them, 34 patients (53.1%)
underwent extended reoperation.
Results: In the LC only group (n = 30), mean age of
the 16 pT1 patients was 65.7  12.5 years and mean
age of the 14 pT2 patients was 66.7  10.1 years. In
the reoperation group (n = 34), mean age of the 8
pT1b patients was 52.6  9.9 years and in 26 pT2
patients, mean age was 59.2  7.9 years. The reopera-
tion group showed a younger patient age pattern than
the LC only group (p = 0.001). The types of reopera-
tion were liver resection with lymph node (LN) dissec-
tion in 17, bile duct resection with LN dissection in 2,
and hepatectomy and bile duct resection with LN dis-
section in 15. In the LC only group, the 5-year survival
rate (5-YSR) was 70.3% in pT1b and 43.2% in pT2. In
the reoperation group, 5-YSR was 62.5% in pT1b
(n = 8) and 59.5% in pT2 (n = 26). A survival compar-
ison between two groups showed no significant survival
gain in pT1 patients (p = 0.69) and in pT2 patients
(p = 0.14). Lymph node metastasis was identified in
11% of pT1b lesions. For pT2N0 lesions, overall 5-
YSR was 62% after R0 resection, showing no survival
difference between primary extended surgery and LC-
redo operation (p = 0.45).
Conclusions: The survival gain of reoperation was not
evident in pT1b lesions. In contrast, some noticeable
but not statistically significant survival difference was
observed in pT2 lesions. Thus, reoperation for pT1b/T2
GBC following LC is indicated for individualized rea-
sons, especially in patients with pT1b lesions.
FO18-08
CLINICOPATHOLOGICAL FEATURES
OF THE INTRADUCTAL PAPILLARY
NEOPLASMS OF THE INTRAHEPATIC
BILE DUCT
Wanjoon Kim, Gi-Woong Jang, Yong-Joo Lee,
Ki-Hun Kim, Kwang-Min Park, Chul-Soo Ahn,
Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song and
Dong-Hwan Jung
Asan Medical Center, Ulsan University, Korea
Introduction: This study is intended to investigate the
clinicopathological features of the intraductal papillary
neoplasms of the intrahepatic bile duct (IPNB), espe-
cially focused on malignant changes.
Method: From the institutional database of liver resec-
tion cases, 18 patients who met the definition of IPNB
were selected. They had undergone liver resection
between February 2002 and October 2006; thus, the
follow-up period was more than 5 years.
Results: Of the 18 patients, 11 patients were male.
Their mean age was 61.3  6.7 years. There were no
differences between the non-malignant and malignant
lesions, in the comparison of the CEA levels (5.6  2.7
vs. 12.6  31.1 ng/mL, p = 0.439) and the CA19-9 lev-
els (29.2  34.7 vs. 31.9  30.2 ng/mL, p = 0.871). The
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common radiologic findings were: intraductal growing
mass in 10; bile duct dilatation in 6; and saccular duct
dilatation in 2. Left and right hepatectomies were per-
formed in 15 and 3, respectively. Five patients showed
benign lesions of IPNB, and 13 patients revealed malig-
nant lesions of intraductal papillary adnocarcinoma or
cholangiocarcinoma. All 4 patients with benign lesions
survived for a mean period of 53 months without
recurrence. In 13 patients with the malignant lesions, 1-
year, 3-year, and 5-year survival rates were 100%,
84.6%, and 59.2%, respectively.
Conclusions: We concluded that intrahepatic IPNB is a
rare type of biliary neoplasm which includes a histolog-
ical spectrum, ranging from benign disease to invasive
malignancy. The long-term survival was anticipated
after complete curative resection.
FO18-09
SURGICAL OUTCOMES AND
PROGNOSTIC FACTORS OF
INTRAHEPATIC
CHOLANGIOCARCINOMA
Shao-jun Zhou, Zhi-yong Huang and Xiao-ping Chen
Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, China
Introduction: Although curative resection was the only
chance of cure in patients suffering from intrahepatic
cholangiocarcinoma (ICC), the prognostic factors of
ICC remains controversial. The purpose of this study
was to analyze the surgical outcomes and prognostic
factors of a cohort of patients with ICC undergoing
curative resection.
Method: The clinicopathological data of 125 patients
with ICC undergoing curative resection between Janu-
ary 2002 and May 2008 were retrospectively reviewed.
The variables including age, sex, hepatitis B virus infec-
tion, cirrhosis, tumor marker, tumor size, number of
tumors, vascular invasion, perineural invasion, bile duct
thrombi, lymph node metastasis, tumor differentiation,
AJCC 7th staging, blood transfusion and adjuvant
therapy were analyzed by using the Kaplan–Meier
method and Cox hazard models. The correlation
between CA19-9 expression and clinicopathological fac-
tors was analyzed using the v2 test and a logistic regres-
sion model.
Results: The cumulative 1-, 3- and 5-year survival rates
of the entire cohort were 81.6%, 39.2% and 18.4%
respectively, and the 1-, 3- and 5-year disease-free sur-
vival rates were 61.6%, 27.2% and 12.8% respectively.
Univariate analysis revealed that CA19-9 level, AJCC
7th staging, tumor size, multiple tumors and lymph
node metastasis were statistically significant factors.
Multivariate analysis further showed that lymph node
metastasis (RR: 3.939; p < 0.001), CA19-9 (>200 U/
mL) (RR: 1.912; p = 0.001), and tumor size (>5 cm)
(RR: 1.82; p = 0.005), multiple tumors (RR: 1.877;
p = 0.010) were independent adverse prognostic factors.
The rate of lymph node metastasis in the CA19-9
(>200 U/mL) group was significantly higher than that
in the CA19-9 (≤200 U/mL) group (OR: 3.208;
p = 0.013).
Conclusions: Curative resection is the most effective
treatment for ICC. CA19-9 (>200 U/mL), tumor size
(>5 cm), multiple tumors, lymph node metastasis were
independent adverse prognostic factors of ICC. High
preoperative CA19-9 level (>200 U/mL) is significantly
associated with lymph node metastasis.
FO18-10
A 5-YEAR EXPERIENCE OF
GALLBLADDER POLYP
SURVEILLANCE AND MANAGEMENT
AT ADDENBROOKE’S HOSPITAL
Krashna Patel, Khaled Dajani,
Saranya Vickramarajah, Raaj Praseedom, Asif Jah,
Neville Jamieson, Simon Harper and
Emmanuel Huguet
Addenbrooke’s Hospital, United Kingdom
Introduction: Recent literature shows active gallbladder
polyp surveillance to be potentially cost effective at
detecting and preventing gallbladder carcinoma. Polyp
enlargement to more than 10 mm or symptomatic pol-
yps warrants cholecystectomy. The aim of this study
was to examine the surveillance programme at a large
teaching hospital including uptake into the programme,
change in polyp characteristics and detection of poten-
tial malignant polyps.
Method: Data was collected retrospectively from all
patients with ultrasonography detected gallbladder pol-
yps between January 2008 and January 2013. Informa-
tion obtained included patient demographics, polyp
characteristics and histology of resected specimens
using Meditech software, discharge summaries and
clinic follow up letters.
Results: 558 patients had ultrasound detected one or
more gallbladder polyps. Following initial ultrasonog-
raphy, 46 patients were managed with an elective chole-
cystectomy. 304 patients went on to have further
formal ultrasound surveillance, of which 43 underwent
surgical management. The median time interval
between ultrasound scans in those under active surveil-
lance was significantly lower than for those not
(205 days (176–364) vs. 514 (385–757), p < 0.0001).
16% of patients exhibited increase in number of polyps
and 33% of polyps demonstrated enlargement in size
over the surveillance period. From the cholecystectomy
resected gallbladder specimens, 2.2% (2/89) demon-
strated histological dysplastic changes.
Conclusions: Gallbladder polyp surveillance uptake was
suboptimal at 62.7%. Polyps monitored demonstrated
increase in size and number over surveillance time. His-
tological dysplasia and adenocarcinoma from resected
gallbladders emphasizes the importance of polyp sur-
veillance to facilitate early detection and management
of potentially malignant and malignant lesions.
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KAMPO MEDICINE “DAIKENCHUTO”
PREVENTS BACTERIAL
TRANSLOCATION AND HEPATIC
FIBROSIS IN BILE DUCT LIGATED RATS
Keigo Yada, Hiroki Mori, Hiroki Ishibashi,
Chie Takasu, Yu Saito, Tetsuya Ikemoto, Yuji Morine,
Satoru Imura, Tohru Utsunomiya and Mitsuo Shimada
The University of Tokushima, Japan
Introduction: Bile duct ligation (BDL) has been used as
a model of biliary atresia. Bacterial translocation (BT)
contributes to liver fibrosis via TLR2 signaling in BDL
mice (Gastroenterology, 2012). We have previously
reported that Kampo-medicine “Daikenchuto (DKT)”
prevents BT in fasting rats (Dig Dis Sci, 2008). The
aim of this study was to clarify the effect of DKT on
BT and liver fibrosis in BDL rats.
Method: Male Wistar rats (250–300 g, 6 weeks old)
were divided into the following three groups: Group1
(n = 5), control; Group2 (n = 5), receiving BDL only;
Group3 (n = 5), receiving BDL and oral administration
of DKT (300 mg/kg/day). In Group2 and Group3, rats
were sacrificed at 3, 7 or 14 days after BDL. (1) Serum
T-Bil, AST, ALT, hyaluronic acid (HA) and total bile
acid (TBA); (2) bacterial culture of mesenteric lymph
nodes; (3) number and height of villus of small intes-
tine; (4) liver fibrosis with AZAN staining and acti-
vated hepatic stellate cells (HSCs) with a-SMA
staining; were investigated, respectively.
Results: (1) Group3 had lower GPT on POD3 and lower
serum HA on POD14 than Group1 and Group2, respec-
tively (p < 0.05). (2) BT was observed 0% in Group1
and 100% in Group2 on POD3, 7 and 14. In contrast, it
was detected 100% on POD3, 20% on POD7, and 0%
on POD14 in Group3. (3) Number and height of villus in
Group3 were preserved compared to Group2, in time
dependent manner (on POD 7, 14, p < 0.01). (4) Area of
liver fibrosis and positive a-SMA staining in Group3
were smaller than those in Group2 (p < 0.05).
Conclusions: These findings suggest that progression of
liver fibrosis in biliary atresia might be caused by activa-
tion of HSCs through BT. DKT may improve liver
fibrosis by suppressing the activated HSCs and main-
taining intestinal integrity in patients with biliary atresia.
FO18-12
ENDOSCOPIC TARGETING OF
MAGNETIC NANOPARTICLES FOR
HYPERTHERMIA AND LOCAL DRUG
DELIVERY APPLICATIONS IN KLATSKIN
TUMORS AND PANCREATIC CANCER
Anjali A. Roeth1, Ioana Slabu2, Martin Baumann2,
Karsten Junge1, Joachim Conze1, Maximilian
Schmeding1, Philipp Bruners1, Gernot Guentherodt1
and Ulf P. Neumann1
1RWTH Aachen University Hospital, Germany;
2Helmholtz Institute, Germany
Introduction: Drug carriers containing magnetic nano-
particles can be used for local cancer treatment to
reduce the enormous side effects of systemic chemo-
therapy. After peripheral injection, the magnetic nano-
particles (MNP) are targeted at the tumor site by a
magnetic field trap. Applying an alternating magnetic
field generates heat that releases the drug locally and
may additionally be used for hyperthermia application.
Until today, only tumors on the surface can be
reached. To treat internal tumors, we aimed to target
the MNP endoscopically. For this endeavor, the ideal
magnetic field trap had to be found. Sample applica-
tions were Klatskin tumors and pancreatic cancer.
Method: The magnetic characteristics of the tumors
and the surrounding organs were investigated in differ-
ent species (human, pig, rat) by SQUID-analysis.
Together with topographical characteristics they were
used to establish a biophysical model of the tumor and
its surrounding structures, in which different magnetic
field trap formations could be simulated and optimized.
Toxicity and interaction with different magnetolipo-
somes were investigated in human cancer and non-
malignant cell lines in vitro (MTT, fluorecscence
microscopy, TEM). The optimized magnetic field traps
and magnetoliposomes were then tested in vivo in a pig
animal model.
Results: The programmed biophysical model closely
mirrored the characteristics of the tumor and its envi-
ronment. We could improve the targeting efficiency by
8fold with the simulation. In vitro, we could identify
the best suitable composition of magnetoliposomes with
the least toxicity and the highest magnetization. In vivo,
we were able to target the injected MNP at the region
of interest. The local accumulation could be detected
directly by MRI and histology and indirectly by change
in the magnetic characteristics of the tissue.
Conclusions: Local treatment of internal tumors is pos-
sible by endoscopic targeting of magnetic nanoparticles.
Further experiments in tumor models are needed.
FO19-01
THE RELATIONSHIP BETWEEN
ABERRANT PROMOTER
METHYLATION OF MULTIPLE GENES
AND PROGNOSIS IN
HEPATOCELLULAR CARCINOMA
Jiang-ming Chen
The Secondary Affiliated Hospital of Anhui Medical
University, China
Introduction: To study the relationship between the
gene promoter methylation state of DAPK, FHIT and
SLIT2 genes and the clinical pronosis of patient in
hepatocellular carcinoma (HCC)
Method: The technique of methylation-specific PCR
(MSP) was adopted to investigate the promoter hyper-
methylation of DAPK、FHIT及SLIT2 genes in 50
HCCs after a curative resection.
Results: In all patients with HCC, the frequency of hy-
permethylation in DAPK, FHIT and SLIT2 were
82.0% (41/50), 68 .0% (34/50) and 54.0% (27/50),
respectively. Those three genes have higer frequency
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among the group of less than one year with tumor
recrudescence. The frequency hypermethylation of
FHIT gene is especially higher in the group of less than
one year with tumor recrudescence (p = 0.036). There
is a statistical prognosis difference between those cases
with two or three promotors hypermethylation and
those cases with none or one (p = 0.006).
Conclusions: The results strongly suggest that, Hyper-
methylation of multiple gene promotors are common
events in HCC. In patients with HCC, aberrant DNA
methylation is significantly associated with poor prog-
nosis. Detection of multiple gene promotors hyperme-
thylation in tumor tissue, especially FHIT gene, is
therefore a useful index to predict the prognosis of
HCC. FHIT maybe can serve as a biomarker for the
prognosis, after a curative resection.
FO19-02
EPIGENETIC REPRESSION OF MIR-132
EXPRESSION BY THE HEPATITIS B
VIRUS X PROTEIN IN HEPATITIS B
VIRUS-RELATED HEPATOCELLULAR
CARCINOMA
Zhongjun Wu, Xufu Wei, Cui Tan,
Chengyong Tang, Guosheng Ren, Tingxiu Xiang,
Zhu Qiu and Rui Liu
The First Affiliated Hospital of Chongqing Medical
University, China
Introduction: Hepatitis B virus x (HBx) protein is
involved in the initiation and progression of HBV-
related hepatocellular carcinoma (HCC) by regulating
host protein-coding genes. However, the role of HBx in
the epigenetic repression of miRNAs, which play
important roles in gene regulation during hepatocarci-
nogenesis, remains largely unknown.
Method: The expression of miR-132 in HCC cells,
HBV-related HCC tissues, and serum were determined
using real-time PCR. The level of DNA methylation on
the promoter of miR-132 was examined using methyla-
tion-specific PCR (MSP). MiR-132 was functionally
characterized in HCC cells with transiently altered
miR-132 expression.
Results: HBx-induced DNA hypermethylation of the
promoter of miR-132 was found to be more prevalent
in HBx-expressing HepG2 cells than in control cells.
Consistently, MiR-132 expression was also more fre-
quently down-regulated in HBV-related HCC tissues
than in adjacent noncancerous hepatic tissues and had
a significant inverse correlation with HBx expression in
HBV-related HCCs. Serum miR-132 levels were found
to be significantly correlated with levels in tumor tissue.
Finally, proliferation and colony formation of HCC
cells were found to be suppressed by miR-132-mediated
inhibition of the Akt-signaling pathway in miR-132
transfected cells.
Conclusions: Our study has demonstrated the epige-
netic repression of miR-132 expression through DNA
methylation induced by HBx. This work provides novel
mechanistic insights into HBV-mediated hepatocarcino-
genesis and suggests that miR-132 may be a promising
biochemical marker and may have therapeutic applica-
tions in HBV-related HCC.
FO19-03
MIR-216B SUPPRESSES TUMOR
GROWTH AND INVASION BY
TARGETING KRAS AND KLF17 IN HCC
Fu-yao Liu, Zhi-yong Huang and Xiao-ping Chen
Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, China
Introduction: MiRNAS, critical mediators in post-tran-
scription stage nearly in all types of tumors. This study
aims to investigate the correlation between expression
status of miRNAs in hepatocellular carcinoma (HCC)
and proliferation, metastasis potential of HCC.
Method: Expression profile of miRNAs in plasma of
peripheral blood between HCC patients with HCC fam-
ily history and healthy people was contrasted by micro-
array. Then 14 miRNAs that had never been reported in
HCC were found. By Real time-PCR,the expressions of
14 miRNAs were detected expression in the paired tis-
sues from 50 patients with HCC who underwent liver
resection. miR-216b was selected for further study. The
relationship between miR-216b expression and the clini-
copathological features of HCC was evaluated. With
RNA interference technique, the correlation of miRNAs
expression and metastatic potential was investigated by
downregulating or upregulating expression in two HCC
cell lines including SMMC-7721 and HepG2. Cell prolif-
eration, migration, and invasion were analyzed. Further-
more, the correlation between miR-216b expression and
the genes related to these biological characters were stud-
ied by western blotting.
Results: Of 50 HCC, 37 (75%) tumors showed reduced
miR-216b expression, compared with their adjacent liver
tissues. The decreased expression of miR-216b were sig-
nificantly correlated with poorer tumor differentiation
(p = 0.033) and vascular invasion (p = 0.001). MiR-216b
overexpression in HepG2 cells resulted in decreased cell
proliferation, aggregation, cell migration and invasion.
And miR-216b down-regulation in SMMC-7721 cells
resulted in oppsite effect both in vitro and in vivo assays.
Furthermore, miR-216b was found to bind to the 3’un-
translatedregion (UTR) of KRAS and KLF17, and inhi-
bit expressions of the KRAS and KLF17. And miR-
216b exerts its tumor suppressor function through inhibi-
tion of the KRAS-related AKT and ERK pathways and
down-regulating Id-1 expression.
Conclusions: miR-216b plays a key role in HCC pro-
gression. miR-216b suppresses proliferation, migration
and invasion of HCC cells by regulating KRAS and
KLF17 expression.
FO19-04
EXPRESSION OF HNF1b AND CK7 IN
CHOLANGIOCARCINOMA BY REAL-
TIME RT-PCR
Yongyut Sirivatanauksorn, Nichaporn Wongsirojkul,
Chatchawan Srisawat, Ananya Pongpaibul,
Patarabutr Masaratana and
Vorapan Sirivatanauksorn
Siriraj Hospital, Thailand
Introduction: To date, the promising genes for cholan-
giocarcinoma (CCA) cells are still limited. HNF1b have
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been suggested as an exclusive biliary epithelial cell
transcription factor and CK7 have been previously
reported to be highly expressed in CCA cell by immu-
nohistochemistry. This study aims to identify genes that
are constitutively expressed in CCA cell from formalin-
fixed and paraffin-embedded (FFPE) tissue specimens
using real-time RT-PCR and validate their expression
in normal liver and CCA sections.
Method: Although RNA retrieved from FFPE tissue
specimens is always degraded and cross-linked but
still, it was particularly relevant for cDNA synthesis
and real-time PCR applications. After RNA was iso-
lated from 24 paired CCA and normal liver FFPE
tissue specimens, its purity and yields were assessed
by nanophotometer and amplification of reference
genes.
Results: The detection rate of HNF1b in CCA sections
were 95.83% (23/24) while in normal liver sections were
83.33% (20/24). Interestingly, the detection rate of CK7
in CCA sections were 83.33% (20/24) while in normal
liver sections were only 16.67% (4/24). Moreover, CK7
showed significantly overexpression in CCA tumour
compare to normal liver when normalised with ACTB.
Also, we found no expression of these two candidate
genes in white blood cell.
Conclusions: Both candidate genes could as well be fur-
ther developed as markers for the detection of CCA in
the variety of differentiation. Furthermore, the detec-
tion of these genes in the circulating blood and perito-
neal fluid from CCA patients might provide the staging
of the disease.
FO19-05
C-MYC DEREGULATION AS NEW
PREDICTIVE FACTOR FOR EARLY
RECURRENCE OF HCC AFTER
SURGICAL RESECTION
Andrea Ruzzenente1, Fabio Bagante1, Calogero
Iacono1, Federica Pedica2, Matteo Brunelli2, Paola
Capelli2, Alessandro Valdegamberi1, Simone Conci1,
Aldo Scarpa2 and Alfredo Guglielmi1
1Unit of HPB surgery, Division of General Surgery A,
University of Verona Medical School, Italy; 2FISH
Molecular Laboratory, University of Verona, Verona,
Italy
Introduction: Recurrence of hepatocellular carcinoma
(HCC) after surgery is a critical issue and it decreases
overall survival (OS). It is well know that c-Myc, as
transcription factor, influences up to 15% of genes and
that its deregulations determinate an aggressive tumor
growth with poor prognosis.
Method: Sixty-five cases of HCC submitted to surgical
resection with curative intent were examined by break-
apart FISH probes to define c-myc status (disomic,
polysomic, amplified). Statistical analysis were per-
formed to find out clinical and molecular features for
recurrence and overall survival.
Results: C-myc status appeared disomic in 26.1%,
polysomic in 55.4% and amplified in 18.5%. The dis-
ease-free survival (DFS) and overall survival (OS) for
disomic, polysomic and amplified groups were signifi-
cantly different (p = 0.02 and p = 0.018, respectively).
Multivariate analysis confirmed that number of nod-
ules, AFP serum level, c -myc amplified status were sig-
nificant prognostic factors for DFS with HRs of 2.62
(IC 95%, 1.21–5.65), 1.28 (IC 95%, 1.09–1.51) and 6.50
(IC 95%, 1.84–22.98), respectively.
We estimate a clinical and molecular model based on
multivariate analysis (number of nodules, serum AFP
levels and c-myc status) able to estimate the risk of
early recurrences (≤12 months). Patients in low-risk of
early recurrence class reached a DFS at 12 months of
70% (CI 95%, 58.6–83.5) and patients in high-risk class
of recurrence had a DFS at 12 months of 0%
(p < 0.001).
Conclusions: C-myc gene amplification is significantly
correlated with DFS and OS in patients with HCC
after surgical resection. Our model based on c-Myc sta-
tus may predict early recurrence helping the clinicians
to offer a better tailored therapeutic choice.
FO19-06
EXPRESSION AND SIGNIFICANCE OF
BMI-1 IN HEPATOCELLULAR
CARCINOMA TISSUE AND PORTAL
VEIN TUMOR THROMBUS
Hongqiang Yang1, Jingxia Tang2, Xinyu Peng1, Shijie
Zhang1, Hong Sun1 and Xiaopin Chen3
1The First Affiliated Hospital of the Medical College,
Shihezi University, China; 2The Medical College, Shihezi
University, Shihezi 832000, China; 3Tongji Hospital,
Huazhong University of Science and Technology, Wuhan
430030, China
Introduction: This study detect the mRNA and protein
expression of Bmi-1 in hepatocellular carcinoma (HCC)
tissue, pericarcinomatous tissue, portal vein tumor
thrombus and normal liver tissue and to investigate the
significance of Bmi-1 in the genesis and progression of
HCC.
Method: Forty tissues of HCC were collected from
2005 to 2009. The mRNA and protein expression of
Bmi-1 in HCC tissue (40 cases), pericarcinomatous tis-
sue (40 cases), portal vein tumor thrombus(11 cases)
and normal liver tissue(10 cases) were detected by
immunohistochemistry, Western-blot and real-time
PCR. The relationship between the expression of Bmi-1
and the clinicopathological features was analyzed.
Results: The median relative mRAN expression of
Bmi-1 in the normal liver tissues, pericarcinomatous tis-
sue, hepatocellular carcinoma and portal vein tumor
thrombus were 0.96, 2.60, 7.51 and 29.95, respectively.
The results of immunohistochemistry showed that the
high protein expression rates of Bmi-1 in normal liver
tissues, pericarcinomatous tissue, HCC tissue and por-
tal vein tumor thrombus was 10.0%, 20.0%, 67.5%
and 100.0%, respectively. The high protein expression
rates of Bmi-1 in HCC and portal vein tumor throm-
bus, the expression of Bmi-1 protein was significantly
higher than those in normal liver tissue and pericarcin-
omatous tissue (p < 0.05). High protein expression of
Bmi-1 was also detected in 11 cases of HCC tissues
with portal vein tumor thrombus. The results of Wes-
tern-blot were consistent with those of the immunohis-
tochemistry. The mRNA and protein expression of
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Bmi-1 was correlated with Edmondson grade and the
portal vein metastasis (p < 0.05), whereas they were
irrelevant to tumor size, serum levels of AFP and hepa-
titis B surface antigen (p > 0.05). Patients with high
expression of Bmi-1 had poor prognosis.
Conclusions: Bmi-1 is correlated with the genesis and
progression of HCC as well as the formation of portal
vein tumor thrombosis. Patients with high Bmi-1
expression have poorer prognosis when compared with
those with low Bmi-1 expression.
FO19-07
CONTRAST-ENHANCED ULTRASOUND
IN THE ASSESSMENT OF
HEPATOCELLULAR CARCINOMA:
COMPARISON WITH MULTIPHASIC
MDCT
Isidoro Di Carlo1, Francesco Loria2, Giuseppe Loria2,
Giuseppe Crea2, Antonio Barone2, Silvia Cantoni3,
Luciano Frosina2, Salvatore Basile2 and Francesca
Catanzariti2
1Hamad General Hospital - Doha Qatar, Qatar; 2ASP 5
RC-Palmi Hospital, Italy; 3ASL CHIAVARESE, Italy
Introduction: The aim of this study was to evaluate
tumour vascularity in hepatocellular carcinoma (HCC)
using contrast-enhanced ultrasonography (CEUS) with
Sonovue and to compare performance with multiphasic
MDCT.
Method: Between January 2008 and February 2013 we
studied 118 nodules in 88 patients with HCC. HCC
was diagnosed as a hyperenhancement lesion in the
arterial phase with wash-out in the portal phase on
multiphasic MDCT or by percutaneous biopsy.
We observed tumour vascularity at the early vascular
phase (0–30 seconds after contrast injection) and Kupf-
fer imaging at post vascular phase (after 10 minutes).
Results: Detection of vascularity at the early vascular
phase was 88% in nodules that were found to be hy-
pervascular on multiphasic MDCT and 28% in hypo/
isovascular nodules.
The detection of vascularity was significantly lower in
nodules >9 cm deep than in those <9 cm deep, but was
not affected by tumour size.
The detection of tumour at the post-vascular phase
on CEUS was 83% in nodules with low density in the
portal phase on MDCT and 82% in nodules with
isodensity.
The rate did not depend on the severity of underlying
liver disease; rates decreased in nodules deeper than
9 cm, those smaller than 2 cm in diameter and in isoen-
hancing nodules at early vascular phase of CEUS.
Conclusions: CEUS with Sonovue is a useful tool for
assessing the vascularity of HCC and is equal to that
of multiphasic MDCT, however, the detectability of
HCC vascularity is affected by location.
FO19-08
PREDICTION OF AGGRESSIVENESS IN
EARLY-STAGE HEPATOCELLULAR
CARCINOMA FOR SELECTION OF
SURGICAL RESECTION
Suk-won Suh, Kwang-Woong Lee, Jeong-Moo Lee,
Youngrol Choi, Nam-Joon Yi and Kyung-Suk Suh
Seoul National University Hospital, Korea
Introduction: In early-stage hepatocellular carcinoma
(eHCC), radiofrequency ablation (RFA) showed com-
parable outcomes with surgical resection (SR), how-
ever, microsatellites can be present near the tumor, and
it results in tumor recurrence after local ablation.
Therefore, we investigated the predictors of aggressive-
ness in eHCC to select high risk patients of recurrence
after RFA who needs SR.
Method: At first step, in SR group, 103 patients of
newly diagnosed eHCC (defined as single tumor within
3 cm) between July 2007 and December 2011 were ana-
lyzed. Risk factors for tumor aggressiveness, which rep-
resents the risk of microsatellites, microvascular
invasion or poor histologic grade (Edmonson and Ste-
ine grade, 3 or 4) were investigated. At second step, in
RFA group, 201 patients of eHCC at same period with
SR group were analyzed. Identified risk factors were
validated to reveal its influence on tumor recurrence. In
total population, recurrence free survival and overall
survival rates were compared by the type of procedure
and presence of identified risk factors.
Results: The only significant risk factor for tumor
aggressiveness in SR group was multiply of AFP and
PIVKA-II (A*P) ≥1,600 (HR 3.264. 95% CI 1.108–
9.610, p = 0.032). After validation in RFA group, it
also had statistical significance in terms of HCC recur-
rence (HR 2.133, 95% CI 1.360–3.346, p = 0.001).
Among total population, patients with A*p ≥ 1,600
who underwent RFA showed significant tumor recur-
rence, especially in early postoperative period
(p = 0.021) and it had influenced on late survival out-
comes (p = 0.011) after adjusting several factors.
Conclusions: Combined AFP and PIVKA is useful pre-
dictor of aggressiveness in eHCC, which predicts tumor
recurrence after RFA, as well. Therefore, by the level
of this predictor, SR should be considered for first-line
therapy.
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FO20-01
CONVERSION TO ENTECAVIR
MONOTHERAPY FROM
COMBINATION THERAPY WITH
HEPATITIS B IMMUNOGLOBULIN FOR
HEPATITIS B PROPHYLAXIS IN LONG
TERM SURVIVOR AFTER LIVER
TRANSPLANTATION: PROSPECTIVE
SINGLE CENTER TR
Jeong-Moo Lee, Kyung-Suk Suh, Youngrok Choi,
Suk-Won Suh, Tae You, Jose Benjamin Navarro
Burgos, Angelica Garcia, Kwang-Woong Lee and
Nam-Joon Yi
Seoul National University Hospital, Korea
Introduction: As a novel hepatitis B prophylaxis after
liver transplantation, Combination therapy of intrave-
nous Hepatitis B immunoglobulin (ivHBIG) and nucle-
oside (NA) analogue, has been the best method for HB
related liver disease. However, because of many contro-
versy of ivHBIG for prophylaxis, we evaluated efficacy
of entecavir (ETV) monotherapy after discontinuation
of ivHBIG in long term survivor after LT.
Method: Between February 2009 and December 2011,
20 candidates (12.9%) were prospectively enrolled
among 154 consecutive LT recipients for HB related
liver disease. All patient (1) had HB related liver cir-
rhosis, (2) Survived more than 2-years after LT, (3) (4)
Underwent post-LT HB prophylaxis over one-year
combination therapy with ETV (0.5 mg daily) and ivH-
BIG (10,000 IU per 5 weeks). Additional inclusion cri-
teria was any one of the follows; (a) NA-na€ıve patient,
(b) If, have NA-treated history, Negative YMDD
Mutation (c) Negative HBe antigen (HBeAg) and HBV
DNA (<100 IU/mL), Primary endpoint was the 2-year
recurrence rate of Hepatitis B (reappearance of HBsAg
or HBV DNA).
Results: All patients were followed up without HB
recurrence during the second year. Only one recipient
(5%) experienced HBV DNA titer elevation at
37.3 month after conversion to ETV monotherapy. But
it was decreased spontaneously without any interven-
tion. 1 patients (5%) were dropped out during the sec-
ond year due to advanced gastric cancer with liver
metastasis. Recurrence free survival rate of the 19
patients were 100% at two-year post-transplant. No
side effects related with ETV monotherapy were noted
during the follow-up period.
Conclusions: ETV monotherapy after discontinuation
of ivHBIG combination therapy 2-year after liver
transplantation was safe and effective in selected
patient.
FO20-02
WHAT IS APPROPRIATE INDICATION
TO INITIATE ISONIAZID PX FOR
LATENT TUBERCULOSIS INFECTION
AFTER LIVER TRANSPLANT
RECIPIENTS IN EDEMIC AREA?
Hyung Hwan Moon, Jae-Won Joh, Jong Man Kim,
Seung Hwan Lee, Jinyong Choi, Wantae Cho,
Choon Hyuck David Kwon, Young Eun Ha and
Kyung Ran Peck
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: The diagnosis and management of latent
TB infection (LTBI) in liver transplant candidate are
necessary because the reactivation of latent TB infec-
tion is the most common form of TB acquisition after
transplantation. However, transplanted liver is believed
to be more vulnerable to INH induced hepatotoxicity.
The objective of this study was to identify the suitabil-
ity of our LTBI treatment criteria, and to evaluate hep-
atotoxicity after INH Prophylaxis (Px) in a TB
endemic area.
Method: From March 2008 to December 2012, we
reviewed 276 patients who were received both Inter-
feron (IFN)-c release assay (IGRA) and Tuberculin
skin test (TST) for LTBI before LT retrospectively.
Results: The number of positive results of IGRAs was
bigger than those of PPD tests (134/276 (48.5%) vs. 92/
276 (33.3%)). Among 276 recipients, post-transplant
TBs were detected on 6 recipients (2.17%). If two
patients who were negative TST and IGRA without
risk factor could be considered as not LTBI, but
acquired from community. Interestingly, the others, all
four recipients who were diagnosed as post LT TB had
positive IGRA. When we analyzed 17 patients who
received post-transplant INH Px, overall INH hepato-
toxicity rate was 11.7% (2/17). There was no hepatic
failure or death after INH treatment. The peak AST
after INH prophylaxsis was significantly lower with
AST of lesser than 50 U/L at start of INH (p = 0.046).
Conclusions: Our study had shown INH hepatotoxicity
on transplanted liver is not serious and it can be safe
to start INH prophyalxis at less than 50 U/L of AST.
In addition, only IGRA positivity without other risk
factors deserve to be considered as INH Px criteria.
FO20-03
THE HEPATIC ENERGY FLOW DURING
LIVER TRANSPLANTATION:
SOMETHING MORE IMPORTANT
BEYOND FLOW AND PRESSURE
An-Chieh Feng, Teng-Wei Chen, Hsiu-Lung Fan and
Chung-Bao Hsieh
Tri-Service General Hospital, National Defense Medical
Center, Taiwan
Introduction: The correlation between portal vein flow
and portal vein pressure during liver transplantation,
which greatly contribute to the surgical outcomes and
also affect the need of performing graft inflow modula-
tion, is not yet confirmed. This study was performed to
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evaluate the correlations between mounts of hemody-
namic parameters during liver transplantation by
applying the law of energy conservation.
Method: The energy flow in the hepatic system could
be explained by applying fluid mechanic theories
including two inflows from hepatic artery and portal
vein and one outflow of hepatic vein. The expected
energy could be presented as flow x pressure. The
energy consumed by liver which could be calculated as
total energy inflow from hepatic artery and portal vein
minus energy outflow from hepatic vein may correlate
to the outcome of liver transplantation and subsequent
liver regeneration. By using the published data, the
energy indexes were calculated and the energy model
was established.
Results: By applying the model of hepatic energy
flow, we used the published data from literatures to
simulate the energy status of normal condition, cirrho-
sis, cadaveric liver transplantation, and living donor
liver transplantation. Energy from hepatic artery will
drop significantly compared to normal or cadaveric
liver transplantation after living donor liver transplan-
tation. The average acceptable energy index is around
23,150 to 35,100 in normal condition and graft inflow
modulations will be required if beyond or below this
range.
Conclusions: By applying the concept of energy conser-
vation, the relationship between portal vein, hepatic
artery and hepatic vein systems can be clearly demon-
strated. The energy consumed by liver graft and the
ratio of the energy provided from the portal vein and
hepatice artery can be considered as the indicators of
performing graft inflow modulations to prevent early
postoperative complications.
FO20-04
PORTAL FLOW IS THE MAIN
PREDICTOR OF EARLY GRAFT
DYSFUNCTION REGARDLESS OF THE
GRWR STATUS IN LIVING DONOR
LIVER TRANSPLANTATION- A
RETROSPECTIVE ANALYSIS OF 147
PATIENTS
Bhavin Vasavada1, Chao Long Chen2 and Muhammad
Zakaria1
1Fellow liver surgery and transplant, India; 2Professor
and Superintendent, Taiwan
Introduction: Sometimes it is seen that even in ade-
quate GRWR settings even after ruling out all other
causes recipients shows features of small for size syn-
drome. Purpose of this study was to evaluate all causa-
tive factors responsible for early graft dysfunction
fulfilling the definition of small for size syndrome
regardless of the GRWR status with particular empha-
sis on portal flow (mL/minute/100g). We also tried to
establish weather high portal flow on Doppler study in-
traoperatively immediately after reperfusion can predict
graft dysfunction.
Method: Early graft dysfunction was defined according
to definitions given for small for size syndrome by cla-
vian et al and Kyushu university group. Patients under-
gone living donor transplantation between January
2010 and December 2012 were analyzed. After applying
exclusion criteria according to above definitions univar-
iate, multivariate analysis and Fisher t test were applied
to predict cut off value of portal vein flow in predicting
graft dysfunction and ROC curves prepared.
Results: 19 patients out of 147 showed features of early
graft dysfunction as per definition. In univeriate analy-
sis HCV and Portal vein flow immediately after reper-
fusion achieved statistical significance in predicting
graft dysfunction.(p = 0.020 and p = 0.0001).In multi-
variate logistic regression Only portal vein flow after
reperfusion achieved statistically significant value in
predicting postoperative graft dysfunction.
(p = 0.001).portal flow greater than 180 and 190 (mL/
minute/100g) achieved statistical significance in predict-
ing graft dysfunction (p = 0.0003 and p = 0.0001
respectively) with AUROC 0.711 and 0.799 respec-
tively. GRWR was not significant at any step.
Conclusions: Portal vein flow immediately after reper-
fusion >180/mL/minute/100 g more reliably predict
weather graft will behave like small for size or not
regardless of grwr status. Portal vein flow is the most
significant factor in predicting graft dysfunction rather
then GRWR.
FO20-05
KINETICS OF ANTI-BLOOD
ISOAGGLUTININ TITERS, B T, NK
LYMPHOCYTES IN ABO
INCOMPATIBLE LIVING DONOR
LIVER TRANSPLANTATION WITH
RITUXIMAB, PLASMA EXCHANGE,
BASILIXIMAB, AND IVIG
Seung Duk Lee and Seong Hoon Kim
National Cancer Center, Korea
Introduction: A novel protocol for ABO incompatible
living donor liver transplantation (ABO-I LDLT) has
been performed using rituximab, plasma exchange, ba-
siliximab, and IVIG. The aim of this study was to
investigate the kinetics of anti-blood type isoagglutinin
titier and the number of B, T, and natural killer lym-
phocytes in ABO-I LDLT with this protocol.
Method: Twenty patients underwent ABO-I LDLT
without splenectomy and local infusion therapy with
previous new protocol between January 2012 and July
2013, and data was reviewed retrospectively.
Results: The initial median antibody titer before
plasma exchange was 1:32 (range, 1:4–1:256). Antibody
isoagglutinin titers were lowered by several pretran-
plant plasma exchanges (range 1–4 times) to less than
1:8 in all patients. Titers were suppressed well until fol-
low-up days. However, CD 19-positive lymphocytes in
the blood rapidly disappeared after 2 weeks of ritux-
imab treatment and began to recover about 6 months
later. The number of CD3, 4, 8-positive lymphocytes
were increased after rituximab and recovered approxi-
mately 6 months later. CD4/CD8 ration was depressed
during 6 months after transplant. However, the number
of CD16, CD56-positive NK cells were decreased in
this period. And there was no antibody-mediated/acute
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cellular rejection and serious viral or bacterial infection
in these patients.
Conclusions: Anti-blood antibody titers were well sup-
pressed with this protocol without antibody-mediated
rejection. CD 19-positive B cells was well decreased
during 6 months, however T and NK cells were
increased. Especially CD4 helper T cells showed more
increasing trend than CD8 cytotoxic T cell.
FO20-06
PGC-1a ATTENUATES HEPATIC
ISCHEMIA/REPERFUSION INJURY IN
MICE: ROLE OF PEROXISOME
PROLIFERATOR-ACTIVATED
RECEPTORS a AND c
Yong Ma, Daewi Wang, Baolei Zhao, Lianxin Liu and
Hongchi Jiang
The 1st Affiliated Hospital of Harbin Medical
University, China
Introduction: Peroxisome proliferator-activated recep-
tors (PPARs) a and c have been show to be protective
in hepatic ischemia-reperfusion (I/R) injury. However,
the precise role of PPARc coactivator-1a (PGC-1a),
which can coactivate both of them, in the hepatic I/R
injury remains unknown.
Method: This study was designed to test our hypothesis
that PGC-1a is protective during hepatic I/R injury by
using a mouse partial hepatic I/R model. The in vitro
effects of PGC-1a on hepatocytes anoxia/reoxygenation
(A/R) injury were also tested.
Results: Our results show that endogenous PGC-1a is
basally expressed in normal livers, and is mildly
increased by I/R. Overexpression of PGC-1a protects
against hepatic I/R and hepatocytes A/R injuries,
whereas knockdown of endogenous PGC-1a aggravates
such injuries, as convinced by detection of the levels of
serum aminotransferase and inflammatory cytokine,
apoptosis, histological examination and cell viability.
The electrophoretic mobility shift assay (EMSA) shows
that the activation of PPARa and PPARc are increased
or decreased by the overexpression or knockdown of
PGC-1a, respectively, during hepatic I/R and hepato-
cytes A/R injuries. In addition, the administration of
special antagonist of either PPARa (MK886) or
PPARc (GW9662) could effectively alleviate the protec-
tive effect of PGC-1a against hepatic I/R and hepato-
cytes A/R injuries.
Conclusions: .These findings indicate that endogenous
intrahepatic PGC-1a protein is protective during hepa-
tic I/R injury in mice. Such hepatoprotective role of
PGC-1a, at least in part, through the activation of
PPARa and PPARc. Thus, PGC-1a may be a new ther-
apeutic target for the protection of the liver against I/R
injury.
FO20-07
RISKS OF LATE SURGICAL
PROCEDURES IN LIVER
TRANSPLANTATION
Daniele Sommacale1, Ganesh Nagarajan2, Federica
Dondero2, Tullio Piardi1, Alain Sauvanet2, Francois
Durand2, Catherine Paugam-Burtz2 and Jacques
Belghiti2
1Dune Pole, France; 2PMAD, France
Introduction: The number of patients with previous
liver transplantation requiring future abdominal surgi-
cal procedures is significantly increasing. The postoper-
ative risk of these patients is not known. We analyze
our data on late surgical procedures after liver trans-
plantation.
Method: From January 1997 to December 2011, we
performed 1211 liver transplantations. 161 transplanted
patients (154 with liver transplantation alone, 6 with
liver/kidney transplantation and 1 with liver/lung trans-
plantation) require 181 (16.5%) late abdominal surgical
procedures, defined as >3 months surgery after the date
of liver transplantation. All surgical procedures were
classified into elective or emergency procedures and
into major or minor procedures. Postoperative morbid-
ity was graded according to the Dindo-Clavien classifi-
cation. Retrospective analysis of prospectively collected
data was performed. Chi-square analysis and Fisher
test were used for statistical analysis.
Results: Late surgical procedures included abdominal
wall surgery in 101 cases (54%), bilioenteric anastomo-
sis in 44 cases (24%), intestinal surgery in 23 cases
(12%), liver surgery in 6 cases (3%), others in 7 cases
(4%). Late surgical procedures were classified as major
in 64 cases (35%) and minor in 117 cases (65%). Emer-
gency surgery was required in 19 cases (11%), while
elective surgery was performed in 162 cases (89%). The
overall postoperative morbidity and mortality were
29% (54/181 cases) and 1.1% (2/181 cases), respec-
tively. According to Dindo-Clavien classification the
commonest late surgical procedure was classified as
grade III (46%), followed by grade II (40%). Morbid-
ity was 36% (23/64) in major procedures, while it was
20% (24/117) in minor procedures (p = 0.02). Morbid-
ity was 31% (6/19) in emergency surgery, while it was
29% (48/162) in elective surgery (p = ns). Overall mor-
tality in late surgery after liver transplantation con-
cerned patients underwent major and emergency
surgical procedures (p = 0.02).
Conclusions: Late surgical procedures after liver trans-
plantation are associated with a significantly higher risk
of morbidity in patients underwent major and emer-
gency surgical procedures.
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FO20-08
USEFULNESS OF PIVKA-II AFTER
LIVING DONOR LIVER
TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
Min-Su Park, Kwang-woong Lee, Suk-Won Suh,
Tae You, YoungRok Choi, Nam-Joon Yi and
Kyung-Suk Suh
Seoul National University Hospital, Korea
Introduction: a-Fetoprotein (AFP) and prothrombin
induced by the absence of vitamin K or antagonist-II
(PIVKA-II) are useful tumor markers for hepatocellu-
lar carcinoma (HCC). However, little is known about
the clinical characteristics and prognosis of HCC with
different levels of AFP and PIVKA-II. We evaluated
the clinical value of perioperative AFP and PIVKA-II
levels in predicting HCC recurrence after living donor
liver transplantation (LDLT).
Method: One hundred twenty patients who were to
receive LDLT for HCC from February 1999 to Decem-
ber 2010 and whose serum AFP and PIVKA-II had
been measured sequentially before and after LDLT
were included in this study. Patients were classified into
four groups according to the level of AFP and PIVKA-
II [Group I, normal AFP (<20 ng/mL) and PIVKA-II
(<40 mAU/mL); Group II, elevated AFP and; Group
III, elevated PIVKA-II; Group IV, elevated both AFP
and PIVKA-II].
Results: Recurrence occurred in 27 cases (22.5%). The
mean value of AFP and PIVKA-II at initial diagnosis
was 3,256.7 ng/mL and 1,194.0 mAU/mL. Pre-operative
PIVKA-II level tended to increase with increasing tumor
size, number of nodule, presence microvascular invasion
and poor differentiation. Group III and IV including ele-
vated PIVKA-II showed higher recurrence rates
(p = 0.000). Elevated PIVKA-II level was the first sign
of recurrence after LDLT even if the level of PIVKA-II
before LDLT was not high (62.5%). In 8 patients with
preoperative normal PIVKA-II level, 87.5% patients
showed elevated PIVKA-II level at recurrence. However,
a transient increase in PIVKA-II levels without evidence
of recurrence was observed in 14 patients; biliary
obstruction (n = 9), unknown (n = 5).
Conclusions: Frequent measurement of PIVKA-II may
be a useful follow-up marker for detecting HCC recur-
rence after LDLT.
FO20-09
OUTFLOW RECONSTRUCTION USING
NATIVE LIVER VEINS: EXPERIENCE IN
210 CASES
Hossam Eldeen Soliman1, Tarek Ibrahim1, Osama
Hegazy1, Hany Shoreim1, Sherif Saleh1, Taha Yasse1,
Khaled Abuelella1, Khaled Yassen2 and
Ibrahim Marwan1
1National Liver Istitute, Egypt; 2National Liver
Institute, Menoufia University, Egypt
Introduction: Living donor liver transplantation is a
good alternative in areas without cadaveric transplants.
Variation of the hepatic veins and portal vein are
important factor in determining suitability of grafts for
living donation especially as regard donor safety and
difficulty in outflow reconstruction due to the lack of
suitable vein grafts. We present our experience in vas-
cular reconstruction of living donor transplants using
vein grafts harvested from the native liver of the recipi-
ent in Rt lobe grafts harvesting.
Method: We had performed 210 living donor liver
transplantation by the transplant team of the depart-
ment of Surgery, National Liver institute, Menoufia
University starting from 28th of April 2003 to the end
of August 2013. They were 33 pediatric patients and
177 adult patients. We reviewed the preoperative
patient’s data, graft characteristics, operative data,
postoperative details including hospital stay, the in-hos-
pital complications and early follow. Accordingly, we
excluded 44 patients with tumors and 13 patients with
portal vein thrombosis.
Results: In right lobe grafts we used vein grafts in 46
out of 120 patients. We tried to minimize the number
of hepatic veins to a maximum of two anastomsies by
this technique. Long grafts were obtained from the por-
tal system and the hepatic veins in reconstruction of V5
and or V8 in 38 cases, middle hepatic vein in 5 cases,
multiple inferior hepatic vein in 3 cases and anterior
patch for the right hepatic vein in 16 cases. In ten cases
these grafts were thrombosed postoperatively but the
rest were completely functioning.
Conclusions: The native liver of the recipient can be used
a source for vein grafts in living donor liver transplants
in absence of portal vein thrombosis and malignancy
FO20-10
CLASS II HLA ANTIBODIES CAN
AFFECT GRAFT OUTCOMES IN LIVING
DONOR LIVER TRANSPLANTATION
Jung Jun Lee, Dong Jin Joo, Myoung Soo Kim,
Su Hyung Lee, A-Lan Lee, Jin Sub Choi,
Gi Hong Choi and Soon Il Kim
Yonsei University College of Medicine, Korea
Introduction: Highly-sensitized organ recipients are at
greater risk of acute rejection, vascular complications,
and poor graft survival. Preformed circulating anti-
HLA antibodies immunologically challenge vascular
endothelium and the bile duct. This study was under-
taken to analyze the outcomes of adult living donor
liver transplantation (LDLT) according to the pre-
transplant panel reactive antibody (PRA).
Method: We retrospectively reviewed 219 LDLT
patients’ records treated at our center between June
2006 and August 2012. We divided all recipients into
three groups; PRA<10%, PRA 10–30%, and PRA
≥30% in HLA class I and II.
Results: Of the 219 patients, class I PRAs <10% were
detected in 160 recipients, 10–29% in 19, and ≥30% in
31. Class II PRA <10% were detected in 192 recipients,
10–29% in 9, and ≥30% in 18. Of the recipients, 32
(14.6%) were donor specific antibody (DSA) + and 187
(85.4%) were DSA. Class I DSAs were present in 18
patients, class II in seven patients, and both in seven
patients. No differences were observed in donor sex or
age, relation, recipient age, or model for end stage liver
disease score in patients with or without DSAs. There
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary Association HPB 2014, 16 (Suppl. 2), 128–187
194 Free Oral
were no significant differences in graft survival rates
with or without DSA. However, the recipients with
multiple DSAs tended to have more acute rejection epi-
sodes and events of biliary stricture, and lower graft
survival rates than did patients in the DSA group.
No significant differences in graft survival rates were
found among the PRA percentage groups according to
the PRA class I and II. However, class II showed more
intervals among the groups.
Conclusions: In LDLT, the highly-sensitized recipient
to class II HLAs can affect poor graft survival. Further
large cohort study is necessary for confirming and ana-
lyzing this phenomenon.
FO20-11
SIMPLE AND SAFE ABO
INCOMPATIBLE ADULT-TO-ADULT
LIVING DONOR LIVER
TRANSPLANTATION PROTOCOL
Toru Ikegami, Ken Shirabe, Yuji Soejima,
Tomoharu Yoshizumi, Hideaki Uchiyama,
Yo-ichi Yamashita, Takeo Toshima and
Yoshihiko Maehara
Kyushu University, Japan
Introduction: The introduction of Rituximab has dra-
matically pushed down the hurdle of ABO incompati-
ble living donor liver transplantation (ABOi-LDLT).
Kyushu University is the first institute, which aban-
doned graft local infusion treatment and introduced
Rituximab-based simple protocol.
Method: Four hundred and eight adult LDLT recipi-
ents, including ABOi-LDLT (n = 19) and Non-ABOi-
LDLT (n = 389) recipients, were reviewd. The current
ABOi-LDLT protocol in our institute s pre-transplant
Rituximab and Plasma exchange (PE) based one.
Results: In ABOi-LDLT cases (n = 19), median isoag-
glutinin titer before PEs, at LDLT and after LDLT
(max) was x256, x32 and x32, respectively. Rituximab
was given at 21.8  6.1 days before LDLT and PE was
performed 3.7  1.6 times. We abandoned local infu-
sion treatment after the initial 3 cases, resulting in no
such treatment in the following 16 cases. Rescue or
prophylactic high-dose intravenous immunoglobulin
(IVIG, 0.6 g/kg/day) was given for 6 cases in total.
Among them, the initial 4 cases were given IVIG for
prophylaxis, and the other 2 cases were for possible
AMR. The recipient and donor backgrounds, including
primary disease, age, MELD score, graft type and graft
volume, were not different between ABOi-LDLTs and
Non-ABOi-LDLTs. Although ABOi-LDLTs had
increased rate of splenectomy (89.4% vs. 44.9%,
p < 0.001) and lower portal venous pressure at the end
of surgery (13.8  2.3 mmHg vs. 16.9  4.4 mmHg,
p = 0.003), other operative factors including graft ische-
mic time, operative time and blood loss were not differ-
ent between the groups. Although ABOi-LDLTs had
increased incidence of cytomegalovirus infection
(52.6% vs. 23.2%, p = 0.003), other post-transplant
complications including bacterial sepsis and acute rejec-
tion were not different between the groups. The 5-year
graft survival rate was 87.9% in ABOi-LDLTs and
80.4% in non-ABOi-LDLTs (p = 0.373).
Conclusions: ABOi-LDLT could be safely performed
under Rituximab-based protocol without the use of
local infusion.
FO20-12
SINGLE CENTER MULTIMODAL
TREATMENT OF HEPATOCELLULAR
CARCINOMA, 10 YEARS OF
EXPERIENCE
Cataldo Doria, Edward Podgorski and Edith Mitchell
Thomas Jefferson University Hospital, USA
Introduction: HCC is the fifth most lethal cancer in
North America. This is a single center retrospective
review, from 2003 to 2013, of patients diagnosed with
HCC undergoing TACE, ablations, radio-sphere treat-
ments, systemic chemotherapy, liver resection and
transplantation alone or in combination.
Method: Three hundred ninety nine patients who under-
went liver transplantation were reviewed. A treatment
algorithm, which will be discussed at the presentation,
was developed. The objective was to downstage patients
into Milan criteria. Demographics, baseline disease,
presence of liver cirrhosis at diagnosis, Child and MELD
scores, location of the lesion/s, number of lesions, pre
transplant treatment, vascular and or neural invasion
seen at the explant, TMN before transplant and on the
explant, post-transplant immunosuppressive treatment,
post-transplant follow-up imaging, rate of recurrence
after transplant, rejection rates, donors characteristics,
pre-implantation biopsy results, surgical technique used,
donor and recipients serology, hepatitis treatment pre
and post transplant, chemistry, were all reviewed and
analyzed. The details of the statistical analysis will be dis-
cussed at the time of presentation.
Results: Our patients and graft survival are comparable
to the ones currently available in the medical literature.
However, our study identified a cohort of patients who
were at higher risk of recurrence because of HCC fea-
tures at presentation and/or at the explant.
Conclusions: Our study shows that HCC pre transplant
treatments are not curative. However, they are essential
in increasing the number of patients eligible for trans-
plant. We have developed a more aggressive treatment for
patients presenting high risk features for recurrence. Our
novel HCC adjuvant treatment has shown to be effective
in improving disease free survival in patients with high
risk HCC who underwent liver transplantation.
FO21-01
VALIDATION OF THE SELECTION
CRITERIA FOR SAFE HEPATECTOMY
FOR HEPATOCELLULAR CARCINOMA:
ANALYSIS OF 312 CONSECUTIVE
HEPATECTOMIES
Matteo Donadon, Fabio Procopio, Matteo Cimino,
Guido Costa, Daniele Del Fabbro, Angela Palmisano,
Andrea Gatti and Guido Torzilli
Humanitas Clinical and Research Center, Italy
Introduction: Hepatectomy is the treatment of choice in
patients with hepatocellular carcinoma (HCC), and the
© 2014 The Authors
HPB 2014, 16 (Suppl. 2), 128–187 HPB © 2014 Americas Hepato-Pancreato-Biliary Association
Free Oral 195
estimation of functional liver reserve is the stronghold
to achieve good results. The aim of this study was the
validation of the selection criteria for safe hepatectomy
for HCC.
Method: Clinical, pathological and short-term data
were reviewed in a prospective cohort of patients who
underwent hepatic resection between 2004 and 2013.
All consecutive patients were submitted to hepatectomy
based on the same selection criteria, which included the
value of bilirubin (BIL), the value of cholinesterases
(CHE), the presence of ascites, the presence of esopha-
geal varices, and the rate of residual liver volume. Uni-
variate and multivariate analyses were performed.
Results: A total of 312 patients were analyzed. One
hundred three patients (33%) had thoracoabdominal
approach, but only 36 (12%) had major or extended
resections. The median tumor number was 1 (range 1–
33), while the median tumor size was 4.5 cm (range
0.8–28). BCLC classes resulted 0-A in 53%, B in 25%,
and C in 22%. Of those patients, 94 (29%) had postop-
erative complications, of which 6% were graded as
major (Dindo>IIIa). The 30- and 90-days mortality
were 1.2% and 1.8%, respectively. The MELD, APRI,
and CPT score were tested. None of these score were
found to be statistically significant at the logistic regres-
sion analysis, while the use of the combination of BIL
>1 and CHE ≤5.900 was the best combination to detect
complications (p = 0.007), and specifically liver-related
complications such as ascites (p = 0.000).
Conclusions: This study shows that our selection crite-
ria that counts mainly on two simple, fast, and cheap
parameters, BIL and CHE, leads to identify patients
potentially at risk of postoperative complications after
hepatic resection for HCC.
FO21-02
SURGICAL OUTCOME OF HCC
GREATER THAN 10 CM: SINGLE-
CENTER EXPERIENCE OF 471 CASES
Shin Hwang, Sung-Gyu Lee, Young-Joo Lee,
Ki-Hun Kim, Kwang-Min Park, Chul-Soo Ahn and
Deok-Bog Moon
Asan Medical Center, Ulsan University, Korea
Introduction: Tumor recurrence is common after hepa-
tic resection of hepatocellular carcinoma (HCC) greater
than 10 cm in diameter. This study evaluated the out-
come of patients with such large HCC after primary
resection and treatment of recurrent lesions.
Method: A retrospective review was undertaken of clin-
ical data for 471 patients with huge HCC who under-
went liver resection from January 2000 to April 2012 in
Asan Medical Center.
Results: Underlying liver diseases were hepatitis B in
79%, hepatitis C in 2%, alcoholic liver disease in 8%,
and others in 11% Mean tumor diameter was
13.3  3.0 cm (range: 10–26 cm); mean tumor volume
was 618  400 mL; 93% were single lesions. System-
atic and non-systematic resections were performed in
91% and 9% of patients respectively, with tumor-free
resection was achieved in 89%. Satellite nodules were
detected in 17%. Micro- and macrovascular invasions
were identified in 56% and 10%, respectively. More
than 90% patients with recurrence underwent active
tumor treatment. Multivariate analysis revealed that
presence of satellite nodules, poor tumor differentiation
and microvascular invasion were independent risk fac-
tors for patient survival. Extensive tumor necrosis >
90% after preoperative transarterial chemoembolization
and increased uptake on PET scan did not become sig-
nificant progrnostic factors. Overall 1-, 3-, 5- and 10-
year survival rates were 69%, 47%, 36% and 19%,
respectively. Perioperative mortality rate within postop-
erative 3 months was 1.5%.
Conclusions: In patients with large HCC >10 cm, hepa-
tic resection combined with active treatment for recur-
rence resulted in longer-term survival. Frequent
protocol-based follow-up appears to be beneficial for
the early detection and timely treatment of recurrence.
FO21-03
ENUCLEATION VERSUS ANATOMICAL
RESECTION IN THE SURGICAL
TREATMENT OF HEPATIC
HEMANGIOMAS – A REPORT FROM
20 YEARS EXPERIENCE
Muthukumarassamy Rajakannu1, Rene Adam1, Gerard
Pascal1, Jean Yves Mabrut2, Vikram Karam1, Chritian
Ducerf2 and Jacques Baulieux2
1Hopital Paul Brousse, France; 2Hopital Croix Rousse,
France
Introduction: Management of the most common pri-
mary tumor the liver, hemangioma, is still controver-
sial. Surgery is usually indicated for the symptomatic
and complicated ones. Enucleation is considered as the
technique of choice as it is associated with lower mor-
bidity and better conservation of normal liver paren-
chyma. In this study we compare the three techniques
of resection namely partial hepatectomy, enucleation
and anatomical resection.
Method: Sixty-one adult patients operated for hepatic
hemangioma were identified from the prospectively
maintained computer database from two specialized he-
patobiliary centers in France. 21 patients had under-
gone enucleation (E), 32 have had anatomical resection
(AR) and 7 had partial hepatectomy (PH). Patients
who had liver transplant were excluded from the analy-
sis. These three groups were compared with respect to
the patient demographics, operative parameters, and
peri-operative outcomes.
Results: Patient age, gender and distribution of heman-
gioma in the liver were similar between the three
groups. Size of the hemangioma is smaller in PH and
lager in E when compared to AR. perative variables
like operation time, type and duration of vascular con-
trol, blood loss and transfusion, and hospital stay were
all comparable. Mortality was seen in the E and AR
groups. No significant difference was observed in the
postoperative complication. High-risk hepatectomy,
vascular exclusion of liver, operation time >4 hours
and blood loss >1.45 L were identified as risk for major
complications.
Conclusions: Evaluating the experience of two special-
ized centers over a period of 20 years shows that the
two operative techniques yield similar results. The
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selection bias could explain the presumed benefit of the
enucleation in the literature. Appropriate choice of
technique should be done based on the site and size of
the hemangioma. Prospective controlled study needs to
be done to compare the two operative techniques.
FO21-04
HEPATIC RESECTION AND
PROGNOSIS FOR PATIENTS WITH
SINGLE HEPATOCELLULAR
CARCINOMA LARGER THAN 5 CM
Yong Hoon Kim, Koo Jeong Kang, Keun Soo Ahn,
Tae Jun Park and Tae Jin Lim
Kyemyung University Dongsan Hospital, Korea
Introduction: This study aims to determine the clinico-
pathological factors that influence the prognosis of
hepatic resection for single hepatocellular carcinoma
(HCC) larger than 5 cm.
Method: Of the 340 surgically resected HCCs, 103
patients (30.6%) were single HCC larger than 5 cm.
Clinical features and factors influencing the outcome of
these patients were retrospectively analyzed.
Results: 55 (53.4%) of the patients underwent major
anatomical resection, 26 (25.2%) patients underwent
sectionectomy and 22 (21.3%) patients received nonan-
atomical tumorectomy. Perioperative morbidity was
observed in 23 patients (22.3%) and 2 patients resulted
in a postoperative mortality (1.9%). The disease free
survival and overall survival rate at 5 years was 21.5%
and 46.4% respectively. Outcome was not significantly
different between HCC smaller than 10 cm (5–10 cm
sized) and that of larger than 10 cm. (p = 0.231 for dis-
ease free survival and p = 0.085 for overall survival)
Multivariate analysis showed that the presence of
microvascular invasion was the independent factor of
worse outcome of disease free and overall survival rates
in single HCC larger than 5 cm.
Conclusions: Hepatic resection is safe and is the pre-
ferred treatment for single HCC larger than 5 cm.
Long term outcome was significantly influenced by the
presence of microvascular invasion. However, larger
than 10 cm sized HCC showed not worse prognosis
compare to HCC between 5 and 10 cm sized.
FO21-05
EXTENSION OF THE CONCEPT OF
SALVAGE TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
PATIENTS WHO UNDERWENT LIVER
RESECTION
Francesco Tuci, Alessandro Vitale, Domenico Bassi,
Enrico Gringeri, Francesco D’Amico, Daniele Neri,
Riccardo Boetto, Francesco Enrico D’Amico,
Giacomo Zanus and Umberto Cillo
Chirurgia Epatobiliare e Trapianto Epatico, Italy
Introduction: Liver resection for hepatocellular carci-
noma (HCC) can be used both for patients suitable for
liver transplantation (LT) as first-line therapy (FLT)
and for non-transplantable patients beyond Milan crite-
ria) with a goal of downstaging (DW).
Method: The aim of this study is to compare the inten-
tion-to-treat survival rates of patients who are listed for
LT, according to these two strategies. We analyzed a
prospective database of 407 consecutive patients who
underwent hepatic resection for HCC from 2000 to
2011 to identify patients on the waiting list with tumor
recurrence.
Results: The study group consists of 42 patients (med-
ian age 59 years, 66% of HCV-positive, median MELD
9, median AFP 22), 28 in the FLT group (BCLC A)
and 14 in the DW (BCLC BC). The 5-year intention-
to-treat survival rate was comparable for the two
groups, being 64% for FLT and 60% for DW
(p > 0.05). Of the 25 patients (15 FLT and 10 DW)
who underwent transplantation (17 are still on the
waiting list for HCC with complete or partial response
to bridge therapies), 7 had tumor recurrence, 4 in the
FLT group (27%) and 3 in the DW group (30%).
Conclusions: Intention-to-treat survival rates are com-
parable to those seen in literature. The risk of HCC
recurrence seems higher and this is explained by the
center policy (LT only for stable HCC or progressive
HCC). Hepatic resection is an efficient therapy both as
an alternative to transplantation and as a downstaging
strategy for intermediate-advanced HCC.
FO21-06
SURGICAL MANAGEMENT OF
PATIENTS WITH HEPATOCELLULAR
CARCINOMA BEYOND BCLC
RECOMMENDATION AND SURVIVAL
ANALYSIS A SINGLE CENTER
EXPERIENCE IN CHINA
Yefan Zhang, Tao Yan, Hong Zhao, Xinyu Bi,
Zhen Huang, Cong Li, Yuan Li and Jianqiang Cai
Cancer Institute and Hospital, Chinese Academy of
Medical Sciences, China
Introduction: BCLC staging is commonly used in the
treatment of hepatocellular carcinoma (HCC). How-
ever, there are few studies about the surgical manage-
ments of HCC patients beyond BCLC
recommendation. In this study, we intend to analyze
the prognosis and risk factors of the patients with
BCLC B or C stage after hepatectomy.
Method: 908 HCC patients who underwent surgical
management in Cancer Institute & Hospital, Chinese
Academy of Medical Sciences from 1999 to 2011 were
included. Survival analysis was performed to evaluate
the overall survival (OS) and disease-free survival
(DFS).
Results: There were 149 cases with BCLC stage B or
C in beyond BCLC group and 759 cases with stage A
in control group. Both the median OS and DFS of
beyond BCLC group were significantly shorter than
the control group (OS: 26 months vs. 83 months;
DFS: 12 months vs. 46 months). Survival analysis
showed that in beyond BCLC group OS was signifi-
cantly associated with solitary mass, extrahepatic
spread, vascular invasion and performance status and
DFS was associated with extrahepatic spread. We fur-
ther divided the beyond BCLC cases into two groups
according to the risk factors and for the high-risk
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group, the median OS was 21 months, and 1-, 3-, 5-
year OS were 45%, 18% and 8%; the median DFS
was 8 months, and 1-, 3-, 5-year DFS were 26%,
16% and 8%. Both were significantly shorter than the
low-risk group (the median OS was 54 months, and 1-,
3-, 5-year OS were 69%, 54% and 27%; the median
DFS was 14 months, and 1-, 3-, 5-year DFS were
41%, 38% and 24%), Large tumor size was more com-
monly seen in high-risk group.
Conclusions: On condition that the operation indica-
tion is strictly grasped, surgical management of HCC
with BCLC stage B or C could bring favorable survival
benefits.
FO21-07
THE TREATMENT STRATEGY FOR
ADVANCED HCC USING SORAFENIB
COMBINED WITH SURGICAL
RESECTION
Yusuke Arakawa, Mitsuo Shimada, Shuichi Iwahashi,
Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto,
Yuji Morine, Satoru Imura, Tohru Utsunomiya and
Hidenori Miyake
The University of Tokushima Graduate School, Japan
Introduction: Sorafenib is one of the standard therapy
for advanced and unresectable HCC. However, its utili-
zation as neoadjuvant therapy to convert complete
resection has not been established. We herein report
our result of new treatment option using sorafenib and
the cases which allowed surgical resection in the
patients with advanced HCC.
Method: Twenty-five adult patients with advanced
HCC were enrolled in this study. Sorafenib therapy
was initiated with dosage of 400 mg orally, twice a
day. One week later, its dosage was increased to
800 mg/day for patient safety. The effect of sorafenib
for HCC was evaluated by modified RECIST after
three months administration of sorafenib.
Results: The median treatment period was 112 days.
The incidence of hand-foot syndrome was 44%. The
1-year overall survival rate was 55%. The rate of par-
tial response according to mRECIST was 8% (only
two patients) and the rate of stable disease was 40%.
These two patients were converted to the surgical
resection. (Case 1) 60-year old male with huge HCC
underwent initial right hepatectomy. Lung and lymph
node metastasis occurred. Sorafenib was administered
during 29 months, and metastatic lesions were
disappeared. Intrahepatic metastasis still remained;
therefore, hepatic resection was performed. (Case 2)
50-year old male with huge HCC in the right lobe of
the liver had standard sorafenib therapy. Size decrease
of main tumor, disappearance of intrahepatic metasta-
sis and normalization of AFP allowed curative right
lobectomy. Those patients are alive without any
recurrence.
Conclusions: The therapy using sorafenib combined
with surgical resection is safe and feasible option in
advanced HCC patients. Sorafenib can be considered
as neoadjuvant chemotherapy for unresectable HCC in
limited cases.
FO21-08
LAPAROSCOPIC VS. OPEN LIVER
RESECTION FOR HEPATOCELLULAR
CARCINOMA ON CIRRHOTIC LIVER:
A CASE-CONTROL STUDY
Riccardo Memeo, Nicola De’Angelis, Gerard Pascal,
Chady Salloum, Philippe Compagnon, Alexis Laurent
and Daniel Azoulay
Hopital Henri Mondor, France
Introduction: Laparoscopic liver resection is considered
a safe and feasible alternative to open surgery for
malignant liver lesions. However, laparoscopic surgery
in cirrhotic patients remains challenging. The aim of
this retrospective case-control study was to compare
morbidity, mortality and long-term patients’ survival
between laparoscopic (LLR) and open (OLR) liver
resections for hepatocellular carcinoma (HCC) in
patients with histologically proven cirrhosis.
Method: Forty-five patients treated with LLR (mean
age of 62 years; range 34–75) were matched by cause of
cirrhosis, Child-Pugh score, type of surgical resection,
tumour number, tumour size, value of alpha-fetopro-
tein with 45 patients treated with OLR (mean age of
60 years; range 43–80). Pre-, intra- and post-operative
variables were compared between groups. The mean
follow-up was 47.7  7.7 months.
Results: Overall, hepatic resections were represented by
bisegmentectomies (33%), unisegmentectomies (29%),
and non anatomical resections (38%). Compared to
OLR, the LLR group showed a significantly shorter
operative time (median duration of 140 minutes vs.
180 minutes; p = 0.02), shorter hospital stay (median
duration of 7 days vs. 12 days; p < 0.0001), and lower
postoperative complications rate (20% vs. 45% of
patients; p = 0.01). Moreover, a higher rate of R0
resection was observed in LLR group compared with
the OLR group (95% vs. 85%; p = 0.03). Postoperative
mortality, overall and disease-free survival rates were
similar between groups. One-year, 5-years and 10 years
survival rates were respectively 88%, 59% and 12% in
the LLR group, and 63%, 44% and 22% in the ORL
group (p = 0.27).
Conclusions: LLR and OLR have similar overall and
disease-free survival rates in cirrhotic HCC patients.
However, significantly shorter operative time, better
resection margins, lower postoperative complications,
and shorter hospital stay were noted in the LLR group.
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FO22-01
THE SPECIFIC GENES RELATED TO
THE INVASION PROCESS IN
PANCREATIC CANCER, AS
DEMONSTRATED BY GENOME-WIDE
EXPRESSION PROFILING – THE ROLE
OF MUC16 AND MESOTHELIN
Atsushi Shimizu, Seiko Hirono, Masaji Tani,
Manabu Kawai, Ken-ichi Okada, Motoki Miyazawa,
Yuji Kitahata and Hiroki Yamaue
Wakayama Medical University, Japan
Introduction: The invasion process is the most crucial
step for PDAC. However, genes associated with inva-
sion of PDAC remain unclear. We used genome-wide
expression profiling in an attempt to identify the spe-
cific genes that are differentially expressed between
infiltrating cancer cells and pancreatic intraepithelial
neoplasms(PanIN)-3 cells in patients with pancreatic
ductal adenocarcinoma (PDAC).
Method: We performed expression profiling using
Human Genome U133 Plus 2.0 GeneChips. Microarray
data of 5 pairs of RNA samples with infiltrating com-
ponents were compared to PanIN-3 cells, which were
harvested from the same PDAC patients. Among the
genes identified by expression profiling, immunohisto-
chemical, coimmunoprecipitation, and invasion analy-
ses of MUC16 and mesothelin were performed to
confirm the biologic significance of these molecules for
patients with PDAC.
Results: A total of 109 genes were differentially
expressed between infiltrating components and PanIN-
3. These included 87 genes that were up-regulated and
22 genes that were down-regulated in the infiltrating
cancer. Immunohistochemical analysis revealed that
MUC16 and mesothelin were expressed only in infil-
trating cancer cells and not in PanIN-3 cells or normal
pancreatic epithelial cells. Immunoprecipitation assay
indicated that MUC16 and mesothelin can bind in
PDAC. The down-regulation of MUC16 by short hair-
pin RNA and the blockage of MUC16 binding to mes-
othelin by antibody inhibited both invasion and
migration of pancreatic cancer cell lines. MUC16 high/
mesothelin high expression in PDAC was an indepen-
dent factor predicting shorter survival.
Conclusions: We identified two specific genes, MUC16
and mesothelin, that are associated with the invasion
process in patients with PDAC.
FO22-02
COMPREHENSIVE ANALYSIS OF
MIRNA EXPRESSION SIGNATURES
ASSOCIATED WITH PANCREATIC
DUCTAL ADENOCARCINOMA USING
MICROARRAY AND SEQUENCING
Junghyun Namkung1, Yongkang Kim2, Wooil Kwon3,
Yongwhan Choi1, Selyeong Lee2, Minsoek Kwon2,
Dongyoon Park1, Sun Whe Kim3, Jin-young Jang3 and
Taesung Park2
1SK Telecom, Healthcare Group, Korea; 2Seoul National
University, Korea; 3Seoul National University College of
Medicine, Korea
Introduction: Altered pattern of miRNA expression is
a typical feature of many cancers. Pancreatic ductal
adenocarcinoma (PDAC) is one of the most lethal can-
cers with little improvement in the mortality rate for
decades. Analysis of miRNA deregulations may be
helpful for elucidating the mechanism of tumorigenesis
that gives clues to discover effective therapeutics. In
addition, this could provide a list of candidate biomar-
kers for early detection or prognosis of PDAC patients.
Microarray and massively parallel sequencing (MPS)
are technologies popularly used for gene expression
profiling. Since the MPS enables the analysis of expres-
sion patterns and mutations simultaneously, we applied
the MPS for the validation of microarray results and
mutations of miRNA sequences were also analyzed.
Method: We have obtained expression profiles of 1,733
miRNAs using microarray for 105 tumor tissues from
PDAC patients and 16 normal pancreas tissues. Differ-
ential expression was tested using SAM and elastic net
was used for modeling of multiple miRNAs and clinical
factors simultaneously. Unsupervised clustering meth-
ods were applied for cancer subtype detection and asso-
ciation of the molecular subtypes with survival time
was also analyzed. To determine biological characteris-
tics of the identified differentially expressed miRNAs,
pathway and network analyses were conducted. For
validation of the expression profiles, 10 of the 121 sam-
ples were analyzed using massively parallel sequencing.
Expression profiles and tumor specific mutations were
analyzed with the sequencing results using our custom-
built analysis pipeline.
Results: A total of 48 significantly differential
expressed miRNAs were identified. Molecular subtypes
having distinctive prognosis were also detected.
Conclusions: We have detected miRNAs deregulated in
PDAC and they could be used as candidate diagnostic
biomarkers of PDAC. The subtype analysis showed the
feasibility of miRNA profiles can be used as prognostic
markers. Further analysis is ongoing.
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FO22-03
THE PROGNOSTIC VALUE OF
STROMA IN PANCREATIC CANCER
Katherine Bever1, Elaine Bigelow1, Elizabeth Sugar2,
Rajni Sharma1, Daniel Laheru1, Christopher
Wolfgang1, Elizabeth Jaffee1, Robert Anders1, AnaDe
Jesus1 and Lei ZHENG1
1Johns Hopkins University School of Medicine, USA;
2Johns Hopkins University School of Public Health,
USA
Introduction: The overall poor prognosis of pancreatic
ductal adenocarcinoma (PDA) has been attributed both
to detection typically at a relatively advanced stage as
well as to lack of effective treatments. The majority of
PDAs are comprised of stromal compartment, with
only 10–40% of the tumor being PDA cells. Emerging
evidence suggests that targeting depletion of the stro-
mal compartment leads to an increase in the efficacy of
chemotherapeutics or lymphocytes-mediated tumor
necrosis in preclincal models of PDA. However, how
stromal components should be assessed and how the
stromal compartment determines the clinical outcome
of the PDA patients remain unknown.
Method: Eighty-eight Consecutive patients who under-
went pancreaticoduodenectomy at Johns Hopkins Hos-
pital between 1998–2004 and whose formalin-fixed
paraffin-embedded (FFPE) resected PDA blocks were
available with good tissue preservation were included in
this retrospective analysis. FFPE slides were stained for
pankeratin followed by counterstaining with aniline
blue and then scanned for quantitative analysis using
ImageScope Viewer. The stromal density was defined
as the number of blue pixels divided by the sum of blue
and brown pixels (blue staining for collagen plus brown
staining for pankeratin) in the selected tumoral area.
Results: After adjusting for margin and tumor size
>3 cm, high stromal density (≥0.8) was associated with
a decreased overall survival compared to low stromal
density (<0.8) (HR: 0.47, 95% CI: 0.28–0.76,
p = 0.0018). High stromal density in resected PDA was
significantly associated with longer disease free survival
(HR: 0.39, 95% CI: 0.23–0.67, p = 0.0003).
Conclusions: In this study, a novel method for quantifi-
cation of tumor stroma was employed by using com-
puter-based image analysis. We found that the quantity
of stroma in PDAs has a prognositic value for patients
who underwent surgical resection of their tumors.
FO22-04
COMPARISON OF MUC4 EXPRESSION
IN PRIMARY PANCREATIC CANCER
AND PAIRED LYMPH NODE
METASTASES
Daniel Ansari, Carlos Urey, Chinmay Gundewar,
Monika Posaric Bauden and Roland Andersson
Lund University, Sweden
Introduction: Mucin 4 (MUC4) is a transmembrane
glycoprotein that is expressed in pancreatic ductal ade-
nocarcinoma (PDAC), but not in normal pancreatic tis-
sue. MUC4 has a proposed role in pancreatic tumor
progression and metastasis. The purpose of this pilot
study was to investigate MUC4 expression during
PDAC metastasis by comparing the expression in the
primary tumor and paired lymph node metastases from
the same patient.
Method: Surgical specimens from cases of primary
PDAC and paired lymph node metastases were immu-
nohistochemically analyzed for MUC4 expression. The
modified histochemical score (H-score) was used for
staining assessment.
Results: Positive staining for MUC4 was detected in
most primary and metastatic PDAC tumors (15/17 vs.
14/17). The concordance for MUC4 expression in pri-
mary tumors and corresponding lymph node metastases
was 82%. In two cases, the primary tumor was MUC4-
positive and the lymph node metastases were negative,
while in one patient with a MUC4-negative primary
tumor, the lymph node metastasis was positive. The
distribution of H-score for expression of MUC4 signifi-
cantly correlated (r = 0.615; p = 0.009) between pri-
mary tumors and paired metastatic lesions.
Conclusions: MUC4 was observed in both primary and
matched metastatic tumors with a high level of concor-
dance, suggesting that MUC4 expression is retained
following PDAC metastasis.
FO22-05
TOTAL MESOPANCREAS EXCISION
(TMPE) IN PANCREATIC TUMORS
Yingbin Liu
Xinhua Hospital, School of Medicine, Shanghai Jiaotong
University, China
Introduction: None R0 resections was frequently
related to an inadequate posterior clearance that
remain one of the main reasons for tumour recurrence.
The aim of this study was to report a standardized
method that ensures posterior clearance with Total
Mesopancreas Excision (TMpE).
Method: Our procedure consisted in a posterior
approach with cranio-caudal dissection at the origin of
the celiac trunk and inferior mesenteric artery all along
their right semi-circumference. This allowed a complete
clearance of retro pancreatic tissues with safe control
of pancreaticoduodenal arteries at their origin.
Results: 92 consecutive pancreatic resections with
TMpE were performed. 25 cases were associated to
vascular resection. Pathology revealed an adenocarci-
noma of the pancreatic duct, distal bile duct, periam-
pullary and neuroendocrine carcinoma. Mesopancreas
was invaded by cancer in 56 cases. Applying the Inter-
national Union Against Cancer criteria, an R0 resec-
tion was thus achieved in 76 patients.
Conclusions: Our procedure is feasible and safe in expe-
rienced hand. It is a description of a standardized
method for TMpE that clearly shows an advantage in
improving posterior clearance and R0 resection.
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FO22-06
EXTENDED PANCREATECTOMIES
AFTER NEOADJUVANT
CHEMOTHERAPY FOR LOCALLY
ADVANCED PANCREATIC
ADENOCARCINOMA: ANALYSIS OF
POSTOPERATIVE, PATHOLOGIC AND
SURVIVAL OUTCOMES
Pietro Addeo, Edoardo Rosso, Elie Oussoultzoglou,
Serena Langella, VitoDe Blasi, Gael Simone and
Philippe Bachellier
Hepato-Pancreato-Biliary Surgery and Liver
Transplantation, France
Introduction: Up to 40% of patients with newly diag-
nosed pancreatic cancer present with a locally advanced
disease. Since this category of patients is currently con-
sidered as unresectable, the benefits of surgery after
neoadjuvant treatment remains poorly investigated.The
aim of this prospective study was to evaluate the early
and medium-term outcomes of pancreatic resection
after neoadjuvant chemotherapy for locally advanced
pancreatic adenocarcinoma (LAPA).
Method: All consecutive patients with a biopsy proven
LAPA referred to our center from January 2007 to
January 2012 were evaluated for neoadjuvant chemo-
therapy. Standardized indications for pancreatectomy
after the completion of neoadjuvant treatment were a
performance status >70 according to the Karnofsky
index, optimized comorbidities and no radiographic or
intraoperative evidence of metastatic progression. The
margin status, the histological grade of neoadjuvant
treatment effect as well as early and medium-term out-
comes were analyzed.
Results: Forty-three patients with a mean age of
60  10 years underwent surgery. All patients had
venous vascular invasion classified as Nakao B (14), C
(20), D (9). Thirty-six (83.7%) had a superior mesen-
teric artery encasement >180° and four (9.3%) preoper-
ative superior mesenteric vein thrombosis. Type of
resection performed included pancreaticoduodenectomy
(28), splenopancreatectomy (6) and total pancreatec-
tomy (9). All patients underwent an associated venous
resection and twenty (46.5%) underwent an arterial
resection. Overall mortality and morbidity were 7.5%
and 32.5%, respectively. Two patients (4.6%) had
ypT0 tumors, twelve (28%) had N0 disease and twenty
nine (67.40%) had a R0 resection. The rate of R0
resection significantly correlated with N0 status
(p = .0486). Thirty one patients (72%) received post-
operative adjuvant chemotherapy and overall median
postoperative survival was 24 months.
Conclusions: In LAPA R0 resection can be achieved in
up to 50% of patients who undergo surgery after neo-
adjuvant chemotherapy. For these patients survival
rates are similar to those observed for initially resect-
able pancreatic cancer.
FO22-07
THE OUTCOME OF PREOPERATIVE
CHEMORADIATION THERAPY FOR
PANCREATIC CANCER
Yusuke Kyoden, Noriyuki Ooba,
Masaya Watanabe, Shinsuke Satou, Ko Oohata and
Masakazu Takagi
Shizuoka general hospital, Japan
Introduction: It is well known that invasive ductal pan-
creatic cancer has a poor prognosis. Preoperative
chemoradiation therapy is expected to be a promising
treatment. We herein report the outcome of preopera-
tive chemoradiation therapy for invasive ductal pancre-
atic cancer in our institution.
Method: From November 2001 to January 2013, we
have performed pancreatectomy for invasive ductal ade-
nocarcinoma of the pancreas in 127 patients. 59 patients
(33 men and 26 women) received preoperative chemora-
diation therapy and were enrolled in this study.
Results: Radiation therapy was delivered to a total
dose of 30 Gy, in 10 fractions over a period of 10 days.
Gemcitabine was given in 56 patients and TS-1 was
given in three patients.
The 59 study patients had a median age 69 years (range
45–84 years). 40 patients underwent PD and 19 patients
underwent DP (including DP-CAR). 17 patients under-
went concomitant PV resection. No perioperative death
occurred. Six patients underwent re-lapartomy for in-
traabdominal abscess and one patient underwent re-
laparotomy for bleeding. Median overall survival was
21 months. The-3 year and 5 year survival rate were 38
and 21% respectively. In multivariate analysis, lymph
node metastasis was significant prognostic factor.
Conclusions: Preoperative chemoradiation therapy is
safe without grave complication. Its outcome was
acceptable, however, more improvement need to be
done to obtain a better prognosis.
FO22-08
PROGNOSTIC FACTORS FOR
SURVIVAL AFTER RESECTION IN
PATIENTS WITH PANCREATIC
DUCTAL ADENOCARCINOMA
Johanna Tol, Wietse Eshuis, ThomasVan Gulik,
Olivier Busch and Dirk Gouma
Academic Medical Center Amsterdam, The Netherlands
Introduction: Survival in patients with pancreatic ductal
adenocarcinoma (PDAC) remains dismal. Several stud-
ies have been published on factors associated with sur-
vival in patients after surgery. The impact of perineural
invasion or angioinvasion is still under discussion; fur-
thermore studies suffer from incomplete follow up on
actual survival. In this study we aimed to analyze the
actual survival of patients with PDAC after surgery
and report independent predictors of survival.
Method: Between 1992 and 2010, 911 consecutive
patients underwent pancreatoduodenctomy including
317 for PDAC. Clinicopathological data was prospec-
tively registered. Tumor differentiation, resection mar-
gin status (R1: 1 mm margin and R2: macroscopic
irradical), tumor and lymph node status, adjuvant ther-
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apy, perineural invasion and angioinvasion were ana-
lyzed using Cox regression. Outcomes were stated as
hazard ratio (HR) with 95% confidence interval (CI).
Results: Median survival of patients with PDAC was
18.9 months. 39 patients (12%) were alive at end of
follow up, 28 patients (9%) were actual 5-year survi-
vors. 100 patients (32%) received adjuvant therapy. In
univariate analysis tumor differentiation, resection mar-
gin, lymph node status, adjuvant therapy, perineural
invasion and angioinvasion significantly influenced sur-
vival. Cox regression model showed patients with poor
tumor differentiation (HR 2.7; 95% CI 1.5–4.7), tumor
positive resection margin R1 (HR 1.6; 95% CI 1.2–2),
R2 (HR 2.3; 95% CI 1.1–4.6) and tumor positive
lymph nodes (HR 1.5; 95% CI 1.1–2.0) had an
increased risk of dying during follow-up. Patients who
received adjuvant therapy (HR 0.8; 95% CI 0.6–0.99)
had a decreased risk of dying during follow up.
Conclusions: Median actual survival of patients with
pancreatic ductal adenocarcinoma after surgery was
18.9 months with a 5-year survival rate of 9%. Poor
tumor differentiation, R1 and R2 resection, tumor posi-
tive lymph nodes and, although not frequently adminis-
tered until 2004, adjuvant therapy were prognostic
factors for survival. Perineural invasion and angioinva-
sion were not independently associated with survival.
FO23-01
EFFICIENT LIVER REGENERATION
FOLLOWING REVERSIBLE PORTAL
VEIN EMBOLIZATION
Hadrien Tranchart, Laurence Catherine,
Panagiotis Lainas, Sophie Maitre and Ibrahim Dagher
Antoine Beclere Hospital, France
Introduction: Before major hepatectomy, a non-absorb-
able material is generally used for portal vein emboliza-
tion (PVE), as it provides effective and permanent
vascular occlusion. Our team has developed an efficient
technique of reversible PVE using gelfoam powder in
primates. The aim of this retrospective study was to
report our initial experience of reversible PVE before
major liver resection.
Method: From January 2009 to January 2013, 12
patients [4 women and 8 men, mean age: 63.8 years
(range: 53–80)] considered for extended hepatic resec-
tions underwent reversible PVE. Evaluation of po-
stembolization syndrome or hepatic insufficiency
included review of patient symptoms and laboratory
data. All patients underwent volumetric CT assessment
before and at 4 to 6 weeks after PVE. We measured
total, non-embolized and embolized liver volumes.
Results: Complete proximal and distal embolization of
the left or right portal branch was successfully carried
out in all patients. One patient underwent right PVE
and embolization of segment IV. Another patient
underwent left PVE and embolization of the right ante-
rior portal branch. A moderate leak of gelfoam powder
was noted in the contralateral branch in one patient,
with no clinical repercussions. This leak was completely
resorbed at 6 weeks. None of the patients developed
liver failure or fever. Volumetric CT assessment showed
that proximal recanalization was complete in 7 patients
while distal was complete in 6 patients. The non-embol-
ized liver volume increased from 502.4  70.5 mL
before embolization to 620.5  82.4 mL after emboli-
zation (p = 0.005). The hypertrophy ratio of the non-
embolized liver was 24.8%. Nine out of 12 patients
underwent surgery. Three patients were not amenable
to surgery because of tumour progression.
Conclusions: Reversible PVE resulted in a sufficient
hypertrophy of the non-embolized liver (25%) which
allowed to plan surgery in all patients. This non inva-
sive and efficient technique could have various clinical
applications.
FO23-02
DOES PERIOPERATIVE ANESTHETIC
MANAGEMENT PLAY A ROLE IN
MORBIDITY AFTER LIVER SURGERY?
Emilie Uldry, Takashi Kokudo, Halkic Nermin and
Demartines Nicolas
University Hospital of Lausanne, Switzerland
Introduction: The last 3 decades saw dramatical
improvement in liver surgery with extended indication
and improved outcome. However, even if mortality
decreased, morbidity remains high (30–45%). The aim
of our study was to correlate anesthesia management
and postoperative morbidity.
Method: Between 2009 and 2012, the pre-, per- and
postoperative data of 260 consecutive patients was col-
lected prospectively and analyzed retrospectively by
univariate analysis. The relation between various anes-
thetic parameters like hemodynamic status, use of epi-
dural analgesia, fluids or transfusion, and post-
operative complications was assessed.
Results: Overall complication rate (Dindo grade >2)
was 25%. Univariate statistical analysis identified intra-
operative hemodynamic instability (defined as use of
NA >10) as risk factor for post-operative surgical and
medical complications (p < 0.001), more specifically for
bilioma, thromboembolic events and liver insufficiency
(p = 0.03, 0.01 and 0.05 respectively). Total fluid bal-
ance (< or >2,000 mL) was also a significant risk factor
for postoperative surgical morbidity (overall, bilioma
and SSI (p < 0.05)) and medical morbidity related to
liver dysfunction or infectious complications. No asso-
ciation to cardiac, pulmonary, digestive or renal com-
plication was observed. Neither intraoperative central
venous pressure of >5 mmHg during liver transsection,
nor the use of epidural anesthesia did significantly
increase morbidity. However, grade of complication
was higher (p = 0.03 and 0.01 respectively). Intraopera-
tive blood transfusion was associated to higher both
surgical (p > 0.05) and medical complication
(p < 0.05). Patients with complications had a significant
longer hospital stay (p > 0.0001).
Conclusions: The analysis of our single center series of
260 liver resections allowed to identify specific anes-
thetic factors associated to postoperative morbidity.
Those were hemodynamic instability (use of NA >10),
total fluid balance >2,000 mL and blood transfusions.
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FO23-03
DIFFERENT RISK FACTORS FOR
INCISIONAL AND ORGAN/SPACE
SURGICAL SITE INFECTIONS AFTER
LIVER RESECTION
Takashi Kokudo1, Emilie Uldry2, Nicolas Demartines2
and Nermin Halkic2
1Graduate School of Medicine, The University of Tokyo,
Japan; 2University Hospital CHUV, Switzerland
Introduction: Surgical site infection (SSI) is a common
cause of major morbidity after liver resection. This
study aimed to identify risk factors for incisional and
organ/space SSIs after liver resection.
Method: Our liver surgery database was retrospectively
analyzed for patients treated between January 2009 and
November 2012 in a tertiary care Swiss hospital. Univar-
iate and multivariate analyses were conducted on preop-
erative, intraoperative, and postoperative variables to
identify risk factors for incisional and organ/space SSIs.
Results: SSI incidences were 12.8% (incisional), 4.0%
(organ/space), and 1.8% (both). Univariate analysis
showed that incisional SSIs were associated with high
American Society of Anesthesiologists (ASA) scores
(p = 0.005), preoperative anemia (p = 0.03), hypoalbu-
minemia (p = 0.02), low prothrombin time (p = 0.002),
viral or alcoholic chronic hepatitis (p = 0.02), liver cir-
rhosis (p = 0.008), and prolonged operation times
(p < 0.001). Organ/space SSIs were associated with high
rates of red blood cell transfusions (p = 0.02), concomi-
tant bowel surgery (p = 0.01), and prolonged operation
times (p = 0.02). Multivariate analysis revealed that risk
factors for incisional SSIs were anemia (odds ratio [OR]
2.81), high ASA scores (OR 2.88), presence of hepatitis
or cirrhosis (OR 5.07), and prolonged operation times
(OR 9.60). The only risk factor for organ/space SSIs
was concomitant bowel surgery (OR 5.53). Hospital
stays were similar in organ/space and incisional SSI
groups, but significantly longer for those with both
organ/space and incisional SSIs (p < 0.001).
Conclusions: Preoperative compromised conditions and
prolonged operations increased the risk of incisional
SSIs; concomitant bowel surgery increased the risk of
organ/space SSI. Specific precautions to prevent organ/
space and incisional SSIs may shorten hospital stays.
FO23-04
EXAMINING ACTUAL HEPATIC
FUNCTIONAL VOLUME USING
TECHNETIUM-99 M GALACTOSYL
SERUM ALBUMIN SCINTIGRAPHY IS
USEFUL FOR EVALUATING
INDICATION OF MAJOR
HEPATECTOMY
Atsushi Nanashima, Takafumi Abo, Junichi Arai,
Katsunori Takagi, Takashi Kudo and
Takeshi Nagayasu
Nagasaki University School of Biomedical Sciences,
Japan
Introduction: Aim of the study is to evaluate the intra-
hepatic differences of hepatic functions by the single-
photon emission computed tomography (SPECT/CT)
imaging in terms of technetium-99 m galactosyl human
serum albumin (99mTc-GSA) scintigraphy before
major hepatectomy in various conditions. To this end,
we emphasize the usefulness of hepatic functional volu-
metry by surgical records of 200 patients with hepatob-
iliary malignancies who underwent major hepatectomy.
Method: Liver functional parameters or functional vol-
ume was estimated by 99mTc-GSA scintigraphy in com-
parison with morphological volume measured by
computed tomography. In case of a large difference of
both volumes, functional volume was applied for evalu-
ating estimated resected volume of the liver. Liver uptake
ratio at 15 minutes (LHL15) of GSA scintigraphy was
also referred for our criterion of hepatic functional tests.
Results: LHL15 was correlated with the indocyanine
green retention rate at 15 minutes (ICGR15; R = 0.56,
p < 0.01); however, 16 patients (7.1%) had values out-
side this correlation. In these patients, LHL15 reflected
actual clinical status and patient outcomes more. After
applying GSA liver scintigraphy since 2004, rates of
uncontrolled ascites or hepatic failure was significantly
decreased and operative death by hepatic failure was
nil. Although morphological and functional volumes in
each hepatic segment were well correlated (R = 0.71,
p < 0.01), functional volume was decreased in the dis-
eased liver with portal vein tumor thrombus, portal
vein embolization or biliary obstruction in 30 patients.
By comparing morphological volume, the diseased
functional volume was more significantly correlated
with portal pressure, alkaline phosphatase level platelet
count and cholesterol level (p < 0.05). By measuring
functional volume or LHL15, eight patients who were
functionally borderline on the basis of the ICGR15 test
safely underwent scheduled major hepatectomy.
Conclusions: Under the ICGR15 test as the standard
for preoperative hepatic function, auxiliary application
of LHL15 and functional volumetry of GSA liver scin-
tigraphy provides useful information on patients with
hepatobiliary malignancies undergoing hepatectomy.
FO23-05
DELAYED COMPLICATIONS OF LIVER
TRAUMA – THE IMPORTANCE OF
ROUTINE FOLLOW UP IMAGING
Matthew Mortimer and Nagappan Kumar
Cardiff Liver Unit, United Kingdom
Introduction: Traumatic injury to the liver is a greatly
feared entity for the general surgeon to manage, owing
greatly to its difficult surgical access and the high per-
centage of cardiac output that runs through the liver.
Surgeons are all too aware of the immediate risk to life
caused by liver trauma, such as uncontrollable bleed-
ing, but it is often not realised by the general surgeon
that these patients can develop late complications
which potentially can be just as catastrophic as the ini-
tial injury itself. The need for follow up imaging in
patients with liver trauma is not very clear. However,
problems detected on such scans can be potentially life
threatening.
We reviewed the patients who were referred to our unit
following liver trauma, identifying those patients who
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developed complications of their injury which weren’t
apparent at the time of their initial injury.
Method: We reviewed the patients who were referred
to our unit following liver trauma, identifying those
patients who developed complications which weren’t
apparent at the time of their initial injury. We describe
these complications, and how they were subsequently
managed at our unit.
Results: Five patients were identified. Two had devel-
oped pseudoaneurysms which were managed radiologi-
cally by embolization. One patient was found to have a
biloma, which was drained radiologically followed by
ERCP They were stented with good effect. One patient
developed necrosis of the right liver, ultimately requiring
a right hepatectomy. One patient had a large bile leak.
Conclusions: Patients with traumatic liver injuries
require follow up scanning to detect delayed complica-
tions. At our unit this is typically done on day 10 in
asymptomatic patients with Grade 3 or greater liver
injury. We feel that there should be a consensus on the
need for, and appropriate timing of routine follow up
scanning
FO23-06
READMISSION AFTER HEPATIC
RESECTION AT A QUATERNARY
ACADEMIC CENTER
Gaya Spolverato, Aslam Ejaz, Donald Lucas,
Rebecca Dodson and Timothy Pawlik
Johns Hopkins Hospital, USA
Introduction: Reducing readmission has become a key
quality improvement target for policymakers. We
sought to define the incidence and identify factors asso-
ciated with readmission after hepatic resection at a qua-
ternary academic center.
Method: Readmission within 30 days of discharge after
hepatic resections between 2008 and 2012 at a major
academic center was analyzed. Modified Poisson regres-
sion with a robust variance estimator was used to cal-
culate risk ratios for readmission.
Results: Among 357 patients identified, median age
was 59 years and 184 (51.5%) were men. Indications
for surgery included colorectal cancer liver metastasis
(42.6%), non-colorectal liver metastasis (35.3%), pri-
mary hepatic tumors (17.7%), and benign disease
(2.8%). Comorbidities were common: 74.2% were ASA
class 3-4, 22.1% patients experienced unplanned weight
loss; 8.1% patients had a MELD score of >10. Opera-
tions included non-anatomic resection (69.5%), hemi-
hepatectomy (17.1%), and trisegmentectomy (12.9%).
Median length-of-stay was 5 days; 48.2% patients expe-
rienced at least one inpatient complication. Overall 30-
day readmission was 11.8% (n = 42); an additional 4
(1.1%) patients died at home within 30-days of dis-
charge. Interestingly, 41 out of the 42 readmitted
patients (97.6%) had a surgical complication prior to
readmission. Causes of readmission included abdominal
infection (40.5%), liver dysfunction (7.1%), other gas-
trointestinal complication (31.0%), venous thromboem-
bolism (7.1%), pulmonary complication (4.8%), and
other (11.9%). Median length-of-stay for the readmis-
sion was 4 days. Factors associated with readmission
included preoperative weight loss (RR-2.38, 95% CI
1.35–4.18), MELD score of >10 (RR-2.26, 95% CI
1.10–4.64), ICU length-of-stay >1 day (RR-2.02, 95%
CI 1.14–3.58), total length-of-stay >5 days (RR-2.60,
95% CI 1.39–4.83), and any inpatient complication
(RR-1.94, 95% CI 1.07–3.52) (all p < 0.05). On multi-
variable analysis, the strongest independent predictor
of readmission was length-of-stay >5 days (adjusted
RR-2.30, 95% CI 1.24–4.28, p = 0.009).
Conclusions: Readmission after hepatic resection
occurred in roughly 1 in 10 patients. Risk of readmis-
sion was associated with patient- (weight loss, MELD
score), surgical- (history of complication) and hospital-
(length of stay) level factors.
FO23-07
LONG TERM RESULTS OF HYDATID
DISEASE OF THE LIVER MANAGED
USING PALANIVELU HYDATID
SYSTEM
Senthilnathan Palanisamy, Palanivelu C,
Praveen Raj P, Parthasarathi R, Swathi I, Sandeep S
and Nalankilli VP
GEM Hospital and Research Centre, Coimbatore, India
Introduction: Surgical management of hydatid disease
of the live can be challenging. Both conservative and
radical surgeries are being followed worldwide with
merits and demerits in each approach. Aim is to review
the presentation, management and longterm outcomes
of patients who underwent laparoscopic surgery for the
hydatid disease using Palanivelu Hydaid Trocar system
(PHS) in a single institution over a 17 years period.
Method: A retrospective review of all patients who
were managed from 1997 to May 2013 for hydatid dis-
ease formed the study group. PHS system is a 12 mm
continuous suction irrigation apparatus, which mini-
mizes spillage of contents and also facilitates intracystic
visualization. Clinical presentation, surgical modalities,
perioperative complications and outcomes were ana-
lyzed.
Results: 116 patients underwent surgery for hydatid
disease over the study period of which 11 patients were
excluded due to radical procedure done in these
patients. Mean age is 32 years with male/female ratio
of 76/29. The most common presentation was abdomi-
nal pain (58%), 16(15%) had multiple cysts of which 9
(8%) were in both lobes. 77(73.3%) cysts were uncom-
plicated. Out of 28 complicated cases 19(17%) had
cyst-biliary communication, 2 were ruptured cysts
(intraperitoneally, mediastinum and stomach) and 7
recurrent cysts. All of them underwent successful lapa-
roscopic management using PHS trocar decompression
and partial cystectomy. Postoperative infection was
noted in 2, bile leak in 14 (all except one were managed
conservatively). Mean hospital stay was 3.2 days and
follow up was 5.2 years with 15 patients lost for follow
up. The recurrence was seen in 2 patients.
Conclusions: PHS is a simple, safe and effective tool to
treat hepatic hydatid cysts with excellent long term
results which are comparable to radical surgery. Its
closed suction and irrigation principle avoids intra peri-
toneal spillage thereby resulting in better outcomes.
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FO23-08
A HYBRID SEMI-AUTOMATIC
METHOD FOR LIVER SEGMENTATION
BASED ON LEVEL-SET METHODS
USING MULTIPLE SEED POINTS
Xiaopeng Yang1, Hee Chul Yu2, Younggeun Choi1,
Wonsup Lee1, Jaedo Yang3, Hongpil Hwang3, Jisoo
Song3, Baik Hwan Cho2 and Heecheon You1
1Pohang University of Science and Technology, Korea;
2Chonbuk National University Medical School, Korea;
3Chonbuk National University Hospital, Korea
Introduction: The present study developed a hybrid
semi-automatic method to extract the liver from
abdominal computerized tomography (CT) images. The
proposed hybrid method consists of a customized fast-
marching level-set method for detection of an optimal
initial liver region from multiple seed points selected by
the user and a threshold-based level-set method for
extraction of the actual liver region based on the initial
liver region.
Method: The performance of the hybrid method was
compared with those of the 2D and 3D region growing
methods implemented in OsiriX using abdominal CT
datasets of 15 patients.
Results: The hybrid method showed a significantly
higher accuracy in liver extraction (similarity index,
SI = 97.6%  0.5%; false positive error, FPE =
2.2%  0.7%; false negative error, FNE = 2.5% 
0.8%; average symmetric surface distance, ASD =
1.4  0.5 mm) than the 2D (SI = 94.0%  1.9%;
FPE = 5.3%  1.1%; FNE = 6.5%  3.7%; ASD =
6.7  3.8 mm) and 3D (SI = 83.4%  6.7%; FPE =
16.5%  7.9%; FNE = 16.6%  6.5%; ASD = 20.0 
5.9 mm) region growing methods. The liver extraction
time per CT dataset of the hybrid method
(77  10 seconds) is significantly less than the 2D
region growing method (575  136 seconds) and
slightly less than the 3D region growing method
(103  22 seconds). The interaction time per CT data-
set between the user and a computer of the hybrid
method (28  4 seconds) is significantly shorter than
the 2D region growing method (484  126 seconds)
and longer (but not statistically significant) than the 3D
region growing method (9  2 seconds).
Conclusions: The proposed hybrid method is found
preferred for liver segmentation in preoperative virtual
liver surgery planning.
FO24-01
TACE WITH BALLOON CATHETER
COULD BE SAFELY AND
EFFECTUALLY ADOPTED FOR
PATIENTS WITH HYPOVASCULER
LIVER CANCER, LONG-TERM RESULTS
OF A RANDOMIZED, SINGLE-BLIND
AND CONTROL TRIAL WITH 178
CASES
Yong-bo Yang1, Yu-fang Chen2, Dong Chen3, Xing-an
Long3, Guo-liang Shao1 and Hong-yan Cheng3
1Zhejiang Cancer Hospital, China; 2Hangzhou First
People’s Hospital, China; 3Eastern Hepatobiliary
Surgery Hospital, China
Introduction: To investigate the safety and efficacy of
TACE with balloon catheter for hypovasculer liver
cancer.
Method: This is a randomized, single-blind and control
trial, and patients with hypovascular liver cancer were
divided into the experimental group(receiving TACE
with balloon catheter) and control group(conventional
catheter) randomly. The enhanced CT or MRI exami-
nation and the laboratory tests were adopted to evalu-
ate its safety and efficacy by the occurrence of adverse
reactions and treatment response during the follow-up.
Results: A total of 178 patients were entered into the
study cohort, 89 cases in either group, and were proved
to be with balanced baseline. The dose of lipiodol used
in TACE and the volume of intrapatic lipidol in the
experimental group were significantly more than those
in the control group (p = 0.016, 0.035). The time to
partial remission in the experimental group was signifi-
cantly earlier than that in the control group by the
mRECIST (p = 0.029). The incidence of gastrointesti-
nal adverse reactions in the control group was signifi-
cantly higher than that in the experimental group
(p = 0.011), which showed close relation to the bilateral
embolization and drug reflux, but had nothing to do
with the dose of lipiodol used in the TACE. There was
no significant difference in the laboratory parameters
and the liver function between the two groups in
1.5 months after the TACE. There were four indepen-
dent prognostic factors during the univariate and multi-
variate analysis, PA less than 170 mg/L (p = 0.014)
and BCLC stage C (p < 0.001) with significantly worse
survival while adopting TACE with balloon catheter
(p = 0.042) and other treatments afterwards (p = 0.001)
with improved survival.
Conclusions: It was preliminarily proved that TACE
with balloon catheter could result in significantly more
lipiodol deposition in the hypovascular lesions, earlier
partial remission and longer survival time. Therefore, it
might be available and safe treatment for hypocascular
liver cancer and have the value for further promotion.
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FO24-02
CLINICAL CHARACTERISTIC OF
NEWLY DEFINED
CHOLANGIOLOCELLULAR
CARCINOMA – SPECIAL REFERENCE
TO IMAGING FINDINGS AND
PROGNOSIS
Yuichiro Maruyama, Koji Okuda, Masafumi
Yasunaga, Hiroyuki Horiuchi, Katsuaki Takagi,
Takahisa Shirahama, Yohei Nakama,
Yusuke Hirakawa and Hisafumi Kinoshita
Kurume University, Japan
Introduction: Cholangiolocellular carcinoma (CLC) was
considered to be derived from hepatic stem cell carci-
noma. In Japan, CLC was classified as an independent
primary liver cancer from 2009. Although the reported
cases is increasing, CLC is still rare event. Preoperative
diagnosis and prognosis is not clear. In the present
study, we reviewed our cases of CLC.
Method: Eight CLC resected cases were enrolled in this
study.
Results: There were seven males and one female, 2
patients were chronic hepatits type C. Hepatitis B was
not seen. Child-Pugh grades was A in all cases. A mean
tumor size was 3.8 cm. A mean CEA level was 4.2, and
a mean CA19-9 level was 59.7. In seven cases tumor
located at the peripheral portion of the liver. In
dynamic CT findings, the contrasting was classified in
two patterns. Type 1; entire enhancement in the arterial
phase, and persistent enhancement in the delayed
phase. Type 2; peripheral enhancement in the arterial
phase, and gradual enhancement in the delayed phase.
The preoperative biopsy were performed in four cases,
and CLC were confirmed in two. Postoperative recur-
rence were confirmed in seven. Recurrent site were at
liver in five cases, lymph node in two and bone in one.
Overall survival rate, one year, 3 year, 5 year were 80,
50, 25 percent respectively. Patient of type 1 had unfa-
vorable prognosis in comparison with type 2.
Conclusions: Preoperative exact diagnosis of CLC were
difficult. The survival rate were equal to cholangiocellu-
lar carcinoma (CCC), and we believe that surgical
treatment of CLC should be done in the same way as
CCC.
FO24-03
IS TUMOR MARKER DOUBLING TIME
BEFORE TREATMENT A RELIABLE
PROGNOSTICATOR IN PATIENTS
WITH HEPATOCELLULAR
CARCINOMA?
Hiroshi Nakano, Nobuyuki Matsumoto,
Masafumi Katayama, Shinya Kishi, Shinjiro
Kobayashi, Satoshi Koizumi, Hiroki Ikeda,
Tetsu Fukunaga and Takehito Otsubo
St. Marianna University Hospital, Japan
Introduction: Identifying reliable prognosticators is
important for considering adjuvant therapies after
hepatic resection (HR), radiofrequency ablation (RFA),
or transarterial chemoembolization (TACE) in hepato-
cellular carcinoma (HCC). Despite some reports, it is
still unclear whether doubling times (DTs) of alpha-
fetoprotein (AFP) and des-gamma-carboxy prothrom-
bin (DCP) were predictive markers. We therefore exam-
ined whether the DTs of AFP and DCP were
predictive in HCC.
Method: Among 141 HCC patients undergoing HR
between 2006 and 2011, 69 patients were selected
because serum AFP and DCP levels were measured at
least twice before surgery to calculate the DTs. In the
same period, 151 HCC patients undergoing TACE and/
or RFA were also selected because DTs were measured.
We investigated whether the DT-AFP and DT-DCP
could predict disease free survival (DFS) or overall sur-
vival (OS).
Results: Cut-off values of the DT-DCP and DT-AFP
were 60 and 170 days, respectively, considering ROC
curves. In HR patients, 5-year OS after HR was signifi-
cantly shorter in the DT-DCP <60 days group than in
the DT-DCP >60 days group (67% vs. 90%, p = 0.02),
and 5-y OS was also significantly shorter in the DT-
AFP <170 days group than in the DT-AFP >170 (67%
vs. 88%; p = 0.04, respectively). There were trends of
shorter DFS in the DT-DCP <60 days group and in
the DT-AFP <170 days group (p = 0.06 and 0.08,
respectively).
In the patients receiving RFA and/or TACE, the DT-
DCP <60 days was the significant predictor of OS
(p = 0.02), but the DT-AFP <170 days was not.
Conclusions: In HCC patients, the DT-DCP <60 days
and the DT-AFP <170 days can be reliable predictors
of poorer OS after HR, and the DT-DCP <60 days can
be a reliable indicator of poorer OS after RFA and
TACE.
FO24-04
RESULTS OF NEOADJUVANT HEPATIC
ARTERIAL INFUSION
CHEMOTHERAPY IN INOPERABLE
HCC PATIENTS WITH CHILD-PUGH
CLASS A
Sung Su Yun, Man Ki Kim, Hwa Kyung Jung,
Dong Shick Lee and Hong Jin Kim
Yeungnam University Medical Center, Korea
Introduction: The prognosis of HCC patients with
main portal vein tumor thrombosis (PVTT) or multi-
ple intrahepatic lesions, or both is extremely poor
and many surgeons regard them inoperable disease
and also not suitable for liver transplant. We tried
neoadjuvant hepatic arterial infusion chemotherapy
(HAI) for them to improve their survival and convert
operability.
Method: Between April 2003 to march 2013, 46 inoper-
able HCC patients with Child-Pugh class A were trea-
ted with neoadjuvant HAI chemotherapy. HAI was
performed via a port inserted through femoral artery.
The patients were treated with 5-FU (750 mg/m2) and
cisplatin (25 mg/m2) from days 1 to 4. HAI was
repeated every 4 weeks. We analysed the chemore-
sponse with RECIST (Response Evaluation Criteria In
Solid Tumors) guidelines and survival rate. Cumulative
survival was calculated using the Kaplan–Meier
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method and all statistical analyses were performed with
SPSS software (version 12.0;SPSS, Inc.,Chicago, IL).
Results: Twelve patients who could not receive more
than 2 cycles HAI chemotherapy were excluded in this
study. We analysed chemoresponse rate and survival in
remaining 34 patients; overall CR, PR, SD and PD
were 11.8% (four), 26.5% (nine), 47.1% (sixteen) and
14.7%(five), respectively. The median survival were
10.0 months. The 6, 12, 18 and 24-month cumulative
survival rate 70.0%, 67.62%, 52.9% and 34.6%,
respectively.
We could do liver surgery in 8 patients (17.3%) and
the median survival was 32.0 months. The 6, 12, 18
and 24-month cumulative survival rates were 87.5%,
65.6%, 65.6%, and 65.6%, respectively. Among of
these patients, 3 patients live now and have no recur-
rence for 54 months, 51 months, 14 months, respec-
tively. After 6 cycle, one patient who did not received
surgery showed CR and survived 15 months without
recurrence.
Conclusions: Neoadjuvant HAI chemotherapy can be
another good option to treat inoperable HCC patients
with good liver function.
FO24-05
INTERFERON-a AND 5-FLUOROURACIL
COMBINATION THERAPY
FOLLOWING HEPATIC RESECTION
FOR ADVANCED HEPATOCELLULAR
CARCINOMA WITH PORTAL VENOUS
TUMOR THROMBUS
Yoshito Tomimaru, Hiroshi Wada, Naoki Hama,
Koichi Kawamoto, Shogo Kobayashi,
Hidetoshi Eguchi, Koji Umeshita, Yuichiro Doki,
Masaki Mori and Hiroaki Nagano
Graduate School of Medicine, Osaka University, Japan
Introduction: The prognosis of patients with advanced
hepatocellular carcinoma (HCC) remains poor, particu-
larly in patients with tumor thrombi in the major trunk
of the portal vein. We have performed combination
therapy of interferon (IFN)-a/5-fluorouracil (5-FU) for
such advanced HCC. This report describes the results
of the IFN-a/5-FU combination therapy for the
advanced HCC.
Method: The combination therapy was performed in
60 patients with advanced HCC with tumor thrombi.
30 patients with HCC and tumor thrombi with multiple
nodules in the whole liver received the combination
therapy after palliative hepatic resection. The remaining
30 patients were treated with the therapy as a postoper-
ative adjuvant following curative surgery. A cycle of
the combination therapy consists of arterial 5-FU infu-
sion (300 mg/mm3/day, 5 days/week, for the initial
2 weeks) and IFN-a subcutaneous injection of (5 MIU,
3 times/week, 4 weeks). 3 cycles and at least 2 cycles of
the combination therapy were performed for the
patients after the palliative hepatic resection and the
patients following the curative surgery, respectively.
Results: In the 30 patients with the therapy after the
palliative surgery, 10 (33.3%) patients showed objective
response [6 (20.0%) showed complete response, 4
(13.3%) partial response], 1 (3.3%) showed no
response, and 19 (63.4%) showed progressive disease.
The 1-, 2-, and 3- year survival rates were 40%, 29%,
and 21%, respectively. The survival in patients with
objective response was significantly better than that
without objective response. In the remaining 30 patients
with the IFN-a/5-FU adjuvant treatment group, the
disease-free survival rates at 1-, 3-, and 5-year were
77%, 60%, and 39%, and the overall survival rates at
1-, 3-, and 5-year were 100%, 69%, and 44%. These
were significantly higher than those in historical con-
trols.
Conclusions: IFN-a/5-FU combination therapy may be
a very promising postoperative treatment for advanced
HCC with tumor thrombi.
FO24-06
USEFULNESS OF A MODIFIED
INFLAMMATION-BASED PROGNOSTIC
SYSTEM FOR PREDICTING
POSTOPERATIVE MORTALITY OF
PATIENTS UNDERGOING SURGERY
FOR PRIMARY HEPATOCELLULAR
CARCINOMA
Keiichi Kubota and Mitsuru Ishizuka
Dokkyo Medical University, Japan
Introduction: The Glasgow Prognostic Score (GPS), an
inflammation-based prognostic score that includes only
serum C-reactive protein (CRP) and albumin, is one of
the most useful scoring systems for the prognostication
of cancer patients. A hepatic version of the GPS,
named the hepatic GPS (hGPS), was proposed to pre-
dict prognosis in patients with hepatocellular carcinoma
(HCC).
Method: The hGPS was calculated as follows: patients
with an elevated level of CRP (>0.3 mg/dL) were allo-
cated a hGPS of 1 or 2 depending on the absence or
presence of hypoalbuminemia (<3.5 g/dL), and patients
without an elevation of the CRP level (≤0.3 mg/dL)
were allocated a hGPS of 0. Univariate and multivari-
ate analyses were performed. Kaplan–Meier analysis
and log rank test were used to compare mortalities pre-
dicted on the basis of the GPS.
Results: Three hundred patients were evaluated. Uni-
variate analyses revealed that the number of HCCs
(p = 0.019), CRP (p = 0.003), AST (p = 0.006), PIVKA
II (p = 0.039), CLIP score (0, 1/≥2) (p = 0.021) and
hGPS (0, 1/2) (p = 0.010) were associated with postop-
erative mortality. However, multivariate analysis dem-
onstrated that PIVKA-II, CLIP score (0, 1/≥2) and
hGPS (0, 1/2) were not associated with postoperative
mortality. Kaplan-Meier analysis and log rank test dis-
closed significant differences among the three groups,
patients with a hGPS of 2 (663  552, days) having
a shorter survival period than those with a hGPS of
0 (1031  729, days) and 1 (798  708, days)
(p < 0.001).
Conclusions: The hGPS is able to divide patients
undergoing surgery for primary HCC into three inde-
pendent groups, and is considered to be an important
factor predictive of postoperative mortality in such
patients.
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FO24-07
COMPARISON OF
CLINICOPATHOLOGIC
CHARACTERISTICS BETWEEN NON-B
NON-C HEPATITIS INDUCED HCC AND
VIRAL HEPATITIS INDUCED HCC
AFTER HEPATECTOMY; SINGLE
INSTITUTIONAL EXPERIENCE DURING
25 YEARS
Ryounggo Kim1, Sang Bum Kim1, Eung-Ho Cho1,
Yong-bae Kim1, Chang-sup Lim1, Dong Wook Choi2
and Eun bin Ryu1
1Korea Cancer Center Hospital, Korea; 2Samsung
Medical Center, Sungkyunkwan University, Korea
Introduction: There is a substantial population of
patients who had non-B non-C hepatitis induced hepa-
tocellular carcinoma (NBNC-HCC). We compared the
clinicopathologic variables between NBNC-HCC and
Viral Hepatitis Induced Hepatocellular Carcinoma (H-
HCC) after hepatectomy.
Method: Between January 1986 and July 2013, 669
patients underwent hepatectomy cause of HCC.
NBNC-HCC patients accounted for 117 people among
all patients. Clinicopahologic variables were retrospec-
tively reviewed between NBNC-HCC group and H-
HCC group after hepatectomy.
Results: Proportion of NBNC-HCC among HCC has
been slightly increasing during past 25 years. In
NBNC-HCC, older age, larger tumor size, lower pro-
portion of pathologic liver cirrhosis, favorable posthep-
atectomy liver function were showed compared with H-
HCC. There was not a difference of overall survival
between NBNC-HCC and H-HCC. NBNC-HCC was
slightly improved disease free survival than H-HCC but
did not showed statistically difference (p = 0.096).
Conclusions: NBNC-HCC has been slightly increasing
during past 25 years. Even though aggressive feature of
HCC at diagnosis, NBNC-HCC seems to be better
prognosis than H-HCC. Further study of management
for NBNC-HCC was needed.
FO24-08
ESTABLISHING CLINICAL
MANIFESTATION AND MALIGNANT
RISK IN GENOTYPED
HEPATOCELLULAR ADENOMAS
Bavahuna Manoharan1, Nicholas O’Rourke1, Richard
Bryant1, Catherine Campbell2 and Andrew Clouston2
1Royal Brisbane Hospital, Queensland, Australia; 2Envoi
Specialist Pathologists, Australia
Introduction: Hepatocellular adenomas (HCAs) present
a diagnostic challenge due to ambiguous histological
and radiological profiles, potential for malignant trans-
formation and bleeding. It is now established that there
are at least four main HCA subtypes with different
genotypic characteristics. The indication and implica-
tion of trucut biopsies and resection for these lesions is
uncertain, as are their phenotypes, clinical manifesta-
tion and malignant risk. This paper aims to present the
surgical experiences in stratifying risk of HCA malig-
nant transformation into Hepatocellular Carcinoma.
Method: Patients with HCA diagnosis and stored tissue
were identified via a HPB database at the Royal Bris-
bane and Wesley Hospital(s) between 2000–2012. Path-
ological techniques for identifying LFABP inactivation,
nuclear beta-catenin activation & Glutamine Syntha-
tase, Serum Amyloid A & C-Reactive Protein were
applied to biopsied and surgically resected specimens.
Clinical correlation data was obtained from patient
records and follow-up surveys.
Results: Seventy-two patients (89% Female; Mean Age
39 years), were identified. 84 HCA specimens, from
either surgical resection (39 laparoscopic, 14 open),
wedge (8) or core biopsies (31) were re-classified
according to the Bordeaux classification. Multiple sub-
types verified the presence of a heterogeneous adenoma
group; Inflammatory (42%; Type C), HNF-1 Alpha
(27%; Type A) and beta-catenin (19%; Type B) and
unclassifiable (18%; Type D). Published literature, rep-
resenting 259 adenomas, suggest Type B proportions of
9%, however all other subtypes were equal. 15 HCAs
were haemorrhagic, with 73% Type C, representing
32% of Type C lesions which was a significantly
greater proportion than others (p < 0.05). Seven
patients had adenomatosis, but none were Type B.
Conclusions: Literature suggests beta-catenin mutants
predispose to malignant change (10–15% of HCAs
transform) and our data verifies the presence of these
mutations in HCAs, showing a heterogeneous group of
tumours, however further validation required to assess
HCA transformation to HCC and if a new diagnostic
and management approach is warranted.
FO25-01
IMPACT OF PREOPERATIVE ERCP ON
LAPAROSCOPIC CHOLECYSTECTOMY
Keun Soo Ahn, Yong Hoon Kim, Koo Jeong Kang,
Tae Jun Park, Kwang Bum Cho, Eun Soo Kim and
Tae Jin Lim
Kyemyung University Dongsan Hospital, Korea
Introduction: The aim of this study was to evaluate
effects of ERCP on laparoscopic cholecystectomy(LC)
in gallstone patients.
Method: From September 1, 2011 to May 30, 2013,
among 722 patients who underwent LC for benign gall-
bladder disease, 448 patients who had not shown acute
cholecystitis or cholangitis preoperatively. These
patients were divided into 2 groups; patients with pre-
operative ERCP prior to LC (ERCP group, n = 81))
and patients who underwent LC without preoperative
ERCP (Non-ERCP group, n = 367). Preoperative
demographic factor, intraoperative finding for degree
of inflammation and technical difficulty, and postopera-
tive outcome were analyzed retrospectively.
Results: There were no difference of degree of preoper-
ative inflammation between 2 groups. However, in
ERCP, degree of intraoperative inflammation was
severe and score of technical difficulty was higher than
those of Non-ERCP group. Operative time was longer
and rates of open conversion was higher in ERCP
group. However, rate of bile duct injury and postopera-
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tive complication were not different between 2 groups.
On multivariate analysis, male sex and preoperative
ERCP were significant factors for difficult operation.
On sub-analysis in ERCP group, degree of inflamma-
tion was more severe in patients who underwent LC
within 72 hours after ERCP than patients who under-
went LC between 3–7 days and 7–14 days after ERCP.
However, operation difficulty was not different each
other.
Conclusions: Preoperative ERCP is a significant factor
for difficult LC. Therefore, experienced surgeon should
perform LC after preoperative ERCP.
FO25-02
RIGHT SECTORAL BILE DUCT INJURY,
DIAGNOSIS AND MANAGEMENT – A
SINGLE INSTITUTIONAL EXPERIENCE
Swapnil Sharma, P.J. Halder, Nikhil S.
Jagjivan Ram Railway Hospital, Mumbai, 400008, India
Introduction: Right sectoral duct injury, an uncommon
entity, accounts for 5%–8% of post cholecystectomy
biliary injuries. Diagnosis is difficult; management is
still controversial.
Method: Data of 9 patients with Right sectoral duct
injury treated during period 2000–2013 was studied.
Results: The age range was 18–46 years. Six patients
were females. Follow – up ranged between 1–12 years.
Delay in diagnosis confirmation ranged between 7–
46 days after the initial cholecystectomy. Various pre
operative biliary imaging was reported normal in all
the 9 cases despite biliary leak. CBD stenting was the
initial treatment in all the 9 cases with no significant
change in biliary output in 8 cases. Persistent high bili-
ary drainage for more than 8 weeks (range 8–14 weeks)
was main indication for surgery in 6 operated patients.
Three patients were not operated. Pre-operative percu-
taneous biliary drainage was the first step in all oper-
ated patients. Two patients with anastomotic
narrowing on follow-up improved with percutaneous
balloon dilatation. None required re - operation. Two
of the non-operated patients had segmental liver atro-
phy on serial imaging studies with recurrent infections
requiring admissions and long-term antibiotics. None
required surgery.
Conclusions:
1. Diagnosis of Right sectoral biliary duct injury
was delayed in most cases.
2. Normal cholangiogram despite bile leak was
“Alert” signal.
3. Prolonged high biliary drainage constituted main
indication for operative treatment.
4. Pre – operative percutaneous biliary drainage
was the first step in all operated patients.
5. Segmental liver atrophy in non – operated cases
had infective complications requiring recurrent
and long – term treatment.
FO25-03
FACTORS PREDICTING INTRA-
OPERATIVE DIFFICULTIES AND
CONVERSION OF LAPAROSCOPIC
CHOLECYSTECTOMY
Kam Wa Jessica Mok, Ramesh Reddy, Jeremy Ward,
Kishore Pursnani, Paul Turner, Punnya Ghosh and
Ravindra Date
Lancashire Teaching Hospitals NHS Trust, United
Kingdom
Introduction: Conversion to open surgery used to be a
marker of difficult cholecystectomy. With increasing
experience conversion rate has reduced significantly,
but the difficulties remain the same. Both, conversion
and difficult cholecystectomy have impact on operation
time. The aim of this study is to evaluate whether C-
reactive protein (CRP) is a predictive factor for ‘diffi-
cult’ cholecystectomies (DC), which are either contin-
ued laparoscopically or subsequently converted (CO).
Method: A retrospective review of all the consecutive
cholecystectomies performed in a single NHS Trust in
the UK, from January to December 2012, was under-
taken. Association of intra-operative difficulties or con-
version to open surgery, with the following factors was
studied- Age, gender, C-reactive protein (CRP), white
cell count (WCC), history or previous pancreatitis,
jaundice and endoscopic retrograde cholangiopancrea-
tography (ERCP).
Results: During the study period 375 patients under-
went cholecystectomy, of which 41 were in CO group
(10.9%), while 47 (12.5%) were in DD group. Patients
in the CO group were significantly older (61) compared
to DD group (55) and laparoscopic cholecystectomy
(LC) group (50). Mean CRP was significantly higher in
the CO group (279) compared to DD group (104) and
LC group (58), p < 0.01. Amongst patients with pre-
operative CRP of more than 250, 74% patients were
either in CO or DD group. Other predictive factors
include previous cholecystitis (n = 158, 41.1% CO or
DD), previous ERCP (n = 34), with 50% in either CO
or DD group and male gender (16.8% CO, 22.1% DD
compared to 8.6% and 9.3% in female).
Conclusions: Increasing age, high pre-operative CRP,
previous ERCP, cholecystitis and male gender appear
to be major predictors of difficult cholecystectomies/
conversion to open surgery. This ability to predict the
difficulty have important implications for organising
the operation lists more effectively and provide more
accurate information and counseling taking into
account of patient’s pre-operative details.
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FO25-04
LAPAROSCOPIC COMBINED
CHOLEDOSCOPIC
CHOLECYSTOLITHOTOMY VERSE
LAPAROSCOPIC CHOLECYSTECTOMY,
A FIVE YEAR FOLLOW-UP
Guoxiang Yao1 and Xiaoping Chen2
1South Campus, University 6th Hospital, Shanghai
Jiaotong Univeristy, China; 2Tongji Hospital, Tongji
Medical College, Huazhong University of Science and
Technology, China
Introduction: Comparation of clinical outcome of Lap-
aroscopic Combined Choledoscopic Cholecystolithoto-
my (LCCC) and Laparoscopic Cholecystectomy (LC).
Method: A prospective and controlled observation
were carried out. In patients with gallbladder stones,
with 200 cases of LCCC and 200 cases of LC. Opera-
tive duration, postoperative inpatient days, symptoms
and relapse were documented. Follow-up period is
5 years.
Results: The operative time of the LCCC was longer
than LC (53.56  15.22 vs. 29.43  10.82 minutes,
p < 0.05). No differences were found on postoperative
time and other immediate complications. Patients were
followed up 5 years, average 3.8 years. Under normal
diet, 110 cases of diarrhea (55%) were found in the LC
group in compare with none in the LCCC group
(p < 0.01), patients have to eat low fat diet to amelio-
rate symptoms. At the beginning of the study
(3 month) 4 cases (2%) of relapse and 4 cases (2%) of
residual were found in the LCCC group in comparing
with none in the LC group, but residual stone disap-
peared after chenodeoxycholic acid (CA) oral consump-
tion, for those with relapse, stones remain the same
after CA consumption .The cost of each group is the
same.
Conclusions: LCCC group takes more time than LC
group without difference on postoperative hospital stay
and other clinical data. LCCC group has no diarrhea
while LC group has a high percentage. LCCC preserves
patient’s organ and deserve further study.
FO25-05
LONG TERM RESULTS OF
LAPAROSCOPIC COMMON BILE
DUCT EXPLORATION BY
CHOLEDOCHOTOMY FOR
CHOLEDOCHOLITHIASIS: 15-YEAR
EXPERIENCE FROM A SINGLE
CENTER
Hyung Mo Lee, Hyeon Kook Lee, Seog Ki Min and
Geun Hong
Ewha Womans University Mokdong Hospital, Korea
Introduction: The aim of this study is to assess the long
term results of laparoscopic common bile duct explora-
tion (LCBDE) and validate its effectiveness primary
treatment modality for CBD stone.
Method: A retrospective review of the medical records
of 157 patients who underwent LCBDE from 1997 to
2011 was conducted. All LCBDE were performed by
choledochotomy. Clinical demographics, operative out-
come, recurrence rate of CBD stones and long term
bile duct complications were analyzed. A mean follow
up period was 51.9 months.
Results: LCBDE was completed in 152 patients
(96.8%) and 5 patients (3.2%) had open conversion.
The male/female ratio was 78/79 and mean age was
67.3 years. Stone clearance was successful in 149 of 152
patients (98.0%). Non-lethal complications were noted
in 11(7.2%) patients, including bile leakage in 6
patients (3.9%). Recurrent CBD stones developed in 9
of 152 patients (5.9%). Pre-operative endoscopic
sphincterotmy (p = 0.492) and choledochotomy repair
type (T-tube drainage vs. primary closure, p = 0.740)
were not significantly related to stone recurrence. There
were no signs of any type of biliary injury or stricture
observed in any of the patients during the follow-up
period.
Conclusions: LCBDE can be performed without
increased risk of long term complications such as bile
duct stricture and recurrent CBD stones. LCBDE is a
safe and effective treatment option for choledocholithi-
asis in terms of long term outcome as well as short-
term outcome.
FO25-06
PRIMARY CLOSURE AFTER LCBD
EXPLORATION COMBINED WITH
FLEXIBLE CHOLEDOCHOSCOPY: MID
TO LONG TERM FOLLOW UP
RESULTS
Hyeon Kook Lee, Hee Jung Yi, Seog Ki Min and
Geun Hong
Ewha Womans University Mokdong Hospital, Korea
Introduction: Laparoscopic common bile duct explora-
tion (LCBDE) is commonly used for treating choledo-
cholithiasis associated with cholelithiasis. There are
many studies that compare short term result of T-tube
insertion versus primary closure after LCBDE. In this
study, we compared the mid to long term (>18 month)
complication of primary closure with that of T-tube
insertion.
Method: This retrospective study included patient who
underwent LCBDE with flexible choledochoscopy in
Ewha Womans University Mokdong Hospital between
1997 and 2011. Patient were divided into two groups:
primary closure (P group) and T-tube insertion (T
group) after LCBDE. We reviewed medical chart and
analyzed clinical features, laboratory data, operative
findings and post operative follow-up evaluation. And
in case of “mid to long term” output, we confined the
patient who visited hospital more than one and a half
years since the operation day. Intraoperative cholangi-
ography (IOC) was not performed in any case.
Results: A total of 156 patients(except open conversion
cases) were included with a median age of 67.4 years
(Range 25–92) A mean follow up period was
34.5 months(Group P 26.2 month, Group T
46.7 months). Among them, 79 patient were included
in “Mid to long term” follow up group.(P group 44, T
group 35). The incidence of immediate post operative
complications had no significant difference between the
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two groups. The mean operation time (172 vs. 214 min-
utes, p < 0.0001) and post operative hospital stay (8 vs.
14 day, p < 0.0001) is significantly shorter in the P
group compared to the T group. P group had 3
(0.068%) recurrent CBD stone while T group had one
(0.029%). And among the T group patient, one had
stricture and the other one had cancer after 2 years
after the operation.
Conclusions: This study shows that primary closure
after LCBDE is feasible according to the long term
outcome as well as immediate post operative outcome.
FO25-07
SINGLE-INCISION LAPAROSCOPIC
CHOLECYSTECTOMY IN ACUTE
CHOLECYSTITIS: WHAT IS THE
CONVERSION RATE?
Chee Wei Tay, Shridhar Ganpathi Iyer,
Alfred Wei Chieh Kow, Krishnakumar Madhavan and
Stephen Kin Yong Chang
National University Health System, Singapore
Introduction: Acute cholecystitis is a relative contrain-
dication to single-incision laparoscopic cholecystectomy
(SILC). With the more matured development in SILC
technique in recent years, we report our experience of
managing acute cholecystitis with SILC.
Method: Two hundred and thirty-two benign gallblad-
der cases managed by SILC were retrospectively stud-
ied. Cases with clinical and histological features of
acute cholecystitis were identified. Patient’s demograph-
ics, biochemical and radiological findings, operating
time, degree of inflammation observed intraoperatively,
conversion rate and complication during follow up
were recorded and analysed. We further compared the
operating time of SILC and conventional laparoscopic
cholecystectomy (CLC) in acute cholecystitis cases and
identify the minimal cases required to achieve similar
operating time as CLC.
Results: 30 cases with acute cholecystitis were identi-
fied. 15, 3 and 12 cases with mild, moderate and severe
inflammation to the gallbladder respectively. No signifi-
cant difference in patient’s demographics, pre-operative
biochemical and radiological results are found between
the 3 groups. Operating time (91 minutes) and conver-
sion rate (25%) are significantly higher in severe
inflammation group. 3 (10%) cases required conversion
to CLC, no open conversion required. 13 cases of SILC
were required to achieve similar operating time as CLC
in acute cholecystitis. No bile duct injuries, port-site
hernia or wound infections were observed.
Conclusions: SILC is a feasible option for the manage-
ment of acute cholecystitis. Severe inflammation is a
predictive factor of conversion to conventional laparo-
scopic cholecystectomy but this is unforeseeable with
pre-operative tests and imaging. 13 cases of SILC were
required to achieve similar operating time as CLC in
acute cases for surgeons who have more than 200 case
experience in SILC for non acute cases. Conversion
rate to CLC is 10%.
FO25-08
ROLE OF LIVER RESECTION FOR THE
TREATMENT OF BILE DUCT INJURY
Giuseppina Ranucci1, Felice Giuliante1, Gerardo
Sarno2, Maria Vellone1, Gennaro Nuzzo1 and
Francesco Ardito1
1University Hospital Agostino Gemelli, Catholic
University of the Sacred Heart, Rome, Italy; 2University
Hospitel “San Giovanni di Dio e Ruggi D’Aragona”,
Salerno, Italy
Introduction: Late complications after treatment of
complex bile duct injury following cholecystectomy
such as recurrent cholangitis, intrahepatic abscess, liver
atrophy, can represent a therapeutic challenge. In these
cases vascular injury and stricture of main biliary con-
fluence or of hepatico-jejunostomy, are often present.
Liver resection in such cases can represent the only
effective treatment.
Method: Between 1994 and 2012, out of the 166
patients treated at our Center for bile duct injuries, 6
(3.6%) underwent liver resection. Indication for surgery
was recurrent cholangitis (more than 4 episodes) with
radiological evidence of hepatic atrophy in all patients.
The main biliary confluence was involved in 2 cases,
the right hepatic duct in 2 cases and the right posterior
biliary duct in 2 cases. In 2 cases (33.3%) there was an
injury of the right hepatic artery. The median time
between the bile duct injury and liver resection was
6 years. Two patients had previously undergone surgi-
cal repair by hepatico-jejunostomy, the other 4 patients
had undergone endoscopic, percutaneous or conserva-
tive treatment.
Results: Type of liver resection was right hepatectomy
in 4 patients, associated in 1 case with left-hepatico-jej-
unostomy, and right posterior sectionectomy in 2
patients. There was no postoperative mortality. Postop-
erative morbidity rate was 50.0% (3 patients): transient
liver failure in 1 case; cholangitis in 1 case and pleural
effusion with thoracentesis and cholangitis in 1 case.
After a median follow-up of 6 years (range 2.5–10), 5
patients (83.3%) have excellent/good results without
symptoms. One patient presented recurrent cholangitis
4 years following liver resection.
Conclusions: Liver resection represents an effective
treatment in selected cases with complex bile duct inju-
ries associated with symptomatic liver atrophy.
FO26-01
DEVELOPMENT OF THE USER-
CENTERED PREOPERATIVE LIVER
SURGERY PLANNING SYSTEM
DR. LIVER
Hee Chul Yu1, Xiaopeng Yang2, Younggeun Choi2,
Wonsup Lee2, Hayoung Jung3, Jaedo Yang4, Jisoo
Song4, Baik Hwan Cho1 and Heecheon You2
1Chonbuk National University Medical School, Korea;
2Pohang University of Science and Technology, Korea;
3Humanopia Co., Ltd, Korea; 4Chonbuk National
University Hospital, Korea
Introduction: The present study is intended to develop
a user-centered preoperative liver surgery planning sys-
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tem called Dr. Liver which has clinical applicability
and effectiveness to support safe liver surgery. Existing
virtual surgery systems needs to be customized to liver
surgery and improved for better usability and time effi-
ciency.
Method: A use scenario of a virtual liver surgery plan-
ning system was established through literature review,
benchmarking, and interviews with surgeons. Based on
the use scenario, detailed liver surgery planning proce-
dures were defined. The major functions of Dr. Liver
include (1) estimation of the standard liver volume of a
patient, (2) receiving abdominal CT images from a
PACS system (3) extraction of the liver, vessels, and
tumors from the CT images, (4) segmentation of the
liver into 8 segments based on structures of the
extracted portal and hepatic veins, (5) simulation of
liver resection, (6) volumetric measurement of the
extracted liver, vessels, tumors, liver segments, graft
and remnant, (7) risk prediction of liver resection, and
(8) providing a standalone viewer program to show the
planned liver surgery.
Results: Novel algorithms were developed and imple-
mented into Dr. Liver for accuracy and time efficiency.
Various user-friendly features such as a procedural user
interface and synchronized 2D and 3D views during
user interaction were integrated into Dr. Liver for bet-
ter usability.
Conclusions: Dr. Liver is being used by several medical
centers in Korea to assist surgeons in safe and rational
liver surgery. New features such as graft weight predic-
tion and intraoperative navigation system are under
development for Dr. Liver for safe and accurate liver
surgery.
FO26-02
A STUDY ON RIGHT
INTERSEGMENTAL PLANE BY
VIRTUAL HEPATECTOMY
Fumiya Sato, Tsuyoshi Igami, Tomoki Ebata,
Yukihiro Yokoyama, Gen Sugwara, Takashi Mizuno
and Masato Nagino
Nagoya University Graduate School of Medicine, Japan
Introduction: There is no landmark between the right
anterior and posterior sector of the liver surface. To
correctly perform left hepatic trisectionectomy from the
anatomical viewpoint, understanding on the right inter-
segmental plane (right portal fissure) is indispensable,
but little is known due to few studies. The aim of this
study was to elucidate 3D anatomy of the right inter-
segmental plane, with special attention of the course of
the right hepatic vein (RHV) and the type of the infe-
rior right hepatic vein (IRHV).
Method: The exposure type of RHV on the transected
plane was evaluated, using 3D virtual trisectionectomy
in 200 patients who underwent multidetector-row com-
puted tomography with enhancement. Virtual hepatec-
tomy was done using a work station (SYNAPSE
VINCENT; Fuji Film Co., Tokyo, Japan).
Results: RHV was exposed in full length on the tran-
sected plane in 109 (55%) patients, whereas it was
exposed only on cranial side of transected plane in the
remaining 91. Of the former 109 patients, 51 (56%)
had “small” IRHV and 58 had no IRHV. None had
“large” IRHV. In contrast, of the latter 91 patients, 46
(51%) had “large” IRHV, and 35 (38%) had “small”
IRHV. The remaining 10 had no IRHV, in whom
peripheral tributaries of the middle hepatic vein ran
across transected plane. The incidence of the presence
of IRHV was statistically significant (p < 0.01) between
the two groups.
Conclusions: Only in about a half of patients, RHV is
exposed in full length on transected plane after left tri-
sectionectomy, indicating that the concept of the right
portal fissure is of less clinical value in actual liver
resection. Exposure type of RHV is closely related to
type of IRHV.
FO26-03
THE APPLICATION OF INTERACTIVE
QUANTITATIVE 3D SURGERY
PLANNING IN PRECISION LIVER
SURGERY
Xuedong Wang, Weidong Duan, Ying Luo, Wenbin Ji,
Jiahong Dong and Zhiqiang Huang
Chinese PLA General Hospital, China
Introduction: The precision of the surgery planning is
crucial in Precision Liver Surgery. The purpose of this
prospective study is to evaluate the precision and effi-
ciency of a real-time interactive and quantitative 3D
planning approach.
Method: 221 consecutive cases were included in this
prospective study. Surgery plans were made via a tradi-
tional 2D planning approach using PACS and a mod-
ern approach using a real-time interactive quantitative
3D planning system respectively. 2D and 3D surgery
plans were compared and verified through the opera-
tion results. The territory analysis of 3D approach was
further assessed regarding its clinical feasibility and reli-
ability.
Results: 3D quantification, reconstruction and virtual
resection were successfully performed in all 221 cases.
203 of 221 patients (91.9%) successfully underwent hep-
atectomies, of which 102 underwent uncomplex hepatec-
tomies and 101 complex hepatectomies. In 102 cases in
uncomplex hepatectomy cases, no significant difference
was observed among different surgery plans; In 101
cases in the complex group, 2D and 3D surgery plans
were different in 38 cases (38/101, 37.6%) and were clas-
sified into 3 grades: I. the lesions were regarded to be
unresectable in 2D surgery plan but resectable in 3D
surgery plan (5); II. 3D modified the operation proce-
dure of 2D surgery plans (4); III. 3D modified the resec-
tion extent of 2D surgery plans (29), including extended
resection (19), reduced resection (8) and combination
with vascular reconstruction (2). The accuracy rate of
3D territory analysis was 92.8% (77/83).
Conclusions: The clinical precision and efficiency of the
real-time interactive and quantitative 3D planning were
validated. Compared with traditional 2D approach, the
real-time interactive and quantitative 3D planning
helped to significantly improve the determinacy, pre-
dictability and controllability of liver surgery and
appropriately increase the resection rate of complex
hepatectomy.
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FO26-04
ELECTROMAGNETIC COMPUTER-
ASSISTED NAVIGATION IN LIVER
SURGERY
Shouichi Satou
Saitama Medical Center, Saitama Medical University,
Japan
Introduction: In this study, a new navigation system
for liver resection utilizing electromagnetic tracking sys-
tem was developed, and the clinical use of the system is
reported.
Method: The navigation system consisted of an ultra-
sound scanner, an electromagnetic tracking device, and
a workstation. A sterilized magnetic sensor was
attached to an intraoperative ultrasound probe, and the
position of the probe was tracked by the system. Based
on the positional information transferred to the work-
station, images of CT and MR corresponding to the
ultrasound image were immediately reconstructed and
displayed adjacent to the intraoperative ultrasound
image, which could be referred to by the surgeons. Fur-
thermore, simulation images showing hepatic tumor or
liver parenchyma to be resected in different colors
could be overlaid on the CT images. Referring to the
simulation image showing the highlighted tumor or
liver parenchyma, the tumor could be easily identified
and the liver resection plane could be navigated.
Because the navigation system utilized electromagnetic
power in the operation room, a preliminary study was
scheduled to confirm the safety and feasibility of the sys-
tem. The system was used in 17 cases of liver resection.
Results: The feasibility and safety of the system were
confirmed because the reference image was not skewed
in the presence of metallic or electric surgical devices in
the operation room, and it did not affect any of the bi-
omonitors. Twenty six out of 28 tumors (93%) sched-
uled for resection were successfully identified by the
navigation system and extirpated. The other two
tumors could not be detected by the system because of
a registration failure. A significantly high correlation
coefficient (R = 0.993, p < 0.0001) was obtained
between the estimated volume of the specimen and its
actual weight.
Conclusions: The system should be useful for intraoper-
ative tumor detection and navigation of liver resection.
FO26-05
OPHTHALMATE LEVELS FOLLOWING
A PARACETAMOL CHALLENGE
DURING LIVER SURGERY: A
POTENTIAL TRANSLATIONAL MODEL
OF LIVER FUNCTION
Simon Dello, KimVan Mierlo, MechteldDe Jong,
HansVan Eijk, TheoDe Kok, J. Briede, Steven Olde
Damink and Cornelis Dejong
Maastricht University Medical Center, The Netherlands
Introduction: Liver failure is a dreaded complication
after extensive liver surgery and prediction of remnant
liver function becomes increasingly important. Unfortu-
nately, most liver function tests cannot predict dynamic
capacity to react to challenge. We aimed to challenge
the homeostasis of glutathione (GSH) with acetamino-
phen, to develop a predictive test for remnant liver
function by using systemic ophthalmic acid (OPH) as
biomarker.
Method: Patients scheduled for liver or pancreatic sur-
gery were included in this prospective trial. PCM chal-
lenges occurred before transection (first challenge),
6 hours after first challenge and 6 hours after second
challenge. Arterial blood samples were obtained at
baseline, intraoperatively and postoperatively to quan-
tify OPH, GSH and vitaminC radicals. Portal and
hepatic venous blood was taken to calculate arterio-
venous (AV) differences of OPH across gut, liver and
hepatosplanchnic area. Liver biopsies were taken to
measure OPH, GSH and thyil radicals.
Results: Nineteen patients scheduled for liver resection
(n = 12) or pancreaticoduodenectomy (n = 7) were
included. Six hours after first PCM challenge there was
a significant decrease in arterial GSH concentration
compared to baseline in the Whipple group, however
also tendency towards a decrease in OPH level. In the
liver resection group GSH and OPH levels measured
6 hours after first PCM challenge were significantly
decreased in comparison to baseline. While GSH
remained decreased, no difference in OPH levels was
seen after next challenges. In both groups hepatic OPH
and GSH levels did not differ significantly following
PCM-administration.
Conclusions: This is the first human study which
assessed plasma OPH as biomarker for hepatic GSH
depletion. It showed that OPH was not inversely pro-
portionally related to the GSH drop after PCM chal-
lenge, probably because the hepatic GSH protection
system was not overwhelmed. Investigating OPH/GSH
in GSH-depleted patients (e.g. sepsis) would be worth-
while to assess OPH as readout for hepatic GSH deple-
tion and herewith marker of liver dysfunction.
FO26-06
HEPATIC STAINING TECHNIQUES
USING FLUORESCENCE IMAGING FOR
ANATOMIC SEGMENTECTOMY
Akinori Miyata, Takeaki Ishizawa, Keigo Tani,
Atsushi Shimizu, Junichi Kaneko, Taku Aoki,
Yoshihiro Sakamoto, Yasuhiko Sugawara,
Kiyoshi Hasegawa and Norihiro Kokudo
The University of Tokyo, Japan
Introduction: The aim of this study was to demonstrate
technical details and advantages of hepatic segment
staining using indocyanine green (ICG)-fluorescence
imaging to complete anatomic hepatectomy.
Method: Following hepatic mobilization, mixture of in-
digocarmine (5 mL) and ICG (0.1 mL, 0.25 mg) was
injected into branches of the portal veins corresponding
to the hepatic segment to be identified without any
hepatic inflow occlusion. Fluorescence images of the
liver surfaces were obtained using a commercially-
available near-infrared light camera system following
injection of ICG solution. Then, hepatic parenchyma
was transected along a demarcation between fluorescing
regions and non-fluorescing lesions.
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Results: Fifteen patients underwent anatomic hepatec-
tomy using the fluorescence-guided staining technique.
Surgical procedures consisted of segmentectomy V
(n = 1), VI (n = 5), VII (n = 1), VIII (n = 2), bisegmen-
tectomy IV and VIII (n = 1), V and VIII (n = 1), VI
and VII (n = 3), and trisegmentectomy IV, V, and VIII
(n = 1). Fluorescence imaging enabled identification of
the hepatic segments to be removed in all patients. Flu-
orescence of ICG was observed only in the hepatic seg-
ment with the injection of ICG, throughout the
segmentectomy procedures. At all cases, demarcation
lines were immediately identified by ICG fluorescent
imaging after injection. Fluorescence imaging visualized
clear demarcation of hepatic segments even in re-hepa-
tectomy patients (n = 6), in whom staining of hepatic
segments with indigocarmine was not clearly identified
because of adhesive tissues on the liver surfaces. No
adverse reactions to the ICG were encountered.
Conclusions: Hepatic staining techniques using the
injection of ICG mixed with indigocarmine solution
into the portal veins enables clear identification of
hepatic segments not only by visual inspection but also
on fluorescence images. The ICG fluorescence imaging
may be useful to complete anatomic segmentectomy,
especially in patients undergoing secondary hepatec-
tomy and in those with liver cirrhosis, in whom con-
ventional staining technique using blue dye sometimes
fails to visualize clear demarcation between the hepatic
segments.
FO26-07
PREDICTING THE POST-
HEPATECTOMY LIVER FAILURE:
APPLICATION AND INTERNAL
VALIDATION OF A NEW
MATHEMATICAL MODEL
Andrea Ruzzenente, Alessandro Valdegamberi,
Calogero Iacono, Simone Conci, Fabio Bagante,
Tommaso Campagnaro, Marco Costa, Marco Piccino,
MichelaDe Angelis and Alfredo Guglielmi
Unit of HPB surgery, Division of General Surgery A,
University of Verona Medical School, Italy
Introduction: Post-hepatectomy liver failure (PHLF) is
one of the main life-threatening complication after liver
resection. Prediction of PHLF is important to plan safe
liver resection. The aim of this study was to develop
and validate a new prognostic model able to predict
the risk of PHLF in patients with injured liver.
Method: From 2009 to 2013 a total of 492 patients
were submitted to liver resection for primary or sec-
ondary liver tumors at our institution. One-hundred
and one patients were submitted to major hepatec-
tomy or to hepatectomy in injured liver (cirrhosis,
cholestasis and post-chemotherapy steathosis or ste-
atohepatitis) and were included in the study. We pro-
spectively collected future remnant liver volume
(FRLV) with CT-volumetry, liver functional test
through indocyanine green retention rate at 15 min-
utes (ICGR15) using pulse dye densitometry (Li-
MON) and preoperative biochemical data including
aspartate transaminase (AST), prothrombine time
(PT-INR) and serum sodium level (Na). International
Study Group of Liver Surgery (ISGLS) definition of
PHLF was adopted.
Results: Morbidity and mortality rate were 50.5% and
4.5%, respectively. 28.7% of patients (n = 29) developed
clinical signs of PHLF. The univariate analysis identified
ICGR15 (p = 0.001), AST (p = 0.004), ALT (p = 0.001),
PT-INR (p = 0.06) and Na (p < 0.008) as risk factors of
PHLF. At multivariate analysis ICGR15 (OR: 2.99; CI:
1.2–7.7), FRLV (OR: 0.31; CI: 0.09–1.0) and Na (OR:
0.42; CI: 0.2–0.7) were associated with PHLF. From
multivariate analysis results, we developed a predictive
mathematic model that includes ICGR15, FRLV and
Na. According to this model we prospectively stratified
patients in high and low risk in which the rate of PHLF
were 68% and 5%, respectively (p < 0.01).
Conclusions: The mathematic model including
ICGR15, FRLV and Na is strongly related to PHLF
and could be proposed as a new predictive model to
increase the limits of safe liver resection.
FO26-08
PREDICTING EPATIC FAILURE USING
PREOPERATIVE REMNANT LIVER
LU15 FROM FUSION IMAGES OF
99MTC-LABELED GALACTOSYL
HUMAN SERUM ALBUMIN LIVER
SCINTIGRAPHY AND COMPUTED
TOMOGRAPHY
Naokazu Chiba, Motohide Shimazu, Shigeyuki
Kawachi, Kiminori Takano, Toru Sano, Masaaki
Okihara and Kiyoshi Koizumi
Tokyo Medical University, Hachioji Medical Center,
Japan
Introduction: A novel index, total liver LU15, has been
identified as a surrogate marker for liver function. We
evaluated the ability of preoperative remnant liver
LU15 values to predict hepatic failure following liver
resection for any disease.
Method: Potential preoperative risk factors for postop-
erative hepatic failure (hepatic coma with hyperbiliru-
binemia, two patients; intractable pleural effusion or
ascites, one patient) and remnant liver LU15 were eval-
uated in 98 patients undergoing liver resection for sev-
eral diseases. We calculated the remnant liver LU15
value from the total liver LU15 value and the functional
remnant liver ratio, using Synapse Vinscent workstation
to perform image fusions of 99mTc-labeled galactosyl
human serum albumin liver scintigraphy SPECT imag-
ing and computed tomography. Prognostic significance
was determined by univariate and multivariate analyses.
Results: Hepatic failure developed postoperatively in
three patients, causing death in two. The remnant liver
LU15 value did not correlate with any histological fac-
tors, and was significantly less than 13.0 in patients
who developed postoperative hepatic failure than in
those without failure (p = 0.0358). Only the remnant
liver LU15 index was an independent preoperative fac-
tor on the multivariate analysis (OR = 0.436, 95% CI:
0.198–0.961, p = 0.0395). Of the four patients who died
of postoperative hepatic failure, all patients had a rem-
nant liver LU15 value of less than 13.0.
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Conclusions: Preoperative remnant liver LU15 values
independently predicted hepatic failure following liver
resection for any disease. Patients with a remnant liver
LU15 value of 13 or less have a high risk of postopera-
tive hepatic failure.
FO27-01
ULTRA-SHORT STAY LAPAROSCOPIC
CHOLECYSTECTOMY IN A DAY
SURGERY CENTER IN INDIA
Radhakrishna Patta
Apollo Hospitals, India
Introduction: Ambulatory laparoscopic cholecystectomy
is being performed in the west for quite a while now
with patients getting back home in less than 24 hours
after surgery. This is generally not accepted in India
for various reasons. Patients want to stay overnight in
the hospital for fear of any sudden eventuality. We
tried discharging patients in less than 6 hours after lap
chole after adequately controlling post operative pain,
nausea and vomiting.
Method: We have chosen patients with symptomatic
gall stones with ASA grade I and Iimand excluded oth-
ers. In addition to general anaesthesia we gave all these
patients TAP (transverse abdominis plane) block for
post op pain control and dexamethasone for control of
PONV. We discharged them the same day once the
patient passed urine and is mobile.
Results: Between November 2011 and August 2013 we
performed day care laparoscopic cholecystectomy on 278
patients. Of these 28 had acute cholecystitis, 32 underwent
LC a day after ERCP and stone removal from CBD. 4
patients had completion cholecystectomy of which one
had situs in versus totalis. No patient was hospitalised
subsequently for any reason whatsoever. Two were dis-
charged with a drain which was removed a day later. One
patient had a mild wound infection and one other patient
developed an abdominal wall hepatoma requiring aspira-
tion. The mean hospital stay was 5.6 hours while the
mean time to oral intake was 3.8 hours.
Conclusions: We believe that ultra-short stay laparo-
scopic cholecystectomy (less than 6 hour stay) is feasi-
ble in a country like ours with a proper selection of
cases, good post operative control of pain and nausea
in a dedicated day surgery Center where everyone is
aware of this day surgery concept and work towards
early discharge of their patients.
FO27-02
SINGLE INCISION LAPAROSCOPIC
CHOLECYSTECTOMY USING
CONVENTIONAL INSTRUMENTS
VERSUS THREE PORT LAPAROSCOPIC
CHOLECYSTECTOMY – OUTCOMES
Kumar Palaniappan
Global Hospitals & Health City, Chennai, India
Introduction: Transumbilical single incision laparo-
scopic surgery (SILS) is a new laparoscopic procedure
in which only one transumbilical incision is made, dem-
onstrated as a scarless procedure. Single incision lapa-
roscopic surgery (SILS) represents the next step in
laparoscopic surgery in further reducing the invasive-
ness of surgical procedures with cosmetic advantage.
We report the outcomes of patients undergoing SILS
Cholecystectomy versus Three port cholecystectomy.
Method: Between February 2010 and March 2011, 75
patients were operated for benign gallbladder diseases.
36 underwent SILS Cholecystectomy using conven-
tional instruments (Group I) & 37 underwent Three
Port Laparoscopic Cholecystectomy (Group II).
Patients with BMI less than 30, benign diseases were
included. Outcome measures included operative time,
intensity of postoperative pain and consumption of
painkillers, hospital stay, need for conversion, compli-
cations, and cosmetic effects
Results: Mean operating time in Group I was 69 min
& in Group II was 41 minutes. Intensity of pain mea-
sured using Visual analogue scale (VAS) at 6 hours,
10 hours & at 24 hours were 3.9, 2.7 and 1.3 in Group
I. In Group II, VAS scores were 4.3, 3.2 & 1.8. The
need for pain killers were less in Group I compared to
Group II. The mean hospital stay in Group I was 1.46
& in Group II 2.1. There were 2 conversions in Group
I to Group II. No patient underwent conversion to
open procedure. Wound infection was the major com-
plication occurred in 1 patient in Group I & 2 patients
in Group II.
Conclusions: Single-incision laparoscopic surgery chole-
cystectomy can be an alternative to three port laparo-
scopic cholecystectomy, especially with reference to
young people with body mass index less than 30 kg/
m2, without serious systemic diseases, operated on elec-
tively due to benign gallbladder diseases.
FO27-03
PERCUTANEOUS
CHOLECYSTOSTOMY VERSUS
CHOLECYSTECTOMY FOR ACUTE
CHOLECYSTITIS IN OCTOGENARIANS
Chin Cheung Cheung, James Tak-kwan Fung,
Wai Man Wong and Chak Fong Mak
Tuen Mun Hospital, Hong Kong, China
Introduction: For elderly patients with acute cholecysti-
tis who are not responding to antibiotics treatment and
considered to be too risky for early cholecystectomy,
percutaneous cholecystostomy (PTC) is an alternative
option. This study aims at reviewing the outcomes of
octogenarians with acute cholecystitis treated by chole-
cystectomy or PTC.
Method: Patients aged 80 years or older who received
cholecystectomy or PTC from January 2003 to Decem-
ber 2012 due to acute cholecystitis not responding to
antibiotics were retrospectively reviewed. Comparison
was made between patients who received cholecystec-
tomy and PTC.
Results: Among the 1564 patients admitted for acute
cholecystitis in the study period, one hundred and
twenty-six octogenarians received cholecystectomy or
PTC as treatment for acute cholecystitis. The median
age was 83 years (range 80–96). There were 50 males.
Thirty-four patients (27%) received PTC. When
patients who received PTC were compared with those
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who received cholecystectomy, there was no difference
in age, gender and comorbidity between the two
groups. The proportion of patients with high ASA
grading (grade III or above) and the duration from
symptom onset to intervention in the two groups was
comparable. While there was no significant difference
in 30-days mortality between the two groups, the one-
year mortality was significantly higher for patients
received PTC (47.1%) instead of cholecystectomy
(19.6%). Significantly more patients who received PTC
had subsequent readmissions due to biliary sepsis (PTC
vs. cholecystectomy: 20.6% vs. 2.2%).
Conclusions: Although PTC is effective in short-term
palliation of sepsis and symptoms for octogenarians
with acute cholecystitis; there is still a high chance of
recurrent sepsis, leading to readmission and mortality
in long-term. In patients who received PTC for control
of biliary sepsis, cholecystectomy should be considered
subsequently as a definitive measure to prevent recur-
rent sepsis and mortality.
FO27-04
TOKYO GUIDELINES 2013 SEVERITY
CHARACTERISTICS AS RISK FACTORS
FOR CONVERSION TO OPEN
SURGERY IN PATIENTS WITH ACUTE
CHOLECYSTITIS
Koji Asai, Manabu Watanabe, Hiroshi Matsukiyo,
Tomoaki Saito, Hajime Kodama, Toshiyuki Enomoto,
Yoichi Nakamura, Yoshihisa Saida, Jiro Nagao and
Shinya Kusachi
Toho university Ohashi medical center, Japan
Introduction: The aim of this retrospective study was to
identify whether Tokyo guidelines 2013 (TG 13) sever-
ity classifications serve as risk factors for conversion to
open surgery in patients with acute cholecystitis (AC)
who are undergoing management with laparoscopic
cholecystectomy (LC).
Method: A total of 225 patients were enrolled. Patients
were classified into one of two groups: the conversion
group and the no-conversion group. Criteria for grade
II AC, such as white blood cell (WBC) counts more
than 18,000 cells/mm3, duration of symptom more than
72 hours, and marked local inflammation, were exam-
ined as risk factors for conversion to open surgery.
Results: Conversion to open surgery occurred in 29
patients (12.9%), including seven patients (6.7%) with
grade I AC and 22 patients (18.5%) with grade II AC.
Univariate analysis showed that risk factors for conver-
sion to open surgery included duration of symptoms
>72 hours, C-reactive protein (CRP) value, and Tokyo
guidelines 2013 (TG 13) severity classification. Multi-
variate analysis showed that risk factors for conversion
to open surgery included duration of symptoms
>72 hours and CRP > 11.5 mg/dL.
Conclusions: Duration of symptoms >72 hours and
CRP >11.5 mg/dL were independent risk factors for
conversion to open surgery.
FO27-05
URGENT ONE STAGE LAPAROSCOPIC
INTRAOPERATIVE SONOSCOPY AND
CHOLEDOCHOSCOPY IN PATIENTS
WITH SUSPECTED
CHOLEDOCHOLYTHIASIS
Haralds Plaudis, Liene Melberga, Ita Kazaka,
Kristaps Atstupens, Vladimir Fokin, Maksims Mukans
and Guntars Pupelis
Riga East Clinical University Hospital, Latvia
Introduction: Laparoscopic cholecystectomy is stan-
dardized procedure in the management of patients with
acute cholecystitis, however definition of indications for
laparoscopic common bile duct exploration in
(LCBDE) is still a matter of debate. The aim of study
was to share our experience in application of urgent
one stage laparoscopic sonoscopy and choledochoscopy
in patients with suspected choledocholithiasis.
Method: 127 urgently admitted surgical patients with
suspected choledocholithiasis (dilation of common bile
duct on abdominal ultrasound, elevated bilirubin levels,
biliary pancreatitis and cholangitis) were prospectively
included in study during the time period from August
2012 till July 2013. All patients had indications for sur-
gery and were chosen for one stage approach consider-
ing intraoperative ultrasound investigation of biliary
tree followed by LCBDE in cases of choledocholithia-
sis. Further analysis of clinical data, overall complica-
tion rate and outcomes was done only if LCBDE was
performed.
Results: LCBDE was done in 53 patients. From all 37
patients were jaundiced, 32 had cholangitis, 13 biliary
pancreatitis and 25 signs of cholecystitis. In 23 patients
procedure was done in 72 hours (median 2 days) and
in 30 > 72 hours (median 6 days) after admission.
There was 29 transcystic and 24 transductal LCBDE
with median IQR operative time of 80 (117–70) versus
127.5 (147–112) minutes, p < 0.001. T-tubes were
placed only in 2 (8.3%) patients with transductal
approach. Complete bile duct clearance was achieved in
92.5% leading to conversion rate of 7.5%. Readmission
and ERCP for missed stones were needed in two
patients. Overall postoperative complication rate
reached 13.2% including bile leak, bleeding form liver
bed and PATE. Median IQR hospital stay was 9 (15–
7) days. There was no mortality in our series.
Conclusions: Intraoperative sonoscopy followed by
LCBDE is feasible and safe procedure that can be pro-
vided in urgently admitted patients with choledocholy-
thiasis.
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FO27-06
INTRA-OPERATIVE ERCP VERSUS
LAPAROSCOPIC CLEARANCE
IN PATIENTS WITH
CHOLEDOCHOLITHIASIS
UNDERGOING EMERGENCY
LAPAROSCOPIC CHOLECYSTECTOMY:
A RANDOMISED TRIAL
Benjamin Poh, Chee Cheen Yeong, Mithra Sritharan,
David Devonshire, Michael Swan, Malcolm Barnes,
Paul Cashin and Daniel Croagh
Monash Medical Centre, Australia
Introduction: With the introduction of laparoscopic
cholecystectomy and the subsequent advent of
advanced endoscopic and laparoscopic techniques, min-
imally-invasive management of choledocholithiasis has
become technically feasible and widely utilized. Both
intra-operative ERCP and laparoscopic bile duct explo-
ration are acceptable means of achieving bile duct
clearance within a single session in a laparoscopic cho-
lecystectomy population. We aim to compare the rates
of bile duct clearance by endoscopic versus laparo-
scopic methods in a population undergoing emergency
laparoscopic cholecystectomy.
Method: We designed a non-blinded, randomized con-
trolled trial performed at our centre. Patients were ran-
domized by simple randomization at the time of intra-
operative cholangiogram upon demonstration of chole-
docholithiasis into either one of the two arms of the
study, intra-operative ERCP, or laparoscopic common
bile duct exploration. The latter could be performed
transcystically or via a choledochotomy at the operat-
ing surgeon’s discretion. Duct clearance was noted
upon procedure completion and patients were followed-
up three-monthly for post-procedural complications,
length of stay, and requirement for further procedures.
Results: Preliminary findings from patients accrued to
date suggest that intra-operative ERCP may be more
effective than laparoscopic common bile duct explora-
tion in terms of duct clearance. Furthermore, the group
randomized to laparoscopic clearance had increased
morbidity rates and appeared to require greater num-
bers of related procedures in their episode of care.
There were non-significant differences in length of stay
between both groups.
Conclusions: The interim findings of our study suggest
that intra-operative ERCP might be superior to laparo-
scopic common bile duct exploration in clearing the
bile duct in patients undergoing emergency laparo-
scopic cholecystectomy.
FO27-07
MANAGEMENT OF HEPATICO-
JEJUNOANASTOMOSIS STRICTURES
SECONDARY TO BILIARY OPERATIVE
INJURY REPAIR BY BIODEGRADABLE
STENTS PLACEMENT
Mariano Gimenez, Mariano Palermo,
Dario Berkowski, Pablo Cordoba, Gary Duran,
Jorge Cardoso and Eduardo Houghton
Hospital de Clinicas, Argentina
Introduction: Once a biliary injury has occurred, espe-
cially in the case of complex lesions, repair is done by a
hepatico-jejunoanastomosis. Success rates range is from
85% to 95%. The initial use of biodegradable stents
was in the digestive tract, its first indications were for
benign esophageal and colonic strictures. Biodegradable
biliary stents should change the treatment of this com-
plication.
Method: In a prospective study, since March 2011, 16
biodegradable stents were placed in 13 hepatico-jejuno-
anastomosis strictures secondary to bile duct repair of
a biliary surgical injury. Average age was 38.7 years
(23–67), 9 patients were female. In 9 patients, the hepa-
tico-jejunoanastomosis stricture was treated with a high
pressure balloon and in 4 patients, with failure of the
balloon dilatation, with prolonged dilatation with 5 to
6 percutaneous plastic stents during 9–12 months. All
cases had a percutaneous drainage at the time of bio-
dregradable stent placement.
Results: 16 stents were placed in 13 patients. In one
case, temporary hemobilia was present requiring blood
transfusion, delaying hospital discharge for 24 hours.
In another case, pain after stent placement required
intravenous medication and delayed the discharge for
72 hours. In the rest 11 patients, hospital discharge was
the next morning following stent placement. During the
patients’ follow-up, none presented symptoms during
the first 9 months. One patient presented significant
alkaline phosphatase elevation 8 months after stent
placement. Stricture recurrence was confirmed, a re-he-
patico-jejunoanastomosis was carried out. Eleven
patients (84.6%) continued asymptomatic with a mean
follow- up of 20 months.
Conclusions: The placement of biodegradable stents is
a safe technique. We have not observed strictures
caused by the stent or its degradation. A long-term fol-
low-up is necessary to establish the actual patency of
the stricture. It could eventually substitute balloon dila-
tion in the treatment of strictures of hepaticojejunoana-
tomoses.
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FO27-08
PRELIMINARY STUDY OF SURGICAL
TREATMENT BASED ON THE
CLINICAL CLASSIFICATION OF
HEPATOLITHIASIS
Fu-bao Liu1, Jiang-ming Chen2, Guo-bing Wang1,
Yi-jun Zhao1, Kun Xie1, Zhi-gong Zhang1,
Yi-zhao Luo1 and Xiao-ping Geng1
1The First Affiliated Hospital of Anhui Medical
University, China; 2The Secondary Affiliated Hospital of
Anhui Medical University, China
Introduction: Hepatolithiasis (HL) is prevalent in
Southeast Asia, especially in China. We have suggested
a new type of classification according to the history
and pathologic changes. The study aims to evaluate the
efficacy the new classification and maybe to provide
new guidance on clinical treatment for HL.
Method: This retrospective analysis includes 68 HL
patients underwent Surgical operation in the first affili-
ated hospital of Anhui medical university from August
2011 and December 2012. All patients were completed
by the same group of Surgeon. All patients had regular
postoperative follow-up every 1 to 3 months by the
same team of surgeons.
Results: The positive diagnosis rate of HL which corre-
spond to intraoperative findings with B-ultrasonogra-
phy, abdominal CT scan and MRCP is 97.1%, 91.9%
and 95.0%. According to our clinical classification,
there were 34 patients of Type I (50.0%), 25 of Type II
(36.8%), 7 of Type III (10.3%) and 2 of Type IV
(2.9%). A total of 52 cases received hepatectomy. A
total of 48 cases given the external drainage and the
other 20 cases received choledochojejunostomy group.
Intraoperative biliary microscopy confirmed 20 cases
had sphincter of Oddi laxity and the immediate stone
clearance rate is 73.5%. The positive rate of bile bacte-
rial culture is 77.6%. 16 cases had postoperative com-
plications (23.5%).There were no perioperative death in
this group. The average follow-up time is
10.4  4.3 month. There were 4 cases suffered cholan-
gitis recurrence and 12 cases had occasional bile duct
inflammatory.
Conclusions: The clinical classification proposed in this
study has a certain sense to guide the surgical treat-
ment. Comined with hepatectomy is the main measure-
ment to improve efficacy and reduce the rate of
residual stone and stone recurrence. Taking the biliary
tract endoscopy can reduce postoperative biliary-enteric
reflux and stones recurrence.
FO28-01
DIAGNOSTIC EFFECTIVENESS IN
PERCUTANEOUS PUNCTURE OF
PANCREAS GUIDED BY TAC
Marcos Diego Garcıa Ejarque1, Fernando Ignacio
Iglesia1, Ursula Tamara Gitter1, Martin Costal1,
Mariano Bregante1, Gustavo Castagneto2 and Eduardo
Agustın Porto1
1British hospital of Buenos Aires, Argentina; 2Sanatorio
Guemes of Buenos Aires, Argentina
Introduction: It has been suggested that for histological
diagnosis of pancreatic mass lesions, the use of percuta-
neous fine needle punctures (PFNP) are well recognized
regarding puncture with tru-cut needles due to their
fewer complications and almost immediate recovery
without hospitalization. However, the diagnostic value
of PFNP in this disease is still unknown. There are no
studies in our country that analyses this feature.
Our objective is to evaluate the diagnostic effectiveness
of PFNP in pancreatic tumors guided by computerized
tomography (CT).
Method: Patients with unreseactable pancreatic lesions
with suspect of malignancy were included, in a period
between January 2001 and July 2013.
All the PFNP of pancreas made guided by CT were
analyzed retrospectively. Spine needles of 21G were
used in all cases. A pathologist was in the operative
room at the moment of all punctions. The samples
were informed as optimal for study. The diagnostic was
them confirmed by the cytological examination.
Results: Thirty-six patients were included. Tumors size
was from 40 to 120 mm. The differed cytological exam-
ination confirmed in all cases the suspect of malig-
nancy.
There were 4 cases of morbidity (two patients with epi-
gastric pain and 2 wall hematomas). There was no
mortality in the series.
Conclusions: Percutaneous pancreatic puncture with
fine needles guided by CT is a well mini-invasive diag-
nostic method for unreseactables pancreatic tumors,
with a positive predictive value of 100% in our series
and with low morbidity rate. So, despite of the need of
randomized prospective studies, PFNP of pancreas
could be an excellent alternative.
FO28-02
REAPPRAISAL OF MORPHOLOGICAL
CLASSIFICATION OF IPMN; CLINICAL
VALIDITY OF THE TERM ‘MIXED TYPE
IPMN’ AND OPTIMAL THRESHOLD
FOR CLASSIFICATION
Mee Joo Kang1, Jin-Young Jang1, Selyeong Lee1,
Taesung Park1, Seung Yeoun Lee2, Kyoung Bun Lee1,
Ye Rim Chang1, Wooil Kwon1, Woohyun Jung1 and
Sun-Whe Kim1
1Seoul National University College of Medicine, Korea;
2Sejong General Hospital, Korea
Introduction: Current morphology classification of
IPMN has a gray zone for mixed type IPMN that are
vaguely defined without statistical evidence. The associ-
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ation between clinicopathologic characteristics of
branch duct predominant type intraductal papillary
mucinous neoplasm (IPMN) and main pancreatic duct
(MPD) size were assessed to determine a new standard
for classifying mixed type IPMN which has increased
risk of malignancy.
Method: We analyzed 350 consecutive patients with
surgical biopsy proven branch duct predominant type
IPMN evaluated at Seoul National University Hospi-
tal.
Results: With logistic regression model, diagnostic
accuracy for malignancy was highest when the cut-off
value of MPD size was 7 mm (area under the
curve = 0.7177). Patients with MPD >7 mm had a sig-
nificantly higher risk of malignancy than patients with
MPD ≤7 mm (58.5% vs. 20.7%, p < 0.001). Mural
nodule negative patients with MPD >7 mm had a sig-
nificantly lower 5-year survival rate than those with
MPD ≤7 mm (71.7% vs. 91.9%, p = 0.006). Patients’
age (p = 0.016), sex (p = 0.002), mural nodule
(p < 0.001), malignancy (p < 0.001) were significantly
different between branch duct predominant type IPMN
with MPD ≤7 mm versus MPD>7 mm. When com-
pared with main duct type IPMN, age, sex, mural nod-
ule, malignancy and survival rate were similar with
those with branch duct predominant type IPMN and
MPD >7 mm.
Conclusions: Branch duct predominant type IPMN
with an MPD size >7 mm have clinicopathologic char-
acteristics that are close to main duct rather than
branch duct type IPMN. This size criterion is a reason-
able standard to define mixed IPMN that requires sur-
gical treatment.
FO28-03
GENE EXPRESSION PROFILE
ACCORDING TO THE HISTOLOGIC
SUBTYPE (GASTRIC, INTESTINAL,
PANCREATOBILIARY AND
ONCOCYTIC TYPE) IN INTRADUCTAL
PAPILLARY MUCINOUS NEOPLASMS
OF PANCREAS
Ye Rim Chang1, Jin-Young Jang1, Mee Joo Kang1,
Selyeong Lee2, Taesung Park2, Seung Yeoun Lee3,
Junghyun Namkung4, Sangjo Han4, Kyoung Bun Lee1
and Sun-Whe Kim1
1Seoul National University College of Medicine, Korea;
2Seoul National University College of Natural Sciences,
Korea; 3Sejong University College of Natural Sciences,
Korea; 4SK Telecom, Korea
Introduction: Intraductal papillary mucinous neoplasms
(IPMN) represent a spectrum of tumors that range
from low-grade dysplastic tumors to invasive cancer.
Recently histologic subtype has been reported to be
related with prognosis and morphologic type. However
gene expression pattern and tumor biology according
to histologic subtype of IPMN have not been exten-
sively evaluated.
Method: We used Affymetrix oligonucleotide micro-
arrays to compare the gene expression profile of 50
IPMN samples including LG IPMN (n = 6), moderate-
grade (MG) IPMN (n = 17), high-grade (HG) IPMN
(n = 12), invasive cancer with IPMN (IPMC; n = 15).
We also compared data with W/D pancreatic ductal
adenocarcinoma without IPMN (PDA; n = 5). Accord-
ing to histologic subtype, there were 15 Gastric type, 9
intestinal type, 7 PB type, 2 Oncocytic type.
Results: 386 mRNAs were differentially expressed in
according to the malignancy of IPMN. By DEG and
clustering analysis, we could select highly expressed 100
genes differently expressed in malignancy IPMN. Hier-
archical clustering demonstrated that 56 mRNAs was
significantly different between gastric, intestinal and PB
type. For example, 25 mRNAs were differentially
expressed between pancreatobiliary and gastric/intesti-
nal type. Hierarchical clustering demonstrated gene
expression profile was significantly different according
to histologic subtypes of IPMN, suggesting that differ-
ent pathways are involved in those types.
Conclusions: This study demonstrates that different
mRNAs are involved in the development and progres-
sion of IPMN according to the subtype and malig-
nancy. Using this finding, we could explore potential
targets for cancinogenesis, diagnosis, prognostication,
and treatment of IPMN.
FO28-04
CLINICAL IMPLICATION OF CEA AND
CA19-9 FOR THE PREDICTION OF
MALIGNANCY IN INTRADUCTAL
PAPILLARY MUCINOUS NEOPLASM
OF PANCREAS
Jae Ri Kim1, Mee Joo Kang1, Jin-Young Jang1,
Selyeong Lee1, Taesung Park1, Seung Yeoun Lee2,
Kyoung Bun Lee1, Wooil Kwon1, Ye Rim Chang1 and
Sun-Whe Kim1
1Seoul National University College of Medicine, Korea;
2Sejong General Hospital, Korea
Introduction: Several malignancy predictors are sug-
gested for intraductal papillary mucinous neoplasm
(IPMN). However, little is known about prognostic sig-
nificance of serum carbohydrate antigen (CA) 19-9 and
carcinoembryonic antigen (CEA).
Method: We analyzed 375 surgical biopsy proven
IPMN patients in order to explore malignancy predict-
ing power of tumor markers. Cut-off value of tumor
markers for malignancy prediction of IPMN was statis-
tically drawn.
Results: Of the patients, 117 (31.1%) patients had
malignant pathology (high grade dysplasia and invasive
IPMN). Serum CEA was elevated (>5 lg/L) in 4.4%,
and serum CA19-9 was elevated (>37 U/mL) in 16.1%
of the patients. Elevated serum CEA was not signifi-
cantly different according to malignancy or ductal type.
Serum CA19-9 was significantly elevated in malignant
IPMN (34.2% vs. 7.6%, p < 0.001) and main duct type
IPMN (40.0% vs. 14.3%, p = 0.001). Furthermore,
invasive IPMN had more frequent elevated serum
CA19-9 than high grade dysplasia (47.9% vs. 11.4%,
p < 0.001). Multivariate analysis revealed main pancre-
atic duct >5 mm (p = 0.047), mural nodule (p < 0.001),
and elevated serum CA19-9 (p < 0.001) as independent
malignancy predictors.
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Conclusions: Unlike serum CEA, serum CA19-9 level
was significantly higher in malignant IPMN and main
duct type IPMN. Invasive IPMN had more frequently
elevated serum CA19-9 than high grade dysplasia.
Serum CA19-9 level can be used as a malignancy pre-
dictor of IPMN.
FO28-05
SOLID PSEUDOPAPILLARY TUMOR
OF THE PANCREAS: ANALYSIS OF
CLINIOPATHOLOGICAL FEATURES
AND SURGICAL OUTCOMES
Ahmed Elgendi1, Saba Elgendi2 and Mohamed
Elgendi3
1Lecturer of Surgery, Egypt; 2Assistant Professor of
Pathology, Egypt; 3Professor of Surgery, Egypt
Introduction: Solid-pseudopapillary tumor (SPT) of the
pancreas is an uncommon pancreatic neoplasm with a
low-grade malignancy that occurs mainly in young
women. This study was undertaken to analyze the clini-
copathological characteristics of the disease and to
evaluate the outcome of surgical intervention in a ter-
tiary referral cancer centre.
Method: A prospectively maintained database of the
characteristics of 14 patients (13 females and 1 male),
with a mean age of 21.6 years (range 17–34 years) who
underwent surgical resection in our institution with a
definitive histological and immunohistochemical diag-
nosis of SPT between 2002 and 2012 was developed
and analyzed.
Results: Five cases (37%) presented with dull aching
pain, palpable mass in 3 cases (21%), with incidental
detection in 3 cases (21%). The tumor was located in
the body/tail in 12 cases and in the head in 2 patients.
Mean tumor diameter was 10.7 cm (range 5–21).
Tumors of the head were smaller (average 6.3 cm) but
more symptomatic than those in the body-tail (average
13 cm). None of the patients had metastases at presen-
tation. 2 cases underwent pancreaticoduodenectomy, 2
enucleations, while 10 patients had left pancreatectomy.
All cases were positive for nuclear b-catenin, and nega-
tive for membranous E-cadherin immunoreactivity.
Overall morbidity rate was 22% with no mortality. At
a median follow-up of 62 months (range 15–110), all
patients are alive without evidence of local recurrence,
metastasis, but one case of diabetes developed.
Conclusions: SPT is an indolent neoplasm with charac-
teristic macroscopic, microscopic, and immunohisto-
chemical features. The low grade biological
aggressiveness makes surgical resection possible despite
its large size and patients can survive a long period
after the operation.
FO28-06
PROGNOSTIC FACTORS AFTER
SURGERY FOR PANCREATIC
NEUROENDOCRINE TUMORS: A
SINGLE CENTER EXPERIENCE
Simona Olimpia Dima, Vlad Herlea,
Traian Dumitrascu, Cezar Stroescu, Florin Botea,
Raluca Purtan, Adina Croitoru, Cristian Gheorghe and
Irinel Popescu
Fundeni Clinical Institute, Romania
Introduction: Several classifications such as the World
Health Organization 2010 and European Neuroendo-
crine Tumor Society (ENET) were proposed to predict
prognosis for pancreatic neuroendocrine tumors
(PNET). The aim of the present study is to assess
potential prognostic factors after surgery for PNETs in
a large single centre experience.
Method: The study group included 98 consecutive
patients with PNETs submitted for surgery at the Cen-
ter of Digestive Diseases and Liver Transplantation of
Fundeni Clinical Institute, Bucharest, Romania,
between 2000 and 2012. All patients were diagnosed
using immunohistochemistry. Uni- and multivariate
analyses for potential prognostic factors for overall sur-
vival were performed.
Results: The patients had mainly non-functional
PNETs (60 patients – 61.2%). Eighteen patients
(18.4%) presented with lymph nodes metastases while
24 patients (24.5%) presented with synchronous distant
metastases (stage IV ENET). The median follow-up
time was 39 months (range, 1–227). For the entire
cohort of patients the 1, 5 and 10-year overall survival
rates were 89.4%, 76.9% and 67.8%, respectively. It
was observed a significant difference in survival
between patients with and without primary tumor
resection (p < 0.001). Furthermore, patients with stages
I, IIA, IIB ENET appears to have a better survival
compared with those with stage III and IV (p = 0.05).
Tumor size was found to positively correlate with
ENET stage (p < 0.01) and presence of distant metasta-
ses (p < 0.01); a negative correlation with the function-
ing syndrome was also noticed (p < 0.01).
Conclusions: Resection of the primary tumor, loco-
regional lymph nodes status and ENET staging system
appears to have an impact on overall survival in patients
with PNETs. Thus, routinely sampling of loco-regional
lymph nodes might potentially be used for better assess-
ment of prognosis in these patients. Resection represents
the most important therapeutical tool in order to obtain
a long-term survival in patients with PNETs.
FO28-07
CONTEMPORARY ASSESSMENT OF
PANCREATICODUODENECTOMY
BASED ON A SINGLE INSTITUTIONAL
EXPERIENCE
Jin He, Neda Rezaee, John Cameron, Martin Makary,
Kenzo Hirose, Michael Choti, Matthew Weiss,
Nita Ahuja, Timothy Pawlik and
Christopher Wolfgang
The Johns Hopkins Hospital, USA
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Introduction: To evaluate current status and trends of
the indications and outcomes for pancreaticoduodenec-
tomy (PD).
Method: Patients undergoing PDs for any indication
between 1990 and 2010 were retrospectively reviewed
from a prospectively maintained database.
Results: This cohort includes 3,661 PD with a median
age of 66 years (range 12–103) and a median length of
stay (LOS) of 10 days. The morbidity rate is 48% while
the 30 and 90-day mortality rates are 1.3% and 3.5%,
respectively. The most common indication for resection
is pancreatic ductal adenocarcinoma (41%), followed by
ampullary adenocarcinoma (11%), cholangiocarcinoma
(8.2%), pancreatic neuroendocrine neoplasm (5.2%) and
duodenal cancer (4.1%). The most common benign indi-
cation for PD is chronic pancreatitis (6.2%). The most
common complications include delayed gastric empting
(15%), post-operative pancreatic fistula (POPF) (14%),
and wound infection (12%). When evaluated by 10-year
intervals, the proportion of patients over 80 years old
undergoing PD increased from 7.5% (1990s) to 10.4%
(2000s) (p = 0.004) while LOS decreased from 13 days
(1990s) to 9 days (2000s) (p < 0.001). There is an
increase in both the number (55–267) and proportion
(4.6–11%) of patients undergoing resection of benign
cystic neoplasms – the majority of these being intraduc-
tal papillary mucinous neoplasm (IPMN) (193, 5.3%).
Non-invasive IPMN increased from 1% to 7%
(p < 0.001), while MCN decreased from 1.4% to 0.2%
(p < 0.001). Autoimmune pancreatitis increased from 0
to 1.6% while chronic pancreatitis decreased from
10.1% to 4.3% (both p < 0.001). The 5-year survival for
patients undergoing resection of benign cystic neoplasms
was 86% and did not change over time nor did the sur-
vival for any of periampullary adenocarcinomas.
Conclusions: PD is a safe operation. More PDs were
done for benign pancreatic lesions. Outcome of PD
depends on the disease biology.
FO28-08
HOW TO OPERATE
DUODENOPANCREATIC
NEUROENDOCRINE TUMOURS IN
MEN1. A SYSTEMATIC REVIEW
Sjoerd Nell, C.R.C. Pieterman,
J.M.J. Schreinemakers, I.H.M. Borel Rinkes,
M.R. Vriens and G. D. Valk
UMC Utrecht, The Netherlands
Introduction: Duodenopancreatic neuroendocrine
tumors (pNETs) are the main cause of death in Multi-
ple Endocrine Neoplasia 1 (MEN1). Surgical strategies
in MEN1 related pNETs are controversial. We investi-
gated the type of surgery required to treat pNETs in
MEN1 patients.
Method: A systematic literature search (Pubmed, Em-
base and Cochrane library) was performed up to the
15th of October 2012. Included studies reported surgi-
cal technique and related patient outcomes i.e. compli-
cations, re-operations, recurrence, metastasis and
survival. Surgical techniques were compared and
related to patient outcomes. For gastrinomas opera-
tions strategies including total duodenectomy were
compared with other types of resections. For insulino-
mas and non-functioning tumors enucleations were
compared with other operation strategies.
Results: Data from only 13 studies of high risk of bias
including 195 operated MEN1 patients were analysed.
For gastrinomas, operation strategies including duo-
denectomy were associated with less biochemical recur-
rence (6/40 vs. 23/42). For insulinomas, enucleation
was associated with more recurrence (8/15 vs. 5/38).
No differences in survival were seen in the investigated
groups. There is insufficient data for comparing the
rates of complications, re-operations and metastasis.
Conclusions: Only scarce literature is available on oper-
ation strategies for MEN1 related pNET. For gastrino-
mas, operation strategies including total duodenectomy
were associated with biochemical cure of patients. Fur-
thermore literature shows that larger pancreasresections
were associated with less biochemical recurrence of a
MEN1 related insulinoma. No benefit for survival was
found.
FO29-01
IMPACT OF HEPATIC RESECTION FOR
HEPATOCELLULAR CARCINOMA
INVADING THE HEPATIC VEIN
Yong Keun Park, Bong-Wan Kim, Weiguang Xu and
Hee Jung Wang
Ajou University School of Medicine, Korea
Introduction: Hepatic venous invasion (HVI) of hepato-
cellular carcinoma (HCC) is not common, but repre-
senting advanced tumor stage. Hepatic resection (HR)
is considered as a curative modality, but there is limited
data on the outcome after HR. The current study is
conducted to evaluate the outcomes of HR for HCC
with HVI, and prognostic significance of HCC with
HVI on outcomes after HR.
Method: We retrospectively analyzed 27 consecutive
patients with HCC with HVI who underwent HR
between 1994 and 2011. Surgical outcome and prognos-
tic factor after HR for this condition were analyzed.
Results: Main tumor size was mean 8.7 (4.4) cm, and
mean serum alpha-fetoprotein level was 9,822
(19,212) ng/mL. Patients who had HCC with HVI
demonstrated a median disease-free survival of
5.5 months and 1-year survival rate of 60.5% after
HR. The extent of tumor thrombus in hepatic vein did
not significantly correlated with oncological outcomes.
However, the disease-free survival was significantly
higher in patients without portal vein tumor thrombus
(PVTT) (n = 14, group A) than in patients with PVTT
(n = 13, group B) (p = 0.013). All patients in group B
had tumor relapse within 1 year after HR. The overall
5 year survival rates were 69.2% in group A and
33.8% in group B, respectively.
Conclusions: The results of HR for HCC with HVI
remain poor, but better than what were reported in
similar patients with non-surgical therapy. Concomitant
PVTT affect the oncological outcome, so HR is justi-
fied in selected patients with HVI, especially without
concomitant PVTT.
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FO29-02
HEPATIC VEIN TUMOR THROMBUS
OF HEPATOCELLULAR CARCINOMA
IS NOT CONTRAINDICATION FOR
SURGERY
Takashi Kokudo, Kiyoshi Hasegawa,
Yasuhiko Sugawara and Norihiro Kokudo
Graduate School of Medicine, The University of Tokyo,
Japan
Introduction: The presence of hepatic vein tumor
thrombus (HVTT) in hepatocellular carcinoma (HCC)
has been regarded as extremely poor prognosis. How-
ever, little is known about the significance of surgical
treatment for HVTT.
Method: Our prospective database of surgical resection
for HCC between October 1994 and December 2011 in
a tertiary care Japanese hospital was retrospectively
analyzed. We statistically compared tumor thrombus in
the peripheral hepatic vein (pHVTT) and tumor throm-
bus in the major hepatic vein (mHVTT). Patients with
tumor thrombus in inferior vena cava (IVCTT) were
also analyzed separately.
Results: Among 1,525 hepatic resections, 153 pHVTT
cases, 21 mHVTT cases, and 13 IVCTT cases were iden-
tified. Compared to the pHVTT group, the mHVTT
group had higher alpha-fetoprotein (AFP) level (AFP
[ng/dL] 49,666 vs. 5,508; p < 0.0001), higher incidence of
portal vein tumor thrombi (95 vs. 56%; p = 0.0005), and
higher incidence of major hepatic resection (67% vs.
42%, p = 0.037). The median survival time (MST) was
5.27 and 3.95 years respectively (p = 0.77), and median
time to recurrence (TTR) was 1.06 and 0.41 years respec-
tively (p = 0.74). Univariate analysis did not show
mHVTT as risk factor in MST or TTR. On the other
hand, MST and TTR for IVCTT patients were
1.39 years and 0.25 year respectively. The most frequent
location of recurrence was intrahepatic in all types of
HVTT (pHVTT 76%, mHVTT 56%, IVCTT 45%).
Conclusions: Hepatic resection for mHVTT has good
prognosis as well as pHVTT and is good indication for
surgery with acceptable MST. IVCTT can also be con-
sidered for surgery in selected cases.
FO29-03
SURGICAL STRATEGY AND OUTCOME
OF HEPATOCELLULAR CARCINOMA
PATIENTS WITH BILE DUCT TUMOR
THROMBUS
Deok-Bog Moon, Sung-Gyu Lee, Shin Hwang,
Ki-Hun Kim, Chul-Soo Ahn, Tae-Yong Ha,
Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park and
Yo-Han Park
Asan Medical Center, Ulsan University, Korea
Introduction: Less than 10% of icteric hepatocellular
carcinoma was related to obstruction of bile duct by
the tumor. Some patients could be treated by hepatec-
tomy with provision of adequate preoperative manage-
ment. This study was to examine the outcome of HCC
patients with bile duct tumor thrombus who underwent
operation.
Method: From October 1994 to August 2010, 53 HCC
patients (1.6%) having bile duct tumor thrombus involv-
ing minimum 2nd order branches were treated surgi-
cally. These were the first surgical treatment of HCC,
and the patients were followed up more than 18 months.
Clinical data were reviewed retrospectively and the pri-
mary end point was survival after surgical treatment.
Results: Common chief complaint was abdominal pain
(33.3%) and then jaundice (29.6%). Child A was77.4%
and 12 patients (22.6%) had cirrhosis. Mean total biliru-
bin level on admission was 9.8 mg/dL. Biliary drainage
was performed in 32 patients (60.4%). Portal vein inva-
sion was accompanied in 24 patients (45.3%). Duration
of preoperative management was 44 days and portal vein
embolization was performed in 6 patients and 9 patients
underwent TACE. Hepatic resection was performed in
49 patients (92.5%). Bile duct resection combined with
hepatectomy was performed in 17 patients (32.1%). 5-
year overall and disease survival rate were 30.7% and
17.5%. R0 resection of HCC was a significant factor
affecting on the overall and disease free survival. When
R0 resection was performed, bile duct resection was not
affected on the survival, but R0 resection was very diffi-
cult in Ueda type III patients without bile duct resection.
Conclusions: Preoperative biliary decompression made
us to perform hepatectomy in HCC with bile duct
tumor thrombus. R0 resection is very important for
good prognosis and hepatectomy with bile duct resec-
tion should be performed actively in Ueda type III
patient, similar to Klatskin’s tumor.
FO29-04
CLINICOPATHOLOGIC FACTORS
ASSOCIATED WITH EARLY LIVER
REGENERATION AFTER RIGHT
HEPATECTOMY IN PATIENTS WITH
HEPATOCELLULAR CARCINOMA
Jeongsu Nam, Kwangmin Park, Youngjoo Lee,
Songcheol Kim, Jaehoon Lee, Kibyung Song,
Jonghee Yoon, Jungwoo Lee and Dongjoo Lee
Asan Medical Center, Ulsan University, Korea
Introduction: This study was conducted to evaluate
liver regeneration by comparing preoperative computed
tomographic (CT) volumetry and CT volumetry on
postoperative day (POD) 7 after right hepatectomy in
patients with hepatocellular carcinoma. We sought for
clinicopathologic factors that could be correlated with
liver regeneration.
Method: Between January 2008 and October 2012, 74
patients with hepatocellular carcinoma underwent right
hepatectomy in our division. All but 1 patient were
Child-Turcotte-Pugh (CTP) class A. Volumes of liver
were measured for future liver remnant (FLR), and
liver remnant(LR). Early regeneration index (ERI) was
defined as [(VLR-VFLR)/VFLR)] 9 100, where VLR
means volume of the liver remnant and VFLR is volume
of the FLR. Clinicopathologic factors that could be
linked to liver regeneration were assessed retrospec-
tively.
Results: Age, prothrombin time, bilirubin did not influ-
ence early liver regeneration.Patients with higher preop-
erative serum albumin (cut off value as 3.5 g/dL) level
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showed higher early regeneration index. (ERI 0.55 vs.
0.34 p = 0.007). Also, remnant liver volume to body
weight ratio (RLV-BWT ratio) (cut off value as 0.5%)
was significantly correlated with early liver regenera-
tion. Interestingly, patients with low RLV-BWT ratio
(≤0.5) ratio showed higher ERI compared with those
who had high RLV-BWT ratio (>0.5) (ERI 0.95 vs.
0.41 p = 0.001).
In subgroup analysis(total of 20 patients), after exclud-
ing patients with large tumor(≥10 cm), right portal vein
thrombus or history of transarterial chemoembolization
(TACE) that might induce compensatory hypertrophy
of the remnant liver, serum albumin and RLV-BWT
still significantly linked to the ERI. (p < 0.05).
Conclusions: Remnant liver volume to body weight
ratio (RLV-BWT ratio) and preoperative serum albu-
min level were significantly correlate with early liver
regeneration. To avoid postoperative liver dysfunction,
these parameters can be used as a reference measure in
major hepatectomy.
FO29-05
CLINICAL IMPACT OF ANATOMICAL
LIVER RESECTION FOR
HEPATOCELLULAR CARCINOMA
WITH MICROSCOPIC PORTAL VEIN
INVASION
Takatsugu Matsumoto, Junji Kita, Yukihiro Iso,
Masato Kato, Mitsugi Shimoda and Keiichi Kubota
Dokkyo Medical University, Japan
Introduction: Hepatocellular carcinoma (HCC) is fre-
quently complicated with portal venous invasion (PVI).
We aimed to investigate the benefit of anatomical liver
resection (ALR) for HCC complicated with PVI.
Method: 97 consecutive patients who underwent initial
curative hepatectomy for single nodule HCC accompa-
nied with PVI were enrolled to this study. Patients were
divided into 2 groups, Group A (n = 74); patients who
received ALR, Group B (n = 23); patients who received
non-ALR. Clinical and pathological factors were com-
pared between both groups. Data were expressed as a
mean  standard deviation (SD) of Group A versus
that of Group B.
Results: There were no significant differences in age
(year) (65.6  9.7 vs. 64.4  9.6; p = 0.825), gender,
alpha-fetoprotein (AFP) level (ng/dL) (14,629.5 
80,754.3 vs. 2,249.3  4,848.8; p = 0.955), protein
induced by vitamin K absence or antagonist-II(PIVKA-
II) level (mAU/mL) (10,280.4  28,587.5 vs.
1,542.8  3,073.9; p = 0.674), intraoperative bleeding
amount (mL) (802.6  873.4 vs. 1,395.7  2,510.0;
p = 0.052) (mL), operation time (minutes) (303.6 
105.2 vs. 307.6  105.4; p = 0.593), total Pringle time
(minutes) (57.0  22.9 vs. 47.9  25.9; p = 0.207) and
tumor size (cm) (7.0  5.3 vs. 4.2  1.7; p = 0.207). On
the other hand, there were significant differences in pro-
thrombin time (%) (86.4  11.3 vs. 78.7  11.0;
p = 0.001), total bilirubin level (mg/mL) (0.7  0.4 vs.
0.9  0.3; p = 0.021), platelet count (9104/lL) (18.0 
8.4 vs. 11.9  5.9; p = 0.001) and ICG R15 (%) (13.7 
6.2 vs. 24.5  13.2; p = 0.96).
Both 5-year survival rate and disease-free survival rate
of Group A were significantly higher than those of
Group B (46.1% vs. 14.3%; p = 0.002 and 33.8% vs.
0%; p = 0.001), respectively.
Multivariate analysis revealed that ALR (absent/ pres-
ent), age (≤65/>65) (years), Alpha-fetoprotein level
(AFP) (≤20/>20) (ng/mL), were associated with postop-
erative survival.
Conclusions: ALR has a survival benefit for HCC
patients with PVI.
FO29-06
COMPARISON OF LIMITED AND
ANATOMIC HEPATIC RESECTION FOR
HEPATOCELLULAR CARCINOMA
WITH HEPATITIS C
Masaki Kaibori, Kosuke Matsui, Morihiko Ishizaki,
Tatsuma Sakaguchi, Hideyuki Matsushima and
Masanori Kwon
Kansai Medical University, Japan
Introduction: The long-term outcome after resection of
hepatocellular carcinoma is influenced by factors
related to the tumor and the underlying liver disease.
The prognosis of hepatocellular carcinoma is worse in
hepatitis C virus antibody-positive patients than in hep-
atitis B surface antigen-positive patients. In patients
with hepatitis C virus infection and hepatocellular car-
cinoma, the optimum extent of surgical resection, i.e.,
limited versus anatomic, is still controversial.
Method: Among 326 patients with hepatitis C virus
infection who underwent curative resection of hepato-
cellular carcinoma between 1992 and 2006, 271 patients
received limited resection and 55 patients had anatomic
resection of at least two Couinaud subsegments with
complete removal of the portal territory containing the
tumor. The clinical characteristics, operative results,
and long-term survival of these two groups were com-
pared.
Results: Although the patients receiving limited resec-
tion had significantly worse preoperative liver function
than the patients undergoing anatomic resection, the
postoperative liver function of the limited resection
group was significantly better. The mortality and mor-
bidity rates were not significantly different after limited
and anatomic resection. Disease-free survival and over-
all survival were similar after both types of resection,
as were the incidence and pattern of intrahepatic tumor
recurrence.
Conclusions: In patients with hepatitis C virus infection
and hepatocellular carcinoma, anatomic resection does
not provide any significant benefit and should not be
performed unless it is technically necessary. In patients
with a limited hepatic functional reserve, removal of
the tumor with preservation of the liver parenchyma
may take priority over wide resection.
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FO29-07
SURGICAL OUTCOMES FOR
HEPATOCELLULAR CARCINOMA IN
PATIENTS WITH NONALCOHOLIC
FATTY LIVER DISEASE
Yuki Hirose, Jun Sakata, Tomohiro Katada,
Natsuru Sudo, Taku Ohashi, Kazuyasu Takizawa,
Kabuto Takano, Takashi Kobayashi,
Masahiro Minagawa and Toshifumi Wakai
Niigata University Graduate School of Medical and
Dental Sciences, Japan
Introduction: The present study investigated outcomes
following surgical resection of hepatocellular carcinoma
(HCC) in nonalcoholic fatty liver disease (NAFLD).
Method: Of 538 consecutive Japanese patients undergo-
ing curative liver resection for HCC, 25 patients had
NAFLD. Clinicopathological characteristics and surgi-
cal outcomes of patients with NAFLD-related HCC
were analyzed.
Results: There were 13 men and 12 women, with a med-
ian age of 73 years (range 54–83 years). The median
value of BMI was 25.6 kg/m2 (range, 19.3–38.3 kg/m2).
Using the NAFLD activity scoring system of Kleiner et
al., the median score was 4 (range, 2–7). Nonalcoholic
steatohepatitis (NASH) was verified histologically in 14
patients. Cirrhosis was verified histologically in 12
patients with NASH. The incidence of postoperative
morbidity was 60% (15/25 patients). The most common
complication was hepatic insufficiency (n = 6), followed
by biliary fistula (n = 4), portal vein thrombosis (n = 2),
ascites (n = 1), paralytic ileus (n = 1), and acute respira-
tory insufficiency (n = 1). The incidence of postoperative
30-day mortality was 8% (2/25 patients). Two patients
giving the postoperative 30-day mortality were NASH-
related cirrhosis and had undergone right hemihepatec-
tomy. The causes of deaths were hepatic failure and mul-
tiple organ failure. The cumulative 5-year survival rate
and cumulative 5-year disease-free survival rate of 25
patients with NAFLD were 69% and 55%, respectively.
Conclusions: Surgical resection may provide a survival
benefit for patients with NAFLD-related HCC. Patients
undergoing resection for NAFLD-related HCC have an
increased risk of postoperative morbidity and mortality.
Patients with NAFLD-related HCC, especially underly-
ing NASH-related cirrhosis, should be treated carefully
to avoid postoperative complications.
FO29-08
HEPATOCELLULAR CARCINOMA
WITH BILE DUCT THROMBI IN NON
CIRRHOTIC LIVERS: IS AGGRESSIVE
SURGERY WORTHWHILE?
Ashwin Rammohan, Jeswanth Sathyanesan,
Anbalagan Pitchaimuthu, Kamalakannan Rajendran,
Senthil Kumar Perumal, Kesavan B,
Ravi Ramasamy, Ravichandran Palaniappan and
Manoharan Govindan
Govt. Stanley Medical College Hospital, India
Introduction: Obstructive jaundice due to bile duct
tumour thrombus (BDTT) is an unusual clinical
entity and an uncommon presenting feature of Hepa-
tocellular carcinoma (HCC). There is a paucity of
studies which have examined the outcome of hepatec-
tomy in this subset of patients. The objective of this
study is to evaluate the outcome of hepatectomy for
HCC with obstructive jaundice due to BDTT in non-
cirrhotic livers.
Method: From 1997 to 2012, out of 426 HCC patients,
39 with non fibrolamellar type HCC with obstructive
jaundice due to BDTT in non-cirrhotic livers, who
underwent hepatectomy at our tertiary care referral
centre were analysed. In all the patients, demographic,
clinicopathological and investigative (biochemical,
radiological) data were noted.
Results: The patients comprised of 28 men and 11
women whose age ranged from 32 to 71 years. Their
serum total bilirubin, serum transaminase levels, Serum
alkaline phosphatase level and serum AFP were in the
range of 3.6–22 mg/dL, 45–210 IU/L, 256–1,020 IU/L,
146 to 12,000 ng/mL respectively. All BDTT were con-
firmed intraoperatively. The operative procedures
included right hepatectomy with thrombectomy
through choledochotomy and t tube drainage (n = 16),
extended right hepatectomy combined with extrahepatic
bile duct excision (n = 10), left hepatectomy(n = 9),
extended left hepatectomy(n = 2) and left lateral seg-
mentectomy(n = 2). Average blood loss and median
operative time were 420 mL and 186 minutes respec-
tively. The diameter of primary tumour ranged from 5
to 18 cm and the length of the thrombi ranged between
3 and 7.5 cm. Postoperative morbidity was 28.2%
(n = 11) which included bile leak in 4 patients. Two
patients died of post hepatectomy failure (mortality
5.1%).The 1, 3, 5 year survival rates were 81.09%,
48%, 10.5% respectively with a median survival of
28.6 months.
Conclusions: The mere presence of BDTT in HCC does
not indicate an advanced or inoperable lesion. When
technically feasible, formal hepatic resection is the pre-
ferred first-line treatment option in these patients.
FO30-01
PREOPERATIVE SELECTIVE BILE
DUCT PORTAL VEIN DOUBLE
LIGATION (PSBPL) SHORTEN THE
WAITING SPAN AND GIVES RISE TO
GREATER TOLERANCE TO EXTENDED
HEPATECTOMY THAN PVL IN RATS
Weizheng Ren, Ai-Qun Zhang, Xiaofeng Zhang,
Chonghui Li and Jiahong Dong
Chinese PLA General Hospital, China
Introduction: Extended hepatectomy is often the only
curative treatment for many liver diseases. Confronting
insufficient FLR, PVE/PVL has been established as
routine procedure. Yet the potential of malignancy pro-
gression during the waiting period and the insufficient
responsiveness in cases calls for a groundbreaking
method to benefit more.
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Method: To investigate the effect of bile-duct and por-
tal-vein double ligation(BPL), we established a model
of 90% BPL and used 90% PVL as control. Second
stage resection preserving 10% of the estimated liver
were performed to evaluated the tolerance of the regen-
erating liver to extended resection. We chose 3 days
after BPL (3B) and 3 or 4 days after PVL (3V or 4V)
to perform second stage resection, and used sham-sub-
total hepatectomy (SS) as control. Alternation of intra-
hepatic bile acids, mitosis, apoptosis were investigated,
canalicular network disturbance and reconstruction
were reveal by ABCB1 IF staining, and activation of
polarity-related pathways were evaluated.
Results: The weight of the regenerating lobes was sig-
nificantly higher after BPL than PVL since 3 days after
ligation (p < 0.05) with 0 mortality. More importantly,
BPL induced more synchronized hepatocyte mitosis
and canalicular network reconstruction, which involves
faster regain of hepatocyte polarity. A primary recon-
struction of canicular network was obtained at as early
as 3 days post ligation in BPL group, preceding that in
PVL group by at least 24 hours. More importantly,
BPL resulted in remarkably improved tolerance of the
liver. The survival rate after second stage resection
were, 23%, 46%, 54%, and 89% in SS, 3V, 4V and 3B
groups, respectively. Our results also indicated that the
effect was induced by enhanced bile acid retention and
preconditioning induced by BPL.
Conclusions: We testified BPL as a safe and easily
applicable preoperative procedure to replace PVL. By
increasing the intrahepatic bile acid, BPL resulted in an
promoted regeneration with synchronized canalicular
network reconstruction, and the regenerating liver
induced manifested significantly enhanced tolerance to
second stage resection.
FO30-02
CHEMOTHERAPY ASSOCIATED LIVER
INJURY AND MAJOR HEPATIC
RESECTION FOR COLORECTAL LIVER
METASTASES: ROLE OF APRI SCORE
AND ENDOTHELIN-1 LEVELS. A
PROSPECTIVE STUDY
Francesca Ratti, Federica Cipriani, Annalisa Gagliano,
Marco Catena, Michele Paganelli and Luca Aldrighetti
San Raffaele Hospital, Italy
Introduction: Chemotherapy associated liver injury
(CALI) is a risk factor for development of liver failure
(LF) following hepatic resection. APRI score, based on
AST level and platelet count, has been proposed as a
marker of oxaliplatin induced parenchymal damage in
patients with metastases. Endothelin-1 is a vasocon-
strictor peptide which might play a role in PLF patho-
genesis, as a mediator of acute phase shear stress. Aim
of this study was to evaluate correlation between APRI
score and Endothelin-1 level in pre- and postoperative
period.
Method: Patients who required major liver resection
for CLM between 1st January 2011 and 31st June 2013
with oxaliplatin based CT entered this prospective
study. In all of them preoperative APRI score was cal-
culated. In all the patients liver function tests including
AST, ALT, bilirubin and PT were dosed preoperatively
and in POD1, 2 and 5, as well as ET-1 serum levels.
Results: 26 patients entered the study. They received
meanly 6  2 cycles of CT. 14 of the whole series
(53.8%) underwent right hepatectomy, 4 (15.4%) right
trisectionectomy, 6 (23.1%) left hepatectomy and 2
(7.7%) left trisectionectomy. 12 (46.2%) patients under-
went portal vein occlusion before surgery. Mortality
was nil. Morbidity was 38.5%: 4 patients (15.4%)
showed signs of LF.Patients developing PLF had a sig-
nificantly higher APRI score (0.66  0.11 vs.
0.49  0.12, p < 0.05), number of CT cycles (9  2 vs.
5  2, p < 0.0) and baseline ET-1 levels (18  4.4
vs. 9.7  3.2, p < 0.05). Pearson analysis showed corre-
lation of APRI score with preoperative and POD2
ET-1 levels and POD5 ET-1.
Conclusions: Correlation of APRI with pre and postop-
erative ET-1 may reflect parenchymal damage induced
by CT, resulting in a higher baseline risk of LF.
Patients with elevated APRI and ET-1 levels should
therefore be evaluated with caution when a major
resection is planned.
FO30-03
HOW SHOULD WE CLASSIFY R0
RESECTION IN PATIENTS
UNDERGOING LIVER RESECTION FOR
COLORECTAL LIVER METASTASES?
SHOULD MORE THAN 1 MM BE THE
NEW CRITERIA?
Anna Powell-Chandler, Adam Christian, Huw Jones,
Zsolt Kaposztas and Nagappan Kumar
University Hospital Wales, United Kingdom
Introduction: R0 is defined as resection margin greater
than 0 mm. This institution uses R0 to mean a margin
greater than 1 mm. We present a case for redefining R0
margin.
Method: We analysed patients undergoing resections
for colorectal liver metastases (CRLM) from January
2003 to December 2012 at Cardiff Liver Unit. Prospec-
tive database recorded demographics, type of resection,
blood loss, transfusion, hospital stay, mortality and
morbidity. Pathology was reported in standard form
using Royal College of Pathologists Dataset. Peri-oper-
ative chemotherapy was not routine. Data on neoadju-
vant chemotherapy (a small proportion of patients) is
being collected. Follow-up data was from our records
and General Practioners. We followed patients up to
30 June 2013. We used SPSS ver 20 for statistical
analysis. Means were compared using Chi Square test.
We used Kaplan Meier method to measure survival
and Log rank test to compare various factors. p < 0.05
was considered significant.
Results: Two hundred and fifteen resections for CRLM
over 10 years; 146 males, 69 females, median age
67 years (range 34–86). Overall mortality 2.7% (6/215).
Operations performed; right hepatectomy (56), left hep-
atectomy (15), left lateral sectionectomy (13), central
hepatectomy (6), segment 6/7 resection (8), caudate
lobectomy (1), combined hepatectomy and metastatec-
tomy (22), other metastatectomy/segmentectomy (94).
Overall actuarial survival at 1, 3, 5 and 10 years was
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93%, 64%, 43% and 21% respectively. 5 year actuarial
survival in patients who had resection with a margin of
0 mm, 0-1 mm and >1 mm were 31%, 31% and 46%
respectively (p = not significant). However median sur-
vival of patients with 0, 0–1 mm and >1 mm were 4.1,
1.8 and 4.6 years. The group with margin between 0
and 1 mm performed poorly (p = 0.024).
Conclusions: R0 resections have traditionally been
defined as histological margin of more than 0 mm.
However, survival in patients who have margins 0–
1 mm was poor. We conclude that margin greater than
1 mm should be used as criteria for R0 resection for
CRLM.
FO30-04
LIVER FAILURE IN PATIENTS
TREATED WITH CHEMOTHERAPY
FOR COLORECTAL LIVER
METASTASES: ROLE OF CHRONIC
DISEASE SCORES IN PATIENTS
UNDERGOING MAJOR LIVER
SURGERY. A CASE-MATCHED
ANALYSIS
Francesca Ratti, Federica Cipriani, Michele Paganelli,
Marco Catena and Luca Aldrighetti
San Raffaele Hospital, Italy
Introduction: An accurate and non-invasive tool to pre-
dict preoperatively histopathologic chemotherapy
induced liver injury still lacks. Objective of this study
was to evaluate the role of chronic liver disease scores
as Postoperative Liver Failure (PLF) predictors in
Colorectal Liver Metastases (CLM) surgery for patients
treated with Oxaliplatin-based chemotherapy and
undergoing major liver resection.
Method: Data regarding 8 patients who developed PLF
after major hepatectomy (Group B) were compared to
those of 24 patients who did not develop PLF (Group
A) in a case-matched analysis for baseline and disease
characteristics and liver resection extension. Pearson
coefficient was calculated to assess chronic liver disease
scores association with biochemical data. ROC curves
analysis was performed too.
Results: In Group A median number of CT cycles was
lower, even without significant difference (6 vs 9, p NS),
interval between treatment and surgery was longer (11 vs
7 weeks, p < 0.05) and bevacizumab was more frequently
administered (66.7% vs 37.5% of patients, p < 0.05). In
Group B the median APRI score was 0,53 (range: 0.86 –
4.26) whereas in Group A median score was 0,30 (range:
0.06 – 2.21), with a statistically significant difference
(p < 0.05). Median FIB-4 score was 2.46 (range: 0.86–
13.65) in Group B and 1.58 (range: 0.27–7.68) in Group
A (p < 0.001). Multivariate analysis showed a significant
correlation between APRI and the onset of PLF. A good
accuracy of APRI score was evident in ROC curves with
an area under the curve of 0.72 (p 0.003).
Conclusions: APRI score is calculated considering both
liver damage and platelet count, it is costless and easy
available. This study demonstrates that it has in a good
accuracy in PLF prediction and consequently in CT
induced liver damage evaluation.
FO30-05
SCORING MODEL TO ASSESS
MORBIDITY OF SURGERY LIVER
HYDATID CYST
Hadj Omar EL Malki1, Amine Souadka2, Badr Serji2,
Amine Benkabbou2, Raouf Mohsine2, Lahcen Ifrine2,
Redouane Abouqal2 and Abdelkader Belkouchi2
1University Mohammed Vth Souissi, Rabat, Morocco,
Biostatical, clinical research and epidemiological
laboratory LBRCE, Medical School, Morocco; 2University
Mohammed Vth Souissi, Rabat, Morocco Medical
School, Morocco
Introduction: Surgery is the mainstay of liver hydatid
cyst (LHC) treatment. It’s still associated with high
morbidity and mortality because of specific postopera-
tive complications (bile leaks, bilomas, deep bleeding,
and deep suppurations). The aim of this study was to
develop a scoring model to identify occurrence of mor-
bidity after LHC surgery.
Method: We conducted a retrospective study of 672
patients with LHC treated at the Surgery Department
“A” at Ibn Sina University Hospital, Rabat, Morocco.
Specific morbidity and 30 variables were assessed. Mul-
tivariate logistic regression was performed to develop a
scoring model to predict morbidity after LHC surgery.
We calculated sensitivity (Sn), specificity (Sp), positive
predictive value, and negative predictive value at the
best cut-off point identified as that which maximized
Sn+Sp.
Results: Five independent predictive factors of morbid-
ity after LHC surgery were retained, ie, presence of cyst
preoperative complications, 3 or more cysts in the liver,
thick pericyst, biliary fistula, and capitonnage alone as
residual cavity management. Multivariate model
showed a good fit. Discriminating ability of the model
was fair. In theoretical risk, scores ranged from 0 to 5.
When the score was 2 or more, sensitivity of the scor-
ing model was 80.3%, specificity was 58.5%, positive
predictive value was 30.3%, and negative predictive
value was 93%. Our scoring-developed model can pre-
dict morbidity occurring with 80.3% Sn and 58.5% Sp
when the score is 2 or more.
Conclusions: Our model has a good negative predictive
value (93%) if the score is 0 or 1. Based on another
cohort of patients, a new study would assign the vali-
dation of this risk scoring system.
FO30-06
ASSESSMENT OF FUTURE REMNANT
LIVER FUNCTION IN HILAR
CHOLANGIOCARCINOMA USING
HEPATOBILIARY SCINTIGRAPHY
Kasia P. Cieslak, Jimme K. Wiggers, Roel J. Bennink,
Oliver R.C. Busch, Dirk J. Gouma and
Thomas M.Van Gulik
Academic Medical Center, Amsterdam, The Netherlands
Introduction: Assessment of future remnant liver (FRL)
function is crucial in resectable hilar cholangiocarcino-
ma (HCCA). Complete biliary drainage of the FRL is
considered essential for postoperative function in
extended resections. Hepatobiliary scintigraphy (HBS)
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using 99mTc-mebrofenin provides segmental, quantita-
tive information on parenchymal function in the uptake
phase, while the excretion of 99mTc-mebrofenin depends
on drainage of the biliary system. Preoperative HBS
therefore, accounts for parenchymal function as well as
for quality of biliary drainage. The aim of this study
was to evaluate the value of HBS in the preoperative
work-up of patients undergoing resection for HCCA.
Method: From August 2008 to August 2013, 69
patients suspected of HCCA underwent resection. Pre-
operatively, HBS was applied according to the planned
resection using time-activity curves generated from
regions of interest (total liver and FRL). A validated
HBS cut-off value of 2.69%/minute/m2 was used to
indicate sufficient FRL function. Postoperative morbid-
ity (Clavien-Dindo ≥3a) and mortality were assessed.
Results: HBS was performed in 52 of the 69 patients
(75%). Preoperative biliary drainage was performed
endoscopically or by percutaneous transhepatic biliary
drainage (PTBD) in 45/52 patients. Based on HBS, 31/
45 patients were considered resectable (group A),
whereas 14/45 patients required additional procedures
(group B), consisting of portal vein embolization
(n = 2), revision of biliary drainage (n = 8), or a modi-
fied (parenchyma sparing) technique (n = 8). Overall
morbidity and in-hospital mortality were 40.6% and
7.2%, respectively. Morbidity was 48.4% and 42.9% in
group A and B, respectively (p = 0.76). Liver failure
related mortality was not different (1 of 31 patients in
group A, and 1 of 14 patients in group B, p = 0.53).
Conclusions: Preoperative HBS accounts for parenchy-
mal liver function as well as quality of biliary drainage,
and identifies patients who require additional or modi-
fied procedures for resection of HCCA.
FO30-07
ROLE OF TRANS-ARTERIAL
EMBOLIZATION IN DOWNSTAGING
HEPATOCELLULAR CARCINOMA TO
FIT UCSF CRITERIA IN PATIENTS
UNDERGOING LIVING DONOR LIVER
TRANSPLANTATION FOR HEPATITIS C
RELATED LIVER DISEASE
Karan Julka, Bhavin Vasavada, Andrzej Komorowski,
Chao-long Chen and Chih-chi Wang
Kaohsiung Chang Gung Memorial Hospital, India
Introduction: Transarterial embolization (TAE) is a
well-established modality of treatment for patients suf-
fering from hepatocellular carcinoma (HCC) while on
the waiting list for deceased donor liver transplantation
(LT). However, the outcome in patients undergoing liv-
ing donor LT (LDLT) for Hepatitis C virus (HCV)
related HCC is arduous because of the almost universal
recurrence of HCV post transplantation and the risk of
the transplanted liver undergoing subsequent fibrosis.
Hence to address this issue, we evaluated the impact of
TAE on downstaging HCV related HCC to fit UCSF
criteria for LDLT.
Method: We retrospectively analyzed the outcome in
patients undergoing LDLT for HCV related HCC, who
were initially outside the UCSF criteria and received
TAE intervention and compared them with those who
fit the criteria and did not receive TAE. The overall
patient survival and the HCC recurrence free survival
were compared between the 2 groups. The tumors were
downstaged in the TAE group to fit the UCSF criteria.
Results: From 2002 to 2010, a total of 82 patients hav-
ing HCV related HCC underwent LDLT at Kaohsiung
Chung Gung Memorial Hospital, Taiwan. For the
entire cohort study, the mean duration of follow-up
was 4.37  2.29 years. The 2 groups were well matched
except for the Childs score, which was more in non-
TAE group (p = 0.034). Post TAE, 40 patients were
within UCSF criteria and 4 were within UCSF but out-
side Milans criteria.The overall survival in the TAE
group at 1 and 3 years was 82% and 72% and in the
non-TAE group was 92% and 70% respectively. The
recurrence rate was 13.15% (5/38) in the non TAE
group and was 6.81% (3/44), in the TAE group
(p = 0.416).
Conclusions: TAE was effective in downstaging HCV
related HCC to fit UCSF criteria with outcomes com-
parable to those presenting initially within the criteria
and without TAE.
FO30-08
INTRAOPERATIVE ABLATION FOR
SMALL HCC NOT AMENABLE FOR
PERCUTANEOUS RADIOFREQUENCY
ABLATION IN CHILD A CIRRHOTIC
PATIENTS
Ahmed Elgendi1, Mohamed Elshafei2, Fatma Abdel-
Azizi3 and Essam Bedewy4
1Lecturer of Surgery, Egypt; 2Lecturer of Radiology,
Egypt; 3Professor of Tropical Medicine, Egypt;
4Lecturer of Tropical Medicine, Egypt
Introduction: Radiofrequency ablation (RFA) was ini-
tially started by radiologists as a percutaneous treat-
ment, but surgeons started to use RFA by surgical
approach for patients with tumors at locations difficult
for the percutaneous procedure. The aim was to evalu-
ate the results of intraoperative RFA for small hepato-
cellular carcinomas (HCCs) (<3 cm) in locations
difficult for a percutaneous approach.
Method: Two hundred forty-seven patients with small
solitary HCC (<3 cm) were treated; 196 via percutane-
ous RFA while 51 patients presented at sites not ame-
nable for percutaneous route. Twenty-seven out of 51
patients underwent surgical resection, while 24/51
patients underwent intraoperative RFA.
Results: The location and depth of the tumor from the
liver capsule was the only significant factors in the
choice of the surgeon between resection and RFA.
RFA was successful in all tumors (complete ablation
rate of 100%). In the surgery group, all patients
achieved R0 resection. Complication rate was compara-
ble (p01.0). After a median follow-up of 37 months
(range, 10–45 months), no tumors showed neither local
progression nor local recurrence and no significant dif-
ference was observed between two groups as regards
early recurrence and number of de novo lesions
(p00.49). One-year and 3-year survival rates were 93%
and 81%, respectively, in the resection group compara-
© 2014 The Authors
HPB 2014, 16 (Suppl. 2), 128–224 HPB © 2014 Americas Hepato-Pancreato-Biliary Association
Free Oral 227
ble to the corresponding rates of 92% and 74% in the
RFA group (p00.9).
Conclusions: For small HCC in locations difficult for a
percutaneous approach, intraoperative RFA can be an
alternative option for deep-seated tumors necessitating
more than one segmentectomy achieving similar tumor
control, and overall and disease-free survival.
FO30-09
REGRESSION OF LIVER INJURY
AFTER BILIARY DECOMPRESSION IN
EXTRAHEPATIC CHOLESTASIS
Adianto Nugroho and Toar Lalisang
Division of Digestive Surgery, Indonesia
Introduction: Liver injury secondary to extra-hepatic
cholestasis may be found in severe obstructive jaun-
dice patients. Bile acid and hepatocyte apoptosis play
an important role in this condition. We did an exper-
imental study to see the regression in liver injury
after biliary decompression in obstructive jaundice
patients.
Method: We evaluate pre- and post-decompression
liver biopsy specimens from 21 patients with severe
obstructive jaundice due to peri-ampullary malignancy.
Liver morphology was assessed with regard to fibrosis,
periportal inflammation, ductal proliferations and cho-
lestasis. Each of the items was graded 0 (none was
observed) to 3 (severe). The sum of all items was
regarded as the liver injury score.
Results: Regression of liver injury score after biliary
decompression was seen in all cases. Changes in mor-
phologic features were followed by a significant
improvement in improvement in serum liver function as
direct consequences of the liver regeneration. This
improvement is very important since well functioning
liver is associated with a lesser rate of morbidity and
mortality following definitive surgery for periampullary
malignancies.
Conclusions: Biliary decompression leads to a signifi-
cant reduction in liver injury score and normalization
of serum liver functions, which is necessary to allow a
safe definitive surgery in periampullary malignancies.
FO30-10
LONG-TERM FOLLOW-UP OF SMALL
EQUIVOCAL HEPATIC LESIONS IN
PATIENTS WITH COLORECTAL
CANCER, WITH A SPECIAL
REFERENCE TO THE ROLE OF
GADOXETIC ACID-ENHANCED
MAGNETIC RESONANCE IMAGING
Jai Young Cho, Jihoon Kim, Ho-Seong Han,
Yoo-Seok Yoon, Dae Wook Hwang, Young Ki Kim,
Hong Kyung Shin and Woohyung Lee
Seoul National University Bundang Hospital, Korea
Introduction: The initial abdominal CT scan for
patients with colorectal cancer may reveal indetermi-
nate hepatic lesions. This study evaluates the indetermi-
nate hepatic lesions on abdominal CT scan and the
diagnostic accuracy of MRI.
Method: From January 1, 2009, to December 31, 2009,
data were collected retrospectively. Those who were
noted to have small equivocal hepatic lesions in size of
less than 1 cm on their preoperative staging CT scans
were included in the study. Gadoxetic acid-enhanced
MRI was additionally checked for all patients. Hepatic
lesions with an increase in size or manifestation of
malignant radiologic features over time were considered
as likely metastases after at least 3 years of follow-up.
Results: Out of 494 patients underwent colorectal sur-
gery, 65 patients (13.2%) had 121 small equivocal hepa-
tic lesions on their preoperative staging work up using
CT. Out of 121 lesions, 11 lesions had definite findings
of metastatic lesions and 100 had definite benign fea-
tures including simple cyst or hemangioma on MRI.
However, 10 out of 121 lesions were still not definitive
even after checking CT and MRI. Out of 11 resected
definite lesions on MRI, 10 lesions were pathologically
proven to be CRLM but one lesion showed benign nod-
ule. All 100 definite benign lesions on MRI were shown
to have stable lesions that were subsequently deemed to
be benign. Out of 10 equivocal lesions on MRI, 6
lesions showed radiologic evidence of progression of the
lesions, suggestive of early metastases and remaining 4
lesions were stable lesions. The sensitivity and specificity
of gadoxetic acid-enhanced MRI for the diagnosis of
CRLM in small equivocal hepatic lesions on CT were
68.8% and 95.2%, respectively. The negative predictive
value of MRI for metastasis was 100%.
Conclusions: Indeterminate hepatic lesions may require
further evaluation and can be clarified by MRI which
is useful diagnostic tool.
FO30-11
MULTICENTRE FRENCH STUDY OF
SURGICAL MANAGEMENT FOR
RUPTURED HEPATOCELLULAR
CARCINOMA – HAVE WE IMPROVED
PROGNOSIS DURING THE LAST
20 YEARS?
Michel Scotte1, Lilian Schwarz1, Yves Patrice Letreut2,
Alexis Laurent3, Astrid Herrero2, Fabrice Muscari4,
Christian Ducerf5, Christian Letoublon6 and Francois
Lacaine7
1Rouen University Hospital, France; 2Hopitaux de
Marseille, France; 3Henri mondor Hospital, France;
4Ho^pitaux de Toulouse, France; 5Ho^piatux de Lyon,
France; 6Ho^pitaux de Grenoble, France; 7French, France
Introduction: Spontaneous rupture of hepatocellular
carcinoma (HCC) is a life-threatening complication of
HCC, with an incidence of 12–15% in Asiatic surgical
series. In Europe, limited data are available related to a
lower incidence of 2–3%. The aim of this study was to
report the French multicentric experience of surgically
treated patients with ruptured HCC and to evaluate
survival improvement during 3 successive periods.
Method: This study was a retrospective analysis of
patients surgically treated for ruptured HCC, by resec-
tion at emergency surgery or staged hepatectomy
between January 1995 and March 2012 in 22 French
teaching hospitals. 3 successive periods were deter-
mined, before 2000, between 2000 and 2006, and after
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2006. Data on clinical features, treatment strategies,
and survival outcomes were collected.
Results: A cohort of 148 patients (120 male and 28
female), with a median age of 68y, was identified..
Eighty one (54%) patients had histologic evidence of
underlying liver disease, and the related etiologies were
alcohol (30 patients), NASH (27 patients), hepatitis C
(20 patients), hepatitis B (12 patients) or, hereditary he-
mochromatosis (5 patients). The mean tumor size was
65 mm [20–250]. Curative HCC treatment was
provided by emergency hepatectomy (36%) or staged
hepatectomy (64%) with pre-treated bleeding by trans-
arterial embolization in 57% of such cases. The cumu-
lative 1-, 3-, and 5-year overall survival (OS) rates were
62, 26 and 9%, respectively. The corresponding dis-
ease-free survival rates were 40, 18 and 6%, respec-
tively. No difference was found between the 3 periods
of time, concerning clinical presentation, patient ‘s
management or long term survival.
Conclusions: No improvement in survival after curative
surgery for ruptured HCC have been observed during
the last twenty years. Despite a poor survival rate, sur-
gical resection remains the only chance for cure, even in
the area of interventional radiology or target therapies.
FO30-12
LAPAROSCOPIC VS ROBOTIC MINOR
LIVER RESECTION OF LESIONS
LOCATED IN THE POSTERO-
SUPERIOR SEGMENTS: A
COMPARATIVE ANALYSIS
Roberto Montalti1, Alberto Patriti2, Vincenzo Scuderi1,
Aude Vanlander1 and Roberto Ivan Troisi1
1Hepato-Biliary Surgery, Liver Transplantation Service,
Belgium; 2General, Minimally Invasive and Robotic
Surgery – Spoleto, Italy
Introduction: Laparoscopic liver resection (LLR) is
worldwide accepted as safe treatment option for ante-
rior lesions of the liver. The approach of lesions located
in the postero-superior (PS) segments (I-IVa-VII-VIII)
is more difficult and usually associated to a higher con-
version rate and intraoperative complications. It has
been speculated that robotic assistance can facilitate
the approach to these segments.
Method: From 2005 to 2013, 122 minor liver resection
were performed in PS segments: 91 of whom with pure
laparoscopic approach (LAP-Group) and 31 with
robotic assistance (ROB-Group). We analyzed retro-
spectively data coming from a prospective kept data-
base looking to pre-intra and postoperative parameters
in both groups.
Results: No perioperative mortality was recorded.
Mean age was of 58.6  15.6 vs. 63.7  12.7 years,
respectively (p = 0.12), male rate was 54.9% vs. 61.3%
(p = 0.68). Contemporaneous colic resection was per-
formed in 4.4 vs. 22.6% (p = 0.006). Type of resection
were: bisegmentectomy in 19% and 16%; monosegmen-
tectomy 24% and 16%; wedge 37% and 42%; mixed
20% and 26%, respectively for Lap and ROB (p = 0.8).
Previous liver resection were 11% vs. 7.4% (p = 0.73),
mean surgical time 286  103 vs. 301  135 minutes
(p = 0.54), blood loss 292  404 vs. 380  381 cc
(p = 0.35) respectively. Pringle maneuver was 13.2% vs.
58.1% respectively for LAP and ROB (p < 0.01). Con-
version rate was 11% vs. 16.1% (0.53). Histology
revealed that the mean nodules number was of
1.6  0.9 vs. 1.9  1.3 (p = 0.2), total lesions dimen-
sion was of 44.4  28.2 vs. 42.9  31.1 mm (p = 0.8)
and R1 margins 15% vs. 11% (p = 0.55). Overall com-
plication rate was of 18.2 vs. 14.8% (p = 0.6), mean
hospital stay 5.6  4.1 vs. 8.6  8 days (p = 0.01).
Conclusions: Pure laparoscopic and robotic liver resec-
tions for lesions located in PS segments have a similar
outcome and conversion rate. A trend for higher blood
losses could be related to differences in operative tech-
niques and resection devices (surgical aspirator in LAP
vs. crush clamping technique in ROB).
FO31-01
PANCREATIC CANCER IN CANADA:
INCIDENCE, MORTALITY, SURVIVAL
AND SURGICAL TREATMENT
Scott Hurton, Geoff Porter, Mark Walsh and
Michele Molinari
Dalhousie University, Canada
Introduction: Although pancreatic cancer (PC) is a
common gastrointestinal tumour, population based
studies on this disease are lacking. The main purpose
of this study was to evaluate the trends in the inci-
dence, survival and surgical therapy of Canadian
patients affected by PC.
Method: Multiple Canadian databases were consulted
to extract the incidence, mortality, number of pancre-
atic resections, outcomes after surgical therapy and
overall survival of patients with PC stratified by year,
gender and province.
Results: In 2012, PC was diagnosed in 4,600 Canadi-
ans and it was responsible for 4,300 deaths. The age-
standardized incidence was 9–10 new cases per
100,000 individuals. The mortality rate remained the
highest among all the solid tumours with a case-to-
fatality ratio of 0.93. The age-standardized five year
relative survival was 9.1% (95% CI; 8.3–10). There
were geographical variations among provinces with
the highest survival registered in Ontario (10.9%; 95%
CI = 9.9–12) and the lowest reported in Nova Scotia
(4.7%; 95% CI = 2.8–7.2). The percentage of patients
who underwent surgery decreased from 19% (2006–
2007) to 17% (2009–2010). Pancreatic resections were
performed in high volume centers in 74% of cases. In
hospital mortality was 5%, 93% of patients were dis-
charged home and 36% required home support after
discharge.
Conclusions: Long-term outcomes of Canadian patients
affected by PC remain unsatisfactory with only 9% sur-
viving at 5-years. The vast majority of patients who
underwent surgery were referred to high volume centers
and despite the good outcomes of patients undergoing
surgery, resections were performed only in 17–19% of
Canadian patients.
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FO31-02
PREOPERATIVE HYPERGLYCEMIA AS
A PROGNOSTIC FACTOR IN
PANCREATIC CANCER
Woohyung Lee, Ho-Seong Han, Yoo-Seok Yoon,
Dae Wook Hwnag, Jai Young Cho, Young Ki Kim
and Hong Kyung Shin
Seoul National University Bundang Hospital, Korea
Introduction: The present study was for clarifying the
effects of preoperative hyperglycemia on the prognosis
and recurrence patterns of pancreatic ductal adenocar-
cinomas.
Method: Between September 2003 and June 2012, 126
patients who were diagnosed as pancreatic cancer
underwent operation in Seoul National University
Bundang Hospital. We retrospectively analyzed survival
outcomes and recurrence patterns according to the pre-
operative glucose level.
Results: The patients were divided into two groups
according the preoperative blood glucose level (BG)
less than 200 mg/dL or higher: BG <200 mg/dL
(n = 96); and BG > 200 mg/dL (n = 30). There were
no differences in age, presence of jaundice, preoperative
biliary drainage, tumor site, tumor size,, cancer stage,
and complication rate between two groups (p > 0.05).
The 3-year disease-free survival rates showed that BG
>200 mg/dL group (6.7%) were significantly lower than
BG <200 mg/dL group (36.4%; p = 0.026). The multi-
variate analysis revealed that preoperative hyperglyce-
mia (p = 0.027; RR = 1.850; 95% confidence interval
[CI] 1.071–3.196), venous invasion (p = 0.016;
RR = 1.830; 95% CI 1.121–2.986), T stage (p = 0.004;
RR = 0.039; 95% CI 0.005–0.322), and N stage
(p = 0.029; RR = 0.568; 95% CI 0.342–0.942) were
independent factors of disease-free survival. Concerning
recurrence patterns, preoperative diabetic patients
tended to recur tumor more distant site than preopera-
tive non-diabetic patients (p = 0.020).
Conclusions: Preoperative hyperglycemia affects prog-
nosis in patients with pancreatic cancer after operation.
FO31-03
AVAILABILITY OF NEW BIOMARKER
ONCO-PDT-PANCTM FOR
PANCREATIC CANCER
Takefumi Niguma, Toru Kojima and
Tetsusige Mimura
Okayama Saiseikai General Hospital, Japan
Introduction: Pancreatic cancer is one of the incurable
cancer since early cancer biomarkers has not been
found. Recently, various new biomarkers were devel-
oped by next-generation sequencing and mass spec-
trometry analysis. Oncomics.Co. developed techniques
which score the presence of pancreatic cancer, based on
proteome analysis in blood plasma. We verified the use-
fulness of Onco-PDT-PanCTM (OPP).
Method: We examined 32 invasive ductal carcinoma of
pancreas, 8 other pancreato-biliary tract cancer (3 car-
cinoma of ampulla, 2 bile duct carcinoma, 2 gallblad-
der carcinoma, 1 pancreatic acinar cell carcinoma) and
6 autoimmune pancreatitis, and 13 non-cancer pancre-
atic disease (5 pancreatic neuroendocrine tumor
(NETG1), 4 pancreatic-benign cyst, 2 IPMA, 1 MCA,
1 chronic pancreatitis) as control. All patients were
pathologically diagnosed after surgery, except for auto-
immune pancreatitis.
Results: The median OPP of invasive ductal carcinoma
is 56.0  7.7 whereas non-cancer is 48.0  6.6
(p = 0.003). ROC curve showed the cutoff value is
50.5, with 75% sensitivity and 62% specificity. In
patients with invasive ductal carcinoma, OPP did not
correlate with known biomarkers. Although size and
local extent of cancer did not correlate with the OPP,
lymph node metastasis showed high OPP significantly.
(n0 vs. n1–3; 53.0  7.6 vs. 58.0  6.5, p = 0.047). 9
invasive ductal carcinoma patients showing OPP over
50.5 before surgery were measured OPP and CA19-9
after surgery. CA19-9 decreased after surgery, in con-
trast, OPP did not change. The median OPP of other
pancreato-biliary tract cancer is significantly high
(59.5  8.6, p = 0.004). The median OPP of autoim-
mune pancreatitis is also significantly high (58.5  5.0,
p = 0.005).
Conclusions: OPP is the first unique new biomarker of
pancreatic cancer developed by proteome analysis in
Japan, however it is necessary to verify the usefulness
and significance in more numerous clinical settings.
FO31-04
IMPACT OF LYMPH NODE RATIO ON
SURVIVAL IN RESECTED
PERIAMPULLARY MALIGNANCIES
Young-Dong Yu1, Dong-Sik Kim1, Sung-won Jung1,
Pyoung-Jae Park2, Sae-Byul Choi2, Tae-Jin Song3,
Sang-Yong Choi2 and Sung-Ock Suh1
1Korea University Anam Hospital, Korea; 2Korea
University Guro Hospital, Korea; 3Korea University
Ansan Hospital, Korea
Introduction: As in other gastrointestinal malignancies,
it has been suggested that lymph node ratio (LNR)
may be associated with survival in patients with pe-
riampullary malignancies. Although LNR has been
studied in pancreatic adenocarcinoma, it has been infre-
quently demonstrated in other periampullary malignan-
cies. The purpose of this study was to determine the
relation between LNR and survival in different types of
periampullary malignancies.
Method: A retrospective review of 253 pancreaticoduo-
denectomies (PDs) performed between 2002 and 2012
was undertaken. Clinicopathologic data were collected,
and LNR was calculated. Patients with positive lymph
node (LN) status were placed into the following
groups: (1) LNR = 0; (2) LNR ≤ 0.2; (3) LNR ≤ 0.4;
and (4) LNR > 0.4.
Results: Of the 253 malignancies identified, there were
80 (31.6%) pancreatic adenocarcinomas, 23 (9%) duo-
denal adenocarcinomas, 75 (29.6%) ampullary adeno-
carcinomas, and 75 (29.6%) cholangiocarcinomas.
Median follow up was 18 months. Tumor size, positive
resection margin, and nodal involvement affected
patient survival in all malignancies studied. Although
the absolute number of positive LNs obtained during
resection did not significantly change prognosis,
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increasing LNR was associated with decreased survival
(p < 0.05) in all types of periampullary tumors except
duodenal adenocarcinomas.
Conclusions: Positive LN status in all patients with pe-
riampullary malignancies is associated with worse sur-
vival rates than in those with no evidence of disease.
LNR is inversely associated with survival rates in
almost all types of periampullary malignancies.
FO31-05
EVALUATION OF TAXANE EFFECTS
ON PANCREATIC CANCER CELLS
Matej Kocik1, Marie Ehrlichova2, Veronika
Brynychova2, Iwao Ojima3, Martin Oliverius1 and
Pavel Soucek2
1IKEM, Czech Republic; 2National Institute of Public
Health, Czech Republic; 3State University of New York
at Stony Brook, USA
Introduction: Taxanes present an attractive alternative
to the generally used gemcitabine treatment which has
limited clinical benefits to pancreatic cancer
patients. Our study investigates mechanisms of taxane
action in pancreatic cancer cell line models in vitro.
Method: Pancreatic carcinoma cell lines MiaPaCa-2,
BxPc-3 and PaTu8902 were used for in vitro analyses
of effects of traditional taxane paclitaxel and experi-
mental second generation taxanes SBT-1214 and SBT-
1216. Taxane efficacy was evaluated by MTT test and
apoptosis was assessed by flow cytometry.
Results: For pancreatic carcinoma cell lines MiaPaCa-
2, BxPc-3 and PaTu8902, paclitaxel IC50 ranged from
15 to 42 nM; SBT-1214 and SBT-1216 IC50 ranges
were from 18 to 83 nM and 20 to 65 nM respectively.
Concentrations close to IC50 (10 or 30 nM) of paclit-
axel or SBT-1214/1216 induced apoptosis and 100 nM
concentrations produced complete G2/M cell cycle
block in PaTu8902 cells. On the other side, paclitaxel
but not SBT 1214/1216 induced apoptosis in MiaPaCa-
2 cells. In BxPc-3 cells, paclitaxel and SBT-1214 but
not 1216 produced G2/M block at 100 nM concentra-
tion. Moreover, solely SBT-1216 induced apoptosis at
this concentration and G2/M block at 300 nM.
Conclusions: Our data show that both traditional tax-
ane paclitaxel and second generation derivatives are
highly cytotoxic in pancreatic cancer cells but mecha-
nisms of their action substantially differ most probably
due to the different expression of apoptotic pathways.
Considering recent data demonstrating preliminary evi-
dence of activity of nab-Paclitaxel in patients who pro-
gressed on gemcitabine-based therapy, underlying
mechanisms of taxane action should be further studied.
Study was supported by GACR No.P301/12/1734 and
IKEM MZO 00023001 grants.
FO31-06
PATHOLOGICAL COMPLETE
REMISSION OF PANCREATIC CANCER
FOLLOWING NEOADJUVANT
CHEMORADIATION THERAPY; NOT
THE END OF BATTLES
Chang Moo Kang, Jin Ho Lee, Ho Koung Hwang,
Sung Hoon Choi and Woo Jung Lee
Yonsei University College of Medicine, Korea
Introduction: In spite of controversial issues, pancrea-
tectomy following neoadjuvant chemoradiation therapy
(NeoCRT) has been applied in treating advanced pan-
creatic cancer. Cases of pathological complete remis-
sion (pCR) following NeoCRT is rare, and its long-
term follow up data is still lacking.
Method: From January 2000 to December 2012, medi-
cal records of the patients who underwent pancreatec-
tomy for pancreatic ductal adenocarcinoma were
retrospectively reviewed. Characteristics of the patients
with pCR were summarized and their long-term follow
up data were analyzed.
Results: Among 86 patients with pancreatic cancer
who underwent radical pancreatectomy following Neo-
CRT, 10 patients (11.6%) were reported to pathologi-
cal CR. Seven patients were female and 3 were male,
with median age, 64 years. Median tumor size was
measured 2.8 cm in greatest diameter. Median pre-Neo-
CRT serum CA 19-9 was 313.5 U/mL, and post-Neo-
CRT serum CA 19-9 was 9.9 U/mL shown to be
significant difference between two serum CA 19-9 level
(p = 0.005). Pylorus-preserving pancreaticoduodenecto-
my was done in 8 patients, the others received distal
pancreatosplenectomy. Combined vascular resection
was performed in 5 patients. Median 5 lymph nodes
were noted to be retrieved and no tumor metastasis
were observed. Postoperative chemotherapy was
received in 6 patients. Overall disease specific survival
rate of patients with pCR was analyzed as 72.9%.
When comparing with patients without pCR following
NeoCRT, disease-free survival was statistically superior
in patients with pCR (p = 0.042). However, five
patients experienced cancer recurrence and recurrence
risk was still increasing until 10 months, postopera-
tively. Three patients developed peritoneal seeding and
2 were found to have liver metastasis.
Conclusions: pCR is rarely reported following neoCRT,
and this condition is not telling the cure of the disease.
Early recurrence in the pattern of liver metastasis and
peritoneal seeding can be expected. However, long-term
survival could be maintained in patients without recur-
rence. Further investigation is necessary for predicting
failure of treatment.
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FO31-07
PROSPECTIVE EVALUATION OF
GEMOX BASED NEO-ADJUVANT
RADIO-CHEMOTHERAPY FOR
BORDERLINE AND LOCALLY
ADVANCED PANCREATIC
ADENOCARCINOMA. ANALYSIS ON 66
PATIENTS
Safi Dokmak
Beaujon Hospital, France
Introduction: To evaluate the results of induction treat-
ment by gemcitabine + oxaliplatine (GEMOX) based
chemotherapy and radiotherapy for borderline (BPA)
and locally advanced pancreatic adenocarcinoma
(LAPA).
Method: From 2007 to 2012, 66 pts were prospectively
evaluated. Histology was obtained (100%) and patients
received a mean of 5 (4–8) cycles of chemotherapy and
54 Grays of radiotherapy. Radiological evaluation was
mainly done by CT scan. Surgery was proposed except
in case of local progression (LP) or distant metastases
(DM). Delay between radiotherapy and surgery was 65
(33–146) days. No patients were lost of PO follow up
(3–75 months).
Results: 37 pts were excluded for DM or LP, 29 under-
went surgery and 27 (41%) had resection for BPA
(20 = 74%) or LAPA (7 = 26%). Mean age was 62
(42–72) years. Resections included pancreaticoduoden-
ectomy (67%) or distal resection (33%), including 44%
with venous resection. The mean operative and blood
loss were 280 minutes (110–630) and 400 (100–1,000),
respectively. No patients died and overall morbidity
was 52% (mainly chylous ascites = 26%). Hospital stay
was 14 days (8–48). Long-term functional results
included intractable diarrhea (33%), weight loss >10%
(100%) and readmission (18%) for parenteral nutrition.
Adjuvant chemotherapy (93%) was delayed >3 months
in 52%. Mean tumour size was 25 (10–110), with
necrosis>50% in 33%; lymph node were present in
48% and R0 resection in 82%. Median (months) and
5 year of OS and DFS were 16 (7–75), 41%, 14 (4–61),
and 22%, respectively for the entire population; sur-
vival was better in resected compared to non resected
patients: median = 23 vs. 13 months, p = 0.004) and 5-
y = 41 vs. 0%, log rank = 12.869).
Conclusions: This strategy was associated with favour-
able rates of resectability, tumor necrosis, and R0
resection. However, PO morbidity is high and delayed
adjuvant treatment. After resection, survival seems sim-
ilar to that obtained for resectable disease at diagnosis.
FO31-08
RETROSPECTIVE ANALYSIS OF 125
PATIENTS FOLLOWING A WIPPLE
PROCEDURE BY MONTENEGROS
TECHNIQUE
Roland Montenegro Costa and Lucio Lucas
IHPBA, Brazil
Introduction: During the last 30 years pancreatic sur-
gery has seen a dramatic improvement in the post-oper-
ative period primarily due to the improvement of ICU
care for post-Whipple patients. Despite these improve-
ments the morbidity remains the same today as in the
1970s, 55%. Moreover, the mortality has decreased
from 35% to an acceptable 0–6%. The central reason
for mortality is pancreatic fistulas, considered the
“Achilles Heel” of the procedure. This complication is
the trigger for the development of delayed gastric empt-
ing, intra-abdominal abscesses, bleeding, sepsis, multi-
organ failure, and death.
Method: The authors analyzed retrospectively 125
patients with various pathology of disease involving the
periampullary regions. A Whipple procedure was per-
formed binding the pancreaticogastrostomy using an
isoperistaltic tube originating from the great curvature.
In this technique, a gastric tube was connected from
the great curvature of the stomach, binding the residual
pancreas by using 2.0 PDS to tie a purse string. For
most of the operations a pancreatic ductal stent was
used if the main duct had a diameter less than 5 mm or
if the pancreas had a soft parenchyma.
Results: Today, the rate of fistulas after a Whipple
procedure ranges from 10 to 29%. With our technique
the rate of pancreatic fistulas was 2.4%. Such fistulas
did not occur due to the breakdown of the pancreatic-
ogastric anastomosis, but due to the mechanism of cut-
ting, originating during the process of tying the purse
string suture in a soft pancreas.
Conclusions: The authors have shown that by binding
the pancreaticogastric anastomosis using this method,
it is both safe and reliable and necessitates more trials
in order to be accepted and used in these complex
operations. This technique has reduced the fistula rate,
thereby decreasing the mortality rate and length of hos-
pital stay.
FO32-01
DIFFUSION-WEIGHTED MR IMAGING
OF GALLBLADDER
ADENOCARCINOMA:
DIFFERENTIATION FROM ADENOMA
AND ANALYSIS WITH EMPHASIS ON
HISTOLOGIC GRADES
Sung Pil Yun, Hyung-Il Seo and Suk Kim
Busan National University Hospital, Korea
Introduction: Generally, histologic grades of gallblad-
der adenocarcinoma correlate with survival. However,
it is difficult to differentiate histologic grades of gall-
bladder adenocarcinoma by imaging. The purpose of
our study was to investigate the value of DWI for dif-
ferentiating gallbladder adenocarcinoma from ade-
noma, and differentiating gallbladder adenocarcinoma
according to histologic grades.
Method: Forty-three patients with gallbladder adeno-
carcinoma and 8 patients with adenoma who had
undergone MR with respiratory-triggered DWI were
included in this retrospective study. Signal intensity of
gallbladder adenocarcinoma and adenoma was ana-
lyzed on DWI (b = 800s/mm2), in comparison with
spleen signal by Chi-square test. ADC value of adeno-
carcinoma and adenoma were compared separately for
1.5-T and 3.0-T by Mann–Whitney U test. Gallbladder
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adenocarcinoma were divided to three groups accord-
ing to histologic grades; Well-differentiated (n = 10),
moderately-differentiated (n = 17), and moderate-to-
poor- and poor-differentiated adenocarcinomas
(n = 16). Qualitative DWI analysis was performed
according to histologic grades by Chi-square test. ADC
values according to histologic grades were also com-
pared separately for 1.5-T and 3.0-T by Kruskal-Wallis
test.
Results: DWI intensity was significantly different
between gallbladder adenocarcinoma and adenoma.
ADC values of gallbladder adenocarcinoma and ade-
noma were 0.999  0.212 9 103 and 1.815  0.332 9
103 mm2/second, respectively at 1.5-T (p = 0.002), and
1.179  0.420 9 103 and 2.105  0.489 9 103 mm2/
second, respectively at 3.0-T (p = 0.006). DWI intensity
was not significantly different according to histologic
grades of gallbladder adenocarcinoma. However, ADC
value of well-differentiated adenocarcinoma were signif-
icantly higher than other high-grade adenocarcinomas.
ADC values of well-differentiated, moderate-differenti-
ated, and moderate-to-poor and poor-differentiated ad-
enocarcinomas were 1.240  0.152 9 103, 0.990 
0.252 9 103, and 0.903  0.064 9 103 mm2/second,
respectively at 1.5-T (p = 0.033), and 1.512  0.382 9
103, 1.088  0.425 9 103, and 0.984  0.260 9 103
mm2/second, respectively at 3.0-T (p = 0.030)
Conclusions: DWI can be reliable for differentiating
gallbladder adenocarcinoma according to histologic
grades as well as differentiating gallbladder adenocarci-
noma from adenoma.
FO32-02
THE ROLE OF IN- VIVO PROTON
MAGNETIC RESONANCE
SPECTROSCOPY IN GALLBLADDER
CANCER PATIENT: A METABONOMIC
APPROACH
Surender Kumar1, Devendra Singh1, Anit Parihaar3,
Nuzhat Hussain2 and Paarijat Suryavanshi1
1King George‘s Medical University, Lucknow, India;
2Dr Ram Manohar Lohia Institute of Medical Sciences,
India, 3King George‘s Medical University, Lucknow, UP,
India
Introduction: Gall bladder cancer is not an uncommon
malignancy in northern Indian females with an inci-
dence of 5–7 per 100,000 women. The clinical presenta-
tion is vague and in spite of several new available
diagnostic modalities most of the cases are detected in
late stage. Local biochemical and metabolic changes
are expected to be evident in malignant lesions much
before the disease is morphological or radiologically
evident. The present study was aimed to assess the
diagnostic role of metabonomics using in-vivo Proton
nuclear magnetic resonance spectroscopy (MRS) in gall
bladder cancer patients.
Method: A total of 30 patients including 10 cases of
advanced gallbladder cancer, 10 cases gall stones and
10 normal gall bladders were subjected to magnetic res-
onance imaging and MRS and the findings were corre-
lated with the FNAC/ biopsy findings. The MRI and
MRS sequences was performed at 1.5 Tesla, GE, excite
machine (WI, US). Axial and coronal T1 FSE sequence
was done. T2 FSE sequence was obtained in three
orthogonal planes and subsequent MRS was done with
PRESS (point resolved spectroscopy) sequence.
Results: The in-vivo MR spectra of all the gallbladder
cancer patients were dominated by choline containing
compounds (TCho) at 3.2 ppm while no such finding
was observed in patients of gall stones and normal gall-
bladder. Raised TCho levels were also found in
involved portion of liver and metastatic lymph node
(s). Overall the technique had a sensitivity and specific-
ity of 100%.
Conclusions: TCho detected by in-vivo NMR is a sensi-
tive and specific non invasive tool for diagnosing gall
bladder cancer. However, the potential clinical uses of
this technique in the management of a gallbladder can-
cer require further multicentric large sample size studies
involving early gallbladder cancer patients.
FO32-03
ROLE OF FDG PET/CT IN DECIDING
RESECTABILITY IN GALL BLADDER
CANCER
Thakur Deen Yadav, Ajeet Pratap Maurya,
Ujwal Zambare, Rahul Parghane, Anish Bhattacharya,
Anupam Lal and Gurpreet Singh
Postgraduate Institute of Medical Education and
Research, Chandigarh, India
Introduction: Gall bladder cancer (GBC) is a rare dis-
ease with dismal prognosis. Most patients of gall blad-
der cancer present in advanced stage. Surgery does not
offer any survival benefit in the presence of metastasis.
Preoperative imaging is critical. MDCT is inseparable
part of preoperative work up. While PET/CT has a
potential to change the course of management in many
cancers, its role in GBC is being defined. This study
aimed to determine role of PET/CT in deciding resect-
ability of GBC.
Method: From July 2009 to August 2013 consecutive
patients suspected to be suffering from GBC underwent
routine work up including MDCT. Only those patients
who were deemed resectable on MDCT included in the
study. All such patients underwent F18-FDG PET/CT
after ruling out diabetes mellitus. Patients with evidence
of distant metastasis were subjected to FNAC for con-
firmation of the diagnosis. Data were prospectively col-
lected. PET/CT assessed for determining malignant
nature of disease and for distant metastasis. Results of
PET/CT analyzed in comparison with MDCT.
Results: Eighty three patients were included in the
study. Fifty seven (68.7%) patients explored with intent
of curative resection. Resection could be completed in
43 (51.8%) patients. Twenty six (31.3%) patients did
not undergo exploration due to identification of metas-
tases. Diagnosis was confirmed using histopathology or
cytology as gold standard. In determining malignant
nature of disease, PET-CT had sensitivity, PPV and
accuracy of 97.3%, 92.2% and 90.4% respectively.
PET-CT findings resulted in change in management
in 31.3% patients deemed resectable by standard
work-up.
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Conclusions: PET-CT is important in detecting distant
metastasis which is missed by conventional imaging.
Thus PET-CT has an impact on the management of
gall bladder cancer.
FO32-04
INCIDENTAL GALL BLADDER CANCER
(IGBC) ERRONEOUSLY INCLUDES
BOTH ‘TRUE IGBC’ AND ‘PSEUDO-
IGBC’!
Satyajit Godhi, Shivendra Singh, Raja Kalayarasan,
Amit Javed and Anil Agarwal
GB Pant Hospital & MAM College, India
Introduction: IGBC is defined as gallbladder cancer
(GBC) detected on histopathological examination
(HPE) with no pre or intraoperative suspicion of malig-
nancy, however in the literature, the term is loosely
applied to all GBC detected in patients operated with a
benign diagnosis i.e. includes those suspected intraoper-
atively and on examination of the removed GB. Hence
this study, to analyse & compare ‘true IGBC’ with
‘labeled IGBC’ with features suggestive of malignancy
on preoperative imaging & intra-operative examination.
Method: The prospective study of patients “labeled” as
IGBC and managed between May 2005–September
2012. Patients with insufficient details were excluded.
Review of preoperative imaging and operative notes
were done to ascertain any suspicion of malignancy in
retrospect. Resectability rate, type of surgery and sur-
vival of true IGBC (GroupA) were compared with
missed GBC (GroupB).
Results: Of 103 patients, USG reported diffuse thicken-
ing (n = 17), not suspicious of malignancy in 10 & sus-
picious thickening in 7. Focal thickening or mass
suspicious of malignancy was present in 33. Preopera-
tive CT/MRI was done in 15 patients for suspected
malignancy. Intraoperatively 47 had focal thickening/
GB mass suspicious of malignancy. In the overall
analysis 53 had preoperative imaging or intraoperative
findings suggestive of malignancy. Majority (96%) had
T1b/T2 disease in GroupA while 79.2% had T2/T3 dis-
ease in GroupB. Overall resectability rate was signifi-
cantly higher in the GroupA vs. GroupB (76% vs.
41.5%, p = 0.001) and adjacent organ resection was
significantly lower in Group A (10.5% vs. 40.9%,
p = 0.009). Median survival in GroupA was signifi-
cantly higher than groupB (60 months vs. 28 months,
p < 0.001).
Conclusions: Only 50 of 103(58.33%) patients “labeled”
as IGBC were found to be true IGBC. True IGBC
patients have early stage disease, better resectability
rate, require limited resection and better survival com-
pared to unsuspected/unexpected & missed GBC. In
the published literature (IGBC) includes both – true
IGBC and Pseudo-IGBC i.e. missed and unsuspected
GBC, hence use caution in interpreting results!
FO32-05
SURGICAL APPROACH FOR
ADVANCED GALLBLADDER CANCER
DEPENDS ON PROGNOSTIC FACTORS
Ryota Higuchi1, Takehiro Ota1, Tatsuo Araida2,
Hideki Kajiyama1, Takehisa Yazawa1, Mimi Okano1
and Masakazu Yamamoto1
1Tokyo Women’s Medical University, Japan; 2Tokyo
Women’s Medical University Yachiyo Medical Center,
Japan
Introduction: To evaluate factors associated with prog-
nosis and unresectablility in advanced gallbladder can-
cer (GBC).
Method: A retrospective review of 300 consecutive
cases of advanced GBC, not included early gallbladder
cancer with cancerous invasion up to subserosa, treated
surgically in a single institution.
Results: On multivariate analysis, JSBS T4 classifica-
tion was the only independent prognostic factor (HR
3.07; p = 0.0014). R0 resection was also important,
although significance was borderline (HR 2.01;
p = 0.0031, significance level 0.0023). There were no
long-term survivors among patients with multiple liver
metastases (2-year survival rate 0%) and dissemination
(3-year survival, 0%). There were few long-term survi-
vors (5-year survival, 3%) among patients with inva-
sion through the hepatoduodenal ligament (Binf3).
Five-year survival with para aortic lymph node metas-
tasis was 14.8%. There was no difference in long-term
survival rates between patients who underwent bile
duct resection or pancreaticoduodenectomy (PD) and
those who did not, or with respect to the type of hepa-
tectomy performed. However, in patients with T2R0
and lymph node metastasis without liver metastasis or
dissemination, there was a difference in survival rate
between those who underwent PD (92%) and those
who did not (68%, p = 0.024). The rate of lymph node
or local recurrence was 0% in patients who underwent
PD and 32% in those who did not (p = 0.034).
Conclusions: Surgery may not be indicated for patients
with multiple liver metastasis, dissemination, Binf3, and
visible para-aortic lymph node metastasis. R0 surgery
is important and PD may improve survival in selected
patients.
FO32-06
REGIONAL LYMPHADENECTOMY FOR
GALLBLADDER CANCER: RATIONAL
EXTENT AND PATIENT OUTCOMES
Jun Sakata1, Taku Ohashi1, Yuki Hirose1, Tomohiro
Katada1, Natsuru Sudo1, Kazuyasu Takizawa1,
Kabuto Takano2, Takashi Kobayashi1, Masahiro
Minagawa1 and Tshifumi Wakai1
1Niigata University Graduate School of Medical and
Dental Sciences, Japan; 2Niitsu Medical Center
Hospital, Japan
Introduction: This study aimed to define the rational
extent of regional lymphadenectomy for gallbladder
cancer and to clarify its effect on long-term survival.
Method: A total of 152 patients with gallbladder can-
cer who underwent a minimum of “extended” portal
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lymph node dissection (defined as en bloc removal of
the first- and second-echelon nodes) from 1982 to 2010
were retrospectively analyzed. Based on previous stud-
ies, regional lymph nodes of the gallbladder were
divided into first-echelon nodes (cystic duct or peric-
holedochal nodes), second-echelon nodes (node groups
posterosuperior to the head of the pancreas or around
the hepatic vessels), and more distant nodes.
Results: Among the 152 patients (total of 3,352 lymph
nodes, median of 19 per patient), 79 patients (52%)
had 356 positive nodes. Among node-positive patients,
the prevalence of nodal metastasis was highest in the
pericholedochal (54%) and cystic duct (38%) nodes,
followed by the second-echelon node groups (29% to
19%), while more distant node groups were only rarely
(5% or less) involved. Disease-specific survival after R0
resection differed according to the nodal status
(p < 0.001): most node-negative patients achieved long-
term survival (median, not reached; 5-year survival,
80%), whereas among node-positive patients, 22 sur-
vived for more than 5 years (median, 37 months; 5-year
survival, 43%).
Conclusions: Gallbladder cancer first spreads to the
first-echelon nodes (cystic duct or pericholedochal
nodes) and then to the second-echelon nodes located
posterosuperior to the head of the pancreas or around
the portal vein/hepatic arteries. The rational extent of
lymphadenectomy for gallbladder cancer should include
the first- and second-echelon nodes. Such aggressive
lymphadenectomy can achieve an acceptable rate of
long-term survival even in patients with nodal metasta-
sis, provided that a potentially curative (R0) resection
is feasible.
FO32-07
MINIMALLY INVASIVE VS.
CONVENTIONAL OPEN SURGICAL
APPROACH OF RADICAL
CHOLECYSTECTOMY FOR
GALLBLADDER CANCER: A
COMPARATIVE STUDY.
Anil Agarwal, Raja Kalayarasan, Amit Javed, Puja
Sakhuja and Rajeev Uppal
GB Pant Hospital & MAM College, India
Introduction: Traditionally laparoscopic surgery has
been contraindicated in patients with suspected gall
bladder cancer (GBC).; However a few recent studies
have advocated minimal invasive approach in GBC.
This study was undertaken to determine the safety and
feasibility of laparoscopic radical cholecystectomy
(LRC) for GBC and to compare with open radical cho-
lecystectomy(ORC).
Method: Prospective study performed between June
2011 and December 2012. Patients of primary GBC
with limited liver infiltration and incidental GBC
(IGBC) following laparoscopic cholecystectomy were
considered for LRC. Extensive liver infiltration, extra-
hepatic adjacent organ involvement and IGBC follow-
ing open cholecystectomy were excluded. Patients who
fulfilled the study criteria and underwent ORC during
the period formed the control group. A Standard radi-
cal cholecystectomy (resection of segments IVB and V
with lymphadenectomy) was performed. All port sites
were excised in IGBC patients.
Results: Of the 25 patients with suspected GBC who
underwent laparoscopic segment IVb, V resection, 19
had GBC (15primary, 4 IGBC) and underwent LRC
(Group A). On comparison with 36 patients who
underwent ORC (Group B), the median operating time
(minutes) was more in GroupA (300 vs. 270,
p = 0.035), however, the median blood loss (mL) was
less in Group A (150 vs. 200, p = 0.016). Postoperative
mortality and morbidity was comparable (p = 1.000).
In LRC group, the pathological T stage in primary
GBC patients was T1b (n = 1), T2 (n = 6) and T3
(n = 8). One of the 4 IGBC patients had residual tumor
in gallbladder fossa. All underwent a R0 resection. The
median lymphnode yield was 8 (4–24) and was compa-
rable between the two groups (p = 0.951). During a
median follow up of 14 (8–26) months 1 patient in
GroupA and 3 in GroupB developed recurrence. None
of the patients in GroupA developed port site recur-
rence.
Conclusions: Laparoscopic radical cholecystectomy
(LRC) is safe and feasible in selected patients of GBC
and results are comparable to Open radical cholecystec-
tomy (ORC).
FO32-08
CAN DEATH RECEPTOR -5 PREDICT
THE PROGNOSIS OF GALLBLADDER
CARCINOMA?
Ji Eun Sung, Chang Woo Nam, Hye Jung Choi and
Yang Won Nah
Ulsan University Hospital, Korea
Introduction: Gallbladder adenocarcinoma (GBC) is
one of the most lethal cancers that tends to present at
an advanced stage. There are approximately 5,600
newly diagnosed cases per year in Korea, and seventh
common cancer with female predominance. The proa-
poptotic death receptor DR5 has been studied exten-
sively in cancer cells recently, because of the ability of
the apoptotic receptor ligand Apo2L/TRAIL to kill
malignant cells selectively. We investigated the expres-
sion of DR5 by immunohistochemistry and its prog-
nostic significance in 105 cases of resected gallbladder
carcinomas.
Method: The 102 cases of adenocarcinomas of gall-
bladder of Ulsan university hospital, from 2002 to 2012
were included. The paraffin embedded formalin fixed
tissue of representative block of tumor was selected
from each case and immunohistochemical stain of DR5
was performed.
Results: The patients were made up of 45 males and
57 females. Age group was the 40–82 age band and
the mean age was 62.82  10.56 years. Stages, exis-
tence of lymphovascular and perineural invasion, sta-
tus of resection margin, and lymph node metastasis
were made a through investigation. 58 cases (56%)
revealed DR5 high expression in cytoplasm and
nucleus and 34 cases showed endothelial expression
in the tumor. But the tumor cell nor endothelial
expression are not correlated with clinical characteris-
tics or survival.
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Conclusions: DR5 expression is relatively common in
gallbladder adenocarcinoma cells and endothelial cells
in the tumor. Their potential of therapeutic target
should be elucidated through further prospective study.
FO33-01
BENEFITS OF PET/CT IN
DIAGNOSTICS OF PANCREATIC
TUMOURS
Jiri Kysucan1, Dusan Klos1, Martin Lovecek1,
Katherine Vomackova1, Cestmir Neoral1, Pavel
Koranda2 and Roman Havlik1
1Surgeon, Czech Republic; 2Nuclear medicine, Czech
Republic
Introduction: Treatment of pancreatic tumours is inter-
disciplinary, but surgery remains the only poten-
tially curative method. Pre-operative imaging methods
are by default provided by conventional methods as
CT and EUS. Nevertheless, only a minority of patients
after extramural investigation are indicated to radical
treatment and of those patients, local inoperability or
generalization of the disease is often discovered perop-
eratively. Implementation of PET/CT seems to be able
to simplify and specify pre-operative staging.
Method: In the past 3 years, PET/CT was performed
in 172 patients with suspicion of pancreatic tumour, as
well as CT and EUS. Agreement or disagreement of
PET/CT results was compared with surgery findings
and definitive histology in TNM modalities. Then,
PET/CT findings were compared with CT and EUS.
Results: CT was performed in 146 patients, EUS in
125 patients. 103 patients were not indicated to surgery,
because of generalization of disease, local inoperability
or exclusion of the tumour. In our study, specificity
and accuracy of PET/CT is significantly higher than
EUS in tumour detection. Sensitivity and accuracy of
the method are higher than CT, as well. Sensitivity and
specificity for affection of regional lymph nodes are
low, but higher than CT. High specificity in detection
of distant metastases makes PET/CT an effective tool
in assessment of resectability of pancreatic tumour.
Conclusions: The implementation of PET/CT to the
pre-operative algorithm notably improves diagnostics
of pancreatic tumours and indications to operation. It′s
main contribution is better selection of patients who
would otherwise uselessly undergo poorely indicated
surgical revision, which brings profit for the patient
and has indispensable economic impact as well. PET/
CT could be considered as the standard of patients
with equivocal findings by conventional methods and
also with borderline resectable pancreatic cancer.
FO33-02
APPLYING WGS-BASED
PERSONALIZED GENETIC MARKER
DISCOVERY FOR MONITORING A
PATIENT WITH PANCREATIC CANCER
AFTER SURGERY
Taegyun Yun1, Wooil Kwon2, Byung-Chul Lee1,
Junghyun Namkung1, Sung Gon Yi1, Kyeongin Seo1,
Sun Whe Kim2, Sangjo Han1 and Jin-Young Jang2
1Healthcare Group, SK telecom, Korea, 2Seoul National
University College of Medicine, Korea
Introduction: Sensitive and specific monitoring marker
is useful for clinical management of cancer patients
after surgery by monitoring treatment effects and recur-
rence of cancer. Recently one group introduced new
monitoring method for patients with large size of solid
cancers or in metastasis, such as breast cancer and
colorectal cancer, which are using patient-specific
genetic markers found by analyzing whole genome
sequence (WGS). However, this approach has not been
tested for patients with relatively small size of solid
cancers. Here, we performed the pilot study using two
Korean patients with pancreatic cancer.
Method: We generated WGS datasets of tumor tissues
and whole blood samples from two patients, and then
analyzed them on our own WGS analysis platform to
identify patient-specific somatic structural variations
(i.e. translocation) as the monitoring markers, which
are basically not present in germline DNA, but only
observed in tumor tissue. To confirm whether such can-
didate somatic markers are specific to each patient’s
tumors, each genomic region specific to each patient
were compared with nine normal Korean WGS data-
sets. Experimentally to confirm whether each marker is
detected only in the corresponding tumor, we designed
PCR primers spanning break-point within each candi-
date structural variation, and performed end-point as
well as quantitative PCR.
Results: More than tens of candidate structural varia-
tion regions useful as patient-specific monitoring mark-
ers were identified, which are confirmed to be not
present in patient’s germline DNA, and even in known
9 normal Korean persons. As well, PCR experiment
showed that most of candidate regions are specific in
patient’s tumor.
Conclusions: Current pilot study showed that patient-
specific somatic structural variations for the monitoring
markers have been successfully discovered, and then
PCR amplifying the discovered region would work well
for monitoring patients. Now we are evaluating it in
the corresponding patient’s time series serum samples
after surgery with digital PCR.
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FO33-03
CLINICOPATHOLOGICAL FINDINGS
OF PANCREATIC DUCTAL
ADENOCARCINOMA CONCOMITANT
WITH INTRADUCTAL PAPILLARY
MUCINOUS NEOPLASMS
Takahiro Ito, Daisuke Noguchi, Takao Omori,
Yasuo Okura, Takashi Hamada, Hiroshi Kaneko,
Hiroki Taoka, Toshifumi Takeuchi, Shimpei Matsusaki
and Tetsuya Murata
Suzuka general hospital, Japan
Introduction: Although branch duct intraductal papil-
lary mucinous neoplasms(IPMN) are slow-growing
tumor with a favorable prognosis, the synchronous
occurrence of pancreatic ductal adenocarcinomas
(PDAC) in patients with IPMN have been reported.
However, it is considered that PDAC concomitant with
IPMN (PDAC-IPMN) have a better prognosis than
PDAC without IPMN. The aim of this study is to
investigate clinicopathological findings of PDAC with
IPMN compared to PDAC without IPMN.
Method: From January 2003 to August 2013, forty-one
patients were undergone the resection for PDAC in our
hospital. We had investigated clinicopathological differ-
ences that were background of the patient, opportunity
of the diagnosis, site and size of the tumor, histological
character, recurrence rate, prognosis, between 5
patients with IPMN and 36 patients without IPMN
(PDAC).
Results: Patients in PDAC-IPMN group showed a
lower rate of clinical symptoms (0% vs. 83%,
p < 0.001) than those from PDAC group. PDAC-
IPMN had showed lower tumor stage (T1; 80% vs.
14% T2; 20% vs. 8% T3; 0% vs. 78%, p = 0.004),
lower recurrence rate (0% vs. 63%, p = 0.026) compar-
ing with PDAC. The median survival times were
30.1 months in PDAC-IPMN group, on the other hand
20.9 months in PDAC group. According to the TS1
(tumor size <2.0 cm) cases, the rate of extrapancreatic
spread of tumor (JPS-rules; S+ and/or RP+) in PDAC-
IPMN group was tended to be lower than those in
PDACs (0% vs. 55%, p = 0.057). According to the
stage IB and II cases, the recurrence rate in PDAC-
IPMN was fewer than those in PDAC (0% vs 69%,
p = 0.034).
Conclusions: PDAC with IPMN had small size of
tumor, less invasive, and lower rate of recurrence com-
paring with PDAC without IPMN. It is considered as
the one reason that they were early diagnosed. How-
ever, the rate of extrapancreatic spread and recurrence
rate were different in similar stage. These findings sug-
gest that PDAC with IPMN may have more favorably
biological behaviors than PDAC without IPMN.
FO33-04
IRREVERSABLE ELECTROPORATION
WITH “NANOKNIFE” SYSTEM IN
TREATMENT OF LOCALLY ADVANCED
PANCREATIC CANCER. THE FIRST
EARLY RESULTS
Dmitry Panchenkov1, Yuri Ivanov2, Nikolay Soloviev2,
Fedor Zabozlaev2, Alexey Nechunaev1 and Dmitry
Astakhov1
1A.I. Evdokimov Moscow State University of Medicine
and Dentistry, Russia; 2Federal Research Clinical Center
of Specialized Medical Care and Medical Technologies
FMBA, Russia
Introduction: The methods of local destruction now a
day are not widely spread in treatment of pancreatic
cancer because of characteristics of blood supply, ana-
tomic and histologic structure of pancreas and high
rate of complications and recurrence. The method if
irreversible electroporation (IRE) is a new unique tech-
nology of non-thermal ablation directed to destruction
of cancerous cells by subjecting them to a series of
short electrical pulses using high-voltage direct current.
This creates multiple holes in the cell membrane, irre-
versibly damaging the cell’s homeostasis mechanisms
and leading to cell death.
Aim of the study: To estimate the possibilities of IRE
in treatment of locally advanced pancreatic cancer
(LAPC).
Method: Seven patients underwent IRE for unresec-
table LAPC with “Nanoknife” surgical system. Our
short experience shows the following advantages of
IRE: comparable technical simplicity, safety for vascu-
lar and duct structures, minimal impact on the pan-
creas.
Results: The efficacy of IRE proved with ultrasound,
CT and histologic (biopsy) investigation in postopera-
tive period. The maximal period of supervision was
7 months. In one case acute pancreatitis noticed on the
8th day after the procedure with following successful
conservative treatment.
Conclusions: Though the definite indications to IRE in
patients with LAPC are not established but the world
results and our own first experience permit to acknowl-
edge the efficacy of this technique in palliative surgical
treatment of LAPC and its safety.
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FO33-05
ENDOSCOPIC STENTING MAY BE
PREFERABLE TO SURGICAL BYPASS
FOR PALLIATION, EVEN IN THE
ABSENCE OF METASTATIC DISEASE,
IN PATIENTS WITH UNRESECTABLE
OBSTRUCTIVE PANCREATIC HEAD
CANCER
Alexandros Kofokotsios, David Taraboulous, Fotini
Maloudi, Christiana Papaefthimiou, Konstantinos
Papazisis, Loukas Kontovinis, Ioannis Andronikidis,
Dimitrios Kardassis, Achilleas Ntinas and Dionisios
Vrochides
“Euromedica Geniki Kliniki” General Hospital, Greece
Introduction: Endoscopic stenting techniques and mate-
rials for gastro-intestinal malignancies are constantly
improving. This study evaluates the efficacy of stenting
compared to the standard operative procedures, in
patients with unresectable obstructive pancreatic head
cancer.
Method: This is a retrospective case control study of
52 patients who were diagnosed with obstructive (bili-
ary, duodenal or both) adenocarcinoma of the pancre-
atic head. Twenty-nine patients (endoscopy group)
underwent palliative endoscopic stenting (biliary: 29
stents, duodenal: 4 stents). Eleven patients (bypass
group) underwent palliative double by-pass. Twelve
patients (Whipple’s group) underwent Whipple’s opera-
tion with curative intent, however histopathology
revealed R1 resection (palliative Whipple’s). Primary
end-point was survival. Tumor characteristics, labora-
tory values and post-intervention complications were
also analyzed.
Results: Metastatic disease was present only in the
endoscopy group (n = 12, 41.3%). T4 disease was iden-
tified in 44.8% (n = 13), 63.6% (n = 7) and 25%
(n = 3) in the endoscopy, bypass and Whipple’s group,
respectively. 27.2% (n = 3) and 25% (n = 3) of patients
in the bypass and Whipple’s group, respectively,
received neoadjuvant chemoradiation, after endoscopic
biliary stenting. 48.3% (n = 14), 54.5% (n = 6) and
100% (n = 12) of patients in the endoscopy, bypass
and Whipple’s group, respectively, received adjuvant
chemotherapy. In the endoscopy group, primary and
secondary anatomic patency rates were 86% and
100%, respectively. There was no intervention-related
mortality. Median survival was 280 (95%CI: 103, 456),
157 (95% CI: 0, 411) and 647 (95% CI: 300, 993) for
the endoscopy, bypass and Whipple’s group, respec-
tively (p = 0.116).
Conclusions: In patients with obstructive pancreatic
head cancer, endoscopic stenting offers equally good
palliation when compared to surgical double by-pass,
even in the absence of metastatic disease. The numeri-
cally better (although not statistically significant) sur-
vival after palliative Whipple’s might be explained by
the smaller tumor burden in this sub-group of patients
and not by the superior efficacy of this operation.
FO33-06
FIRST JEJUNAL VEIN-ORIENTED
MESENTERIC EXCISION FOR
PANCREATODUODENECTOMY
REDUCES INTRAOPERATIVE
BLEEDING
Toshiya Abe, Hiroshi Nakashima, Atsushi Urakami,
Toshihiro Hirai and Masafumi Nakamura
Kawasaki Medical College, Kurashiki, Japan
Introduction: Dissection of the pancreatic head from
the superior mesenteric vein (SMV) and artery (SMA)
are major points of bleeding in pancreaticoduodenecto-
my (PD) because of congestion of the pancreatic head.
Ligatinon of IPDA is effective for preventing conges-
tion. However, detection of IPDA is not easy and
sometimes dupicated. We applied a new surgical
approach, first jejunal vein-oriented mesenteric excision
(FME) for PD, by which we totally resected meso-
duodenum before cutting branches of SMV.This study
aimed to clarify the effect of FME on reduction of
bleeding during PD.
Method: We retrospectively analyzed the perioperative
outcome of 54 patients who underwent resection of the
pancreatic head, PD and total pancreatectomy (TP)
from Janualy 2010 through June 2013 in Kawasaki
Medical College. 33 patients underwent pancreatic head
resection by FME, and 21 patients underwent the con-
ventional method. Analysis of anatomical findings of
the FJV: Computed tomography (CT) images of 56
patients who underwent surgery for the treatment of
hepato-biliary-pancreatic disease were analyzed to
determine the anatomy of the FJV and spatial relation-
ship between FJV and IPDA.
Results: FME-based PD significantly reduced intraop-
erative blood loss compared with conventional PD
(571 mL vs. 1,234 mL, p = 0.0061). The median dis-
tance of the FJV was 0 mm from the middle colic
artery and 0 mm from the 3rd portion of the duode-
num. The FJV was posterior to the SMA in the major-
ity of the patients but was anterior to the SMA in
16.7% of patients.
Conclusions: FME is useful for reducing intraoperative
bleeding.
FO33-07
USE OF HARMONIC FOCUS IN
CUTTING PANCREAS FOR SOFT
TEXTURE REDUCES THE RATE OF
PANCREATIC FISTULA AFTER
PANCREATICODUODENECTOMY
Kei Sato, Koichi Taniguchi, Ryusei Matsuyama,
Ryutaro Mori, Kazuhisa Takeda, Takafumi
Kumamoto, Kazunori Nojiri, Michio Ueda, Kuniya
Tanaka and Itaru Endo
Yokohama City University, Japan
Introduction: Harmonic FOCUS (Ethicon Endo-Sur-
gery, Inc, Cincinnati, OH) is an ultrasonic surgical scal-
pel that cuts and coagulates tissues using lower
temperatures than those used by electrosurgical equip-
ment. It has been reported to occlude and seal small to
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medium-sized arteries, veins and lymphatic vessels by
the coagulation effect. The aim of this report is to
assess the outcome of cutting pancreas with Harmonic
FOCUS in pancreaticoduodenectomy for soft pancre-
atic texture.
Method: Amylase concentration of postoperative drain-
age fluid, incidence of pancreatic fistula was compared
between patients who underwent pancreaticoduodenec-
tomy with Harmonic FOCUS (FOCUS group,
n = 44) and with surgical knife (Knife group, n = 112)
as a prospective observational study. Also, risk factors
for ISGPF grade B or C pancreatic fistula were ana-
lyzed by univariate and multivariate analysis.
Results: Mean drain amylase level was relatively lower
in FOCUS group on postoperative day 1 with marginal
significance (p = 0.08). In Knife group, exponential
increase of amylase level was observed on postoperative
day 6. Serum CRP level in FOCUS group was signifi-
cantly lower compared with Knife group on postopera-
tive day 2 and 3. The rate of grade B or C pancreatic
fistula was significantly lower in FOCUS group com-
pared to Knife group (27% vs. 44%, p = 0.047). No
use of Harmonic FOCUS (OR 6.457, 95% CI 2.0–
20.848, p = 0.002) and operative time (≧660 min) (OR
11.08, 95% CI 3.45–35.586, p < 0.001) were the inde-
pendent predictive factors for developing clinically rele-
vant pancreatic fistula of grade B or C.
Conclusions: Use of Harmonic FOCUS in cutting
pancreas for soft texture may seal branch pancreatic
ducts and suppress leakage of pancreatic juice from
pancreatic cut end and thus reduces the rate of pancre-
atic fistula after pancreaticoduodenectomy.
FO33-08
END-TO-SIDE INSERTING
PANCREATICO-JEJUNOSTOMY: A
PROSPECTIVE STUDY OF 41
CONSECUTIVE
PANCRETICODUODENECTOMIES
Daisuke Hashimoto1, Masahiko Hirota2, Akira
Chikamoto1 and Hideo Baba1
1Kumamoto University Graduate School of Medical
Sciences, Japan; 2Kumamoto Regional Medical Center,
Japan
Introduction: Leakage from pancreatic anastomosis
remains the most important cause of morbidity, and it
also contributes significantly to prolonged hospitaliza-
tion and mortality after pancreatico-duodenectomy.
Therefore, generating a method for anastomosing the
pancreas with the jejunum which might reduce the rate
of complication is important. We have developed end-
to-side inserting pancreatico-jejunostomy (Hashimoto
et al. Surg Today 2013; 43:821–4.). The aim of this pro-
spective study was to assess the safety of this new anas-
tomosis.
Method: In this novel anastomosis technique, the pan-
creatic stump was isolated from the surrounding tissue.
An incision which has the same diameter with the pan-
creatic stump was made on the opposite side of the
mesenterium of the jejunum. A purse string suture was
applied around the incision of the jejunum. Five to 6
stay sutures were also applied on the pancreas. The
pancreatic stump was inserted into the jejunal incision
by end-to-side, applying the stay sutures on the incision
to secure the depth of inserting. A stent tube was
inserted to a main pancreatic duct. Finally, the purse
string suture was tied to seal the anastomosis. We per-
formed this new anastomosis to 41 patients prospec-
tively in Kumamoto University Hospital from April
2012 to July 2013.
Results: There was no hospital death. Postoperative
pancreatic fistula was observed as grade A in 2 cases
(4.9%), grade B in one case (2.5%) and grade C in 2
cases (4.9%). Importantly, 2 patients (4.9%) developed
hemorrhage from pancreatic cut end into the jejunum.
Conclusions: Whereas careful hemostasis of the pancre-
atic cut end should be complete before inserting into
the jejunum avoiding hemorrhage, this new method
would be expected to minimize leakage from pancreati-
co-jejunostomy. Further studies should be planned in a
randomized controlled trial compared with another tra-
ditional pancreatico-jejunostomy.
FO33-09
60 TOTAL LAPAROSCOPIC
PANCREATICODUODENECTOMIES.
Igor Khatkov2, Victor Tsvirkun3, Roman Izrailov2 and
Pavel Tyutyunnik1
1MSUMD, Russia; 2Moscow Scientific Research
Institute of Gastroenterology, MSUMD, Russia;
3Clinical Hospital 119, FMBA, Russia, Russia
Introduction: Nowadays progress in pancreatic surgery
is related with successful applying of minimally invasive
technology for periampullare area’s cancer patients.
Total laparoscopic pancreaticoduodenectomy (LPD) is
still technically challenging. As a result just several cen-
ters in the world have experience more than 30–40 pro-
cedures.
Method: Single surgical team performed all procedures.
60 patients underwent LPD. There were 37 females and
23 males. Mean age was 59.09 (range, 45–76) years. In
a retrospective study we analyzed the main outcome
measures: conversion rate, blood loss, operative time,
length of hospital stay, number of lymph nodes, TNM
stage, postoperative morbidity and mortality.
Results: Median operative time was 445 minutes
(range, 255–705 minutes) and median blood loss was
300 mL (range, 10–2,100 mL). Diagnosis: benign and
malignant 6.6% (n = 4) and 93.4% (n = 56) respec-
tively. The final pathology examination results: Pancre-
atic adenocarcinoma (n-51), seal ring cancer 1.6%
(n = 1), indifferent cancer 3.3% (n = 2), neuroendo-
crine tumor of the duodenum 1.6% (n = 1), chronic
pancreatitis 3.3% (n = 2). Mean number of lymph
nodes – 19. TNM: I – 30%; II – 46.1%; III – 17.3%.
The complication rate (Clavien-Dindo Classification)
38.3%: I or II – 11.6%; IIIA – 13.3%; IIIB – 6.6%; IV
– 1.6%; V – 5%. Resected margins were positive in
three cases.
Conclusions: Laparoscopic approach permits to per-
form pancreaticoduodenectomy as open approach.
Time of procedure is decreasing with growing of experi-
ence.
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FO33-10
COMPARATIVE STUDY OF
LAPAROSCOPIC AND OPEN
PANCREATODUODENECTOMIES OVER
15 YEARS IN A TERTIARY CENTRE
Senthilnathan Palanisamy, Palanivelu C, Paramesh
KN, Sandeep S, Nalankilli VP, Parathasarathi R,
Sathiyamurthy R and Praveen Raj P
GEM Hospital and Research Centre, Coimbatore, India
Introduction: Pancreatoduodenectomy is a formidable
procedure involving complex resection and reconstruc-
tion. In this fast growing minimal access surgery era,
such complex and challenging surgeries are being per-
formed by laparoscopic method in increasing numbers.
Though technical feasibility had been established
beyond doubt, very few studies compared its outcome
with open approach. This article aims to review our
comparative experience of Laparoscopic pancreatoduo-
denectomy (LPD) with its open counterpart, open pan-
creatoduodenectomy (OPD) in reference to
perioperative and long term outcome.
Method: A retrospective review of prospectively main-
tained data from 1998 to 2013 was done. Out of 533
patients who underwent pancreatoduodenectomy for
pancreatic and periampullary tumours, 393 underwent
OPD and 140LPD. Patients with borderline resectabil-
ity and associated vascular resections were excluded
from the study. These two groups were compared on
the basis of overall survival as the primary end point
and perioperative variables as the secondary end
points.
Results: Patients in both arms were similar in terms of
age, sex, BMI, ASA grade and comorbidities. The
mean tumor size is 3.1 cm in LPD and 3.6 cm in OPD
and location is comparable. Operative time is more in
LPD group whereas blood loss is significantly less com-
pared to OPD. Perioperative morbidity profiles includ-
ing pancreatic fistula (8.57% LPD vs. 9.66% OPD)
rates are comparable between the groups. Mean hospi-
tal stay is less in LPD group but this difference fades
out in complicated patients. No significant difference
was noticed in terms of margin status, no of lymph
nodes harvested, node positivity and pTMN stage. The
overall five year survival was 29.4% in LPD and
27.1% in OPD.
Conclusions: This comparative study reinforces the
already proven facts about feasibility, safety of LPD.
With added benefits in terms of reduced hospital stay,
blood loss combining with comparable oncological
safety and overall outcome, LPD is a treatment option
in expert hands for pancreatic and periampullary
tumours.
FO33-11
LAPAROSCOPIC CENTRAL
PANCREATECTOMY FOR BENIGN OR
LOW-GRADE MALIGNANT LESIONS IN
PANCREATIC NECK AND PROXIMAL
BODY
Ki Byung Song, Song Cheol Kim, Young-Joo Lee,
Kwang-Min Park, Jae Hoon Lee, Jeong Su Nam,
Jong Hee Yoon, Dong Joo Lee and Jung Woo Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Laparoscopic central pancreatectomy
(LCP) is a parenchyma-sparing minimal invasive sur-
gery that enables the removal of benign or low-grade
malignant lesions from the neck and proximal body of
the pancreas. The aim of this study was to compare the
short and long-term clinical outcomes between LCP
and other pancreatectomies.
Method: In the study period (From January 2007 to
December 2010, median follow up time: 40.6 months),
we performed 279 cases of pancreatectomy for benign
or low-grade malignant tumors of pancreatic neck and
proximal body. For comparative study of clinical out-
comes between LCP and other pancreatectomies, we
selected 26 cases of LCP, 14 cases of open central pan-
createctomy (OCP), and 96 cases of laparoscopic distal
pancreatectomy (LDP).
Results: The tumor size of LCP (2.2 cm) and OCP
(2.9 cm) groups were smaller than LDP (4.0 cm)
groups. The mean operation time for LCP group
(350.2 minutes) was longer than for OCP (270.3 min-
utes) and LDP group (210.6 minutes). There were more
surgical complications in LCP (38.5%) and OCP
groups (50%) compared to that of the LDP group
(14.6%). The mean duration of postoperative hospital
stay was 13.8 days for the LCP group, which was sig-
nificantly shorter than the OCP group (22.4 days). New
onset diabetes was less frequent following LCP than
LDP (11.5 vs. 30.8%).
Conclusions: In selected patients, with small and benign
tumors in pancreatic neck and proximal body, LCP are
associated with early postoperative recovery (compared
with OCP) and an increased postoperative morbidity
but an excellent postoperative pancreatic function
(compared with LDP). Therefore, they should be con-
sidered as a valid therapeutic option in selected
patients.
FO33-12
MINIMALLY INVASIVE VERSUS OPEN
DISTAL PANCREATECTOMY FOR
TREATMENT OF PANCREATIC
LESIONS: A SINGLE CENTER
EXPERIENCE
Gazi B. Zibari1, Mohammad Kazem Fallahzadeh1,
Navid Mokhtari1, Alireza Hamidian2, Quyen Chu2,
Sophia T. Abdehou1 and Hosein Shokouh-Amiri1
1WK John C. McDonald Regional Transplant Center,
USA; 2LSUHSC-Shreveport, USA
Introduction: Minimally invasive surgery of pancreas is
increasingly gaining more popularity among the surgi-
cal community. The aim of this study was to compare
the surgical and oncological outcomes of minimally
invasive distal pancreatectomy (MIDP) vs. open distal
pancreatectomy (ODP) in patients with pancreatic
lesions who were treated at our center.
Method: In this IRB approved study, the charts of 341
patients who underwent pancreatic resection at our
center were retrospectively reviewed. Among them, 40
consecutive patients who had MIDP and 34 consecu-
tive patients who had ODP were enrolled in the study.
The surgical and oncological outcomes including OR
time, estimated blood loss, the length of hospital stay,
the amount of blood transfusion requirement, and
postoperative complication rate were compared
between 2 groups. Moreover, free resection margin and
survival rates were compared between patients with
pancreatic adenocarcinoma in 2 groups.
Results: Demographic data were similar between two
groups. In MIDP group, 30 had laparoscopic and 10
had robotic DP. Twelve patients in the MIDP group
and 14 patients in ODP group had pancreatic adeno-
carcinoma. There were no statistically significant differ-
ences between two groups in terms of OR time, the
amount of blood transfusion requirement or post-
operative complications. There were also no statistically
significant differences between patients with adenocarci-
noma in MIDP and ODP in terms of free resection
margin and survival rates. However, the length of hos-
pital stay was significantly shorter in the MIS group as
compared with ODP group (8.6 vs. 12.4 days,
p = 0.05).
Conclusions: Our results show that while surgical and
oncological outcomes of MIDP and ODP are compara-
ble, MIDP has shorter length of hospital stay. The
long-term outcomes of MIDP and ODP should be eval-
uated in future randomized controlled trials.
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